USPatent applicationPatented

Substituted nucleosides, nucleotides and analogs thereof

Granted 16 Jun 2020 · no office action yet

Life of the application

9 dated events
⤢ drag to zoom20152020202520302035ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Description

115 parts
›INCORPORATION BY REFERENCE TO ANY PRIORITY APPLICATIONS

Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application, are hereby incorporated by reference under 37 CFR 1.57.

›REFERENCE TO SEQUENCE LISTING

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled SEQLISTING_065C7—Substitute, created Dec. 14, 2018, which is 2 Kb in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.

BACKGROUND
›Field

The present application relates to the fields of chemistry, biochemistry and medicine. More particularly, disclosed herein are nucleotide analogs, pharmaceutical compositions that include one or more nucleotide analogs and methods of synthesizing the same. Also disclosed herein are methods of treating diseases and/or conditions with a nucleotide analog, alone or in combination therapy with one or more other agents.

Description

Nucleoside analogs are a class of compounds that have been shown to exert antiviral and anticancer activity both in vitro and in vivo, and thus, have been the subject of widespread research for the treatment of viral infections. Nucleoside analogs are usually therapeutically inactive compounds that are converted by host or viral enzymes to their respective active anti-metabolites, which, in turn, may inhibit polymerases involved in viral or cell proliferation. The activation occurs by a variety of mechanisms, such as the addition of one or more phosphate groups and, or in combination with, other metabolic processes.

›SUMMARY

Some embodiments disclosed herein relate to a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Some embodiments disclosed herein relate to a method of ameliorating and/or treating a hepatitis C viral (HCV) infection that can include administering to a subject identified as suffering from the HCV infection an effective amount of one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ameliorating and/or treating a HCV infection. Still other embodiments described herein relate to one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, that can be used for ameliorating and/or treating a HCV infection.

Some embodiments disclosed herein relate to a method of ameliorating and/or treating a HCV infection that can include contacting a cell infected with the hepatitis C virus with an effective amount of one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein, or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, in the manufacture of a medicament for ameliorating and/or treating a HCV infection that can include contacting a cell infected with the hepatitis C virus with an effective amount of said compound(s). Still other embodiments described herein relate to one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein, or a pharmaceutically acceptable salt thereof, that can be used for ameliorating and/or treating a HCV infection by contacting a cell infected with the hepatitis C virus with an effective amount of said compound(s).

Some embodiments disclosed herein relate to a method of inhibiting replication of a hepatitis C virus that can include contacting a cell infected with the hepatitis C virus with an effective amount of one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein, or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, in the manufacture of a medicament for inhibiting replication of a hepatitis C virus that can include contacting a cell infected with the hepatitis C virus with an effective amount of said compound(s). Still other embodiments described herein relate to one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein, or a pharmaceutically acceptable salt thereof, that can be used for inhibiting replication of a hepatitis C virus by contacting a cell infected with the hepatitis C virus with an effective amount of said compound(s).

Some embodiments disclosed herein relate to a method of ameliorating and/or treating a HCV infection that can include administering to a subject identified as suffering from the HCV infection an effective amount of a compound described herein or a pharmaceutically acceptable salt thereof (for example, one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition that includes a compound described herein, or a pharmaceutically acceptable salt thereof, in combination with an agent selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an other antiviral compound, a compound of Formula (AA), a compound of Formula (BB) and a compound of Formula (CC), or a pharmaceutically acceptable salt of any of the foregoing. Some embodiments disclosed herein relate to a method of ameliorating and/or treating a HCV infection that can include contacting a cell infected with the HCV infection with an effective amount of a compound described herein or a pharmaceutically acceptable salt thereof (for example, one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition that includes a compound described herein, in combination with an agent selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an other antiviral compound, a compound of Formula (AA), a compound of Formula (BB) and a compound of Formula (CC), or a pharmaceutically acceptable salt of any of the foregoing. Some embodiments disclosed herein relate to a method of inhibiting replication of a hepatitis C virus that can include administering to a subject identified as suffering from a HCV infection an effective amount of a compound described herein or a pharmaceutically acceptable salt thereof (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition that includes a compound described herein, or a pharmaceutically acceptable salt thereof, in combination with an agent selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, another antiviral compound, a compound of Formula (AA), a compound of Formula (BB) and a compound of Formula (CC), or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, the agent can be a compound, or a pharmaceutically acceptable salt thereof, selected from Compound 1001-1016, 2001-2012, 3001-3014, 4001-4012, 5001-5012, 6001-6078, 7000-7027 and 8000-8016, or a pharmaceutical composition that includes one or more of the aforementioned compounds, or a pharmaceutically acceptable salt of the foregoing. In some embodiments, the method can include administering a second agent selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an other antiviral compound, a compound of Formula (AA), a compound of Formula (BB) and a compound of Formula (CC), or a pharmaceutically acceptable salt of any of the foregoing.

›BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows example HCV protease inhibitors.

FIG. 2 shows example nucleoside HCV polymerase inhibitors.

FIG. 3 shows example non-nucleoside HCV polymerase inhibitors.

FIG. 4 shows example NS5A inhibitors.

FIG. 5 shows example other antivirals.

FIG. 6 shows example compounds of Formula (CC) and alpha-thiotriphosphates thereof, wherein Formula (CC) and alpha-thiotriphosphates thereof are described herein.

FIG. 7 shows example compounds of Formula (AA), wherein Formula (AA) is described herein.

FIG. 8 shows example compounds of Formula (BB), wherein Formula (BB) is described herein.

FIG. 9 shows example compounds of Formula (I), wherein Formula (I) is described herein.

FIG. 10 shows the gels from the assessment of incorporation of several compound with a uracil base by the human mitochondrial RNA polymerase.

FIG. 11 shows the gels from the assessment of incorporation of several compounds with a guanine base by the human mitochondrial RNA polymerase.

FIGS. 12A-D shows the results of the inhibition of mitochondrial protein synthesis assays.

DETAILED DESCRIPTION
›Definitions · 1 of 25

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications referenced herein are incorporated by reference in their entirety unless stated otherwise. In the event that there are a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

As used herein, any “R” group(s) such as, without limitation, R 1 , R 2 , R 3 , R 4 , R 5A , R 5B , R 6A , R 6B , R 6C , R 6D , R 6E , R 6F , R 6G , R 6H , R 7A , R 7B , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R A1 , R A2 , R A3 and R A4 represent substituents that can be attached to the indicated atom. An R group may be substituted or unsubstituted. If two “R” groups are described as being “taken together” the R groups and the atoms they are attached to can form a cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocycle. For example, without limitation, if R a and R b of an NR a R b group are indicated to be “taken together,” it means that they are covalently bonded to one another to form a ring:

In addition, if two “R” groups are described as being “taken together” with the atom(s) to which they are attached to form a ring as an alternative, the R groups are not limited to the variables or substituents defined previously.

Whenever a group is described as being “optionally substituted” that group may be unsubstituted or substituted with one or more of the indicated substituents. Likewise, when a group is described as being “unsubstituted or substituted” if substituted, the substituent(s) may be selected from one or more the indicated substituents. If no substituents are indicated, it is meant that the indicated “optionally substituted” or “substituted” group may be substituted with one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl), (heterocyclyl)alkyl, hydroxy, alkoxy, acyl, cyano, halogen, thiocarbonyl, 0-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, an amino, a mono-substituted amino group and a di-substituted amino group.

As used herein, “C a to C b ” in which “a” and “b” are integers refer to the number of carbon atoms in an alkyl, alkenyl or alkynyl group, or the number of carbon atoms in the ring of a cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocyclyl group. That is, the alkyl, alkenyl, alkynyl, ring of the cycloalkyl, ring of the cycloalkenyl, ring of the aryl, ring of the heteroaryl or ring of the heterocyclyl can contain from “a” to “b”, inclusive, carbon atoms. Thus, for example, a “C 1 to C 4 alkyl” group refers to all alkyl groups having from 1 to 4 carbons, that is, CH 3 —, CH 3 CH 2 —, CH 3 CH 2 CH 2 —, (CH 3 ) 2 CH—, CH 3 CH 2 CH 2 CH 2 —, CH 3 CH 2 CH(CH 3 )— and (CH 3 ) 3 C—. If no “a” and “b” are designated with regard to an alkyl, alkenyl, alkynyl, cycloalkyl cycloalkenyl, aryl, heteroaryl or heterocyclyl group, the broadest range described in these definitions is to be assumed.

As used herein, “alkyl” refers to a straight or branched hydrocarbon chain that comprises a fully saturated (no double or triple bonds) hydrocarbon group. The alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., “1 to 20 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated). The alkyl group may also be a medium size alkyl having 1 to 10 carbon atoms. The alkyl group could also be a lower alkyl having 1 to 6 carbon atoms. The alkyl group of the compounds may be designated as “C 1 -C 4 alkyl” or similar designations. By way of example only, “C 1 -C 4 alkyl” indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl and t-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl and hexyl. The alkyl group may be substituted or unsubstituted.

As used herein, “alkenyl” refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more double bonds. An alkenyl group may be unsubstituted or substituted.

As used herein, “alkynyl” refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more triple bonds. An alkynyl group may be unsubstituted or substituted.

As used herein, “cycloalkyl” refers to a completely saturated (no double or triple bonds) mono- or multi-cyclic hydrocarbon ring system. When composed of two or more rings, the rings may be joined together in a fused fashion. Cycloalkyl groups can contain 3 to 10 atoms in the ring(s) or 3 to 8 atoms in the ring(s). A cycloalkyl group may be unsubstituted or substituted. Typical cycloalkyl groups include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

As used herein, “cycloalkenyl” refers to a mono- or multi-cyclic hydrocarbon ring system that contains one or more double bonds in at least one ring; although, if there is more than one, the double bonds cannot form a fully delocalized pi-electron system throughout all the rings (otherwise the group would be “aryl,” as defined herein). When composed of two or more rings, the rings may be connected together in a fused fashion. A cycloalkenyl can contain 3 to 10 atoms in the ring(s) or 3 to 8 atoms in the ring(s). A cycloalkenyl group may be unsubstituted or substituted.

›Definitions · 2 of 25

As used herein, “aryl” refers to a carbocyclic (all carbon) monocyclic or multicyclic aromatic ring system (including fused ring systems where two carbocyclic rings share a chemical bond) that has a fully delocalized pi-electron system throughout all the rings. The number of carbon atoms in an aryl group can vary. For example, the aryl group can be a C 6 -C 14 aryl group, a C 6 -C 10 aryl group, or a C 6 aryl group. Examples of aryl groups include, but are not limited to, benzene, naphthalene and azulene. An aryl group may be substituted or unsubstituted.

As used herein, “heteroaryl” refers to a monocyclic, bicyclic and tricyclic aromatic ring system (a ring system with fully delocalized pi-electron system) that contain(s) one or more heteroatoms (for example, 1 to 5 heteroatoms), that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur. The number of atoms in the ring(s) of a heteroaryl group can vary. For example, the heteroaryl group can contain 4 to 14 atoms in the ring(s), 5 to 10 atoms in the ring(s) or 5 to 6 atoms in the ring(s). Furthermore, the term “heteroaryl” includes fused ring systems where two rings, such as at least one aryl ring and at least one heteroaryl ring, or at least two heteroaryl rings, share at least one chemical bond. Examples of heteroaryl rings include, but are not limited to, furan, furazan, thiophene, benzothiophene, phthalazine, pyrrole, oxazole, benzoxazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, thiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, benzothiazole, imidazole, benzimidazole, indole, indazole, pyrazole, benzopyrazole, isoxazole, benzoisoxazole, isothiazole, triazole, benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, purine, pteridine, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline and triazine. A heteroaryl group may be substituted or unsubstituted.

As used herein, “heterocyclyl” or “heteroalicyclyl” refers to three-, four-, five-, six-, seven-, eight-, nine-, ten-, up to 18-membered monocyclic, bicyclic and tricyclic ring system wherein carbon atoms together with from 1 to 5 heteroatoms constitute said ring system. A heterocycle may optionally contain one or more unsaturated bonds situated in such a way, however, that a fully delocalized pi-electron system does not occur throughout all the rings. The heteroatom(s) is an element other than carbon including, but not limited to, oxygen, sulfur and nitrogen. A heterocycle may further contain one or more carbonyl or thiocarbonyl functionalities, so as to make the definition include oxo-systems and thio-systems such as lactams, lactones, cyclic imides, cyclic thioimides and cyclic carbamates. When composed of two or more rings, the rings may be joined together in a fused fashion. Additionally, any nitrogens in a heteroalicyclic may be quaternized. Heterocyclyl or heteroalicyclic groups may be unsubstituted or substituted. Examples of such “heterocyclyl” or “heteroalicyclyl” groups include but are not limited to, 1,3-dioxin, 1,3-dioxane, 1,4-dioxane, 1,2-dioxolane, 1,3-dioxolane, 1,4-dioxolane, 1,3-oxathiane, 1,4-oxathiin, 1,3-oxathiolane, 1,3-dithiole, 1,3-dithiolane, 1,4-oxathiane, tetrahydro-1,4-thiazine, 2H-1,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, trioxane, hexahydro-1,3,5-triazine, imidazoline, imidazolidine, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine, morpholine, oxirane, piperidine N-Oxide, piperidine, piperazine, pyrrolidine, pyrrolidone, pyrrolidione, 4-piperidone, pyrazoline, pyrazolidine, 2-oxopyrrolidine, tetrahydropyran, 4H-pyran, tetrahydrothiopyran, thiamorpholine, thiamorpholine sulfoxide, thiamorpholine sulfone and their benzo-fused analogs (e.g., benzimidazolidinone, tetrahydroquinoline and 3,4-methylenedioxyphenyl).

As used herein, “aralkyl” and “aryl(alkyl)” refer to an aryl group connected, as a substituent, via a lower alkylene group. The lower alkylene and aryl group of an aryl(alkyl) may be substituted or unsubstituted. Examples include but are not limited to benzyl, 2-phenylalkyl, 3-phenylalkyl and naphthylalkyl.

As used herein, “heteroaralkyl” and “heteroaryl(alkyl)” refer to a heteroaryl group connected, as a substituent, via a lower alkylene group. The lower alkylene and heteroaryl group of heteroaralkyl may be substituted or unsubstituted. Examples include but are not limited to 2-thienylalkyl, 3-thienylalkyl, furylalkyl, thienylalkyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, imidazolylalkyl and their benzo-fused analogs.

A “(heteroalicyclyl)alkyl” and “(heterocyclyl)alkyl” refer to a heterocyclic or a heteroalicyclylic group connected, as a substituent, via a lower alkylene group. The lower alkylene and heterocyclyl of a (heteroalicyclyl)alkyl may be substituted or unsubstituted. Examples include but are not limited tetrahydro-2H-pyran-4-yl)methyl, (piperidin-4-yl)ethyl, (piperidin-4-yl)propyl, (tetrahydro-2H-thiopyran-4-yl)methyl and (1,3-thiazinan-4-yl)methyl.

“Lower alkylene groups” are straight-chained —CH 2 — tethering groups, forming bonds to connect molecular fragments via their terminal carbon atoms. Examples include but are not limited to methylene (—CH 2 —), ethylene (—CH 2 CH 2 —), propylene (—CH 2 CH 2 CH 2 —) and butylene (—CH 2 CH 2 CH 2 CH 2 —). A lower alkylene group can be substituted by replacing one or more hydrogen of the lower alkylene group with a substituent(s) listed under the definition of “substituted.”

As used herein, “alkoxy” refers to the formula —OR wherein R is an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl is defined herein. A non-limiting list of alkoxys are methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, phenoxy and benzoxy. An alkoxy may be substituted or unsubstituted.

As used herein, “acyl” refers to a hydrogen, alkyl, alkenyl, alkynyl, or aryl connected, as substituents, via a carbonyl group. Examples include formyl, acetyl, propanoyl, benzoyl and acryl. An acyl may be substituted or unsubstituted.

›Definitions · 3 of 25

As used herein, “hydroxyalkyl” refers to an alkyl group in which one or more of the hydrogen atoms are replaced by a hydroxy group. Exemplary hydroxyalkyl groups include but are not limited to, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl and 2,2-dihydroxyethyl. A hydroxyalkyl may be substituted or unsubstituted.

As used herein, “haloalkyl” refers to an alkyl group in which one or more of the hydrogen atoms are replaced by a halogen (e.g., mono-haloalkyl, di-haloalkyl and tri-haloalkyl). Such groups include but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1-chloro-2-fluoromethyl and 2-fluoroisobutyl. A haloalkyl may be substituted or unsubstituted.

As used herein, “haloalkoxy” refers to an —O-alkyl group in which one or more of the hydrogen atoms are replaced by a halogen (e.g., mono-haloalkoxy, di-haloalkoxy and tri-haloalkoxy). Such groups include but are not limited to, chloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 1-chloro-2-fluoromethoxy and 2-fluoroisobutoxy. A haloalkoxy may be substituted or unsubstituted.

A “sulfenyl” group refers to an “—SR” group in which R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl. A sulfenyl may be substituted or unsubstituted.

A “sulfinyl” group refers to an “—S(═O)—R” group in which R can be the same as defined with respect to sulfenyl. A sulfinyl may be substituted or unsubstituted.

A “sulfonyl” group refers to an “SO 2 R” group in which R can be the same as defined with respect to sulfenyl. A sulfonyl may be substituted or unsubstituted.

An “O-carboxy” group refers to a “RC(═O)O—” group in which R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl, as defined herein. An O-carboxy may be substituted or unsubstituted.

The terms “ester” and “C-carboxy” refer to a “—C(═O)OR” group in which R can be the same as defined with respect to O-carboxy. An ester and C-carboxy may be substituted or unsubstituted.

A “thiocarbonyl” group refers to a “—C(═S)R” group in which R can be the same as defined with respect to O-carboxy. A thiocarbonyl may be substituted or unsubstituted.

A “trihalomethanesulfonyl” group refers to an “X 3 CSO 2 —” group wherein each X is a halogen.

A “trihalomethanesulfonamido” group refers to an “X 3 CS(O) 2 N(R A )—” group wherein each X is a halogen, and R A is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl.

The term “amino” as used herein refers to a —NH 2 group.

As used herein, the term “hydroxy” refers to a —OH group.

A “cyano” group refers to a “—CN” group.

The term “azido” as used herein refers to a —N 3 group.

An “isocyanato” group refers to a “—NCO” group.

A “thiocyanato” group refers to a “—CNS” group.

An “isothiocyanato” group refers to an “—NCS” group.

A “mercapto” group refers to an “—SH” group.

A “carbonyl” group refers to a C═O group.

An “S-sulfonamido” group refers to a “—SO 2 N(R A R B )” group in which R A and R B can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl. An S-sulfonamido may be substituted or unsubstituted.

An “N-sulfonamido” group refers to a “RSO 2 N(R A )—” group in which R and R A can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl. An N-sulfonamido may be substituted or unsubstituted.

An “O-carbamyl” group refers to a “—OC(═O)N(R A R B )” group in which R A and R B can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl. An O-carbamyl may be substituted or unsubstituted.

An “N-carbamyl” group refers to an “ROC(═O)N(R A )—” group in which R and R A can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl. An N-carbamyl may be substituted or unsubstituted.

An “O-thiocarbamyl” group refers to a “—OC(═S)—N(R A R B )” group in which R A and R B can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl. An O-thiocarbamyl may be substituted or unsubstituted.

An “N-thiocarbamyl” group refers to an “ROC(═S)N(R A )—” group in which R and R A can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl. An N-thiocarbamyl may be substituted or unsubstituted.

A “C-amido” group refers to a “—C(═O)N(R A R B )” group in which R A and R B can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl. A C-amido may be substituted or unsubstituted.

An “N-amido” group refers to a “RC(═O)N(R A )—” group in which R and R A can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), (heteroaryl)alkyl or (heterocyclyl)alkyl. An N-amido may be substituted or unsubstituted.

The term “halogen atom” or “halogen” as used herein, means any one of the radio-stable atoms of column 7 of the Periodic Table of the Elements, such as, fluorine, chlorine, bromine and iodine.

Where the numbers of substituents is not specified (e.g. haloalkyl), there may be one or more substituents present. For example “haloalkyl” may include one or more of the same or different halogens. As another example, “C 1 -C 3 alkoxyphenyl” may include one or more of the same or different alkoxy groups containing one, two or three atoms.

›Definitions · 4 of 25

As used herein, the abbreviations for any protective groups, amino acids and other compounds, are, unless indicated otherwise, in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (See, Biochem. 11:942-944 (1972)).

The term “nucleoside” is used herein in its ordinary sense as understood by those skilled in the art, and refers to a compound composed of an optionally substituted pentose moiety or modified pentose moiety attached to a heterocyclic base or tautomer thereof via a N-glycosidic bond, such as attached via the 9-position of a purine-base or the 1-position of a pyrimidine-base. Examples include, but are not limited to, a ribonucleoside comprising a ribose moiety and a deoxyribonucleoside comprising a deoxyribose moiety. A modified pentose moiety is a pentose moiety in which an oxygen atom has been replaced with a carbon and/or a carbon has been replaced with a sulfur or an oxygen atom. A “nucleoside” is a monomer that can have a substituted base and/or sugar moiety. Additionally, a nucleoside can be incorporated into larger DNA and/or RNA polymers and oligomers. In some instances, the nucleoside can be a nucleoside analog drug.

The term “nucleotide” is used herein in its ordinary sense as understood by those skilled in the art, and refers to a nucleoside having a phosphate ester bound to the pentose moiety, for example, at the 5′-position.

As used herein, the term “heterocyclic base” refers to an optionally substituted nitrogen-containing heterocyclyl that can be attached to an optionally substituted pentose moiety or modified pentose moiety. In some embodiments, the heterocyclic base can be selected from an optionally substituted purine-base, an optionally substituted pyrimidine-base and an optionally substituted triazole-base (for example, a 1,2,4-triazole). The term “purine-base” is used herein in its ordinary sense as understood by those skilled in the art, and includes its tautomers. Similarly, the term “pyrimidine-base” is used herein in its ordinary sense as understood by those skilled in the art, and includes its tautomers. A non-limiting list of optionally substituted purine-bases includes purine, adenine, guanine, hypoxanthine, xanthine, alloxanthine, 7-alkylguanine (e.g. 7-methylguanine), theobromine, caffeine, uric acid and isoguanine. Examples of pyrimidine-bases include, but are not limited to, cytosine, thymine, uracil, 5,6-dihydrouracil and 5-alkylcytosine (e.g., 5-methylcytosine). An example of an optionally substituted triazole-base is 1,2,4-triazole-3-carboxamide. Other non-limiting examples of heterocyclic bases include diaminopurine, 8-oxo-N 6 -alkyladenine (e.g., 8-oxo-N 6 -methyladenine), 7-deazaxanthine, 7-deazaguanine, 7-deazaadenine, N 4 ,N 4 -ethanocytosin, N 6 ,N 6 -ethano-2,6-diaminopurine, 5-halouracil (e.g., 5-fluorouracil and 5-bromouracil), pseudoisocytosine, isocytosine, isoguanine, and other heterocyclic bases described in U.S. Pat. Nos. 5,432,272 and 7,125,855, which are incorporated herein by reference for the limited purpose of disclosing additional heterocyclic bases. In some embodiments, a heterocyclic base can be optionally substituted with an amine or an enol protecting group(s).

The term “—N-linked amino acid” refers to an amino acid that is attached to the indicated moiety via a main-chain amino or mono-substituted amino group. When the amino acid is attached in an —N-linked amino acid, one of the hydrogens that is part of the main-chain amino or mono-substituted amino group is not present and the amino acid is attached via the nitrogen. N-linked amino acids can be substituted or unsubstituted.

The term “—N-linked amino acid ester derivative” refers to an amino acid in which a main-chain carboxylic acid group has been converted to an ester group. In some embodiments, the ester group has a formula selected from alkyl-O—C(═O)—, cycloalkyl-O—C(═O)—, aryl-O—C(═O)— and aryl(alkyl)-O—C(═O)—. A non-limiting list of ester groups include substituted and unsubstituted versions of the following: methyl-O—C(═O)—, ethyl-O—C(═O)—, n-propyl-O—C(═O)—, isopropyl-O—C(═O)—, n-butyl-O—C(═O)—, isobutyl-O—C(═O)—, tert-butyl-O—C(═O)—, neopentyl-O—C(═O)—, cyclopropyl-O—C(═O)—, cyclobutyl-O—C(═O)—, cyclopentyl-O—C(═O)—, cyclohexyl-O—C(═O)—, phenyl-O—C(═O)—, benzyl-O—C(═O)— and naphthyl-O—C(═O)—. N-linked amino acid ester derivatives can be substituted or unsubstituted.

The term “—O-linked amino acid” refers to an amino acid that is attached to the indicated moiety via the hydroxy from its main-chain carboxylic acid group. When the amino acid is attached in an —O-linked amino acid, the hydrogen that is part of the hydroxy from its main-chain carboxylic acid group is not present and the amino acid is attached via the oxygen. O-linked amino acids can be substituted or unsubstituted.

As used herein, the term “amino acid” refers to any amino acid (both standard and non-standard amino acids), including, but not limited to, α-amino acids, β-amino acids, γ-amino acids and δ-amino acids. Examples of suitable amino acids include, but are not limited to, alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. Additional examples of suitable amino acids include, but are not limited to, ornithine, hypusine, 2-aminoisobutyric acid, dehydroalanine, gamma-aminobutyric acid, citrulline, beta-alanine, alpha-ethyl-glycine, alpha-propyl-glycine and norleucine.

The terms “phosphorothioate” and “phosphothioate” refer to a compound of the general formula

its protonated forms (for example,

and its tautomers (such as

As used herein, the term “phosphate” is used in its ordinary sense as understood by those skilled in the art, and includes its protonated forms (for example,

As used herein, the terms “monophosphate,” “diphosphate,” and “triphosphate” are used in their ordinary sense as understood by those skilled in the art, and include protonated forms.

›Definitions · 5 of 25

The terms “protecting group” and “protecting groups” as used herein refer to any atom or group of atoms that is added to a molecule in order to prevent existing groups in the molecule from undergoing unwanted chemical reactions. Examples of protecting group moieties are described in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3. Ed. John Wiley & Sons, 1999, and in J. F. W. McOmie, Protective Groups in Organic Chemistry Plenum Press, 1973, both of which are hereby incorporated by reference for the limited purpose of disclosing suitable protecting groups. The protecting group moiety may be chosen in such a way, that they are stable to certain reaction conditions and readily removed at a convenient stage using methodology known from the art. A non-limiting list of protecting groups include benzyl; substituted benzyl; alkylcarbonyls and alkoxycarbonyls (e.g., t-butoxycarbonyl (BOC), acetyl, or isobutyryl); arylalkylcarbonyls and arylalkoxycarbonyls (e.g., benzyloxycarbonyl); substituted methyl ether (e.g. methoxymethyl ether); substituted ethyl ether; a substituted benzyl ether; tetrahydropyranyl ether; silyls (e.g., trimethylsilyl, triethylsilyl, triisopropylsilyl, t-butyldimethylsilyl, tri-iso-propylsilyloxymethyl, [2-(trimethylsilyl)ethoxy]methyl or t-butyldiphenylsilyl); esters (e.g. benzoate ester); carbonates (e.g. methoxymethylcarbonate); sulfonates (e.g. tosylate or mesylate); acyclic ketal (e.g. dimethyl acetal); cyclic ketals (e.g., 1,3-dioxane, 1,3-dioxolanes and those described herein); acyclic acetal; cyclic acetal (e.g., those described herein); acyclic hemiacetal; cyclic hemiacetal; cyclic dithioketals (e.g., 1,3-dithiane or 1,3-dithiolane); orthoesters (e.g., those described herein) and triarylmethyl groups (e.g., trityl; monomethoxytrityl (MMTr); 4,4′-dimethoxytrityl (DMTr); 4,4′,4″-trimethoxytrityl (TMTr); and those described herein).

The term “pharmaceutically acceptable salt” refers to a salt of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. In some embodiments, the salt is an acid addition salt of the compound. Pharmaceutical salts can be obtained by reacting a compound with inorganic acids such as hydrohalic acid (e.g., hydrochloric acid or hydrobromic acid), sulfuric acid, nitric acid and phosphoric acid. Pharmaceutical salts can also be obtained by reacting a compound with an organic acid such as aliphatic or aromatic carboxylic or sulfonic acids, for example formic, acetic, succinic, lactic, malic, tartaric, citric, ascorbic, nicotinic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, salicylic or naphthalenesulfonic acid. Pharmaceutical salts can also be obtained by reacting a compound with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, C 1 -C 7 alkylamine, cyclohexylamine, triethanolamine, ethylenediamine, and salts with amino acids such as arginine and lysine.

Terms and phrases used in this application, and variations thereof, especially in the appended claims, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing, the term ‘including’ should be read to mean ‘including, without limitation,’ ‘including but not limited to,’ or the like; the term ‘comprising’ as used herein is synonymous with ‘including,’ ‘containing,’ or ‘characterized by,’ and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; the term ‘having’ should be interpreted as ‘having at least;’ the term ‘includes’ should be interpreted as ‘includes but is not limited to;’ the term ‘example’ is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; and use of terms like ‘preferably,’ ‘preferred,’ ‘desired,’ or ‘desirable,’ and words of similar meaning should not be understood as implying that certain features are critical, essential, or even important to the structure or function, but instead as merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment. In addition, the term “comprising” is to be interpreted synonymously with the phrases “having at least” or “including at least”. When used in the context of a process, the term “comprising” means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound, composition or device, the term “comprising” means that the compound, composition or device includes at least the recited features or components, but may also include additional features or components. Likewise, a group of items linked with the conjunction ‘and’ should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as ‘and/or’ unless expressly stated otherwise. Similarly, a group of items linked with the conjunction ‘or’ should not be read as requiring mutual exclusivity among that group, but rather should be read as ‘and/or’ unless expressly stated otherwise.

With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity. The indefinite article “a” or “an” does not exclude a plurality. A single processor or other unit may fulfill the functions of several items recited in the claims. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage. Any reference signs in the claims should not be construed as limiting the scope.

›Definitions · 6 of 25

It is understood that, in any compound described herein having one or more chiral centers, if an absolute stereochemistry is not expressly indicated, then each center may independently be of R-configuration or S-configuration or a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure, enantiomerically enriched, racemic mixture, diastereomerically pure, diastereomerically enriched, or a stereoisomeric mixture. In addition it is understood that, in any compound described herein having one or more double bond(s) generating geometrical isomers that can be defined as E or Z, each double bond may independently be E or Z a mixture thereof.

Likewise, it is understood that, in any compound described, all tautomeric forms are also intended to be included. For example all tautomers of a phosphate and a phosphorothioate groups are intended to be included. Examples of tautomers of a phosphorothioate include the following:

Furthermore, all tautomers of heterocyclic bases known in the art are intended to be included, including tautomers of natural and non-natural purine-bases and pyrimidine-bases.

It is to be understood that where compounds disclosed herein have unfilled valencies, then the valencies are to be filled with hydrogens or isotopes thereof, e.g., hydrogen-1 (protium) and hydrogen-2 (deuterium).

It is understood that the compounds described herein can be labeled isotopically. Substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements. Each chemical element as represented in a compound structure may include any isotope of said element. For example, in a compound structure a hydrogen atom may be explicitly disclosed or understood to be present in the compound. At any position of the compound that a hydrogen atom may be present, the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen-1 (protium) and hydrogen-2 (deuterium). Thus, reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.

It is understood that the methods and combinations described herein include crystalline forms (also known as polymorphs, which include the different crystal packing arrangements of the same elemental composition of a compound), amorphous phases, salts, solvates and hydrates. In some embodiments, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, or the like. In other embodiments, the compounds described herein exist in unsolvated form. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, or the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.

Where a range of values is provided, it is understood that the upper and lower limit, and each intervening value between the upper and lower limit of the range is encompassed within the embodiments.

Compounds

Some embodiments disclosed herein relate to a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

wherein: B 1 can be selected from an optionally substituted

an optionally substituted

an optionally substituted

an optionally substituted

an optionally substituted

and an optionally substituted

R 1 can be selected from an optionally substituted C 1-6 alkyl, an optionally substituted C 2-6 alkenyl, an optionally substituted C 2-6 alkynyl and an optionally substituted C 3-6 cycloalkyl; each -------- can be absent or a single bond, provided that both -------- are each absent or both -------- are each a single bond; when both ------ are each a single bond, then R 2 can be halo, N 3 , —OR 7A or —N(R 7B R 7C ); R 4 can be absent; R 3 can be oxygen (O); and R p can be

wherein Z P can be oxygen (O) or sulfur (S) and R p1 can be selected from O − , OH, an —O-optionally substituted C 1-6 alkyl.

an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; when both ------ are each absent, then R P can be absent; R 2 can be halo, N 3 , —OR 7A or —N(R 7B R 7C ); R 3 can be —OH or —OC(═O)R 8 ; or R 2 and R 3 can be each an oxygen atom which are linked together by a carbonyl group; and R 4 can be hydrogen or

R 5A can be selected from O − , OH, an optionally substituted N-linked amino acid, an optionally substituted N-linked amino acid ester derivative,

R 5B can be selected from O − , OH, an —O-optionally substituted aryl, an —O-optionally substituted heteroaryl, an —O-optionally substituted heterocyclyl, an optionally substituted N-linked amino acid, an optionally substituted N-linked amino acid ester derivative,

R 6A can be an optionally substituted C 1-6 alkyl or an optionally substituted C 3-6 cycloalkyl; R 6B and R 6C can be independently selected from hydrogen, an unsubstituted C 1-6 alkyl, an unsubstituted C 3-6 alkenyl, an unsubstituted C 3-6 alkynyl and an unsubstituted C 3-6 cycloalkyl; R 6D can be NHR 6G ; R 6E can be hydrogen, halogen or NHR 6H ; R 6F can be NHR 6I ; R 6G can be selected from hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 3-6 alkenyl, an optionally substituted C 3-6 cycloalkyl, —C(═O)R A1 and —C(═O)OR A2 ; R 6H can be selected from hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 3-6 alkenyl, an optionally substituted C 3-6 cycloalkyl, —C(═O)R A3 and —C(═O)OR A4 ; R 6I can be selected from hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 3-6 alkenyl, an optionally substituted C 3-6 cycloalkyl, —C(═O)R A5 and —C(═O)OR A6 ; X 1 can be N (nitrogen) or —CR 6J , R 6J can be selected from hydrogen, halogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 2-6 alkenyl and an optionally substituted C 2-6 alkynyl; R A1 , R A2 , R A3 , R A4 , R A5 and R A6 can be independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 6-10 aryl, heteroaryl, heterocyclyl, aryl(C 1-6 alkyl), heteroaryl(C 1-6 alkyl) and heterocyclyl(C 1-6 alkyl); R 7A can be hydrogen or —C(═O)R 12 ; R 7B and R 7C can be independently hydrogen or an optionally substituted C 1-6 alkyl; R 8 and R 12 can be independently an optionally substituted C 1-6 alkyl or an optionally substituted C 3-6 cycloalkyl; R 9 , R 10 and R 11 can be independently absent or hydrogen; R 8A , R 9A , R 11A , R 12A R 8B , R 9B , R 11B , R 12B , R p2 , R p3 , R p5 and R p6 can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl and an optionally substituted aryl; R 10A , R 10B , R 13A , R 13B R p4 and R p7 can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O-heteroaryl and an optionally substituted —O-monocyclic heterocyclyl; R 14A , R 14B , R 15A , R 15B , R p8 and R p9 can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl and an optionally substituted aryl; n can be 0 or 1; p, q, and r can be independently 1 or 2; s, t and u can be independently 3, 4 or 5; Z 1 , Z 1A , Z 1B and Z p1 can be independently O (oxygen) or S (sulfur); and provided that when R 4 is

›Definitions · 7 of 25

R 5A is O − or OH, then R 5B is O − , OH,

an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

The substituents attached to the 2′-carbon can vary. In some embodiments, R 2 can be halo. For example, R 2 can be fluoro or chloro. In other embodiments, R 2 can be N 3 . In some embodiments, R 2 can be —OH. In other embodiments, R 2 can be OR 7A , wherein R 7A can be —C(═O)R 12 , and R 12 can be an optionally substituted C 1-6 alkyl. Suitable alkyl groups include, but are not limited to optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained) and hexyl (branched and straight-chained). In yet still other embodiments, R 2 can be OR 7A , wherein R 7A can be —C(═O)R 12 , and R 12 can be an optionally substituted C 3-6 cycloalkyl. Suitable cycloalkyl groups include, but are not limited to optionally substituted variants of the following: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In some embodiment, R 2 can be —N(R 7B R 7C ), wherein R 7B and R 7C can be independently hydrogen or an optionally substituted C 1-6 alkyl. In some embodiments, R 7B and R 7C can be both hydrogen, such that R 2 can be —NH 2 . In other embodiments, at least one of R 7B and R 7C can be an optionally substituted C 1-6 alkyl. In some embodiments, R 7B and R 7C can be both an optionally substituted C 1-6 alkyl. In some embodiments, R 7B and R 7C can be the same. In other embodiments, R 7B and R 7C can be different.

Various substituents can be attached to the 3′-carbon of the pentose ring. In some embodiments, R 3 can be —OH. In other embodiments, R 3 can be —OC(═O)R 8 , wherein R 8 can be an optionally substituted C 1-6 alkyl such as those described herein. In still other embodiments, R 3 can be —OC(═O)R 8 , wherein R 8 can be an optionally substituted C 3-6 cycloalkyl. Examples of suitable optionally substituted C 3-6 cycloalkyl groups are described herein.

In some embodiments, R 2 and R 3 can each be an oxygen atom and the oxygen atoms can be linked together by a carbonyl group. In other embodiments, R 2 and R 3 can be both —OH. In other embodiments, R 2 can be halo and R 3 can be —OH. In still other embodiments, R 2 can be halo and R 3 can be —OC(═O)R 8 .

In some embodiments, R 1 can be an optionally substituted C 1-6 alkyl. In some embodiments, R 1 can be an unsubstituted C 1-6 alkyl. For example, R 1 can be unsubstituted methyl, unsubstituted ethyl, unsubstituted n-propyl, unsubstituted isopropyl, unsubstituted n-butyl, unsubstituted isobutyl, unsubstituted tert-butyl, unsubstituted pentyl (branched and straight-chained) or unsubstituted hexyl (branched and straight-chained). In some embodiments, R 1 can be a substituted C 1-6 alkyl. Suitable substitutions are described herein. As an example, R 1 can be a halo-substituted C 1-6 alkyl (such as —CF 3 or —CH 2 CH 2 F). In other embodiments, R 1 can be an optionally substituted C 2-6 alkenyl. Suitable alkenyl groups include, but are not limited to optionally substituted variants of the following: ethenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, tert-butenyl, pentenyl (branched and straight-chained), hexenyl (branched and straight-chained), vinyl and allenyl. In still other embodiments, R 1 can be an optionally substituted C 2-6 alkynyl. In yet still other embodiments, R 1 can be an optionally substituted C 3-6 cycloalkyl, such as those described herein.

In some embodiments, both ------ can be each absent, R P can be absent; R 2 can be halo, N 3 , —OR 7A or —N(R 7B R 7C ); R 3 can be —OH or —OC(═O)R 8 ; or R 2 and R 3 can be each an oxygen atom which are linked together by a carbonyl group; and R 4 can be hydrogen or

When both ------ are absent, Formula (I) can have the structure:

In some embodiments, R 4 can be hydrogen. In other embodiments, R 4 can be

In some embodiments, the compound of Formula (I) can be a monophosphate. In other embodiments, the compound of Formula (I) can be a thiomonophosphate. In some embodiments, the compound of Formula (I) can be a diphosphate. In other embodiments, the compound of Formula (I) can be an alpha-thiodiphosphate. In some embodiments, the compound of Formula (I) can be a triphosphate. In other embodiments, the compound of Formula (I) can be an alpha-thiotriphosphate. In some embodiments, R 4 can be

R 5A can be O − or OH; and R 5B can be O − or OH. In other embodiments, R 4 can be

R 5A can be O − or OH; R 5B can be

and n can be 0. In still other embodiments, R 4 can be

R 5A can be O − or OH; R 5B can be

and n can be 1.

The substituents attached to the phosphorus can vary. In some embodiments, a compound of Formula (I) can be a phosphoroamidate. In other embodiments, a compound of Formula (I) can be a thiophosphoroamidate. In still other embodiments, a compound of Formula (I) can be a phosphorbisamidate. In yet still other embodiments, a compound of Formula (I) can be a thiophosphorbisamidate.

In some embodiments, R 5A can be an optionally substituted N-linked amino acid. Various amino acids are suitable, including those described herein. Examples of suitable amino acids include, but are not limited to, alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. In other embodiments, R 5A can be an optionally substituted N-linked amino acid ester derivative. Examples of N-linked amino acid ester derivatives include, but are not limited to, ester derivatives of any of the following amino acids: alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. Additional examples of N-linked amino acid ester derivatives include, but are not limited to, an ester derivative of any of the following amino acids: alpha-ethyl-glycine, alpha-propyl-glycine and beta-alanine. In some embodiments, the N-linked amino acid ester derivative can be a C 1-6 alkyl ester derivative, for example, an isopropyl ester of alanine. In other embodiments, the N-linked amino acid ester derivative can be a C 3-6 cycloalkyl ester derivative, such as a cyclohexyl ester of alanine.

›Definitions · 8 of 25

In some embodiments, R 5A can have the structure

wherein R 13 can be selected from hydrogen, an optionally substituted C 1-6 -alkyl, an optionally substituted C 3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C 1-6 alkyl) and an optionally substituted haloalkyl; R 14 can be selected from hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 1-6 haloalkyl, an optionally substituted C 3-6 cycloalkyl, an optionally substituted C 6 aryl, an optionally substituted C 10 aryl and an optionally substituted aryl(C 1-6 alkyl); and R 15 can be hydrogen or an optionally substituted C 1-4 -alkyl; or R 14 and R 15 can be taken together to form an optionally substituted C 3-6 cycloalkyl.

When R 14 is substituted, R 14 can be substituted with one or more substituents selected from N-amido, mercapto, alkylthio, an optionally substituted aryl, hydroxy, an optionally substituted heteroaryl, O-carboxy and amino. In some embodiments, R 14 can be an unsubstituted C 1-6 -alkyl, such as those described herein. In some embodiments, R 14 can be hydrogen. In other embodiments, R 14 can be methyl. In some embodiments, R 13 can be an optionally substituted C 1-6 alkyl. Examples of optionally substituted C 1-6 -alkyls include optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained) and hexyl (branched and straight-chained). In some embodiments, R 13 can be methyl or isopropyl. In some embodiments, R 13 can be ethyl or neopentyl. In other embodiments, R 13 can be an optionally substituted C 3-6 cycloalkyl. Examples of optionally substituted C 3-6 cycloalkyl include optionally substituted variants of the following: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In some embodiments, R 13 can be an optionally substituted cyclohexyl. In still other embodiments, R 13 can be an optionally substituted aryl, such as phenyl and naphthyl. In yet still other embodiments, R 13 can be an optionally substituted aryl(C 1-6 alkyl). In some embodiments, R 13 can be an optionally substituted benzyl. In some embodiments, R 13 can be an optionally substituted C 1-6 haloalkyl, for example, CF 3 . In some embodiments, R 15 can be hydrogen. In other embodiments, R 15 can be an optionally substituted C 1-4 alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl. In some embodiments, R 15 can be methyl. In some embodiments, R 14 and R 15 can be taken together to form an optionally substituted C 3-6 cycloalkyl. Examples of optionally substituted C 3-6 cycloalkyl include optionally substituted variants of the following: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Depending on the groups that are selected for R 14 and R 15 , the carbon to which R 14 and R 15 are attached may be a chiral center. In some embodiment, the carbon to which R 14 and R 15 are attached may be a (R)-chiral center. In other embodiments, the carbon to which R 14 and R 15 are attached may be a (S)-chiral center.

Examples of suitable

groups include the following:

In some embodiments, R 5B can be an —O-optionally substituted aryl. For example, R 5B can be an —O-optionally substituted phenyl. When the phenyl is substituted, the ring can be substituted 1, 2, 3 or more than 3 times. Suitable mono-substituted phenyl groups include, ortho-substituted phenyl, meta-substituted phenyl and para-substituted phenyl. In other embodiments, R 5B can be an —O-unsubstituted aryl. Alternatively, R 5B can be an —O-optionally substituted naphthyl. In other embodiments, R 5B can be an —O-optionally substituted heteroaryl. For example, R 5B can be an —O-optionally substituted quinolinyl. In still other embodiments, R 5B can be an —O-optionally substituted heterocyclyl.

In some embodiments, R 5B is an optionally substituted N-linked amino acid, such as those described for R 5A . In other embodiments, R 5B is an optionally substituted embodiments, R 5B can have the structure

wherein R 16 can be selected from hydrogen, an optionally substituted C 1-6 -alkyl, an optionally substituted C 3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C 1-6 alkyl) and an optionally substituted haloalkyl; R 17 can be selected from hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 1-6 haloalkyl, an optionally substituted C 3-6 cycloalkyl, an optionally substituted C 6 aryl, an optionally substituted C 10 aryl and an optionally substituted aryl(C 1-6 alkyl); and R 18 can be hydrogen or an optionally substituted C 1-4 -alkyl; or R 17 and R 18 can be taken together to form an optionally substituted C 3-6 cycloalkyl.

When R 17 is substituted, R 17 can be substituted with one or more substituents selected from N-amido, mercapto, alkylthio, an optionally substituted aryl, hydroxy, an optionally substituted heteroaryl, O-carboxy and amino. In some embodiments, R 17 can be an unsubstituted C 1-6 -alkyl, such as those described herein. In some embodiments, R 17 can be hydrogen. In other embodiments, R 17 can be methyl. In some embodiments, R 16 can be an optionally substituted C 1-6 alkyl. Examples of optionally substituted C 1-6 -alkyls include optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained) and hexyl (branched and straight-chained). In some embodiments, R 16 can be methyl or isopropyl. In some embodiments, R 16 can be ethyl or neopentyl. In other embodiments, R 16 can be an optionally substituted C 3-6 cycloalkyl. Examples of optionally substituted C 3-6 cycloalkyl include optionally substituted variants of the following: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In some embodiments, R 16 can be an optionally substituted cyclohexyl. In still other embodiments, R 16 can be an optionally substituted aryl, such as phenyl and naphthyl. In yet still other embodiments, R 16 can be an optionally substituted aryl(C 1-6 alkyl). In some embodiments, R 16 can be an optionally substituted benzyl. In some embodiments, R 16 can be an optionally substituted C 1-6 haloalkyl, for example, CF 3 . In some embodiments, R 18 can be hydrogen. In other embodiments, R 18 can be an optionally substituted C 1-4 -alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl. In some embodiments, R 18 can be methyl. In some embodiments, R 17 and R 18 can be taken together to form an optionally substituted C 3-6 cycloalkyl. Examples of optionally substituted C 3-6 cycloalkyl include optionally substituted variants of the following: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Depending on the groups that are selected for R 17 and R 18 , the carbon to which R 17 and R 18 are attached may be a chiral center. In some embodiment, the carbon to which R 17 and R 18 are attached may be a (R)-chiral center. In other embodiments, the carbon to which R 17 and R 18 are attached may be a (S)-chiral center.

›Definitions · 9 of 25

Examples of suitable

groups include the following:

In some embodiments, R 5A can be an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative and R 5B can be an —O-optionally substituted aryl. In other embodiments, R 5A can be an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative and R 5B can be an —O-optionally substituted heteroaryl. In some embodiments, R 5A can be an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative and R 5A can be an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

In some embodiments, R 5A can be

When R 5A is

R 8A and R 9A can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl and an optionally substituted aryl; and R 10A can be selected from hydrogen, an optionally substituted C 1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O— heteroaryl and an optionally substituted —O-monocyclic heterocyclyl. In some embodiments, R 8A and R 9A can be hydrogen. In other embodiments, at least one of R 8A and R 9A can be an optionally substituted C 1-24 alkyl or an optionally substituted aryl. In some embodiments, R 10A can be hydrogen. In other embodiments, R 10A can be an optionally substituted C 1-24 alkyl. In some embodiments, R 10A can be an unsubstituted C 1-4 alkyl. In still other embodiments, R 10A can be an optionally substituted aryl. In yet still other embodiments, R 10A can be —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O— heteroaryl or an optionally substituted —O-monocyclic heterocyclyl. In some embodiments, R 10A can be an unsubstituted —O—C 1-4 alkyl.

In some embodiments, R 5B can be

When R 5B is

R 8B and R 9B can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl and an optionally substituted aryl; and R 10B can be selected from hydrogen, an optionally substituted C 1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O— heteroaryl and an optionally substituted —O-monocyclic heterocyclyl. In some embodiments, R 8B and R 9B can be hydrogen. In other embodiments, at least one of R 8B and R 9B can be an optionally substituted C 1-24 alkyl or an optionally substituted aryl. In some embodiments, R 10B can be hydrogen. In other embodiments, R 10B can be an optionally substituted C 1-24 alkyl. In some embodiments, R 10B can be an unsubstituted C 1-4 alkyl. In still other embodiments, R 10B can be an optionally substituted aryl. In yet still other embodiments, R 10B can be —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O— heteroaryl or an optionally substituted —O-monocyclic heterocyclyl. In some embodiments, R 10B can be an unsubstituted —O—C 1-4 alkyl. In some embodiments, R 5A can be

and R 5B can be

In some embodiments, R 5A can be

wherein R 11A and R 12A can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl and an optionally substituted aryl; R 13A can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O-heteroaryl and an optionally substituted —O-monocyclic heterocyclyl; and Z 1A can be independently O (oxygen) or S (sulfur). In some embodiments, R 11A and R 12A can be hydrogen. In other embodiments, at least one of R 11A and R 12A can be an optionally substituted C 1-24 alkyl or an optionally substituted aryl. In some embodiments, R 13A can be an optionally substituted C 1-24 alkyl. In some embodiments, R 13A can be an unsubstituted C 1-4 alkyl. In other embodiments, R 13A can be an optionally substituted aryl. In still other embodiments, R 13A can be an optionally substituted —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O— heteroaryl or an optionally substituted —O-monocyclic heterocyclyl. In some embodiments, R 13A can be an unsubstituted —O—C 1-4 alkyl. In some embodiments, Z 1A can be O (oxygen). In other embodiments, Z 1A can be or S (sulfur).

In some embodiments, R 5B can be

wherein R 11B and R 12B can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl and an optionally substituted aryl; R 13B can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O-heteroaryl and an optionally substituted —O-monocyclic heterocyclyl; and Z 1B can be independently O (oxygen) or S (sulfur). In some embodiments, R 11B and R 12B can be hydrogen. In other embodiments, at least one of R 11B and R 12B can be an optionally substituted C 1-24 alkyl or an optionally substituted aryl. In some embodiments, R 13B can be an optionally substituted C 1-24 alkyl. In some embodiments, R 13B can be an unsubstituted C 1-4 alkyl. In other embodiments, R 13B can be an optionally substituted aryl. In still other embodiments, R 13B can be an optionally substituted —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O— heteroaryl or an optionally substituted —O-monocyclic heterocyclyl. In some embodiments, R 13B can be an unsubstituted —O—C 1-4 alkyl. In some embodiments, Z 1B can be O (oxygen). In other embodiments, Z 1B can be or S (sulfur). In some embodiments, R 5A can be

and R 5B can be

In some embodiments, R 5A can be

In some embodiments, R 14A can be hydrogen. In other embodiments, R 14A can be an optionally substituted C 1-24 alkyl. In still other embodiments, R 14A can be an optionally substituted aryl. In some embodiments, R 14A can be a C 1-6 alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained). In some embodiments, p can be 1. In other embodiments, p can be 2.

›Definitions · 10 of 25

In some embodiments, R 5B can be

In some embodiments, R 14B can be hydrogen. In other embodiments, R 14B can be an optionally substituted C 1-24 alkyl. In still other embodiments, R 14B can be an optionally substituted aryl. In some embodiments, R 14B can be a C 1-6 alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained). In some embodiments, q can be 1. In other embodiments, q can be 2. In some embodiments, R 5A can be

and R 5B can be

In some embodiments, R 5A can be

In some embodiments, R 15A can be hydrogen. In other embodiments, R 15A can be an optionally substituted C 1-24 alkyl. In still other embodiments, R 15A can be an optionally substituted aryl, for example, an optionally substituted phenyl. In some embodiments, R 15A can be an optionally substituted C 1-6 alkyl. In some embodiments, R 15A can be an unsubstituted C 1-6 alkyl. In some embodiments, s can be 3. In other embodiments, s can be 4. In still other embodiments, s can be 5.

In some embodiments, R 5B can be

In some embodiments, R 15B can be hydrogen. In other embodiments, R 15B can be an optionally substituted C 1-24 alkyl. In still other embodiments, R 15B can be an optionally substituted aryl, for example, an optionally substituted phenyl. In some embodiments, R 15B can be an optionally substituted C 1-6 alkyl. In some embodiments, R 15B can be an unsubstituted C 1-6 alkyl. In some embodiments, t can be 3. In other embodiments, t can be 4. In still other embodiments, t can be 5. In some embodiments, R 5A can be

and R 5B can be

In some embodiments, R 5A and/or R 5B can be isopropyloxycarbonyloxymethoxy (POC) group. In some embodiments, R 5A and/or R 5B can be pivaloyloxymethoxy (POM) group. In some embodiments, R 5A and R 5B can be both a isopropyloxycarbonyloxymethoxy (POC) group, and form a bis(isopropyloxycarbonyloxymethoxy) (bis(POC)) prodrug. In other embodiments, R 5A and R 5B can be both a pivaloyloxymethoxy (POM) group, and form a bis(pivaloyloxymethoxy) (bis(POM)) prodrug. In still other embodiments, R 5A and R 5B can be both a S-acylthioethyl (SATE)-O— group and form a SATE ester prodrug. In some embodiments, R 5A and R 5B can be the same. In other embodiments, R 5A and R 5B can be different.

In some embodiments, both -------- can be each a single bond; R 4 can be absent; R 3 can be oxygen (O); and R p can be

wherein Z p can be oxygen (O) or sulfur (S) and R p1 can be selected from O − , OH, an —O-optionally substituted C 1-6 alkyl.

an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative. When both ------ are each a single bond, Formula (I) can have the structure:

In some embodiments, R p1 can be O − . In other embodiments, R p1 can be OH. In other embodiments, R p1 can be an —O-optionally substituted C 1-6 alkyl. For example, R p1 can be a substituted or an unsubstituted version of the following: methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy, pentoxy (branched or straight chained) and hexoxy (branched or straight chained).

In some embodiments, R p1 can be

wherein R p2 and R p3 can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl and an optionally substituted aryl; and R p4 can be selected from hydrogen, an optionally substituted C 1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O-heteroaryl and an optionally substituted —O-monocyclic heterocyclyl. In some embodiments, R p2 and R p3 can be hydrogen. In other embodiments, at least one of R p2 and R p3 can be an optionally substituted C 1-24 alkyl or an optionally substituted aryl. In some embodiments, R p4 can be an optionally substituted C 1-24 alkyl. In some embodiments, R p4 can be an unsubstituted C 1-4 alkyl. In other embodiments, R p4 can be an optionally substituted aryl. In still other embodiments, R p4 can be an optionally substituted —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O-heteroaryl or an optionally substituted —O-monocyclic heterocyclyl. In some embodiments, R p4 can be an unsubstituted —O—C 1-4 alkyl.

In some embodiments, R p1 can be

wherein R p and R p6 can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl and an optionally substituted aryl; R p7 can be independently selected from hydrogen, an optionally substituted C 1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O-heteroaryl and an optionally substituted —O-monocyclic heterocyclyl; and Z p1 can be independently O (oxygen) or S (sulfur). In some embodiments, R p5 and R p6 can be hydrogen. In other embodiments, at least one of R p5 and R p6 can be an optionally substituted C 1-24 alkyl or an optionally substituted aryl. In some embodiments, R p7 can be an optionally substituted C 1-24 alkyl. In some embodiments, R p7 can be an unsubstituted C 1-4 alkyl. In other embodiments, R p7 can be an optionally substituted aryl. In still other embodiments, R p7 can be an optionally substituted —O—C 1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O— heteroaryl or an optionally substituted —O-monocyclic heterocyclyl. In some embodiments, R p7 can be an unsubstituted —O—C 1-4 alkyl. In some embodiments, Z p1 can be O (oxygen). In other embodiments, Z p1 can be or S (sulfur). In some embodiments, R p1 can be isopropyloxycarbonyloxymethyloxy (POC) group. In some embodiments, R p1 can be pivaloyloxymethyloxy (POM) group.

In some embodiments, R p1 can be

In some embodiments, R p8 can be hydrogen. In other embodiments, R p8 can be an optionally substituted C 1-24 alkyl. In still other embodiments, R p8 can be an optionally substituted aryl. In some embodiments, R p8 can be a C 1-6 alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained). In some embodiments, r can be 1. In other embodiments, r can be 2.

›Definitions · 11 of 25

In some embodiments, R p1 can be

In some embodiments, R p9 can be hydrogen. In other embodiments, R p9 can be an optionally substituted C 1-24 alkyl. In still other embodiments, R p9 can be an optionally substituted aryl, for example, an optionally substituted phenyl. In some embodiments, R p9 can be an optionally substituted C 1-6 alkyl. In some embodiments, R p9 can be an unsubstituted C 1-6 alkyl. In some embodiments, u can be 3. In other embodiments, u can be 4. In still other embodiments, u can be 5. In some embodiments, R p1 can be a S-acylthioethyl (SATE) group and form a SATE ester prodrug.

In some embodiments, R p1 can be an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative. For example, R p1 can be optionally substituted version of the following: alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof. In some embodiments, R p1 can be selected from N-alanine isopropyl ester, N-alanine cyclohexyl ester, N-alanine neopentyl ester, N-valine isopropyl ester and N-leucine isopropyl ester. In some embodiments, R p1 can have the structure

wherein R p10 can be selected from hydrogen, an optionally substituted C 1-6 -alkyl, an optionally substituted C 3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C 1-6 alkyl) and an optionally substituted haloalkyl; R p11 can be selected from hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 1-6 haloalkyl, an optionally substituted C 3-6 cycloalkyl, an optionally substituted C 6 aryl, an optionally substituted C 10 aryl and an optionally substituted aryl(C 1-6 alkyl); and R p12 can be hydrogen or an optionally substituted C 1-4 -alkyl; or R p11 and R p12 can be taken together to form an optionally substituted C 3-6 cycloalkyl.

When R p11 is substituted, R p11 can be substituted with one or more substituents selected from N-amido, mercapto, alkylthio, an optionally substituted aryl, hydroxy, an optionally substituted heteroaryl, O-carboxy, and amino. In some embodiments, R p11 can be an unsubstituted C 1-6 -alkyl, such as those described herein. In some embodiments, R p11 can be hydrogen. In other embodiments, R p1 can be methyl. In some embodiments, R p10 can be an optionally substituted C 1-6 alkyl. Examples of optionally substituted C 1-6 -alkyls include optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained). In some embodiments, R p10 can be methyl or isopropyl. In some embodiments, R p10 can be ethyl or neopentyl. In other embodiments, R p10 can be an optionally substituted C 3-6 cycloalkyl. Examples of optionally substituted C 3-6 cycloalkyl include optionally substituted variants of the following: cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In some embodiments, R p10 can be an optionally substituted cyclohexyl. In still other embodiments, R p10 can be an optionally substituted aryl, such as phenyl and naphthyl. In yet still other embodiments, R p10 can be an optionally substituted aryl(C 1-6 alkyl). In some embodiments, R p10 can be an optionally substituted benzyl. In some embodiments, R p10 can be an optionally substituted C 1-6 haloalkyl, for example, CF 3 . In some embodiments, R p12 can be hydrogen. In other embodiments, R p12 can be an optionally substituted C 1-4 -alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl. In some embodiments, R p12 can be methyl. In some embodiments, R p11 and R p12 can be taken together to form an optionally substituted C 3-6 cycloalkyl. Examples of optionally substituted C 3-6 cycloalkyl include optionally substituted variants of the following: cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Depending on the groups that are selected for R p11 and R p12 , the carbon to which R p11 and R p12 are attached may be a chiral center. In some embodiment, the carbon to which R p11 and R p12 are attached may be a (R)-chiral center. In other embodiments, the carbon to which R p11 and R p12 are attached may be a (S)-chiral center.

Examples of suitable

groups include the following:

The nucleobase can vary. In some embodiments, B 1 can be uracil. In some embodiments, B 1 can be an optionally substituted

In some embodiments, B 1 can be unsubstituted

In other embodiments, B 1 can be an optionally substituted

In some embodiments, B 1 can be unsubstituted

In some embodiments, R 6A can be an optionally substituted C 1-6 alkyl. For example, R 6A can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained) or hexyl (branched and straight-chained). In other embodiments, R 6A can be an optionally substituted C 3-6 cycloalkyl, for example, optionally substituted variants of the following: cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

In some embodiments, B 1 can be guanine. In some embodiments, B 1 can be an optionally substituted

In other embodiments, B 1 can be an optionally substituted

wherein R 6B can be selected from hydrogen, an unsubstituted C 1-6 alkyl, an unsubstituted C 3-6 alkenyl, an unsubstituted C 3-6 alkynyl and an unsubstituted C 3-6 cycloalkyl. In some embodiments, B 1 can be unsubstituted

In some embodiments, R 6B can be an unsubstituted C 1-6 alkyl. For example, R 6B can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained) or hexyl (branched and straight-chained). In some embodiments, R 6B can be an unsubstituted C 3-6 alkenyl. In other embodiments, R 6B can be an unsubstituted C 3-6 alkynyl. In still other embodiments, R 6B can be an unsubstituted C 3-6 cycloalkyl, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

In some embodiments, B 1 can be an optionally substituted

›Definitions · 12 of 25

wherein R 6C can be selected from hydrogen, an unsubstituted C 1-6 alkyl, an unsubstituted C 3-6 alkenyl, an unsubstituted C 3-6 alkynyl and an unsubstituted C 3-6 cycloalkyl. In some embodiments, B 1 can be unsubstituted

In some embodiments, R 6C can be hydrogen. In some embodiments, R 6C can be an unsubstituted C 1-6 alkyl. For example, R 6C can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained) or hexyl (branched and straight-chained). In some embodiments, R 6C can be an ethyl. In some embodiments, R 6C can be an unsubstituted C 3-6 alkenyl. In other embodiments, R 6C can be an unsubstituted C 3-6 alkynyl. In other embodiments, R 6C can be an unsubstituted C 3-6 cycloalkyl, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

In some embodiments, B 1 can be adenine. In some embodiments, B 1 can be an optionally substituted

wherein X 1 can be N (nitrogen) or —CR 6J ; R 6J can be selected from hydrogen, halogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 2-6 alkenyl and an optionally substituted C 2-6 alkynyl; R 6D can be NHR 6G ; R 6E can be hydrogen, halogen or NHR 6H ; R 6G can be selected from hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 3-6 alkenyl, an optionally substituted C 3-6 cycloalkyl, —C(═O)R A1 and —C(═O)OR A2 ; R 6H can be selected from hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 3-6 alkenyl, an optionally substituted C 3-6 cycloalkyl, —C(═O)R A3 and —C(═O)OR A4 ; R A1 , R A2 , R A3 and R A4 can be independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 6-10 aryl, heteroaryl, heterocyclyl, aryl(C 1-6 alkyl), heteroaryl(C 1-6 alkyl) and heterocyclyl(C 1-6 alkyl). In some embodiments, X 1 can be N (nitrogen). In other embodiments, X 1 can be —CR 6I , wherein CR 6I can be selected from hydrogen, halogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 2-6 alkenyl and an optionally substituted C 2-6 alkynyl. In some embodiments, X 1 can be CH. In some embodiments, R 6D and R 6E can be both NH 2 . In other embodiments, at least one of R 6D and R 6E can be NH 2 . In some embodiments, R 6D can be NHR 6G , wherein R 6G can be an optionally substituted C 1-6 alkyl. In some embodiments, R 6E can be hydrogen. In other embodiments, R 6E can be halogen. In still other embodiments, R 6E can be NHR 6H , wherein R 6H can be an optionally substituted C 1-6 alkyl. In other embodiments, R 6D can be NHR 6G , wherein R 6G can be selected from an optionally substituted C 3-6 alkenyl, an optionally substituted C 3-6 cycloalkyl, —C(═O)R A1 and —C(═O)OR A2 . In other embodiments, R 6E can be NHR 6H , wherein R 6H can be selected from an optionally substituted C 3-6 alkenyl, an optionally substituted C 3-6 cycloalkyl, —C(═O)R A3 and —C(═O)OR A4 . In some embodiments, R 6D and R 6E can be the same. In other embodiments, R 6D and R 6E can be different.

In some embodiments, B 1 can be cytosine. In some embodiments, B 1 can be an optionally substituted

wherein R 6F can be NHR 6I ; R 6I can be selected hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 3-6 alkenyl, an optionally substituted C 3-6 cycloalkyl, —C(═O)R A5 and —C(═O)OR A6 ; and R A5 and R A6 are independently selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 6-10 aryl, heteroaryl, heterocyclyl, aryl(C 1-6 alkyl), heteroaryl(C 1-6 alkyl) and heterocyclyl(C 1-6 alkyl). In some embodiments, R 6F can be NH 2 . In other embodiments, R 6F can be NHR 6I , wherein R 6I can be an optionally substituted C 1-6 alkyl, an optionally substituted C 3-6 alkenyl or an optionally substituted C 3-6 cycloalkyl. In still other embodiments, R 6F can be NHR 6I , wherein R 6I can be —C(═O)R A5 or —C(═O)OR A6 . When R 6I is —C(═O)R A5 or —C(═O)OR A6 , R A5 and R A6 can be C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl. R A5 and R A6 can also be C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 6-10 aryl or heteroaryl, heterocyclyl. Additionally, R A5 and R A6 can be aryl(C 1-6 alkyl), heteroaryl(C 1-6 alkyl) or heterocyclyl(C 1-6 alkyl).

In some embodiments, Z 1 can be O (oxygen). In other embodiments, Z 1 can be S (sulfur).

In some embodiments, R 2 is not halo. In some embodiments, R 2 is not fluoro. In some embodiments, R 5B is not an —O-optionally substituted aryl. In some embodiments, R 5B is not an —O-unsubstituted aryl. In some embodiments, R 5A is not N-alanine isopropyl ester. In some embodiments, R 1 is not an optionally substituted C 1-6 alkyl. For example, R 1 is not an unsubstituted C 1-6 alkyl, such as methyl. In some embodiments, B 1 is not an optionally substituted uracil, for example, a halo-substituted uracil. In some embodiment, when both -------- are each absent; R p is absent; R 3 is OH or —OC(═O)R 8 ; R 2 is F; and R 1 is methyl, ethyl or ethenyl; then R 4 cannot be selected from H and

wherein R 5B is an —O-unsubstituted aryl; R 5A is

and Z 1 is oxygen. In some embodiments, R 2 is not halo (such as fluoro) when B 1 is uracil. In some embodiments, a compound of Formula (I) is not a compound in WO 2013/092481 (filed Dec. 17, 2012).

Example structures of a compound of Formula (I) include the following:

or a pharmaceutically acceptable salt of the foregoing. In some embodiments of this paragraph, R 3 can be OH. In some embodiments of this paragraph, R 6C can be an unsubstituted C 1-6 alkyl, such as CH 2 CH 3 . In some embodiments of this paragraph, R p1 can be —O-unsubstituted C 1-6 alkyl. In some embodiments, of this paragraph, R 4 can be H. In other embodiments, of this paragraph, R 4 can be a phosphoroamidate group. In still other embodiments, of this paragraph, R 4 can be a phosphate group (such as a mono-, di- or tri-phosphate). In yet still other embodiments, of this paragraph, R 4 can be a thiophosphoroamidate group. In some embodiments, of this paragraph, R 4 can be thiophosphate group (such as an alpha-thiomono-, alpha-thiodi- or alpha-thiotri-phosphate). In some embodiments of this paragraph, R p1 can be —O-ethyl, —O— isopropyl or —O-isobutyl.

›Definitions · 13 of 25

Examples of compounds of Formula (I) include the following:

or a pharmaceutically acceptable salt of the foregoing.

Additional examples of compounds of Formula (I) include the following:

or a pharmaceutically acceptable salt of the foregoing.

Still further examples of compounds of Formula (I) include the following:

or a pharmaceutically acceptable salt of the foregoing.

Examples of compounds of Formula (I) include the following:

or a pharmaceutically acceptable salt of the foregoing.

Further examples of compounds of Formula (I) include the following:

or a pharmaceutically acceptable salt of the foregoing.

Further examples of compounds of Formula (I) include the following:

or a pharmaceutically acceptable salt of the foregoing.

Additional examples of compounds of Formula (I) include the following:

or a pharmaceutically acceptable salt of the foregoing

In some embodiments, a compound of Formula (I) cannot be selected from:

or a pharmaceutically acceptable salt of the foregoing.

As described herein, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have R 4 being

R 5A being an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative; and R 5B being an —O-optionally substituted aryl, an —O-optionally substituted heteroaryl, an —O-optionally substituted heterocyclyl, an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative. By neutralizing the charge on the phosphate or thiophosphate, penetration of the cell membrane may be facilitated as a result of the increased lipophilicity of the compound. Once absorbed and taken inside the cell, the groups attached to the phosphorus can be easily removed by esterases, proteases and/or other enzymes. In some embodiments, the groups attached to the phosphorus can be removed by simple hydrolysis. Inside the cell, the phosphate thus released may then be metabolized by cellular enzymes to the diphosphate or the active triphosphate. Likewise, the thio-phosphate may be metabolized to the alpha-thiodiphosphate or the alpha-thiotriphosphate. Furthermore, in some embodiments, varying the substituents on a compound described herein, such as compound of Formula (I), can help maintain the efficacy of such the compound by reducing undesirable effects, such as isomerization.

In some embodiments, the phosphorylation of a thio-monophosphate of a compound of Formula (I), or pharmaceutically acceptable salt thereof, can be stereoselective. For example, a thio-monophosphate of a compound of Formula (I) can be phosphorylated to give an alpha-thiodiphosphate and/or an alpha-thiotriphosphate compound that can be enriched in the (R) or (S) diastereomer with respect to the 5′-O-phosphorous atom. For example, one of the (R) and (S) configuration with respect to the 5′-O-phosphorous atom of the alpha-thiodiphosphate and/or the alpha-thiotriphosphate compound can be present in an amount >50%, ≥75%, ≥90%, ≥95% or ≥99% compared to the amount of the other of the (R) or (S) configuration with respect to the 5′-O-phosphorous atom. In some embodiments, phosphorylation of a compound of Formula (I), or pharmaceutically acceptable salt thereof, can result in the formation of a compound that has the (R)-configuration at the 5′-O-phosphorous atom. In some embodiments, phosphorylation of a compound of Formula (I), or pharmaceutically acceptable salt thereof, can result in formation of a compound that has the (S)-configuration at the 5′-O-phosphorous atom.

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can act as a chain terminator of HCV replication. For example, compounds of Formula (I) can contain a moiety at the 2′-carbon position such that once the compound is incorporated into an RNA chain of HCV no further elongation is observed to occur. For example, a compound of Formula (I) can contain a 2′-carbon modification wherein R 1 is a non-hydrogen group selected from an optionally substituted C 1-6 alkyl, an optionally substituted C 2-6 alkenyl, an optionally substituted C 2-6 alkynyl and an optionally substituted C 3-6 cycloalkyl.

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have increased metabolic and/or plasma stability. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be more resistant to hydrolysis and/or more resistant to enzymatic transformations. For example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have increased metabolic stability, increased plasma stability, can be more resistant to hydrolysis and/or can be more resistant to enzymatic transformations compared to a compound that is identical in structure but for having a hydrogen in place of the fluoro at the 4′-position. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have improved properties. A non-limiting list of example properties include, but are not limited to, increased biological half-life, increased bioavailability, increase potency, a sustained in vivo response, increased dosing intervals, decreased dosing amounts, decreased cytotoxicity, reduction in required amounts for treating disease conditions, reduction in viral load, reduction in time to seroconversion (i.e., the virus becomes undetectable in patient serum), increased sustained viral response, a reduction of morbidity or mortality in clinical outcomes, increased subject compliance, decreased liver conditions (such as liver fibrosis, liver cirrhosis and/or liver cancer), and compatibility with other medications. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have a biological half-life of greater than 24 hours. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have a biological half-life greater than a compound that is identical in structure but for having a hydrogen in place of the fluoro at the 4′-position. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have more potent antiviral activity (for example, a lower EC 50 in an HCV replicon assay) as compared to the current standard of care. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, does not significantly inhibit mitochondrial function of the mitochondrial RNA polymerase. For example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is incorporated in the human mitochondrial RNA polymerase less than 10% compared to the natural 5′-triphosphate nucleotide with the same B 1 .

›Definitions · 14 of 25

Additionally, in some embodiments, the presence of a thiophosphoroamidate, phosphoroamidate, thiophosphorbisamidate or phosphorbisamidate in a compound of Formula (I) can increase the stability of the compound by inhibiting its degradation. Also, in some embodiments, the presence of a thiophosphoroamidate, phosphoroamidate, thiophosphorbisamidate or phosphorbisamidate can make the compound more resistant to cleavage in vivo and provide sustained, extended efficacy. In some embodiments, a thiophosphoroamidate, phosphoroamidate, thiophosphorbisamidate or phosphorbisamidate can facilitate the penetration of the cell membrane by a compound of Formula (I) by making the compound more lipophilic. In some embodiments, a thiophosphoroamidate, phosphoroamidate, thiophosphorbisamidate or phosphorbisamidate can have improved oral bioavailability, improved aqueous stability and/or reduced risk of byproduct-related toxicity. In some embodiments, for comparison purposes, a compound of Formula (I) can be compared to a compound that is identical in structure but for having a hydrogen in place of the fluoro at the 4′-position.

Synthesis

Compounds of Formula (I) and those described herein may be prepared in various ways. General synthetic routes to the compound of Formula (I), and some examples of starting materials used to synthesize the compounds of Formula (I) are shown in Scheme 1 and 2, and described herein. The routes shown and described herein are illustrative only and are not intended, nor are they to be construed, to limit the scope of the claims in any manner whatsoever. Those skilled in the art will be able to recognize modifications of the disclosed syntheses and to devise alternate routes based on the disclosures herein; all such modifications and alternate routes are within the scope of the claims.

Compounds of Formula (I) can be prepared using various methods known to those skilled in the art. Examples of methods are shown in Schemes 1 and 2. Suitable phosphorus containing precursors can be commercially obtained or prepared by synthetic methods known to those skilled in the art. Examples of general structures of phosphorus containing precursors are shown in Schemes 1 and 2, and include phosphorochloridates and thiophosphorochloridates. Suitable phosphorochloridates and thiophosphorochloridates are commercially available and/or can be synthetically prepared.

One method for forming a compound of Formula (I) is shown in Scheme 1. In Scheme 1, R 1a , R 2a , R 3a and B 1a can be the same as R 1 , R 2 , R 3 and B 1 as described herein for Formula (I). In some embodiments, a compound of Formula (I) can be generated from a compound of Formula (A) and a compound of Formula (B) or a compound of Formula (A) and a compound of Formula (C) using an organometallic reagent, such as a Grignard reagent. Suitable Grignard reagents are known to those skilled in the art and include, but are not limited to, alkylmagnesium chlorides and alkylmagnesium bromides. In other embodiments, an appropriate base can be used to form a compound of Formula (I). Examples of suitable bases include, but are not limited to, an amine base, such as an alkylamine (including mono-, di- and tri-alkylamines (e.g., triethylamine)), optionally substituted pyridines (e.g. collidine) and optionally substituted imidazoles (e.g., N-methylimidazole)).

When compounds of Formula (I) has Z 1 being sulfur, the sulfur can be added in various manners. In some embodiments, the sulfur can be part of the phosphorus containing precursor, for example,

Alternatively, one of the oxygens attached to the phosphorus can be exchanged with a sulfur using a sulfurization reagent. Suitable sulfurization agents are known to those skilled in the art, and include, but are not limited to, elemental sulfur, Lawesson's reagent, cyclooctasulfur, 3H-1,2-Benzodithiole-3-one-1,1-dioxide (Beaucage's reagent), 3-((N,N-dimethylaminomethylidene)amino)-3H-1,2,4-dithiazole-5-thione (DDTT) and bis(3-triethoxysilyl)propyl-tetrasulfide (TEST).

A phosphorus containing precursor can be coupled to the nucleoside, for example, a compound of Formula (A). Following the coupling of the phosphorus containing precursor, any leaving groups can be cleaved under suitable conditions, such as hydrolysis. In Scheme 2, R 1a , R 2a , R 3a and B 1a can be the same as R 1 , R 2 , R 3 and B 1 as described herein for Formula (I). Further phosphorus containing groups can be added using methods known to those skilled in the art, for example using a pyrophosphate. If desired, one or more bases can be used during the addition of each phosphorus-containing group. Examples of suitable bases are described herein.

As described herein, in some embodiments, R 2 and R 3 can be each an oxygen atom, wherein the oxygen atoms are linked together by a carbonyl groups. The —O—C(═O)—O— group can be formed using methods known to those skilled in the art. For example, a compound of Formula (I), wherein R 2 and R 3 are both hydroxy groups, can be treated with 1,1′-carbonyldiimidazole (CDI).

In some embodiments, R 2 and/or R 3 can be —OC(═O)R 12 and —OC(═O)R 8 , respectively. The —OC(═O)R 12 and —OC(═O)R 8 groups can be formed at the 2′- and 3′-positions using various methods known to those skilled in the art. As an example, a compound of Formula (I), wherein R 2 and R 3 are both hydroxy groups, can be treated with an alkyl anhydride (e.g., acetic anhydride and propionic anhydride) or an alkyl acid chloride (e.g., acetylchloride). If desired, a catalyst can be used to facilitate the reaction. An example of suitable catalyst is 4-dimethylaminopyridine (DMAP). Alternatively, the —OC(═O)R 12 and —OC(═O)R 8 groups can be formed at the 2′- and 3′-positions by reacting an alkyl acid (e.g. acetic acid and propionic acid) in the presences of a carbodiimide or a coupling reagent. Examples of carbodiimides include, but are not limited to, N,N′-dicyclohexylcarbodiimide (DCC), N,N′-diisopropylcarbodiimide (DIC) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).

›Definitions · 15 of 25

To reduce the formation of side products, one or more the groups attached to the pentose ring can be protected with one or more suitable protecting groups. As an example, if R 2 and/or R 3 is/are hydroxy group(s), the hydroxy group(s) can be protected with suitable protecting groups, such as triarylmethyl and/or silyl groups. Examples of triarylmethyl groups include but are not limited to, trityl, monomethoxytrityl (MMTr), 4,4′-dimethoxytrityl (DMTr), 4,4′,4″-trimethoxytrityl (TMTr), 4,4′,4″-tris-(benzoyloxy) trityl (TBTr), 4,4′,4″-tris (4,5-dichlorophthalimido) trityl (CPTr), 4,4′,4″-tris (levulinyloxy) trityl (TLTr), p-anisyl-1-naphthylphenylmethyl, di-o-anisyl-1-naphthylmethyl, p-tolyldipheylmethyl, 3-(imidazolylmethyl)-4,4′-dimethoxytrityl, 9-phenylxanthen-9-yl (Pixyl), 9-(p-methoxyphenyl) xanthen-9-yl (Mox), 4-decyloxytrityl, 4-hexadecyloxytrityl, 4,4′-dioctadecyltrityl, 9-(4-octadecyloxyphenyl) xanthen-9-yl, 1,1′-bis-(4-methoxyphenyl)-1′-pyrenylmethyl, 4,4′,4″-tris-(tert-butylphenyl) methyl (TTTr) and 4,4′-di-3,5-hexadienoxytrityl. Examples of suitable silyl groups are described herein and include trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), triisopropylsilyl (TIPS), tert-butyldiphenylsilyl (TBDPS), tri-iso-propylsilyloxymethyl and [2-(trimethylsilyl)ethoxy]methyl. Alternatively, R 2 and/or R 3 can be protected by a single achiral or chiral protecting group, for example, by forming an orthoester, a cyclic acetal or a cyclic ketal. Suitable orthoesters include methoxymethylene acetal, ethoxymethylene acetal, 2-oxacyclopentylidene orthoester, dimethoxymethylene orthoester, 1-methoxyethylidene orthoester, 1-ethoxyethylidene orthoester, methylidene orthoester, phthalide orthoester 1,2-dimethoxyethylidene orthoester, and alpha-methoxybenzylidene orthoester; suitable cyclic acetals include methylene acetal, ethylidene acetal, t-butylmethylidene acetal, 3-(benzyloxy)propyl acetal, benzylidene acetal, 3,4-dimethoxybenzylidene acetal and p-acetoxybenzylidene acetal; and suitable cyclic ketals include 1-t-butylethylidene ketal, 1-phenylethylidene ketal, isopropylidene ketal, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal and 1-(4-methoxyphenyl)ethylidene ketal.

Pharmaceutical Compositions

Some embodiments described herein relates to a pharmaceutical composition, that can include an effective amount of one or more compounds described herein (e.g., a compound of Formula (I)), or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof. In some embodiments, the pharmaceutical composition can include a single diastereomer of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, (for example, a single diastereomer is present in the pharmaceutical composition at a concentration of greater than 99% compared to the total concentration of the other diastereomers). In other embodiments, the pharmaceutical composition can include a mixture of diastereomers of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. For example, the pharmaceutical composition can include a concentration of one diastereomer of >50%, ≥60%, ≥70%, ≥80%, ≥90%, ≥95%, or ≥98%, as compared to the total concentration of the other diastereomers. In some embodiments, the pharmaceutical composition includes a 1:1 mixture of two diastereomers of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The term “pharmaceutical composition” refers to a mixture of one or more compounds disclosed herein with other chemical components, such as diluents or carriers. The pharmaceutical composition facilitates administration of the compound to an organism. Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and salicylic acid. Pharmaceutical compositions will generally be tailored to the specific intended route of administration. A pharmaceutical composition is suitable for human and/or veterinary applications.

The term “physiologically acceptable” defines a carrier, diluent or excipient that does not abrogate the biological activity and properties of the compound.

As used herein, a “carrier” refers to a compound that facilitates the incorporation of a compound into cells or tissues. For example, without limitation, dimethyl sulfoxide (DMSO) is a commonly utilized carrier that facilitates the uptake of many organic compounds into cells or tissues of a subject.

As used herein, a “diluent” refers to an ingredient in a pharmaceutical composition that lacks pharmacological activity but may be pharmaceutically necessary or desirable. For example, a diluent may be used to increase the bulk of a potent drug whose mass is too small for manufacture and/or administration. It may also be a liquid for the dissolution of a drug to be administered by injection, ingestion or inhalation. A common form of diluent in the art is a buffered aqueous solution such as, without limitation, phosphate buffered saline that mimics the composition of human blood.

As used herein, an “excipient” refers to an inert substance that is added to a pharmaceutical composition to provide, without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability etc., to the composition. A “diluent” is a type of excipient.

The pharmaceutical compositions described herein can be administered to a human patient per se, or in pharmaceutical compositions where they are mixed with other active ingredients, as in combination therapy, or carriers, diluents, excipients or combinations thereof. Proper formulation is dependent upon the route of administration chosen. Techniques for formulation and administration of the compounds described herein are known to those skilled in the art.

The pharmaceutical compositions disclosed herein may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tableting processes. Additionally, the active ingredients are contained in an amount effective to achieve its intended purpose. Many of the compounds used in the pharmaceutical combinations disclosed herein may be provided as salts with pharmaceutically compatible counterions.

›Definitions · 16 of 25

Multiple techniques of administering a compound exist in the art including, but not limited to, oral, rectal, topical, aerosol, injection and parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, intrathecal, direct intraventricular, intraperitoneal, intranasal and intraocular injections.

One may also administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into the infected area, often in a depot or sustained release formulation. Furthermore, one may administer the compound in a targeted drug delivery system, for example, in a liposome coated with a tissue-specific antibody. The liposomes will be targeted to and taken up selectively by the organ.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Compositions that can include a compound described herein formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.

Methods of Use

Some embodiments disclosed herein relate to a method of treating and/or ameliorating a disease or condition that can include administering to a subject an effective amount of one or more compounds described herein, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound described herein, or a pharmaceutically acceptable salt thereof. Other embodiments disclosed herein relate to a method of treating and/or ameliorating a disease or condition that can include administering to a subject identified as suffering from the disease or condition an effective amount of one or more compounds described herein, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound described herein, or a pharmaceutically acceptable salt thereof.

Some embodiments disclosed herein relates to a method of ameliorating or treating a HCV infection that can include administering to a subject identified as suffering from a HCV infection an effective amount of one or more compounds described herein (for example, a compound of Formula (I)), or a pharmaceutical composition that includes one or more compounds described herein, or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, in the manufacture of a medicament for ameliorating and/or treating a HCV infection that can include administering to a subject identified as suffering from a HCV infection an effective amount of one or more compounds described herein. Still other embodiments described herein relate to one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, that can be used for ameliorating and/or treating a HCV infection by administering to a subject identified as suffering from a HCV infection an effective amount of one or more compounds described herein.

Some embodiments disclosed herein relate to methods of ameliorating and/or treating a HCV infection that can include contacting a cell infected with the hepatitis C virus with an effective amount of one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, or a pharmaceutical composition that includes one or more compounds described herein, or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, in the manufacture of a medicament for ameliorating and/or treating a HCV infection that can include contacting a cell infected with the hepatitis C virus with an effective amount of said compound(s). Still other embodiments described herein relate to one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, that can be used for ameliorating and/or treating a HCV infection by contacting a cell infected with the hepatitis C virus with an effective amount of said compound(s).

Some embodiments disclosed herein relate to methods of inhibiting replication of a hepatitis C virus that can include contacting a cell infected with the hepatitis C virus with an effective amount of one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, or a pharmaceutical composition that includes one or more compounds described herein, or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, in the manufacture of a medicament for inhibiting replication of a hepatitis C virus that can include contacting a cell infected with the hepatitis C virus with an effective amount of said compound(s). Still other embodiments described herein relate to a compound described herein, or a pharmaceutically acceptable salt of a compound described herein, that can be used for inhibiting replication of a hepatitis C virus by contacting a cell infected with the hepatitis C virus with an effective amount of said compound(s).

›Definitions · 17 of 25

In some embodiments, the compound can be a compound of Formula (I), or a pharmaceutical acceptable salt thereof, wherein R 4 is hydrogen. In other embodiments, the compound can be a compound of Formula (I), wherein compound of Formula (I) is a mono, di, or triphosphate, or a pharmaceutically acceptable salt of the foregoing. In still other embodiments, the compound can be a compound of Formula (I), wherein compound of Formula (I) is a thiomonophosphate, alpha-thiodiphosphate, or alpha-thiotriphosphate, or a pharmaceutically acceptable salt of the foregoing. In yet still other embodiments, the compound can be a compound of Formula (I), wherein compound of Formula (I) is phosphoroamidate or phosphorbisamidate, or a pharmaceutically acceptable salt of the foregoing. In some embodiments, the compound can be a compound of Formula (I), wherein compound of Formula (I) is thiophosphoroamidate or thiophosphorbisamidate, or a pharmaceutically acceptable salt of the foregoing. In some embodiments, the compound of Formula (I), or a pharmaceutical acceptable salt thereof, that can be used for ameliorating and/or treating a viral infection (for example, a HCV infection) and/or inhibit replication of a virus (such as a HCV virus) can be any of the embodiments provided in any of the embodiments described above beginning at the first paragraph after the section heading entitled “Compounds” and ending with the sentence: “In some embodiments, a compound of Formula (I) cannot be selected from:

or a pharmaceutically acceptable salt of the foregoing.

HCV is an enveloped positive strand RNA virus in the Flaviviridae family. There are various nonstructural proteins of HCV, such as NS2, NS3, NS4, NS4A, NS4B, NS5A and NS5B. NS5B is believed to be an RNA-dependent RNA polymerase involved in the replication of HCV RNA.

Some embodiments described herein relate to a method of inhibiting NS5B polymerase activity that can include contacting a cell infected with hepatitis C virus with an effective amount of a compound of Formula (I), or a pharmaceutical acceptable salt thereof. Some embodiments described herein relate to a method of inhibiting NS5B polymerase activity that can include administering to a subject infected with hepatitis C virus an effective amount of a compound of Formula (I), or a pharmaceutical acceptable salt thereof. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can inhibit a RNA dependent RNA polymerase, and thus, inhibit the replication of HCV RNA. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can inhibit a HCV polymerase (for example, NS5B polymerase).

Some embodiments described herein relate to a method of treating a condition selected from liver fibrosis, liver cirrhosis and liver cancer in a subject suffering from one or more of the aforementioned liver conditions that can include administering to the subject an effective amount of a compound or a pharmaceutical composition described herein (for example, a compound of Formula (I), or a pharmaceutical acceptable salt thereof), wherein the liver condition is caused by a HCV infection. Some embodiments described herein relate to a method of increasing liver function in a subject having a HCV infection that can include administering to the subject an effective amount of a compound or a pharmaceutical composition described herein (for example, a compound of Formula (I), or a pharmaceutical acceptable salt thereof). Also contemplated is a method for reducing or eliminating further virus-caused liver damage in a subject having an HCV infection by administering to the subject an effective amount of a compound or a pharmaceutical composition described herein (for example, a compound of Formula (I), or a pharmaceutical acceptable salt thereof). In some embodiments, this method can include slowing or halting the progression of liver disease. In other embodiments, the course of the disease can be reversed, and stasis or improvement in liver function is contemplated. In some embodiments, liver fibrosis, liver cirrhosis and/or liver cancer can be treated; liver function can be increased; virus-caused liver damage can be reduced or eliminated; progression of liver disease can be slowed or halted; the course of the liver disease can be reversed and/or liver function can be improved or maintained by contacting a cell infected with hepatitis C virus with an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof.)

There are a variety of genotypes of HCV, and a variety of subtypes within each genotype. For example, at present it is known that there are eleven (numbered 1 through 11) main genotypes of HCV, although others have classified the genotypes as 6 main genotypes. Each of these genotypes is further subdivided into subtypes (1a-1c; 2a-2c; 3a-3b; 4a-4e; 5a; 6a; 7a-7b; 8a-8b; 9a; 10a; and 11a). In some embodiments, an effective amount of a compound of Formula (I), or a pharmaceutical acceptable salt thereof, or a pharmaceutical composition that includes an effective amount of a compound of Formula (I), or a pharmaceutical acceptable salt thereof, can be effective to treat at least one genotype of HCV. In some embodiments, a compound described herein (for example, a compound of Formula (I), or a pharmaceutical acceptable salt thereof) can be effective to treat all 11 genotypes of HCV. In some embodiments, a compound described herein (for example, a compound of Formula (I), or a pharmaceutical acceptable salt thereof) can be effective to treat 3 or more, 5 or more, 7 or more, or 9 or more genotypes of HCV. In some embodiments, a compound of Formula (I), or a pharmaceutical acceptable salt thereof can be more effective against a larger number of HCV genotypes than the standard of care. In some embodiments, a compound of Formula (I), or a pharmaceutical acceptable salt thereof, can be more effective against a particular HCV genotype than the standard of care (such as genotype 1, 2, 3, 4, 5 and/or 6).

›Definitions · 18 of 25

Various indicators for determining the effectiveness of a method for treating a HCV infection are known to those skilled in the art. Examples of suitable indicators include, but are not limited to, a reduction in viral load, a reduction in viral replication, a reduction in time to seroconversion (virus undetectable in patient serum), an increase in the rate of sustained viral response to therapy, a reduction of morbidity or mortality in clinical outcomes, a reduction in the rate of liver function decrease; stasis in liver function; improvement in liver function; reduction in one or more markers of liver dysfunction, including alanine transaminase, aspartate transaminase, total bilirubin, conjugated bilirubin, gamma glutamyl transpeptidase and/or other indicator of disease response. Similarly, successful therapy with an effective amount of a compound or a pharmaceutical composition described herein (for example, a compound of Formula (I), or a pharmaceutical acceptable salt thereof) can reduce the incidence of liver cancer in HCV infected subjects.

In some embodiments, an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is an amount that is effective to reduce HCV viral titers to undetectable levels, for example, to about 100 to about 500, to about 50 to about 100, to about 10 to about 50, or to about 15 to about 25 international units/mL serum. In some embodiments, an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is an amount that is effective to reduce HCV viral load compared to the HCV viral load before administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. For example, wherein the HCV viral load is measured before administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and again after completion of the treatment regime with the compound of Formula (I), or a pharmaceutically acceptable salt thereof (for example, 1 month after completion). In some embodiments, an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be an amount that is effective to reduce HCV viral load to lower than about 25 international units/mL serum. In some embodiments, an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is an amount that is effective to achieve a reduction in HCV viral titer in the serum of the subject in the range of about 1.5-log to about a 2.5-log reduction, about a 3-log to about a 4-log reduction, or a greater than about 5-log reduction compared to the viral load before administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof. For example, the HCV viral load can be measured before administration of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and again after completion of the treatment regime with the compound of Formula (I), or a pharmaceutically acceptable salt thereof (for example, 1 month after completion).

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can result in at least a 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, 75, 100-fold or more reduction in the replication of the hepatitis C virus relative to pre-treatment levels in a subject, as determined after completion of the treatment regime (for example, 1 month after completion). In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can result in a reduction of the replication of the hepatitis C virus relative to pre-treatment levels in the range of about 2 to about 5 fold, about 10 to about 20 fold, about 15 to about 40 fold, or about 50 to about 100 fold. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can result in a reduction of the hepatitis C virus replication in the range of 1 to 1.5 log, 1.5 log to 2 log, 2 log to 2.5 log, 2.5 to 3 log, 3 log to 3.5 log or 3.5 to 4 log more reduction of the hepatitis C virus replication compared to the reduction of the hepatitis C virus reduction achieved by pegylated interferon in combination with ribavirin, administered according to the standard of care, or may achieve the same reduction as that standard of care therapy in a shorter period of time, for example, in one month, two months, or three months, as compared to the reduction achieved after six months of standard of care therapy with ribavirin and pegylated interferon.

In some embodiments, an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is an amount that is effective to achieve a sustained viral response, for example, non-detectable or substantially non-detectable HCV RNA (e.g., less than about 500, less than about 200, less than about 100, less than about 25, or less than about 15 international units per milliliter serum) is found in the subject's serum for a period of at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, or at least about six months following cessation of therapy.

In some embodiments, an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can reduce a level of a marker of liver fibrosis by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80%, or more, compared to the level of the marker in an untreated subject, or to a placebo-treated subject. Methods of measuring serum markers are known to those skilled in the art and include immunological-based methods, e.g., enzyme-linked immunosorbent assays (ELISA), radioimmunoassays, and the like, using antibody specific for a given serum marker. A non-limiting list of examples of markers includes measuring the levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT) and total bilirubin (TBIL) using known methods. In general, an ALT level of less than about 45 IU/L (international units/liter), an AST in the range of 10-34 IU/L, ALP in the range of 44-147 IU/L, GGT in the range of 0-51 IU/L, TBIL in the range of 0.3-1.9 mg/dL is considered normal. In some embodiments, an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be an amount effective to reduce ALT, AST, ALP, GGT and/or TBIL levels to with what is considered a normal level.

›Definitions · 19 of 25

Subjects who are clinically diagnosed with HCV infection include “naïve” subjects (e.g., subjects not previously treated for HCV, particularly those who have not previously received IFN-alpha-based and/or ribavirin-based therapy) and individuals who have failed prior treatment for HCV (“treatment failure” subjects). Treatment failure subjects include “non-responders” (i.e., subjects in whom the HCV titer was not significantly or sufficiently reduced by a previous treatment for HCV (≤0.5 log IU/mL), for example, a previous IFN-alpha monotherapy, a previous IFN-alpha and ribavirin combination therapy, or a previous pegylated IFN-alpha and ribavirin combination therapy); and “relapsers” (i.e., subjects who were previously treated for HCV, for example, who received a previous IFN-alpha monotherapy, a previous IFN-alpha and ribavirin combination therapy, or a previous pegylated IFN-alpha and ribavirin combination therapy, whose HCV titer decreased, and subsequently increased).

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a treatment failure subject suffering from HCV. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a non-responder subject suffering from HCV. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a relapsed subject suffering from HCV.

After a period of time, infectious agents can develop resistance to one or more therapeutic agents. The term “resistance” as used herein refers to a viral strain displaying a delayed, lessened and/or null response to a therapeutic agent(s). For example, after treatment with an antiviral agent, the viral load of a subject infected with a resistant virus may be reduced to a lesser degree compared to the amount in viral load reduction exhibited by a subject infected with a non-resistant strain. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a subject infected with an HCV strain that is resistant to one or more different anti-HCV agents (for example, an agent used in a conventional standard of care). In some embodiments, development of resistant HCV strains is delayed when a subject is treated with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, compared to the development of HCV strains resistant to other HCV drugs (such as an agent used in a conventional standard of care).

In some embodiments, an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a subject for whom other anti-HCV medications are contraindicated. For example, administration of pegylated interferon alpha in combination with ribavirin is contraindicated in subjects with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) and other subjects at risk from the hematologic side effects of current therapy. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be provided to a subject that is hypersensitive to interferon and/or ribavirin.

Some subjects being treated for HCV experience a viral load rebound. The term “viral load rebound” as used herein refers to a sustained ≥0.5 log IU/mL increase of viral load above nadir before the end of treatment, where nadir is a ≥0.5 log IU/mL decrease from baseline. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a subject experiencing viral load rebound, or can prevent such viral load rebound when used to treat the subject.

The standard of care for treating HCV has been associated with several side effects (adverse events). In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can decrease the number and/or severity of side effects that can be observed in HCV patients being treated with ribavirin and pegylated interferon according to the standard of care. Examples of side effects include, but are not limited to fever, malaise, tachycardia, chills, headache, arthralgias, myalgias, fatigue, apathy, loss of appetite, nausea, vomiting, cognitive changes, asthenia, drowsiness, lack of initiative, irritability, confusion, depression, severe depression, suicidal ideation, anemia, low white blood cell counts, and thinning of hair. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be provided to a subject that discontinued a HCV therapy because of one or more adverse effects or side effects associated with one or more other HCV agents (for example, an agent used in a conventional standard of care).

Table 1 provides some embodiments of the percentage improvement obtained using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as compared to the standard of care. Examples include the following: in some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, results in a percentage of non-responders that is 10% less than the percentage of non-responders receiving the standard of care; in some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, results in a number of side effects that is in the range of about 10% to about 30% less than compared to the number of side effects experienced by a subject receiving the standard of care; and in some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, results in a severity of a side effect (such as one of those described herein) that is 25% less than compared to the severity of the same side effect experienced by a subject receiving the standard of care. Methods of quantifying the severity of a side effect are known to those skilled in the art.

As used herein, a “subject” refers to an animal that is the object of treatment, observation or experiment. “Animal” includes cold- and warm-blooded vertebrates and invertebrates such as fish, shellfish, reptiles and, in particular, mammals. “Mammal” includes, without limitation, mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, horses, primates, such as monkeys, chimpanzees, and apes, and, in particular, humans. In some embodiments, the subject is human.

›Definitions · 20 of 25

As used herein, the terms “treating,” “treatment,” “therapeutic,” or “therapy” do not necessarily mean total cure or abolition of the disease or condition. Any alleviation of any undesired signs or symptoms of a disease or condition, to any extent can be considered treatment and/or therapy. Furthermore, treatment may include acts that may worsen the patient's overall feeling of well-being or appearance.

The terms “therapeutically effective amount” and “effective amount” are used to indicate an amount of an active compound, or pharmaceutical agent, that elicits the biological or medicinal response indicated. For example, an effective amount of compound can be the amount needed to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated This response may occur in a tissue, system, animal or human and includes alleviation of the signs or symptoms of the disease being treated. Determination of an effective amount is well within the capability of those skilled in the art, in view of the disclosure provided herein. The effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including human, being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize.

As will be readily apparent to one skilled in the art, the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight, the severity of the affliction, and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed. The determination of effective dosage levels, that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine methods, for example, human clinical trials and in vitro studies.

The dosage may range broadly, depending upon the desired effects and the therapeutic indication. Alternatively dosages may be based and calculated upon the surface area of the patient, as understood by those of skill in the art. Although the exact dosage will be determined on a drug-by-drug basis, in most cases, some generalizations regarding the dosage can be made. The daily dosage regimen for an adult human patient may be, for example, an oral dose of between 0.01 mg and 3000 mg of each active ingredient, preferably between 1 mg and 700 mg, e.g. 5 to 200 mg. The dosage may be a single one or a series of two or more given in the course of one or more days, as is needed by the subject. In some embodiments, the compounds will be administered for a period of continuous therapy, for example for a week or more, or for months or years. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered less frequently compared to the frequency of administration of an agent within the standard of care. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered one time per day. For example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered one time per day to a subject suffering from a HCV infection. In some embodiments, the total time of the treatment regime with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can less compared to the total time of the treatment regime with the standard of care.

In instances where human dosages for compounds have been established for at least some condition, those same dosages may be used, or dosages that are between about 0.1% and 500%, more preferably between about 25% and 250% of the established human dosage. Where no human dosage is established, as will be the case for newly-discovered pharmaceutical compositions, a suitable human dosage can be inferred from ED 50 or ID 50 values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.

In cases of administration of a pharmaceutically acceptable salt, dosages may be calculated as the free base. As will be understood by those of skill in the art, in certain situations it may be necessary to administer the compounds disclosed herein in amounts that exceed, or even far exceed, the above-stated, preferred dosage range in order to effectively and aggressively treat particularly aggressive diseases or infections.

Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations. Dosage intervals can also be determined using MEC value. Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity or organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.

›Definitions · 21 of 25

Compounds disclosed herein can be evaluated for efficacy and toxicity using known methods. For example, the toxicology of a particular compound, or of a subset of the compounds, sharing certain chemical moieties, may be established by determining in vitro toxicity towards a cell line, such as a mammalian, and preferably human, cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans. Alternatively, the toxicity of particular compounds in an animal model, such as mice, rats, rabbits, or monkeys, may be determined using known methods. The efficacy of a particular compound may be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials. When selecting a model to determine efficacy, the skilled artisan can be guided by the state of the art to choose an appropriate model, dose, route of administration and/or regime.

Combination Therapies

In some embodiments, the compounds disclosed herein, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound described herein, or a pharmaceutically acceptable salt thereof, can be used in combination with one or more additional agent(s). Examples of additional agents that can be used in combination with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, include, but are not limited to, agents currently used in a conventional standard of care for treating HCV, HCV protease inhibitors, HCV polymerase inhibitors, NS5A inhibitors, other antiviral compounds, compounds of Formula (AA), (including pharmaceutically acceptable salts and pharmaceutical compositions that can include a compound of Formula (AA), or a pharmaceutically acceptable salt thereof), compounds of Formula (BB) (including pharmaceutically acceptable salts and pharmaceutical compositions that can include a compound of Formula (BB), or a pharmaceutically acceptable salt thereof), compounds of Formula (CC) (including pharmaceutically acceptable salts and pharmaceutical compositions that can include a compound of Formula (CC), or a pharmaceutically acceptable salt thereof), and/or combinations thereof. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used with one, two, three or more additional agents described herein. A non-limiting list of examples of combinations of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided in Tables A, B, C, D and E.

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with an agent(s) currently used in a conventional standard of care therapy. For example, for the treatment of HCV, a compound disclosed herein can be used in combination with Pegylated interferon-alpha-2a (brand name PEGASYS®) and ribavirin, Pegylated interferon-alpha-2b (brand name PEG-INTRON®) and ribavirin, Pegylated interferon-alpha-2a, Pegylated interferon-alpha-2b, or ribavirin.

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be substituted for an agent currently used in a conventional standard of care therapy. For example, for the treatment of HCV, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in place of ribavirin.

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with an interferon, such as a pegylated interferon. Examples of suitable interferons include, but are not limited to, Pegylated interferon-alpha-2a (brand name PEGASYS®), Pegylated interferon-alpha-2b (brand name PEG-INTRON®), interferon alfacon-1 (brand name INFERGEN®), pegylated interferon lambda and/or a combination thereof.

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a HCV protease inhibitor. A non-limiting list of example HCV protease inhibitors include the following: VX-950 (TELAPREVIR®), MK-5172, ABT-450, BILN-2061, BI-201335, BMS-650032, SCH 503034 (BOCEPREVIR®), GS-9256, GS-9451, IDX-320, ACH-1625, ACH-2684, TMC-435, ITMN-191 (DANOPREVIR®) and/or a combination thereof. Additional HCV protease inhibitors suitable for use in combination with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, include VP-19744, PSI-879, VCH-759/VX-759, HCV-371, IDX-375, GL-60667, JTK-109, PSI-6130, R1479, R-1626, R-7182, MK-0608, INX-8014, INX-8018, A-848837, A-837093, BILB-1941, VCH-916, VCH-716, GSK-71185, GSK-625433, XTL-2125 and those disclosed in PCT Publication No. WO 2012/142085, which is hereby incorporated by reference for the limited purpose of its disclosure of HCV protease inhibitors, HCV polymerase inhibitors and NS5A inhibitors. A non-limiting list of example HCV protease inhibitors includes the compounds numbered 1001-1016 in FIG. 1 .

›Definitions · 22 of 25

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a HCV polymerase inhibitor. In some embodiments, the HCV polymerase inhibitor can be a nucleoside inhibitor. In other embodiments, the HCV polymerase inhibitor can be a non-nucleoside inhibitor. Examples of suitable nucleoside inhibitors include, but are not limited to, RG7128, PSI-7851, PSI-7977, INX-189, PSI-352938, PSI-661, 4′-azidouridine (including known prodrugs of 4′-azidouridine), GS-6620, IDX-184, and TMC649128 and/or combinations thereof. A non-limiting list of example nucleoside inhibitors includes compounds numbered 2001-2012 in FIG. 2 . Examples of suitable non-nucleoside inhibitors include, but are not limited to, ABT-333, ANA-598, VX-222, HCV-796, BI-207127, GS-9190, PF-00868554 (FILIBUVIR®), VX-497 and/or combinations thereof. A non-limiting list of example non-nucleoside inhibitors includes the compounds numbered 3001-3014 in FIG. 3 . Further HCV polymerase inhibitors suitable for use in combination with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, include VX-500, VX-813, VBY-376, TMC-435350, EZ-058, EZ-063, GS-9132, ACH-1095, IDX-136, IDX-316, ITMN-8356, ITMN-8347, ITMN-8096, ITMN-7587, VX-985, and those disclosed in PCT Publication No. WO 2012/142085.

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a NS5A inhibitor. Examples of NS5A inhibitors include BMS-790052, PPI-461, ACH-2928, GS-5885, BMS-824393 and/or combinations thereof. A non-limiting list of example NS5A inhibitors includes the compounds numbered 4001-4012 in FIG. 4 . Additional NS5A inhibitors suitable for use in combination with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, include A-832, PPI-1301 and those disclosed in PCT Publication No. WO 2012/142085.

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with other antiviral compounds. Examples of other antiviral compounds include, but are not limited to, Debio-025, MIR-122, cyclosporin A and/or combinations thereof. A non-limiting list of example other antiviral compounds includes the compounds numbered 5001-5012 in FIG. 5 .

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a compound of Formula (AA), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (AA), or a pharmaceutically acceptable salt thereof (see, U.S. Publication No. 2013/0164261, published Jun. 27, 2013, the contents of which are incorporated by reference in its entirety):

wherein: B AA1 can be an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group; R AA1 can be selected from O − , OH, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; R AA2 can be absent or selected from hydrogen, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl and

wherein R AA6 , R AA7 and R AA8 can be independently absent or hydrogen, and n can be 0 or 1; provided that when R AA1 is O − or OH, then R AA2 is absent, hydrogen or

R AA3 can be selected from hydrogen, halogen, —OR AA9 and —OC(═O)R AA10 ; R AA4 can be selected from halogen, —OR AA11 and —OC(═O)R AA12 ;or R AA3 and R AA4 can be both an oxygen atom which are linked together by a carbonyl group; R AA5 can be selected from an optionally substituted C 2-6 alkyl, an optionally substituted C 2-6 alkenyl, an optionally substituted C 2-6 alkynyl and an optionally substituted C 3-6 cycloalkyl; or R AA4 and R AA5 together can form —(C 1-6 alkyl)-O— or —O—(C 1-6 alkyl)-; R AA9 and R AA11 can be independently hydrogen or an optionally substituted C 1-6 alkyl; and R AA10 and R AA12 can be independently an optionally substituted C 1-6 alkyl or an optionally substituted C 3-6 cycloalkyl. A non-limiting list of examples of compounds of Formula (AA) includes the compounds numbered 7000-7027 in FIG. 7 .

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a compound of Formula (BB), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (BB), or a pharmaceutically acceptable salt thereof (see, U.S. Publication No. 2012/0165286, published Jun. 28, 2012, the contents of which are incorporated by reference in their entireties):

wherein B BB1 can be an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group; X BB can be O (oxygen) or S (sulfur); R BB1 can be selected from —Z BB —R BB9 , an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; Z BB can be selected from O (oxygen), S (sulfur) and N(R BB10 ); R BB2 and R BB3 can be independently selected from hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 2-6 alkenyl, an optionally substituted C 2-6 alkynyl, an optionally substituted C 1-6 haloalkyl and an optionally substituted aryl(C 1-6 alkyl); or R BB2 and R BB3 can be taken together to form a group selected from an optionally substituted C 3-6 cycloalkyl, an optionally substituted C 3-6 cycloalkenyl, an optionally substituted C 3-6 aryl and an optionally substituted C 3-6 heteroaryl; R BB4 can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C 1-6 alkyl, an optionally substituted C 2-6 alkenyl, an optionally substituted C 2-6 alkynyl and an optionally substituted allenyl; R BB5 can be hydrogen or an optionally substituted C 1-6 alkyl; R BB6 can be selected from hydrogen, halogen, azido, amino, cyano, an optionally substituted C 1-6 alkyl, —OR BB11 and —OC(═O)R BB12 ; R BB7 can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C 1-6 alkyl, —OR BB13 and —OC(═O)R BB14 ; R BB8 can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C 1-6 alkyl, —OR BB15 and —OC(═O)R BB16 ; R BB9 can be selected from an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C 1-6 alkyl), an optionally substituted heteroaryl(C 1-6 alkyl) and an optionally substituted heterocyclyl(C 1-6 alkyl); R BB10 can be selected from hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C 1-6 alkyl), an optionally substituted heteroaryl(C 1-6 alkyl) and an optionally substituted heterocyclyl(C 1-6 alkyl); R BB11 , R BB13 and R BB15 can be independently hydrogen or an optionally substituted C 1-6 alkyl; and R BB1 2, R BB14 and R BB16 can be independently an optionally substituted C 1-6 alkyl or an optionally substituted C 3-6 cycloalkyl. In some embodiments, at least one of R BB2 and R BB3 is not hydrogen. A non-limiting list of example compounds of Formula (BB) includes the compound numbered 8000-8016 in FIG. 8 .

›Definitions · 23 of 25

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a compound of Formula (CC), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (CC), or a pharmaceutically acceptable salt thereof (see, U.S. Publication No. 2012/0071434, published Mar. 22, 2012, the contents of which are incorporated by reference in its entirety):

wherein B CC1 can be an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group; R CC1 can be selected from O − , OH, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; R CC2 can be selected from an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl and

wherein R CC19 , R CC20 and R CC21 can be independently absent or hydrogen, and n CC can be 0 or 1; provided that when R CC1 is O − or OH, then R CC2

R CC3a and R CC3b can be independently selected from hydrogen, deuterium, an optionally substituted C 1-6 alkyl, an optionally substituted C 2-6 alkenyl, an optionally substituted C 2-6 alkynyl, an optionally substituted C 1-6 haloalkyl and aryl(C 1-6 alkyl); or R CC3a and R CC3b can be taken together to form an optionally substituted C 3-6 cycloalkyl; R CC4 can be selected from hydrogen, azido, an optionally substituted C 1-6 alkyl, an optionally substituted C 2-6 alkenyl and an optionally substituted C 2-6 alkynyl; R CC5 can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C 1-6 alkyl, —OR CC10 and —OC(═O)R CC11 ; R CC6 can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C 1-6 alkyl, —OR CC12 and —OC(═O)R CC13 ; R CC7 can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C 1-6 alkyl, —OR CC14 and —OC(═O)R CC15 ; or R CC6 and R CC7 can be both oxygen atoms and linked together by a carbonyl group; R CC8 can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C 1-6 alkyl, —OR CC16 and —OC(═O)R CC17 ; R CC9 can be selected from hydrogen, azido, cyano, an optionally substituted C 1-6 alkyl and —OR CC18 ; R CC10 , R CC12 , R CC14 , R CC16 and R CC18 can be independently selected from hydrogen and an optionally substituted C 1-6 alkyl; and R CC11 , R CC13 , R CC15 and R CC17 can be independently selected from an optionally substituted C 1-6 alkyl and an optionally substituted C 3-6 cycloalkyl. In some embodiments, when R CC3a R CC3b , R CC4 , R CC5 , R CC7 , R CC8 and R CC9 are all hydrogen, then R CC6 is not azido. In some embodiments, R CC2 cannot be

when R CC3a is hydrogen, R CC3b is hydrogen, R CC4 is H, R CC5 is OH or H, R CC6 is hydrogen, OH, or —OC(═O)CH 3 , R CC7 is hydrogen, OH, OCH 3 or —OC(═O)CH 3 , R CC8 is hydrogen, OH or OCH 3 , R CC9 is H and B CC1 is an optionally substituted adenine, an optionally substituted guanine, an optionally substituted uracil or an optionally substituted hypoxanthine. In some embodiments, R CC2 cannot be

A non-limiting list of examples of compounds of Formula (CC) includes the compounds numbered 6000-6078 in FIG. 6 .

Some embodiments described herein relate to a method of ameliorating or treating a HCV infection that can include contacting a cell infected with the HCV infection with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more agents selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a compound of Formula (BB) and a compound of Formula (CC), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

Some embodiments described herein relate to a method of ameliorating or treating a HCV infection that can include administering to a subject suffering from the HCV infection an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more agents selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a compound of Formula (BB) and a compound of Formula (CC), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

Some embodiments described herein relate to a method of inhibiting the replication of a hepatitis C virus that can include contacting a cell infected with the hepatitis C virus with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more agents selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a compound of Formula (BB) and a compound of Formula (CC), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

Some embodiments described herein relate to a method of inhibiting the replication of a hepatitis C virus that can include administering to a subject infected with the hepatitis C virus an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more agents selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a compound of Formula (BB) and a compound of Formula (CC), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered with one or more additional agent(s) together in a single pharmaceutical composition. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt the thereof, can be administered with one or more additional agent(s) as two or more separate pharmaceutical compositions. For example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered in one pharmaceutical composition, and at least one of the additional agents can be administered in a second pharmaceutical composition. If there are at least two additional agents, one or more of the additional agents can be in a first pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one of the other additional agent(s) can be in a second pharmaceutical composition.

›Definitions · 24 of 25

The dosing amount(s) and dosing schedule(s) when using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional agents are within the knowledge of those skilled in the art. For example, when performing a conventional standard of care therapy using art-recognized dosing amounts and dosing schedules, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered in addition to that therapy, or in place of one of the agents of a combination therapy, using effective amounts and dosing protocols as described herein.

The order of administration of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, with one or more additional agent(s) can vary. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered prior to all additional agents. In other embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered prior to at least one additional agent. In still other embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered concomitantly with one or more additional agent(s). In yet still other embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered subsequent to the administration of at least one additional agent. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered subsequent to the administration of all additional agents.

In some embodiments, the combination of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 1-8 (including pharmaceutically acceptable salts and prodrugs thereof) can result in an additive effect. In some embodiments, the combination of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 1-8 (including pharmaceutically acceptable salts and prodrugs thereof) can result in a synergistic effect. In some embodiments, the combination of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 1-8 (including pharmaceutically acceptable salts and prodrugs thereof) can result in a strongly synergistic effect. In some embodiments, the combination of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 1-8 (including pharmaceutically acceptable salts and prodrugs thereof) is not antagonistic.

As used herein, the term “antagonistic” means that the activity of the combination of compounds is less compared to the sum of the activities of the compounds in combination when the activity of each compound is determined individually (i.e. as a single compound). As used herein, the term “synergistic effect” means that the activity of the combination of compounds is greater than the sum of the individual activities of the compounds in the combination when the activity of each compound is determined individually. As used herein, the term “additive effect” means that the activity of the combination of compounds is about equal to the sum of the individual activities of the compound in the combination when the activity of each compound is determined individually.

A potential advantage of utilizing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 1-8 (including pharmaceutically acceptable salts thereof) may be a reduction in the required amount(s) of one or more compounds of FIGS. 1-8 (including pharmaceutically acceptable salts thereof) that is effective in treating a disease condition disclosed herein (for example, HCV), as compared to the amount required to achieve same therapeutic result when one or more compounds of FIGS. 1-8 (including pharmaceutically acceptable salts thereof) are administered without a compound of Formula (I), or a pharmaceutically acceptable salt thereof. For example, the amount of a compound in FIGS. 1-8 (including a pharmaceutically acceptable salt thereof), can be less compared to the amount of the compound in FIGS. 1-8 (including a pharmaceutically acceptable salt thereof), needed to achieve the same viral load reduction when administered as a monotherapy. Another potential advantage of utilizing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 1-8 (including pharmaceutically acceptable salts thereof) is that the use of two or more compounds having different mechanism of actions can create a higher barrier to the development of resistant viral strains compared to the barrier when a compound is administered as monotherapy.

Additional advantages of utilizing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 1-8 (including pharmaceutically acceptable salts thereof) may include little to no cross resistance between a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional agent(s) in FIGS. 1-8 (including pharmaceutically acceptable salts thereof) thereof; different routes for elimination of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional agent(s) in FIGS. 1-8 (including pharmaceutically acceptable salts thereof); little to no overlapping toxicities between a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional agent(s) in FIGS. 1-8 (including pharmaceutically acceptable salts thereof); little to no significant effects on cytochrome P450; little to no pharmacokinetic interactions between a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional agent(s) in FIGS. 1-8 (including pharmaceutically acceptable salts thereof); greater percentage of subjects achieving a sustained viral response compared to when a compound is administered as monotherapy and/or a decrease in treatment time to achieve a sustained viral response compared to when a compound is administered as monotherapy.

›Definitions · 25 of 25

A non-limiting list of example combination of compounds of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound described herein, with one or more additional agent(s) are provided in Tables A, B, C, D and E. Each numbered X and Y compound in Tables A, B, C, D and E has a corresponding name and/or structure provided in FIGS. 1-8 . The numbered compounds in Tables A, B, C, D and E includes pharmaceutically acceptable salts of the compounds and pharmaceutical compositions containing the compounds or a pharmaceutically acceptable salt thereof. For example, 1001 includes the compound corresponding to 1001, pharmaceutically acceptable salts thereof, and pharmaceutical compositions that include compound 1001 and/or a pharmaceutically acceptable salt thereof. The combinations exemplified in Tables A, B, C, D and E are designated by the formula X:Y, which represents a combination of a compound X with a compound Y. For example, the combination designated as 1001:9004 in Table A represents a combination of compound 1001 with compound 9004, including pharmaceutically acceptable salts of compound 1001 and/or 9004, and pharmaceutical compositions including compound 1001 and 9004 (including pharmaceutical compositions that include pharmaceutically acceptable salts of compound 1001 and/or compound 9004). Thus, the combination designated as 1001:9004 in Table A represents the combination of Telaprevir (compound 1001, as shown in FIG. 1 ) and

(compound 9004, as shown in FIG. 9 ), including pharmaceutically acceptable salts of compound 1001 and/or 9004, and pharmaceutical compositions including compound 1001 and 9004 (including pharmaceutical compositions that include pharmaceutically acceptable salts of compound 1001 and/or compound 9004). Each of the combinations provided in Tables A, B, C, D and E can be used with one, two, three or more additional agents described herein. In some embodiments described herein, the combination of agents can be used to treat, ameliorate and/or inhibit a virus and/or a viral infection, wherein the virus can be HCV and the viral infection can be an HCV viral infection.

›EXAMPLES

Additional embodiments are disclosed in further detail in the following examples, which are not in any way intended to limit the scope of the claims.

›Examples82
›Example 1

2′-C-Methyl-4′-Fluorouridine 1

To a stirred suspension of 1-1 (20 g, 77.5 mmol), PPh 3 (30 g, 114.5 mmol), imidazole (10 g, 147 mmol) and pyridine (90 mL) in anhydrous THF (300 mL) was added a solution of 12 (25 g, 98.4 mmol) in THF (100 mL) dropwise at 0° C. The mixture was warmed to room temperature (R.T.) and stirred at R.T. for 10 h. The reaction was quenched by MeOH (100 mL). The solvent was removed, and the residue was re-dissolved in a mixture ethyl acetate (EA) and THF (2 L, 10:1). The organic phase was washed with saturated Na 2 S 2 O 3 aq., and the aqueous phase was extracted with a mixture of EA and THF (2 L, 10:1). The organic layer was combined and concentrated to give a residue, which was purified on a silica gel column (0-10% MeOH in DCM) to give 1-2 (22.5 g, 78.9%) as a white solid. 1 H NMR: (DMSO-d 6 , 400 MHz) δ 11.42 (s, 1H), 7.59 (d, J=8.4 Hz, 1H), 5.82 (s, 1H), 5.63 (d, J=8.0 Hz, 1H), 5.50 (s, 1H), 5.23 (s, 1H), 3.77-3.79 (m, 1H), 3.40-3.62 (m, 3H), 0.97 (s, 3H).

To a stirred solution of 1-2 (24.3 g, 66.03 mmol) in anhydrous MeOH (240 mL) was added NaOMe (10.69 g, 198.09 mmol) at R.T. under N 2 . The mixture was refluxed for 3 h. The solvent was removed, and the residue was re-dissolved in anhydrous pyridine (200 mL). To the mixture was added Ac 2 O (84.9 g, 833.3 mmol) at 0° C. The mixture was warmed to 60° C. and stirred for 10 h. The solvent was removed, and the residue was diluted with DCM, washed with saturated NaHCO 3 and brine. The organic layer was concentrated and purified on a silica gel column (10-50% EA in PE) to give 1-3 (15 g, 70.1%) as a white solid. 1 H NMR: (CDCl 3 , 400 MHz) δ 8.82 (s, 1H), 7.23 (d, J=2.0 Hz, 1H), 6.54 (s, 1H), 5.85 (s, 1H), 5.77 (dd, J=8.0, 2.0 Hz, 1H), 4.69 (d, J=2.4 Hz, 1H), 4.58 (d, J=2.8 Hz, 1H), 2.07 (d, J=5.2 Hz, 6H), 1.45 (s, 3H).

To an ice-cooled solution of 1-3 (15 g, 46.29 mmol) in anhydrous DCM (300 mL) was added AgF (29.39 g, 231.4 mmol). I 2 (23.51 g, 92.58 mmol) in anhydrous DCM (1.0 L) was added dropwise to the solution. The reaction mixture was stirred at R.T. for 5 h. The reaction was quenched with saturated Na 2 S 2 O 3 and NaHCO 3 , and extracted with DCM. The organic layer was separated, dried and evaporated to dryness. The residue was purified on a silica gel column (10-30% EA in PE) to give 1-4 (9.5 g, 43.6%) as a white solid. 1 H NMR: (Methanol-d4, 400 MHz) δ 7.52 (d, J=8.0 Hz, 1H), 6.21 (s, 1H), 5.80 (d, J=17.2 Hz, 1H), 5.73 (d, J=8.0 Hz, 1H), 3.58 (s, 1H), 3.54 (d, J=6.8 Hz, 1H), 2.17 (s, 3H), 2.09 (s, 3H), 1.58 (s, 3H).

To a solution of 1-4 (7.0 g, 14.89 mmol) in anhydrous DMF (400 mL) were added NaOBz (21.44 g, 148.9 mmol) and 15-crown-5 (32.75 g, 148.9 mmol). The reaction mixture was stirred at 130° C. for 6 h. The solvent was removed, diluted with EA and washed with water and brine. The organic layer was evaporated and purified on a silica gel column (10-30% EA in PE) to give 1-5 (2.8 g, 40.5%). 1 H NMR: (CDCl 3 , 400 MHz) δ 8.84 (s, 1H), 8.04-8.06 (m, 2H), 7.59 (t, J=7.2 Hz, 1H), 7.44-7.47 (m, 2H), 7.21-7.26 (m, 1H), 6.21 (s, 1H), 5.85 (d, J=18 Hz, 1H), 5.67 (d, J=8.0 Hz, 1H), 4.59-4.72 (m, 2H), 2.14 (s, 6H), 1.64 (d, J=6.0 Hz, 3H). ESI-MS: m/z 444.9 [M-F+H] + .

A mixture of 1-5 (4.0 g; 8.6 mmol) and liquid ammonia was kept overnight at R. T. in a high-pressure stainless-steel vessel. Ammonia was then evaporated, and the residue purified on silica (50 g column) with a CH 2 Cl 2 /MeOH solvent mixture (4-12% gradient) to yield compound 1 as a colorless foam (2.0 g; 84% yield). ESI-MS: m/z 275.1 [M−H] − .

›Example 2

Compound 2

To a solution of 1 (1.2 g; 4.3 mmol) in dioxane (30 mL) were added p-toluenesulphonic acid monohydrate (820 mg; 1 eq.) and trimethyl orthoformate (14 mL; 30 eq.). The mixture was stirred overnight at R.T. The mixture was then neutralized with methanolic ammonia and the solvent evaporated. Purification on silica gel column with CH 2 Cl 2 -MeOH solvent system (4-10% gradient) yielded 2-1 (1.18 g, 87%).

To an ice cold solution of 2-1 (0.91 g; 2.9 mmol) in anhydrous THF (20 mL) was added iso-propylmagnesium chloride (2.1 mL; 2 M in THF). The mixture was stirred at 0° C. for 20 mins. A solution of phosphorochloridate reagent (2.2 g; 2.5 eq.) in THF (2 mL) was added dropwise. The mixture was stirred overnight at R.T. The reaction was quenched with saturated aq. NH 4 Cl solution and stirred at R.T. for 10 mins. The mixture was then diluted with water and CH 2 Cl 2 , and the two layers were separated. The organic layer was washed with water, half saturated aq. NaHCO 3 and brine, and dried with Na 2 SO 4 . The evaporated residue was purified on silica gel column with CH 2 Cl 2 -iPrOH solvent system (4-10% gradient) to yield Rp/Sp-mixture of 2-2 (1.59 g; 93%).

A mixture of 2-2 (1.45 g; 2.45 mmol) and 80% aq. HCOOH (7 mL) was stirred at R.T. for 1.5 h. The solvent was evaporated and coevaporated with toluene. The obtained residue was dissolved in MeOH, treated with Et 3 N (3 drops) and the solvent was evaporated. Purification on silica gel column with CH 2 Cl 2 -MeOH solvent system (4-10% gradient) yielded Rp/Sp-mixture of compound 2 (950 mg; 70%). 31 P-NMR (DMSO-d 6 ): δ 3.52, 3.47. MS: m/z=544 [M−1] − .

›Example 3

Compound 3

To an ice cold solution of 3-1 (80 mg; 015 mmol) in anhydrous THF (2 mL) was added isopropylmagnesium chloride (0.22 mL; 2 M in THF). The mixture was stirred at 0° C. for 20 mins. A solution of the phosphorochloridate reagent (0.16 g; 0.45 mmol) in THF (0.5 mL) was added dropwise. The mixture was stirred overnight at R.T. The reaction was quenched with saturated aq. NH 4 Cl solution and stirred at R.T. for 10 mins. The mixture was diluted with water and CH 2 Cl 2 , and the two layers were separated. The organic layer was washed with water, half saturated aq. NaHCO 3 and brine, and dried with Na 2 SO 4 . The evaporated residue was purified on silica gel column with CH 2 C 12 -MeOH solvent system (2-10% gradient) to yield Rp/Sp-mixture of 3-2 (102 mg; 80%).

A mixture of 3-2 (100 mg; 0.12 mmol) in EtOH (3 mL) and 10% Pd/C (10 mg) was stirred under the H 2 atmosphere for 1.5 h. The mixture was filtered through a Celite pad, evaporated and purified on silica gel column with CH 2 C 12 -MeOH solvent system (4-10% gradient) to yield Rp/Sp-mixture of compound 3 (52 mg, 74%). 31 P-NMR (DMSO-d 6 ): δ 3.51, 3.48. MS: m/z=584 [M−1] − .

›Example 4

Compounds 4 and 6

Dry 1 (14 mg, 0.05 mmol) was dissolved in the mixture of PO(OMe) 3 (0.750 mL) and pyridine (0.5 mL). The mixture was evaporated in vacuum for 15 mins at bath temperature 42 OC, and then cooled down to R.T. N-Methylimidazole (0.009 mL, 0.11 mmol) was added followed by POCl 3 (0.009 mL, 0.1 mmol). The mixture was kept at R.T. for 45 mins. Tributylamine (0.065 mL, 0.3 mmol) and N-tetrabutyl ammonium salt of pyrophosphate (100 mg) was added. About 1 mL of dry DMF was added to get a homogeneous solution. In 1 h, the reaction was quenched with 2M ammonium acetate buffer (1 mL, pH=7.5), diluted water (10 mL) and loaded on a column HiLoad 16/10 with Q Sepharose High Performance. The separation was done in linear gradient of NaCl from 0 to 1N in 50 mM TRIS-buffer (pH7.5). The fractions eluted at 60% buffer B contained Compound 4 and at 80% buffer B contained Compound 6. The corresponding fractions were concentrated, and the residue purified by RP HPLC on Synergy 4 micron Hydro-RP column (Phenominex). A linear gradient of methanol from 0 to 30% in 50 mM triethylammonium acetate buffer (pH 7.5) was used for elution. The corresponding fractions were combined, concentrated and lyophilized 3 times to remove excess of buffer. Compound 4: 31 P-NMR (D 2 O): −3.76 (s); MS: m/z 355.3 [M−H] − . Compound 6: 31 P-NMR (D 2 O): −9.28 (d, 1H, Pa), −12.31 (d, 1H, Pγ), −22.95 (t, 1H, Pβ); MS: m/z 515.0 [M−1] − .

›Example 5

Compound 5

Compound 5 was synthesized as described for 2 on 0.1 mmol scale and with neopentyl ester of phosphorochloridate reagent. Yield was 36 mg (63%). 31 P-NMR (CDCl 3 ): δ 2.57 (s), 2.43 (s). MS: 572.6 [M−1] − .

›Example 6

Compound 7

Dry 1 (14 mg, 0.05 mmol) was dissolved in the mixture of PO(OMe) 3 (0.750 mL) and pyridine (0.5 mL). The mixture was evaporated in vacuum for 15 mins at bath temperature 42 OC, and then cooled down to R.T. N-Methylimidazole (0.009 mL, 0.11 mmol) was added followed by PSCl 3 (0.01 mL, 0.1 mmol). The mixture was kept at R.T. for 1 h. Tributylamine (0.065 mL, 0.3 mmol) and N-tetrabutyl ammonium salt of pyrophosphate (200 mg) was added. About 1 mL of dry DMF was added to get a homogeneous solution. In 2 h, the reaction was quenched with 2M ammonium acetate buffer (1 mL, pH=7.5), diluted with water (10 mL) and loaded on a column HiLoad 16/10 with Q Sepharose High Performance. Separation was done in linear gradient of NaCl from 0 to 1N in 50 mM TRIS-buffer (pH7.5). The fractions eluted at 80% buffer B contained 7 (compounds 7a and 7b). The corresponding fractions were concentrated, and the residue purified by RP HPLC on Synergy 4 micron Hydro-RP column (Phenominex). A linear gradient of methanol from 0 to 20% in 50 mM triethylammonium acetate buffer (pH 7.5) was used for elution. Two peaks were collected. The corresponding fractions were combined, concentrated and lyophilized 3 times to remove excess of buffer. Peak 1 (more polar): 31 P-NMR (D 2 O): +42.68 (d, 1H, Pα), −9.05 (d, 1H, Pγ), −22.95 (t, 1H, Pβ); MS 530.90 [M−1] − . Peak 2 (less polar): 31 P-NMR (D 2 O): +42.78 (d, 1H, Pa), −10.12 (bs, 1H, Pγ), −23.94 (t, 1H, Pβ); and MS 530.90 [M−1] − .

›Example 7

Compound 23

To a stirred suspension of 23-1 (20.0 g, 81.3 mmol), imidazole (15.9 g, 234.0 mmol), PPh 3 (53.5 g, 203.3 mmol) and pyridine (90 mL) in anhydrous THF (100 mL) was added a solution of 12 (41.3 g, 162.6 mmol) in THF (150 mL) dropwise at 0° C. The mixture was slowly warmed to R.T. and stirred for 14 h. The reaction was quenched with sat. aq. Na 2 S 2 O 3 (150 mL) and extracted with THF/EA (1/1) (100 mL×3). The organic layer was dried over Na 2 SO 4 , and concentrated at a low pressure. The residue was recrystallized from EtOH to afford pure 23-2 (23 g, 79%) as a white solid.

To a stirred solution of 23-2 (23 g, 65 mmol) in anhydrous MeOH (200 mL) was added NaOCH 3 (10.5 g, 195 mmol) in MeOH (50 mL) at R.T. The mixture was stirred at 60° C. for 3 h, and quenched with dry ice. A solid precipitated and removed by filtration. The filtrate was concentrated at a low pressure. The residue was purified on column silica gel column (MeOH in DCM from 1% to 10%) to provide 23-3 (13.1 g, 92.5%) as a white foam solid.

To a stirred solution of 23-3 (12.0 g, 53 mmol) in anhydrous CH 3 CN was added TEA.3HF (8.5 g, 53 mmol) and NIS (10.2 g, 63.6 mmol) at 0° C. The mixture was stirred for 30 mins, and slowly warmed to R.T. The mixture was stirred for another 30 mins. The solid was removed by filtration, and washed with DCM to give 23-4 (14 g, 73%) as a yellow solid. ESI-MS: m/z 373.0 [M+H] + .

To a stirred solution of 23-4 (12.0 g, 32 mmol) and DMAP (1.2 g, 9.6 mmol) in pyridine (100 mL) was added Bz 2 O (21.7 g, 96 mmol) at R.T. The mixture was stirred at 50° C. for 16 h. The resulting solution was quenched with water, and concentrated to dryness at low pressure. The crude was purified on silica gel column (50% EA in PE) to give 23-5 (15 g, 81%) as a white solid. ESI-TOF-MS: m/z 581.0 [M+H] + .

Tetra-butylammonium hydroxide (288 mL as 54-56% aqueous solution, 576 mmol) was adjusted to pH-4 by adding TFA (48 mL). The resulting solution was treated with a solution of 23-5 (14 g, 24 mmol) in DCM (200 mL). m-Cloroperbenzoic acid (30 g, 60-70%, 120 mmol) was added portion wise with vigorous stirring, and the mixture was stirred overnight. The organic layer was separated and washed with brine. The resulting solution was dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography to give 23-6 (7.5 g, 68%)

Compound 23-6 (5.0 g, 10.6 mmol) was treated with 7N NH 3 .MeOH (100 mL), and the mixture was stirred for 5 h. The mixture was then concentrated to dryness at low pressure. The residue was washed with DCM, and the solid was filtered to give 23-7 (2.1 g, 75%) as a white foam. ESI-MS: m/z 263.0 [M+H] + .

To a solution of 23-7 (2.1 g, 8.0 mmol) in pyridine was added TIDPSCl (2.5 g, 8.0 mmol) dropwise at 0° C., and stirred for 12 h. at R.T. The solution was quenched with water, and concentrated to dryness at low pressure. The crude was purified by column chromatography (EA in PE from 10% to 50%) to give pure 23-8 (1.6 g, 40%) as a white foam.

A solution of 23-8 (1.5 g, 3.0 mmol) and IBX (1.69 g, 6.0 mmol) in anhydrous CH 3 CN (10 mL) was stirred at 80° C. for 3 h. The mixture was cooled down to R.T. and filtered. The filtrate was concentrated to dryness at low pressure. The residue was purified by column chromatography (EA in PE from 2% to 50%) to give pure 23-9 (1.2 g, 80%) as a white foam. ESI-MS: m/z 503.0 [M+H] +

Compound 23-9 (500 mg, 1 mmol) was dissolved in dry THF (8 mL). Ethynyl magnesium bromide (8 mL of 0.5M solution in cyclohexane) was added at R.T. After 30 mins, additional ethynyl magnesium bromide (8 mL) was added. The mixture was left for 30 mins, and then quenched with sat. solution of ammonium chloride. The product was extracted with EA. The organic extracts were washed with brine, dried, and concentrated. The residue was purified by flash chromatography on silica gel in EA to remove the dark color. The yellow compound was dissolved in THF (3 mL) and treated with TBAF (1 mL, 2M solution in THF) for 30 mins. The solvent was evaporated, and the residue was subjected to silica gel chromatography on a Biotage cartridge (25 g). EA saturated with water was used for isocratic elution. Each fractions were analyzed by TLC in DCM-MeOH (9:1 v/v). Fractions containing only the isomer with a high Rf were concentrated to give pure compound 23 (110 mg). MS: 285.1 [M−1] − .

›Example 8

Compound 22

Compound 23 (57 mg, 0.2 mmol) was dissolved in CH 3 CN (2 mL), containing N-methylimidazole (40 uL). The phosphorochloridate (207 mg, 0.6 mmol) was added, and the mixture was kept overnight at 40° C. The mixture was distributed between water and EA. The organic layer was separated, washed with brine, dried and evaporated. The product was isolated by silica gel chromatography in gradient of methanol in DCM from 0% to 15%. Compound 22 was obtained (46 mg, 39%). MS: m/z 593.9 [M−1] − .

›Example 9

Compound 51

To a solution of triethylammonium bis(isopropyloxycarbonyloxymethyl)phosphate (0.74 mmol) in THF was added 51-1 (0.16 gg; 0.49 mmol). The mixture evaporated and rendered anhydrous by coevaporating with pyridine follow by toluene. The residue was dissolved in anhydrous THF and cooled in an ice-bath. Diisopropylethyl amine (0.34 mL) was added, followed by BOP-Cl (250 mg) and 3-nitro-1,2,4-triazole (112 mg) in THF (5 mL). The mixture was stirred at 0° C. for 90 mins, diluted with EtOAc, washed with sat. aq. NaHCO 3 and brine, and dried (Na 2 SO 4 ). The residue was purified on silica column with 3-10% i-PrOH in DCM to give 51-2 (0.2 g, 64%).

A solution of 51-2 (0.20 g; 0.31 mmol) in 80% aq. HCOOH was stirred at R.T. for 2 h, and then concentrated. The residue was coevaporated with toluene and then with MeOH containing a small amount of Et 3 N (2 drops). Purification on silica gel (10 g column) with CH 2 Cl 2 /MeOH (4-10% gradient) was followed by RP-HPLC purification in 5 runs on a Synergi Hydro RP column 250×30 mm (Phenomenex P/N 00G-4375-U0-AX) using H 2 O and ACN both 50 mM TEAA. The Gradient was 25-75% ACN in 20 mins at 24 mL/mins, 254 nM detection. The compound eluted at 16.0 minutes; and the pure fractions were pooled and lyophilized. TEAA was removed by dissolving the compound in DMSO (2 mL) and using the same column and same gradient, using only H 2 O and ACN. Pure fractions were pooled and lyophilized to give compound 51 (18 mg). MS: m/z=1197 [2M+1] + .

›Example 10

Compound 8

Compound 8-1 (5.0 g, 8.5 mmol) and 2-amino-6-chloropurine (3.0 g, 17.7 mmol) were co-concentrated with anhydrous toluene for 3 times. To a stirred suspension of the above mixtures in anhydrous MeCN (50 mL) was added DBU (7.5 g, 49 mmol) at 0° C. The mixture was stirred at 0° C. for 15 mins, and then TMSOTf (15 g, 67.6 mmol) was added dropwise at 0° C. The mixture was stirred at 0° C. for 15 mins. The mixture was heated at 70° C. overnight. The mixture was cooled to R.T., and diluted with EA (100 mL). The solution was washed with sat. NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 and concentrated at low pressure. The residue was purified by column on silica gel (PE/EA: from 15/1 to 3/1) to give 8-2 (2.5 g, 46.3%) as a white foam.

To a solution of 8-2 (10 g, 15.7 mmol), AgNO 3 (8.0 g, 47 mmol) and collidine (10 mL) in anhydrous DCM (20 mL) was added MMTrCl (14.5 g, 47 mmol) in small portions under N 2 . The mixture was stirred at R.T. overnight. The mixture was filtered, and the filtrate was washed with sat. aq. NaHCO 3 and brine. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (PE/ME=20/1 to 8/1) to give 8-3 (10 g, 70%) as a yellow solid.

To a solution of 3-hydroxy-propionitrile (3.51 g, 49.4 mmol) in anhydrous THF (100 mL) was added NaH (2.8 g, 70 mmol) at 0° C., and the mixture was stirred at R.T. for 30 mins. A solution of 8-3 (8.5 g, 9.35 mmol) in anhydrous THF (100 mL) at 0° C. was added, and the mixture was stirred at R.T. overnight. The reaction was quenched with water, and extracted with EA (100 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (DCM/MeOH=100/1 to 20/1) to give 8-4 (4.5 g, 83%) as a white solid.

Compound 8-4 (1.5 g, 2.6 mmol) was co-concentrated with anhydrous pyridine 3 times. To an ice-cooled solution of 8-4 in anhydrous pyridine (30 mL) was added TsCl (1.086 g, 5.7 mmol), and the mixture was stirred at 0° C. for 1 h. The reaction was quenched with water, and extracted with EA (80 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (DCM/MeOH=100/1 to 15/1) to give 8-5 (1.4 g, 73%) as a white solid.

To a solution of 8-5 (4.22 g, 5.7 mmol) in acetone (60 mL) was added NaI (3.45 g, 23 mmol), and the mixture was refluxed overnight. The reaction was quenched with sat. aq. Na 2 S 2 O 3 and extracted with EA (100 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (DCM/MeOH=100/1 to 15/1) to give 8-6 (4 g, 73%) as a white solid.

To a solution of 8-6 (4.0 g, 5.8 mmol) in anhydrous THF (60 mL) was added DBU (3.67 g, 24 mmol), and the mixture was stirred at 60° C. overnight. The mixture was diluted with EA (80 mL), and the solution was washed with brine. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (DCM/MeOH=100/1 to 20/1) to give 8-7 (2 g, 61%) as a white solid.

To an ice-cooled solution of 8-7 (500 mg, 0.89 mmol) in anhydrous DCM (20 mL) was added AgF (618 mg, 4.9 mmol) and a solution of 12 (500 mg, 1.97 mmol) in anhydrous DCM (20 mL). The mixture was stirred at R.T. for 3 h. The reaction was quenched with sat Na 2 S 2 O 3 and NaHCO 3 aqueous, and the mixture was extracted with DCM (50 mL). The organic layer was separated, dried over anhydrous Na 2 SO 4 , and concentrated to give the crude 8-8 (250 mg) as a yellow solid.

To a solution of crude 8-8 (900 mg, 1.28 mmol) in anhydrous DCM (50 mL) was added DMAP (1.0 g, 8.2 mmol) and BzCl (795 mg, 5.66 mmol). The mixture was stirred at R.T. overnight. The mixture was washed with sat. aq. NaHCO 3 and brine. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by prep-TLC (DCM/MeOH=15:1) to give 8-9 (300 mg, 26%) as a white solid.

To a solution of crude 8-9 (750 mg, 0.82 mmol) in anhydrous HMPA (20 mL) was added NaOBz (1.2 g, 8.3 mmol) and 15-crown-5 (1.8 g, 8.3 mmol). The mixture was stirred at 60° C. for 2 d. The mixture was diluted with EA, and the solution was washed with brine. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by prep-TLC (PE/EA=1:1) to give crude 8-10 (550 mg, 73%) as a white solid.

The crude 8-10 (550 mg, 0.6 mmol) was dissolved in NH 3 /MeOH (7N, 50 mL). The mixture was stirred at R.T. overnight. The mixture was concentrated, and the residue was purified by silica gel column (DCM/MeOH from 100/1 to 20/1) to give 8-11 (62 mg, 17%) as a white solid. ESI-MS: m/z 598.0 [M+H] +

A solution of 8-11 (12 mg) in 80% formic acid (0.5 mL) stood at R.T. for 3.5 h and then was concentrated. The residue was co-evaporated with MeOH/toluene 4 times in a vial, and triturated with EtOAc at 40° C. The EtOAc solution removed with pippet. The trituration step was repeated several times, and the remaining solid was dissolved in MeOH. The solution was concentrated and dried to give compound 8 as off white solid (4.7 mg). ESI-MS: m/z 326.6 [M+H] + .

›Example 11 · 1 of 2

Compounds 34 and 35

To a stirred suspension of 8-1 (50 g, 84.8 mmol) and 2-amino-6-chloropurine (28.6 g, 169.2 mmol) in anhydrous MeCN (500 mL) was added DBU (77.8 g, 508 mmol) at 0° C. The mixture was stirred at 0° C. for 30 mins, and TMSOTf (150.5 g, 678 mmol) was added dropwise at 0° C. The mixture was stirred at R.T. for 20 mins until a clear solution was formed. The mixture was stirred at 90-110° C. overnight. The mixture was cooled to R.T., and diluted with EA. The solution was washed with sat. NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 and then concentrated at low pressure. The residue was purified by silica gel column (PE/EA=2/1) to give 34-1 (30 g, 55.5%) as a white solid.

To a solution of 34-1 (30 g, 47.1 mmol) in anhydrous DCM (300 mL) was added collidine (30 mL), AgNO 3 (24 g, 141.4 mmol) and MMTrCl (43.6 g, 141.4 mmol). The mixture was stirred at R.T. overnight. The mixture was filtered, and the filtrate was washed with water and brine. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (PE/EA=4/1) to give 34-2 (35 g, 82%) as a white solid.

To a stirred solution of 34-2 (35 g, 38.5 mmol) in anhydrous EtOH (150 mL) was added a solution of EtONa in EtOH (2N, 150 mL). The mixture was stirred at R.T. overnight, and then concentrated at low pressure. The residue was dissolved in EA (200 mL) and the solution was washed with water and brine. The organic layer was dried over Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (DCM/MeOH=100/2) to give 34-3 (19 g, 81%) as a white solid.

Compound 34-3 (19 g, 31.3 mmol) was co-concentrated with anhydrous pyridine for 3 times. To an ice-cooled solution of 34-3 in anhydrous pyridine (120 mL) was added a solution of TsCl (6.6 g, 34.6 mmol) in pyridine (40 mL) dropwise at 0° C. The mixture was stirred at 0° C. for 16 h. The mixture was quenched with water, and the reaction mixture was concentrated. The residue was re-dissolved in EA (200 mL). The solution was washed with sat. aq. NaHCO 3 and brine. The organic layer was dried over anhydrous Na 2 SO 4 and filtered, and the filtrate was concentrated. The residue was purified by silica gel column (DCM/MeOH=100/1) to give 34-4 (16 g, 67%) as a yellow solid.

To a solution of 34-4 (15 g, 19.7 mmol) in acetone (100 mL) was added NaI (30 g, 197 mmol). The mixture was refluxed overnight, and then concentrated at low pressure. The residue was purified by silica gel column (DCM/MeOH=100/1) to give 34-5 (9 g, 63.7%) as a white solid.

To a solution of 34-5 (8 g, 11.2 mmol) in anhydrous THF (60 mL) was added DBU (5.12 g, 33.5 mmol), and the mixture was heated at 60° C. overnight. The mixture was diluted with EA, and washed with water and brine. The organic layer was dried over anhydrous Na 2 SO 4 and filtered, and the filtrate was concentrated. The residue was purified by silica gel column (PE/acetone=4/1) to give 34-6 (5.7 g, 86%) as a white solid. 1 H-NMR (CD 3 OH, 400 MHz) δ=8.18 (s, 1H), 7.17-7.33 (m, 12H), 6.80 (d, J=8.8 Hz, 2H), 5.98 (s, 1H), 5.40 (d, J=8.6 Hz, 1H), 3.87 (m, 5H), 3.75 (s, 3H), 2.69 (s, 1H), 1.05 (s, 3H).

To an ice-cooled solution of 34-6 (4.44 g, 7.5 mmol) in anhydrous MeCN (45 mL) was added TEA.3HF (1.23 g, 7.6 mmol) and NIS (2.16 g, 9.5 mmol). The mixture was stirred at R.T. for 2-3 h. The reaction was quenched with sat. Na 2 SO 3 and NaHCO 3 solution. The mixture was extracted with EA (3×100 mL). The organic layer was separated, dried over anhydrous Na 2 SO 4 and concentrated at low pressure. The residue was purified by silica gel column (DCM/acetone=100/2) to give 34-7 (4.4 g, 79.8%) as a white solid.

To a solution of 34-7 (5.36 g, 7.3 mmol) in anhydrous DCM (50 mL) was added DMAP (3.6 g, 29.8 mmol) and BzCl (3.1 g, 22.1 mmol) at 0° C. The mixture was stirred at R.T. overnight. The mixture was washed with sat. aq. NaHCO 3 and brine. The organic layer was concentrated, and the residue was purified by silica gel column (PE/EA=5/1) to give 34-8 (5.6 g, 81.3%) as a white solid.

To a solution of 34-8 (5.0 g, 5.3 mmol) in anhydrous DMF (150 mL) was added NaOBz (7.64 g, 53 mmol) and 15-crown-5 (14 g, 68 mmol). The mixture was stirred at 90-100° C. for 48 h. The mixture was diluted with EA, and washed with water and brine. The organic layer was concentrated, and the residue was purified by silica gel column (PE/EA=5/1) to give 34-9 (3.9 g, 78.5%) as a white solid.

Compound 34-9 in NH 3 in MeOH (7N, 60 mL) was stirred at R.T. for 18 h. The mixture was concentrated at low pressure. The residue was purified by silica gel column (DCM/acetone=50/1) to give 34-10 (500 mg, 74.7%) as a white solid. ESI-MS: m/z 626.3 [M+H] + .

To a solution of 34-10 (350 mg, 0.56 mmol) in anhydrous pyridine (4 mL) was added imidazole (50 mg, 0.72 mmol) and TBSCl (108 mg, 0.72 mmol) at 0 to 5° C., and stirred at R.T. for 15 h. The reaction was quenched with absolute EtOH (0.5 mL). The solution was concentrated to dryness under reduced pressure. The residue was dissolved in EA (150 mL), and washed with water, sat. NaHCO 3 and brine. The combined organic layers were dried over Na 2 SO 4 , filtered and evaporated at low pressure. The residue was purified by silica gel column (10-30% EA in hexanes) to give 34-11 (338 mg, 81.8%) as a white solid.

To a solution of compound 34-11 (328 mg, 0.44 mmol), AgNO 3 (226 mg, 1.33 mmol) and collidine (0.59 mL, 4.84 mmol) in anhydrous DCM (4 mL) was added MMTrCl (410 mg, 1.33 mmol) under N 2 . The mixture was stirred at R.T. overnight under N 2 , and monitored by TLC to completion. The mixture was filtered through pre-packed Celite filter, and the filtrate was washed with water, 50% aqueous citric acid, and brine. The organic layer was separated, dried over anhydrous Na 2 SO 4 , filtered and concentrated at low pressure. The residue was purified by silica gel column (EA in hexanes from 0% to 30%) to give 34-12 (337 mg).

To a solution of 34-12 (337 mg, 0.33 mmol) in anhydrous THF (4 mL) was added 1.0 M solution of TBAF (0.66 ML, 0.66 mmol) at 0 to 5° C. The reaction was slowly warmed to R.T., and stirred for 1 h. The mixture was quenched with silica gel, and filtered. The solvents were evaporated to give the crude product, which was purified by silica gel column (EA in hexanes from 0% to 50%) to give 34-13 (188 mg).

›Example 11 · 2 of 2

To a stirred solution of 34-13 (180 mg, 0.16 mmol) in anhydrous CH 3 CN (2.5 mL) was added N-methylimidazole (132 μL, 1.6 mmol) at 0-5° C. (ice/water bath) followed by solution of phenyl (cyclohexanoxy-L-alaninyl) phosphorochloridate (207 mg, 0.6 mmol, dissolved in 2 mL of CH 3 CN). The solution was stirred at R.T. for 2.5 h, and the mixture was diluted with EA followed by addition of water (15 mL). The solution was washed H 2 O, 50% aqueous citric acid solution and brine. The organic layer was separated, dried over anhydrous MgSO 4 and filtered. The filtrate was concentrated in vacuum to give a residue, which was purified on silica gel with 0 to 40% EA/hexanes to give 34-14 (75.8 mg) and 34-15 (108 mg) as a slower eluting isomer.

Compound 34-14 (76 mg, 0.063 mmol) was dissolved in_anhydrous CH 3 CN (0.5 mL), and 4N HCl in dioxane (47 μL) was added at 0 to 5° C. (ice/water bath). The mixture was stirred at R.T. for 40 mins, and anhydrous EtOH (200 μL) was added. The solvents were evaporated at R.T. and co-evaporated with toluene 3 times. The residue was dissolved in 50% CH 3 CN/H 2 O, purified on a reverse-phase HPLC (C18) using acetonitrile and water, and lyophilized to give compound 34 (26.6 mg). ESI-LCMS: m/z=663.3 [M+H] + .

Compound 34-15 (108 mg, 0.089 mmol) was dissolved in_anhydrous CH 3 CN (0.7 mL), and 4N HCl in dioxane (67 μL) was added at 0 to 5° C. (ice/water bath). The mixture was stirred at R.T. for 60 mins, and anhydrous EtOH (200 μL) was added. The solvents were evaporated at R.T. and co-evaporated with toluene 3 times. The residue was dissolved in 50% CH 3 CN/H 2 O, purified on a reverse-phase HPLC (C18) using acetonitrile and water, and lyophilized to give compound 35 (40.3 mg). ESI-LCMS: m/z=663.2 [M+H] + .

›Example 12

Compound 25

To a solution of 25-1 (260 mg, 1 mmol), PPh 3 (780 mg, 3 mmol) and pyridine (0.5 mL) in anhydrous THF (8 mL) were added 12 (504 mg, 2 mmol) at R.T., and the mixture was stirred at R.T. for 12 h. The mixture was diluted with EtOAc and washed with 1M HCl solution. The organic layer was dried over Na 2 SO 4 , filtered and concentrated at low pressure. The residue was purified by silica gel column (5% MeOH in DCM) to give 25-2 (190 mg, 85%) as a white solid.

To a solution of 25-2 (190 mg, 0.52 mmol) in THF (4 mL) was added DBU (760 mg, 5 mmol) at R.T., and the mixture was heated at 50° C. overnight. The mixture was diluted with EtOAc, and washed with water. The organic layer was dried over anhydrous Na 2 SO 4 and concentrated at low pressure. The residue was purified by silica gel column (30% EA in PE) to give 25-3 (75 mg, 52%) as a white solid.

To a solution of 25-3 (200 mg, 0.82 mmol) in MeCN (anhydrous, 4 mL) was added NIS (337 mg, 1.5 mmol) and TEA.3HF (213 mg, 1.25 mmol) at R.T., and the mixture was stirred at R.T. for 7 h. The reaction was quenched with sat. Na 2 SO 3 solution and sat. aq. NaHCO 3 solution. The mixture was extracted with EA. The organic layer was separated, dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (20% EA in PE) to give 25-4 (300 mg, 62%) as a white solid.

To a solution of 25-4 (194 mg, 0.5 mmol) in pyridine (5 mL) was added BzCl (92 mg, 0.55 mmol) at 0° C. The mixture was stirred at R.T. for 5 h, and the reaction was quenched with water. The mixture was concentrated at low pressure, and the residue was purified by silica gel column (20% EA in PE) to give 25-5 (397 mg, 81%) as a white solid.

To a solution of 25-5 (1.05 g, 2.13 mmol) in DCM (12 mL) was added a mixture of TFA (0.5 mL) and Bu 4 NOH (1 mL), followed by addition of m-CPBA (1.3 g, 6 mmol) at R.T. The mixture was stirred at R.T. for 5 h. The mixture was washed with sat. Na 2 SO 3 solution and aq. NaHCO 3 solution. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (30% EA in PE) to give 25-6 (450 mg, 63%) as a white solid.

Compound 25-6 (250 mg, 0.65 mmol) was dissolved in NH 3 /MeOH (5 mL). The mixture was stirred at R.T. for 5 h, and then concentrated at low pressure. The residue was purified by silica gel column (5% MeOH in DCM) to give compound 25 (120 mg, 66%) as a white powder. ESI-MS: m/z 279.0 [M+H] + .

›Example 13

Compound 31

To a stirred solution of compound 25 (100 mg, 0.36 mmol) in anhydrous THF (3.0 mL) was added N-methylimidazole (236 μL, 2.87 mmol) at 0° C. (dry ice/acetone bath) followed by a solution of the phosphorochloridate (329 mg, 1.08 mmol, dissolved in 2 mL of THF). The solution was stirred at 0° C. for 1 h, the reaction temperature was raised up-to 10° C. during the next 1 h, and the solution was left at 10° C. for the next 4 h. The mixture was cooled to 0 to 5° C., diluted with EA, and water was added (15 mL). The solution was washed H 2 O, 50% aqueous citric acid solution and brine. The organic layer was separated, dried over anhydrous MgSO 4 and filtered. The filtrate was concentrated in vacuum to give a residue, which dissolved in 25% CH 3 CN/H 2 O. The residue was purified on a reverse-phase HPLC (C18) using acetonitrile and water, followed by lyophilization to give a mixture of two isomers of compound 31 (17.5 mg). MS: m/z 546.05 [M−H] − .

›Example 14

Compound 27

To a solution of compound 25 (139 mg, 0.5 mmol) in pyridine (5 mL) was added BzCl (92 mg, 0.55 mmol) at 0° C. The mixture was stirred at R.T. for 5 h, diluted with EtOAc and washed with 1N HCl solution. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (20% EA in PE) to give 27-1 (274 mg, 79%) as a white solid.

To a solution of 27-1 (490 mg, 1 mmol), DMAP (244 mg, 2 mmol) and TEA (205 mg, 2.1 mmol) in MeCN (10 mL) were added TPSCl (604 mg, 2 mmol) at 0° C. The mixture was stirred at R.T. for 2 h., and then NH 4 OH aq. was added at R.T. The mixture was stirred for 0.5 h, diluted with EtOAc and washed with sat. aq. NaHCO 3 and brine. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (30% EA in PE) to give 27-2 (250 mg, 41%) as a white solid.

Compound 27-2 (250 mg, 0.51 mmol) was dissolved in NH 3 /MeOH (15 mL). The mixture was stirred at R.T. for 5 h. and then concentrated at low pressure. The residue was purified by silica gel column (5% DCM in DCM) to give compound 27 (95 mg, 66%) as a white powder. ESI-MS: m/z 278.1 [M+H] + .

›Example 15

Compound 29

To a solution of compound 29-1 (30 g, 0.08 mol) in anhydrous THF (300 mL) was added a solution of lithium tri-tert-butoxyaluminohydride (120 mL, 0.12 mol) dropwise at −78° C. under N 2 . The mixture was stirred at −20° C. for 1 h. The reaction was quenched with sat. aq. NH 4 Cl and then filtered. The filtrate was extracted with EA (3×300 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (10% EA in PE) to give 29-2 (26 g, 86%) as a colorless oil.

To a stirred solution of PPh 3 (37.7 g, 0.144 mol) in DCM (100 mL) was added compound 29-2 (27 g, 0.072 mol) at −20° C. under N 2 . After the mixture was stirred at R.T. for 15 mins, CBr 4 (42 g, 0.129 mol) was added while maintaining the reaction temperature between −25 and −20° C. under N 2 . The mixture was then stirred below −17° C. for 20 mins. Silica gel was added into the solution, and then purified by flash silica gel column separation to give the crude oil product. The crude was purified by silica gel column (EA in PE from 2% to 20%) to give 29-3 (α-isomer, 17 g, 55%) as a colorless oil.

A mixture of 6-Cl-guanine (11.6 g, 68.8 mmol) and t-BuOK (8.2 g, 73 mmol) in t-BuOH (200 mL) and MeCN (150 mL) was stirred at 35° C. for 30 mins, and then 29-3 (10 g, 22.9 mmol) in MeCN 100 mL) was added at R.T. The mixture was heated at 50° C. overnight. The reaction was quenched with a solution of NH 4 Cl (5 g) in water (40 mL), and the mixture was filtered. The filtrate was evaporated at low pressure. The residue was purified by silica gel column (20% EA in PE) to give 29-4 (6 g, 42%) as a yellow solid.

To a solution of 29-4 (12.5 g, 23.8 mol) in DCM (50 mL) was added AgNO 3 (8.1 g, 47.6 mmol), collidine (5.77 g, 47.6 mmol) and MMTrCl (11 g, 35.7 mmol). The mixture was stirred at R.T. overnight. The reaction was quenched with MeOH (5 mL), filtered and concentrated at low pressure. The residue was purified by silica gel column (5% MeOH in DCM) to give the intermediate (16 g, 86%) as a yellow solid. To a solution of HOCH 2 CH 2 CN (4.7 g, 66 mmol) in THF (200 mL) was added NaH (3.7 g, 92 mmol) at 0° C. The mixture was stirred at R.T. for 30 mins. A solution of the intermediate (10.5 g, 13 mmol) in THF (50 mL) was added, and the reaction mixture was stirred at R.T. for 12 h. The reaction was quenched with MeOH (2 mL), diluted with EA (100 mL), and washed with brine. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (5% MeOH in DCM) to give 29-5 (5.8 g, 77%) as a yellow solid.

To a solution of PPh 3 (7.0 g, 26.6 mmol) in anhydrous pyridine (100 mL) was added 12 (6.3 g, 24.9 mmol), and stirred at R.T. for 30 mins. The mixture was treated with a solution of 29-5 (9.5 g, 16.6 mmol) in pyridine (40 mL). The mixture was stirred at R.T. overnight. The reaction was quenched with sat. Na 2 S 2 O 3 solution, and the mixture was extracted with EA. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (30% EA in PE) to give 29-6 (7 g, 66%) as a yellow solid.

To a solution of 29-6 (7.5 g, 11 mmol) in dry THF (50 mL) was added DBU (5.4 g, 33 mmol), and the mixture was heated to reflux for 4 h. The mixture was diluted with EA (3×100 mL), and washed with brine. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (30% EA in PE) to give 29-7 (4.0 g, 67%) as a white solid.

To an ice-cooled solution of 29-7 (3.0 g, 5.4 mmol) in anhydrous MeCN (20 mL) was added TEA.3HF (0.65 g, 4.1 mmol) and NIS (1.53 g, 6.78 mmol) at R.T., and the reaction mixture was stirred at R.T. for 2 h. The mixture was diluted with EA (50 mL), and washed with sat. Na 2 S 2 O 3 solution and NaHCO 3 aq. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated to dryness at low pressure. The residue was purified by prep-HPLC (0.1% HCOOH in water and MeCN) to separate the two isomers (about 1:1). NOE showed the polar one was 29-8 (0.6 g, 16%) as a white solid.

To a solution of 29-8 (0.7 g, 1 mmol) in dry pyridine (10 mL) was added BzCl (147 mg, 1.05 mmol) at 0° C. The mixture was stirred at R.T. for 3 h. The mixture was then diluted with EA, and washed with sat. NaHCO 3 aq. and brine. The organic layer was dried over Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column (20% EA in PE) to give 29-9 (0.65 g, 81%) as a white solid.

To a solution of 29-9 (0.65 g, 0.8 mmol) in dry DMF (40 mL) was added NaOBz (1.15 g, 8 mmol) and 15-crown-5 (1.77 g, 8 mmol). The mixture was stirred at 100° C. for 48 h. The solvent was evaporated at low pressure, and the residue was dissolved in EA (30 mL), and washed with water and brine. The organic layer was dried over Na 2 SO 4 and concentrated at low pressure. The residue was purified by silica gel column (20% EA in PE) to give 29-10 (500 mg, 78%) as a white solid.

Compound 29-10 (400 mg, 0.5 mmol) in NH 3 /MeOH (7N, 100 mL) was stirred at R.T. for 18 h. The mixture was concentrated at low pressure, and the residue was purified by silica gel column (5% MeOH in DCM) to give 29-11 (220 mg, 63%) as a white solid. ESI-MS: m/z 590.3 [M+H] + .

Compound 29-11 (59 mg, 0.1 mmol) was dissolved in 50% TFA in methanol (10 mL), and the mixture was kept at R.T. for 2 h. The solvent was evaporated and co-evaporated with a methanol/toluene mixture to remove traces of the acid. The residue was suspended in CH 3 CN (1 mL) and centrifuged. The precipitate was washed with CH 3 CN (1 mL) and dried. Compound 29 was obtained as a colorless solid (21 mg, 65%. MS: m/z 316.2 [M−1] − .

›Example 16

Compounds 42 and 43

A freshly prepared EtONa in dry EtOH (2N, 150 mL) was added to a solution of 29-4 (13.67 g, 17.15 mmol) in EtOH (50 mL) at 0° C. The mixture was stirred at R.T. for 1 h, and then concentrated at low pressure. The residue was purified by silica gel column (5% MeOH in DCM) to give 42-1 (10 g, 98%) as a yellow solid.

To a solution of PPh 3 (2.73 g, 10.4 mol) in anhydrous pyridine (60 mL) was added 12 (2.48 g, 9.76 mmol) at R.T., and the reaction mixture was stirred R.T. for 30 mins. A solution of 42-1 (3.9 g, 6.51 mmol) in pyridine (10 mL) was added. The mixture was stirred at R.T. overnight. The reaction was quenched with sat. Na 2 S 2 O 3 solution and NaHCO 3 aq., and then extracted with EA (100 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column (2% MeOH in DCM) to give 42-2 (3.0 g, 75%) as a yellowed solid.

To a solution of 42-2 in dry THF (300 mL) was added DBU (14.0 g, 91.8 mmol), and the mixture was heated to reflux for 3 h. The mixture was concentrated at low pressure. The residue was dissolved in EA (100 mL), and washed with brine. The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column (20% EA in PE) to give 42-3 (0.6 g, 37.5%) as a white solid.

To an ice-cooled solution of 42-3 (2.0 g, 3.44 mmol) in anhydrous MeCN (20 mL) was added NIS (0.975 g, 4.3 mmol) and TEA.3HF (0.82 g, 5.16 mmol) at 0° C. The mixture was stirred at R.T. for 2 h. The reaction was quenched with sat. Na 2 SO 3 and NaHCO 3 aqueous solution, and then concentrated at low pressure. The residue was dissolved in EA (50 mL), washed with brine, dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column (20% EA in PE) to give 42-4 (1.5 g, 60%) as a white solid.

To a solution of 42-4 (1 g, 1.37 mmol) in dry pyridine (100 mL) was added BzCl (0.23 g, 1.65 mmol) at 0° C. The reaction was stirred for 30 mins and checked by LCMS. The mixture was concentrated at low pressure, and the residue was dissolved in EA (50 mL). The solution was washed with brine. The organic layer was dried over MgSO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (10% EA in PE) to give 42-5 (0.9 g, 78%) as a white solid.

To a solution of 42-5 (2 g, 2.4 mmol) in dry DMF (40 mL) was added NaOBz (3.46 g, 24 mmol) and 15-crown-5 (4.5 mL). The mixture was stirred at 95° C. for 72 h. The mixture was then diluted with EA (100 mL), and washed with water and brine. The organic phase was dried over MgSO 4 , and concentrated at low pressure. The residue was purified by silica gel column (15% EA in PE) to give 42-6 (1.5 g, 75%) as a white solid.

Compound 42-6 (1.35 g, 1.64 mmol) in NH 3 /MeOH (150 mL) was stirred at R.T. for 18 h. The mixture was concentrated at low pressure, and the residue was purified by silica gel column (5% MeOH in DCM) to give 42-7 (0.9 g, 90%) as a white solid. ESI-MS: m/z 618.3 [M+H] + .

To a solution of 42-7 (99 mg, 0.16 mmol) in DCM (1.0 mL), triethylamine (92.7 μL, 0.64 mmol) was added at R.T. The mixture was cooled to 0 to 5° C. (ice/water bath), and freshly prepared and distilled isopropyl phosphorodichloridate (36.6 μL, 0.2 mmol, prepared according to a procedure, Reddy et al. J. Org. Chem. 2011, 76 (10), 3782-3790) was added to the mixture. The mixture was stirred 0 to 5° C. (ice/water bath) for 15 mins, followed by addition of N-methylimidazole (26.3 μL, 0.32 mmol). The mixture was then stirred for 1 h at 0 to 5° C. TLC showed absence of 42-7. EA (100 mL) was added, followed by water. The organic layer was washed H 2 O, saturated aqueous NH 4 Cl solution and brine. The organic layer was separated, dried over anhydrous MgSO 4 and filtered. The filtrate was concentrated in vacuum to give a residue, which was purified on silica gel with 0 to 10% iPrOH/DCM to give a mixture of 42-a and 42-b (61.5 mg).

A mixture of 42-a and 42-b (61.5 mg, 0.085 mmol) was dissolved in anhydrous CH 3 CN (0.5 mL), and 4N HCl in dioxane (64 μL) was added at 0 to 5° C. (ice/water bath). The mixture was stirred at R.T. for 40 mins, and anhydrous EtOH (200 μL) was added. The solvents were evaporated at R.T. and co-evaporated with toluene 3 times. The residue was dissolved in 50% CH 3 CN/H 2 O, was purified on a reverse-phase HPLC (C18) using acetonitrile and water, followed by lyophilization to give compound 42 (1.8 mg) and compound 43 (14.5 mg).

Compound 42: 1 H NMR (CD 3 OD-d 4 , 400 MHz) δ 8.0 (s, 1H), 6.69 (d, J=16.0 Hz, 1H), 5.9-5.6 (br s, 1H), 4.94-4.85 (m, 1H), 4.68-4.52 (m, 3H), 1.49-1.3 (m, 12H); 19 F NMR (CD 3 OD-d 4 ) δ −122.8 (s), −160.06 (s); 31 P NMR (CD 3 OD-d 4 ) δ −7.97 (s). ESI-LCMS: m/z=450.1 [M+H] + ; Compound 43: 1 H NMR (CD 3 OD-d 4 , 400 MHz) δ 7.96 (s, 1H), 6.68 (s, 1H), 6.69 (d, J=16.8 Hz, 1H), 6.28-6.1 (br s, 1H), 4.81-4.5 (m, 4H), 1.45-1.39 (m, 12H); 31 P NMR (CD 3 OD-d 4 ) δ −5.84 (s). ESI-LCMS: m/z=450.0 [M+H] + .

›Example 17

Compounds 32 and 33

To a solution of 42-7 (0.47 g, 0.65 mol) in DCM (3 mL) was added AgNO 3 (0.22 g, 1.29 mmol), collidine (0.15 g, 1.29 mmol) and MMTrCl (0.3 g, 0.974 mmol) at 0° C. The mixture was stirred at R.T. overnight. The mixture was filtered, and the filter was washed with sat. aq. NaHCO 3 solution and brine. The organic layer was separated, dried over anhydrous Na 2 SO 4 and concentrated at low pressure. The residue was purified by silica gel column to give 32-1 (0.55, 85%) as a white solid.

To a solution of 32-1 (0.5 g, 0.5 mmol) in dry DMF (10 mL) was added NaOBz (0.72 g, 5 mmol) and 15-crown-5 (0.9 mL). The mixture was stirred at 95° C. for 72 h. The mixture was diluted with EA, and washed with water and brine. The organic phase was dried over MgSO 4 and concentrated at low pressure. The residue was purified by silica gel column (10% EA in PE) to give 32-2 (0.3 g, 60%) as a white solid.

Compound 32-2 (0.3 g, 0.3 mmol) in NH 3 /MeOH (30 mL) was stirred at R.T. for 18 h. The mixture was concentrated at low pressure, and the residue was purified by silica gel column (20% EA in PE) to give 32-3 (145 mg, 56%) as a white solid. ESI-LCMS: m/z 890.5 [M+H] + .

To a stirred solution of 32-3 (161 mg, 0.16 mmol) in anhydrous CH 3 CN (2.0 mL) was added N-methylimidazole (118 μL, 2.87 mmol) at 0 to 5° C. (ice/water bath) followed by solution of 32-4 (186 mg, 0.54 mmol, dissolved in 2 mL of CH 3 CN). The solution was stirred at 0 to 5° C. for 4 h. The mixture was diluted with EA, and water was added (15 mL). The solution was washed H 2 O, 50% aqueous citric acid solution and brine. The organic layer was separated, dried over anhydrous MgSO 4 and filtered. The filtrate was concentrated in vacuum to give a residue, which was purified on silica gel with 0 to 40% EA/hexanes to give as 32-5 (82.6 mg) as the faster eluting isomer and 32-6 (106 mg) as the slower eluting isomer.

Compound 32-5 (82.6 mg, 0.07 mmol) was dissolved in_anhydrous CH 3 CN (0.5 mL), and 4N HCl in dioxane (35 μL) was added at 0 to 5° C. The mixture was stirred at R.T. for 1 h, and anhydrous EtOH (100 μL) was added. The solvents were evaporated at R.T. and co-evaporated with toluene 3 times. The residue was dissolved in 50% CH 3 CN/H 2 O, and purified on a reverse-phase HPLC (C18) using acetonitrile and water, followed by lyophilization to give compound 32 (19.4 mg). 1 H NMR (CD 3 OD-d 4 , 400 MHz) δ 7.9 (s, 1H), 7.32-7.28 (t, J=8.0 Hz, 2H), 7.2-7.12 (m, 3H), 6.43 (d, J=17.6 Hz, 1H), 4.70-4.63 (m, 2H), 4.55-4.4 (m, 3H), 3.94-3.9 (m, 1H), 1.79-1.67 (m, 4H), 1.53-1.49 (m, 1H), 1.45-1.22 (m, 15H); 31 P NMR (CD 3 OD-d 4 ) δ 4.06 (s); ESI-LCMS: m/z=655.2 [M+H] + , 653.15 [M−H] − .

Compound 32-6 (100 mg, 0.083 mmol) was dissolved in_anhydrous CH 3 CN (0.5 mL), and 4N HCl in dioxane (50 μL) was added at 0 to 5° C. Following the procedure for obtaining compound 32, compound 33 (31.8 mg) was obtained. 1 H NMR (CD 3 OD-d 4 , 400 MHz) δ 7.93 (s, 1H), 7.33-7.29 (m, 2H), 7.24-7.14 (m, 3H), 6.41 (d, J=17.6 Hz, 1H), 4.70-4.60 (m, 2H), 4.54-4.49 (m, 2H), 4.44-4.39 (m, 1H), 3.92-3.89 (m, 1H), 1.77-1.66 (m, 4H), 1.54-1.24 (m, 16H); 31 P NMR (CD 3 OD-d 4 ) δ 3.91 (s); ESI-LCMS: m/z=655.2 [M+H] + , 653.1 [M−H] − .

›Example 18

Compound 53

Compound 53-1 (70 mg, 58%) was prepared from 32-3 (90 mg; 0.1 mmol) and triethylammonium bis(isopropyloxycarbonyloxymethyl)phosphate (0.2 mmol) with DIPEA (87 μL), BopCl (44 mg), and 3-nitro-1,2,4-triazole (29 mg) in THF (2 mL) according to a method described for compound 51-2. Purification was done with hexanes/EtOAc solvent system, 20-80% gradient.

Compound 53 (25 mg, 64%) was prepared from 53-1 (70 mg) in acetonitrile (0.6 mL) and 4 N HCl/dioxane (50 μL) according to a method described for compound 51. MS: m/z=658 [M+1] + .

›Example 19 · 1 of 2

Compounds 40 and 41

To a mixture of pre-silylated 6-Cl-guanine (using HMDS and (NH 4 ) 2 SO 4 ) (25.2 g, 150 mmol) in DCE (300 mL) was added 40-1 (50 g, 100 mmol) and TMSOTf (33.3 g, 150 mmol) at 0° C. The mixture was stirred at 70° C. for 16 h, and then concentrated at low pressure. The residue was re-dissolved in EA, and washed with sat. aq. NaHCO 3 and brine. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified on silica gel column (PE/EA=2/1) to give pure 40-2 (45 g, 73%) as a white solid.

To a solution of 40-2 (45 g, 73.4 mmol) in EtOH (73 mL) was added with EtONa (1N in EtOH, 360 mL). The mixture was stirred at R.T. for 16 h. The mixture was then concentrated to give a residue, which was purified by silica gel column (DCM/MeOH=10/1) to give pure 40-3 (19 g, 83%) as a white solid.

To a solution of 40-3 (19 g, 61.1 mmol) in pyridine (120 mL) was added with TIPDSCl 2 (19.2 g, 61 mmol) dropwise at 0° C. The mixture was stirred at R.T. for 16 h, and then concentrated at low pressure. The residue was re-dissolved in EA, and washed with sat. aq. NaHCO 3 . The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (DCM/MeOH=20/1) to give pure 40-4 (22 g, 65%) as a white solid.

To a solution of 40-4 (22 g, 39.8 mmol) in DMF/pyridine (5/1, 100 mL) was added TMSCl (12.9 g, 119 mmol) dropwise at 0° C. The mixture was stirred at R.T. for 1 h and then treated with isobutyryl chloride (5.4 g, 50 mmol). The mixture was stirred at R.T. for 3 h and then quenched by NH 4 OH. The mixture was concentrated at low pressure. The residue was dissolved in EA (200 mL). The solution was washed with sat. aq. NaHCO 3 , and then the organic layer was dried and concentrated at low pressure. The residue was purified by silica gel column (DCM/MeOH=50/1) to give pure 40-5 (15 g, 60%) as a white solid.

To a solution of 40-5 (15 g, 24.1 mmol) in DCM (100 mL) was added PDC (13.5 g, 26 mmol) and Ac 2 O (9.8 g, 96 mmol) at 0° C. The mixture was stirred at R.T. for 16 h. The reaction was quenched by sat. aq. NaHCO 3 , and then extracted with EA. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was dissolved in anhydrous THF (100 mL). To a solution of TMSCCH (12 g, 112 mmol) in THF (200 mL) was added n-BuLi (2.5 N, 44 mL) at −78° C. The mixture was stirred at −78° C. for 15 mins and 0° C. for 15 mins. The mixture was treated with a solution of crude ketone in THF at −78° C. and stirred at −30° C. for 2 h. The reaction was quenched by sat. aq. NH 4 Cl, and then extracted by EA. The combined organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (PE/EA=10/1) to give pure 40-6 (3.1 g, 18%) as a white solid.

To a solution of 40-6 (7 g, 7.5 mmol) and pyridine (1.4 g, 17 mmol) in DCM (35 mL) was added with DAST (5.6 g, 35 mmol) at −78° C. The mixture was stirred at −78° C. for 3 h. The reaction was quenched by sat. aq. NaHCO 3 , and then extracted with EA. The combined organic layer was dried over anhydrous, and concentrated at low pressure. The residue was purified by silica gel column (PE/EA=10/1) to give pure 40-7 (3.1 g, 18%) as a white solid.

Compound 40-7 (4.1 g, 5.7 mmol) in sat. NH 3 /MeOH (100 mL) was stirred at R.T. for 16 h, and concentrated at low pressure. The residue was re-dissolved in anhydrous DCM (300 mL), and was treated with AgNO 3 (27.0 g, 160 mmol), collidine (22 mL) and MMTrCl (23.0 g, 75.9 mmol) in small portions under N 2 . The mixture was stirred at R.T. for 16 h. The mixture was filtered, and the filtrate was washed with sat. NaHCO 3 solution and brine. The organic layer was separated, dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (PE/EA=10/1) to give the pure intermediate. The intermediate was dissolved in a solution of TBAF/THF (1N, 20 mL). The mixture was stirred at R.T. for 2 h and then concentrated at low pressure. The residue was purified by silica gel column (DCM/MeOH=50/1) to give pure 40-8 (3.0 g, 86%) as a white solid.

To a solution of 40-8 (3.0 g, 4.9 mmol) in THF (50 mL) was added imidazole (840 mg, 12 mmol), PPh 3 (3.2 g, 12 mmol), and 12 (2.4 g, 9.2 mmol) at 0° C. The mixture was stirred at R.T. for 16 h. The reaction was quenched by sat. aq. Na 2 S 2 O 3 , and then extracted with EA. The combined organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (PE/EA=2/1) to give crude 40-9 (4.2 g, >100%, containing TPPO) as a white solid.

To a solution of crude 40-9 in anhydrous THF (30 mL) was added DBU (2.7 g, 18 mmol), and heated to 80° C. The mixture was stirred for 1 h and checked by LCMS. The mixture was quenched by water, and extracted with EA. The organic layer was dried over anhydrous Na 2 SO 4 and filtered, and the filtrate was concentrated at low pressure. The residue was purified by silica gel column (PE/EA=2/1) to give 40-10 (2.0 g, 69%) as a white solid.

To an ice-cooled solution of 40-10 (2.0 g, 3.38 mmol) in anhydrous MeCN (15 mL) was added NIS (777 mg, 3.5 mmol) and NEt 3 .3HF (536 g, 3.3 mmol) at 0° C. The mixture was stirred at R.T. for 16 h and checked by LCMS. After completion, the mixture was quenched by sat. Na 2 SO 3 and sat. NaHCO 3 solution, and extracted with EA. The organic layer was separated, dried over anhydrous Na 2 SO 4 and concentrated at low pressure. The residue was purified by silica gel column chromatography (PE/EA=10/1 to 3/1) to give 40-11 (2.1 g, 84.0%) as a white solid.

To a solution of crude 40-11 (2.1 g, 2.85 mmol) in anhydrous DCM (100 mL) was added DMAP (490 mg, 4 mmol), and BzCl (580 mg, 4 mmol) at 0° C. The mixture was stirred overnight and checked by LCMS. The reaction was washed with sat. NaHCO 3 solution. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column chromatography (PE/EA=8/1 to 3/1) to give 40-12 (2.0 g, 83.4%) as a white solid.

›Example 19 · 2 of 2

To a solution of 40-12 (2.0 g, 2.4 mmol) in anhydrous DMF (60 mL) was added NaOBz (3.3 g, 23.0 mmol) and 15-crown-5 (5.11 g, 23 mmol). The mixture was stirred at 110° C. for 36 h. The reaction was quenched by water, and the mixture was extracted with EA. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (PE/EA=5/1 to 3/1) to give 40-13 (830 mg, 42.0%) as a white solid. ESI-MS: m/z 836.11 [M+H] + .

A solution of 40-13 (831 mg, 1.0 mmol) in anhydrous n-butylamine (4 mL) was stirred at R.T. for 3 h under N 2 atmosphere. The reaction was monitored by TLC. The solvent was evaporated in vacuo, and the residue was purified by silica gel column (MeOH in DCM from 0% to 10%) to give the crude product, which as re-purified using silica gel column to give 40-14 as a light pink solid (563 mg).

To a solution of 40-14 (560 mg, 0.89 mmol) in anhydrous pyridine (5 mL) was added imidazole (78.6 mg, 1.16 mmol) and TBSCl (202 mg, 1.34 mmol) at 0 to 5° C. The mixture was stirred at R.T. for 15 h. The reaction was quenched by adding absolute EtOH (0.3 mL). The solution was concentrated to dryness under reduced pressure, and co-evaporated with toluene 3 times. The residue was dissolved in EA (150 mL), and washed with water, sat. NaHCO 3 , and brine. The combined organic layer was dried over Na 2 SO 4 , filtered and evaporated at low pressure. The residue was purified by silica gel column (0-20% EA in hexanes) to give 40-15 (303 mg) as a white solid.

To a solution of 40-15 (303 mg, 0.41 mmol), AgNO 3 (208 mg, 1.23 mmol) and collidine (0.55 mL, 4.51 mmol) in anhydrous DCM (4 mL) was added MMTrCl (378 mg, 1.3 mmol) under N 2 . The mixture was stirred at R.T. overnight under N 2 , and monitored by TLC. The mixture was filtered through pre-packed celite filter, and the filtrate was washed with water and, 50% aqueous citric acid, and brine. The organic layer was separated, dried over anhydrous Na 2 SO 4 , filtered and concentrated at low pressure. The residue was purified by silica gel column (EA in hexanes from 0% to 30%) to give 40-16 (374 mg, 90%).

To a solution of 40-16 (374 mg, 0.37 mmol) in anhydrous THF (4 mL) was added 1.0 M solution of TBAF (0.74 mL, 0.74 mmol) at 0 to 5° C. The mixture was stirred at R.T. for 1 h. The mixture was quenched with silica gel, and filtered. The solvents were evaporated to give the crude product, which was purified by silica gel column (EA in hexanes from 0% to 50%) to give 40-17 (265 mg).

To a stirred solution of 40-17 (187.5 mg, 0.16 mmol) in anhydrous CH 3 CN (2.5 mL) was added N-methylimidazole (136 μL, 1.66 mmol) at 0-5° C. (ice/water bath) followed by solution of phenyl (cyclohexanoxy-L-alaninyl) phosphorochloridate (214 mg, 0.62 mmol, dissolved in 0.5 mL of CH 3 CN). The solution was stirred at R.T. for 3 h, and then diluted with EA followed by the addition of water (15 mL). The solution was washed with H 2 O, 50% aqueous citric acid solution and brine. The organic layer was separated, dried over anhydrous MgSO 4 and filtered. The filtrate was concentrated in vacuum to give a residue, which was purified on silica gel with 0 to 40% EA/hexanes to give (single isomers) of 40-18 (108 mg) Elution of the latter fraction gave (single isomers) of 40-19 (120 mg) as glassy solid.

Compound 40-18 (108 mg, 0.089 mmol) was dissolved in_anhydrous CH 3 CN (0.5 mL), and 4N HCl in dioxane (67 μL) was added at 0 to 5° C. (ice/water bath). The mixture was stirred at R.T. for 40 mins, and anhydrous EtOH (200 μL) was added. The solvents were evaporated at R.T. and co-evaporated with toluene 3 times. The residue was dissolved in 50% CH 3 CN/H 2 O, was purified on a reverse-phase HPLC (C18) using acetonitrile and water, followed by lyophilization to give compound 40 (26.6 mg) as a white foam. 1 H NMR (CD 3 OD-d 4 , 400 MHz) δ 7.89 (s, 1H), 7.33-7.29 (m, 2H), 7.20-7.13 (m, 3H), 7.17 (m, 1H), 6.62 (d, J=15.6 Hz, 1H), 5.39 (t, J=25.2 Hz, 1H), 4.75-4.42 (m, 6H), 3.92 (t, J=8.8 Hz, 1H), 3.24 (d, J=5.6 Hz, 1H), 1.76-1.51 (m, 5H), 1.45-1.25 (m, 12H); 31 P NMR (CD 3 OD-d 4 ) δ4.04 (s); ESI-LCMS: m/z=665.2 [M+H] + .

Compound 41 (44.4 mg, single isomer) was obtained according to the procedure described for compound 40 using 40-19. 1 H NMR (CD 3 OD-d 4 , 400 MHz) δ 7.93 (s, 1H), 7.32 (t, J=8.0 Hz, 1H), 7.24 (d, J=7.6 Hz, 2H), 7.16 (t, J=7.6 Hz, 1H), 6.61 (d, J=16.0 Hz, 1H), 4.68-4.60 (m, 2H), 4.54-4.39 (m, 3H), 3.93-3.89 (m, 1H), 3.24 (d, J=5.6 Hz, 1H), 1.75-1.5 (m, 5H), 1.48-1.23 (m, 12H); 19 F NMR (CD 3 OD-d 4 ) δ −122.95 (s), −155.84-155.99 (m); 31 P NMR (CD 3 OD-d 4 ) δ3.94 (s); ESI-LCMS: m/z=665.15 [M+H] + .

›Example 20

Compound 49

To a solution of triethylammonium bis(isopropyloxycarbonyloxymethyl)phosphate (0.33 mmol, prepared from 110 mg of bis(POC)phosphate and 46 μL of Et 3 N) in THF was added 49-1 (91 mg, 0.11 mmol). The mixture evaporated and rendered anhydrous by co-evaporating with pyridine follow by toluene. The residue was dissolved in anhydrous THF (1.5 mL) and cooled in an ice-bath. Diisopropylethyl amine (0.19 mL, 10 eq.) was added, followed by BOP-Cl (0.14 g, 5 eq.), and 3-nitro-1,2,4-triazole (63 mg, 5 eq.). The mixture was stirred 0° C. for 90 mins, diluted with EtOAc (30 mL), washed with sat. aq. NaHCO 3 , brine, and dried (Na 2 SO 4 ). The residue was purified on silica (10 g column) with CH 2 Cl 2 /i-PrOH solvent system (2-10% gradient) to obtain 49-2 (13 mg, 10%) and 49-3 (95 mg, 58%).

A solution of 49-2 and 49-3 (13 mg and 95 mg, respectively) in 80% aq. HCOOH (3 mL) was stirred at R.T. for 3 h, then evaporated and co-evaporated with toluene. The residue was purified on silica (10 g column) with CH 2 Cl 2 /MeOH (4-10% gradient) to obtain compound 49 in (42 mg, 94%) yield. MS: m/z=628 [M+1] + .

›Example 21

Compound 52

Compound 52-2 (158 mg, 50%) was from 52-1 (0.21 g; 0.35 mmol) and triethylammonium bis(isopropyloxycarbonyloxymethyl)phosphate (0.54 mmol) with DIPEA (0.18 mL), BopCl (178 mg), and 3-nitro-1,2,4-triazole (80 mg) in THF (4 mL).

A solution of 52-2 (158 mg) in acetonitrile (1 mL) and HCl (4 N/dioxane; 85 μL) was stirred at R.T. for 30 mins. The reaction was quenched with MeOH and concentrated. The residue was purified on silica gel (10 g column) with CH 2 Cl 2 /i-PrOH (3-10% gradient) to give compound 52 (85 mg, 76%). MS: m/z=656 [M+1] + .

›Example 22

Compound 11

A mixture of 11-1 (170 mg, 0.19 mmol) and methanolic ammonia (7 N; 3 mL) was stirred at R.T. for 8 h, concentrated and purified on silica gel (10 g column) with CH 2 Cl 2 /MeOH (4-11% gradient) to give 11-2 (100 mg, 90%).

Compound 11-2 was rendered anhydrous by co-evaporating with pyridine, followed by toluene. To a solution of 11-2 (24 mg, 0.04 mmol), and N-methylimidazole (17 μL, 5 eq.) in acetonitrile (1 mL) was added the phosphorochloridate (50 mg, 3.5 eq.) in 2 portions in 6 h intervals. The mixture was stirred at R.T. for 1 d and evaporated. Purification on silica (10 g column) with CH 2 Cl 2 /MeOH (4-12% gradient) yielded 11-3 (10 mg, 28%).

A solution of 11-3 (9 mg, 0.01 mmol) in 80% formic acid was stirred 3 h at R.T. The mixture was evaporated and purified on silica (10 g column) with CH 2 Cl 2 /MeOH (5-15% gradient) to give compound 11 (3 mg, 50%). MS: m/z=624 [M−1] − .

›Example 23

Compound 14

A mixture of 14-1 (1.2 g, 4.3 mmol), PTSA monohydrate (0.82 g, 1 eq.), and trimethyl orthoformate (14 mL, 30 eq.) in dioxane (30 mL) was stirred overnight at R.T. The reaction was neutralized with 7 N NH 3 /MeOH and a white solid removed by filtration. The residue was dissolved in THF (10 mL) and treated with 80% aq. AcOH (5 mL). The mixture was kept at R.T. for 45 mins and then evaporated. The residue was purified on silica gel (25 g column) with CH 2 Cl 2 /MeOH (4-10% gradient) to give 14-2 (1.18 g, 87%).

Compound 14-3 (137 mg, 75%) was prepared from 14-2 (93 mg, 0.29 mmol) and triethylammonium bis(isopropyloxycarbonyloxymethyl)phosphate (0.44 mmol) with DIPEA (0.2 mL), BopCl (147 mg), and 3-nitro-1,2,4-triazole (66 mg) in THF (3 mL). Purification was done with CH 2 Cl 2 /i-PrOH solvent system (3-10% gradient).

A solution of 14-3 (137 mg) in 80% aq. HCOOH was stirred at R.T. for 2 h, and then concentrated. The residue was co-evaporated with toluene and then MeOH containing a small amount of a small amount of Et 3 N (2 drops). Purification on silica (25 g column) with CH 2 Cl 2 /MeOH (4-10% gradient) gave compound 14 (100 mg, 77%). MS: m/z=1175 [2M−1] − .

›Example 24 · 1 of 2

Compound 16

Compound 16-1 (50 g, 86.0 mmol) and 6-Cl-guanine (16.1 g, 98.2 mmol) were co-evaporated with anhydrous toluene 3 times. To a solution of 10-1 in MeCN (200 mL) was added DBU (39.5 g, 258.0 mmol) at 0° C. The mixture was stirred at 0° C. for 30 mins, and then TMSOTf (95.5 g, 430.0 mmol) was added dropwise at 0° C. The mixture was stirred at 0° C. for 30 mins. The mixture was heated to 70° C., and stirred overnight. The solution was cooled to R.T. and diluted with EA (100 mL). The solution was washed with sat. NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , and concentrated at low pressure. The residue was purified by column on silica gel (EA in PE from 10% to 40%) to give 16-2 (48.0 g, yield: 88.7%) as a yellow foam. ESI-MS: m/z 628 [M+H] + .

To a solution of 16-2 (48.0 g, 76.4 mol), AgNO 3 (50.0 g, 294.1 mmol) and collidine (40 mL) in anhydrous DCM (200 mL) was added MMTrCl (46.0 g, 149.2 mmol) in small portions under N 2 . The mixture was stirred at R.T. for 3 h under N 2 . The reaction was monitored by TLC. The mixture was filtered, and the filter was washed with sat. NaHCO 3 solution and brine. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (EA in PE from 5% to 50%) to the give crude 16-3 (68 g, 98%). ESI-MS: m/z 900.1 [M+H] + .

Sodium (8.7 g, 378.0 mmol) was dissolved in dry EtOH (100 mL) at 0° C., and slowly warmed to R.T. Compound 16-3 (68.0 g, 75.6 mmol) was treated with freshly prepared NaOEt solution, and stirred overnight at R.T. The reaction was monitored by TLC, and the mixture was concentrated at low pressure. The mixture was diluted with H 2 O (100 mL), and extracted with EA (3×100 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (MeOH in DCM from 1% to 5%) to give 16-4 (34.0 g, 75.2%) as a yellow solid. ESI-MS: m/z 598 [M+H] + .

Compound 16-4 (32.0 g, 53.5 mmol) was co-evaporated with anhydrous pyridine 3 times. To an ice-cooled solution of 16-4 in anhydrous pyridine (100 mL) was added TsCl (11.2 g, 58.9 mmol) in pyridine (50 mL) dropwise at 0° C. The mixture was stirred for 18 h. at 0° C. The reaction was checked by LCMS (about 70% was the desired product). The reaction was quenched with H 2 O, and the solution was concentrated at low pressure. The residue was dissolved in EA (100 mL), and washed with sat. NaHCO 3 solution. The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (MeOH in DCM from 1% to 5%) to give crude 16-5 (25.0 g, 62.2%) as a yellow solid. ESI-MS: m/z 752 [M+H] + .

To a solution of 16-5 (23.0 g, 30.6 mmol) in acetone (150 mL) was added NaI (45.9 g, 306.0 mmol) and TBAI (2.0 g), and refluxed overnight. The reaction was monitored by LCMS. After the reaction was complete, the mixture was concentrated at low pressure. The residue was dissolved in EA (100 mL), washed with brine, and dried over anhydrous Na 2 SO 4 . The organic solution was evaporated at low pressure. The residue was purified by silica gel column chromatography (DCM:MeOH=100:1 to 20:1) to give the crude product. To a solution of the crude product in dry THF (200 mL) was added DBU (14.0 g, 91.8 mmol), and heated to 60° C. The mixture was stirred overnight, and checked by LCMS. The reaction was quenched with sat. NaHCO 3 , and the solution was extracted with EA (100 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (MeOH in DCM from 1% to 5%) to give 16-6 (12.0 g, 67.4%) as a yellow solid. ESI-MS: m/z 580 [M+H] + .

To an ice-cooled solution of 16-6 (8.0 g, 13.8 mmol) in dry MeCN (100 mL) was added NIS (3.9 g, 17.2 mmol) and TEA.3HF (3.3 g, 20.7 mmol) at 0° C. The mixture was stirred at R.T. for 18 h and checked by LCMS. After the reaction was complete, the reaction was quenched with sat Na 2 SO 3 and sat. NaHCO 3 solution. The solution was extracted with EA. The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (EA in PE from 10% to 50%) to give 16-7 (7.2 g, 72.0%) as a solid. ESI-MS: m/z 726 [M+H] + .

To a solution of crude 16-7 (7.2 g, 9.9 mmol) in dry DCM (100 mL) was added DMAP (3.6 g, 29.8 mmol), and BzCl (2.8 g, 19.8 mmol) at 0° C. The mixture was stirred overnight, and checked by LCMS. The mixture was washed with sat. NaHCO 3 solution. The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (EA in PE from 10% to 30%) to give 16-8 (8.0 g, 86.4%) as a solid. ESI-MS: m/z 934 [M+H] + .

To a solution of 16-8 (7.5 g, 8.0 mmol) in dry DMF (100 mL) was added NaOBz (11.5 g, 80.0 mmol) and 15-crown-5 (15.6 mL). The mixture was stirred for 36 h. at 90° C. The mixture was diluted with H 2 O (100 mL), and extracted with EA (3×150 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (EA in PE from 10% to 30%) to give crude 16-9 (6.0 g, 80.0%) as a solid. ESI-MS: m/z 928 [M+H] + .

Compound 16-9 (4.0 g, 4.3 mmol) was co-evaporated with anhydrous toluene 3 times, and treated with NH 3 /MeOH (50 mL, 4N) at R.T. The mixture was stirred for 18 h at R.T. The reaction was monitored by LCMS, and the mixture was concentrated at low pressure. The residue was purified by silica gel column chromatography (EA in PE from 30% to 50%) to give 16-10 (1.9 g, 71.7%) as a solid. ESI-MS: m/z 616 [M+H] + .

Compound 16-10 (300.0 mg, 0.49 mmol) was co-evaporated with anhydrous toluene 3 times, and was dissolved in MeCN (2 mL). The mixture was treated with NMI (120.5 mg, 1.47 mmol) and the phosphorochloridate reagent (338.1 mg, 0.98 mmol) in MeCN (1 mL) at 0° C. The mixture was stirred for 18 h at R.T. The reaction was monitored by LCMS. The mixture was diluted with 10% NaHCO 3 solution, and extracted with EA. The residue was purified by silica gel column chromatography (EA in PE from 30% to 50%) to give 16-11 (240 mg, 53.3%) as a solid. ESI-MS: m/z 925 [M+H] + .

›Example 24 · 2 of 2

Compound 16-11 (240.0 mg, 0.26 mmol) was treated with 80% AcOH (10 mL), and the mixture was stirred for 18 h at R.T. The reaction was monitored by LCMS. The mixture was concentrated at low pressure. The residue was purified by silica gel column chromatography (MeOH in DCM from 1% to 3%) to give compound 16 (87.6 mg, 51.7%) as a solid. ESI-MS: m/z 653 [M+H] + .

›Example 25

Compound 30

To a stirred solution of compound 25 (60 mg, 0.22 mmol) in anhydrous THF (2.0 mL) was added N-methylimidazole (0.142 mL, 1.73 mmol) at 0° C. (dry ice/acetone bath) followed by solution of phenyl (cyclohexanoxy-L-alaninyl) phosphorochloridate (235 mg, 0.68 mmol, dissolved in THF (2 mL). The resulting solution was stirred at 0° C. for 1 h, and the temperature was raised up-to 10° C. over the next 1 h. The reaction left at 10° C. for 3 h. The mixture was cooled to 0 to 5° C., diluted with EA, and water (5 mL) was added. The solution was washed with H 2 O and brine. The organic layer was separated, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated in vacuum to give a residue, which dissolved in 25% CH 3 CN/H 2 O. The compound was purified on a reverse-phase HPLC (C18) using acetonitrile and water, followed by lyophilization gave a white foam. The produce was re-dissolved in EtOAc, washed with 50% aqueous citric acid solution, dried over anhydrous MgSO 4 and filtered. The filtrate was concentrated in vacuum, and lyophilized to give two isomers (Rp/Sp) of compound 30 (6.3 mg). MS: m/z 586.05 [M−H] − .

›Example 26 · 1 of 2

Compound 17

Compound 17-1 (50 g, 86.0 mmol) and 6-Cl-guanine (16.1 g, 98.2 mmol) were co-evaporated with anhydrous toluene 3 times. To a solution of 17-1 (50 g, 86.0 mmol) and 6-Cl-guanine (16.1 g, 98.2 mmol) in MeCN (200 mL) was added DBU (39.5 g, 258.0 mmol) at 0° C. The mixture was stirred at 0° C. for 30 mins, and TMSOTf (95.5 g, 430.0 mmol) was added dropwise at 0° C. The mixture was stirred at 0° C. for 30 mins until a clear solution was observed. The mixture was heated to 70° C., and stirred overnight. The solution was cooled to R.T., and diluted with EA (100 mL). The solution was washed with sat. NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , and concentrated at low pressure. The residue was purified by column on silica gel (EA in PE from 10% to 40%) to give 17-2 (48.0 g, 88.7%) as a yellow foam. ESI-MS: m/z 628 [M+H] + .

To a solution of 17-2 (48.0 g, 76.4 mol), AgNO 3 (50.0 g, 294.1 mmol) and collidine (40 mL) in anhydrous DCM (200 mL) was added MMTrCl (46.0 g, 149.2 mmol) in small portions under N 2 . The mixture was stirred at R.T. for 3 h under N 2 . Completion of the reaction was determined by TLC. After filtration, the filtrate was washed with sat. NaHCO 3 solution and brine. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column (EA in PE from 5% to 50%) to the give crude 17-3 (68 g, 98%). ESI-MS: m/z 900.1 [M+H] + .

Sodium (8.7 g, 378.0 mmol) was dissolved in dry EtOH (100 mL) at 0° C., and slowly warmed to R.T. Compound 17-3 (68.0 g, 75.6 mmol) was treated with freshly prepared NaOEt solution, and stirred overnight at R.T. Completion of the reaction was determined by TLC and LCMS. The mixture was concentrated at a low pressure, diluted with H 2 O (100 mL), and extracted with EA (3×100 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (MeOH in DCM from 1% to 5%) to give 17-4 (34.0 g, 75.2%) as a yellow solid. ESI-MS: m/z 598 [M+H] + .

Compound 17-4 (32.0 g, 53.5 mmol) was co-evaporated with anhydrous pyridine 3 times. To an ice-cooled solution of 17-4 (32.0 g, 53.5 mmol) in anhydrous pyridine (100 mL) was added a solution of TsCl (11.2 g, 58.9 mmol) in pyridine (50 mL) dropwise at 0° C. The mixture was stirred for 18 h. at 0° C. The reaction was monitored by LCMS, and quenched with H 2 O. The solution was concentrated at low pressure, and the residue was dissolved in EA (100 mL), and washed with sat. NaHCO 3 solution. The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at a low pressure. The residue was purified by silica gel column chromatography (MeOH in DCM from 1% to 5%) to give crude 17-5 (25.0 g, 62.2%) as a yellow solid. ESI-MS: m/z 752 [M+H] + .

To a solution of 17-5 (23.0 g, 30.6 mmol) in acetone (150 mL) was added NaI (45.9 g, 306.0 mmol) and TBAI (2.0 g), and the mixture was refluxed overnight. Completion of the reaction was determined by LCMS. The mixture was concentrated at low pressure, and the residue was dissolved in EA (100 mL). The solution was washed with brine, and dried over anhydrous Na 2 SO 4 . The organic solution was evaporated at low pressure, and the residue was purified by silica gel column chromatography (DCM:MeOH=100:1 to 20:1) to give a crude product. To a solution of the crude product in dry THF (200 mL) was added DBU (14.0 g, 91.8 mmol), and the mixture was heated to 60° C. and stirred overnight. The reaction was monitored by LCMS. The reaction was quenched with sat. NaHCO 3 solution, and the solution was extracted with EA (100 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (MeOH in DCM from 1% to 5%) to give 17-6 (12.0 g, 67.4%) as a yellow solid. ESI-MS: m/z 580 [M+H] + .

To an ice-cooled solution of 17-6 (8.0 g, 13.8 mmol) in anhydrous MeCN (100 mL) was added NIS (3.9 g, 17.2 mmol) and TEA.3HF (3.3 g, 20.7 mmol) at 0° C. The mixture was stirred at R.T. for 18 h, and the reaction was checked by LCMS. After the reaction was completed, the reaction was quenched with sat. Na 2 SO 3 solution and sat. NaHCO 3 solution. The solution was extracted with EA (3×100 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (EA in PE from 10% to 50%) to give 17-7 (7.2 g, 72.0%) as a solid. ESI-MS: m/z 726 [M+H] + .

To a solution of 17-7 (7.2 g, 9.9 mmol) in dry DCM (100 mL) was added DMAP (3.6 g, 29.8 mmol), and BzCl (2.8 g, 19.8 mmol) at 0° C. The mixture was stirred overnight, and checked by LCMS. The mixture was washed with sat. NaHCO 3 solution. The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (EA in PE from 10% to 30%) to give 17-8 (8.0 g, 86.4%) as a solid. ESI-MS: m/z 934 [M+H] + .

To a solution of 17-8 (7.5 g, 8.0 mmol) in dry DMF (100 mL) was added NaOBz (11.5 g, 80.0 mmol) and 15-crown-5 (15.6 mL). The mixture was stirred for 36 h. at 90° C. The mixture was diluted with H 2 O (100 mL), and extracted with EA (3×150 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (EA in PE from 10% to 30%) to give crude 17-9 (6.0 g, 80.0%) as a solid. ESI-MS: m/z 928 [M+H] + .

Compound 17-9 (4.0 g, 4.3 mmol) was co-evaporated with anhydrous toluene 3 times, and treated with NH 3 /MeOH (50 mL, 4N) at R.T. The mixture was stirred for 18 h. at R.T. Completion of the reaction was determined by LCMS. The mixture was concentrated at low pressure, and the residue was purified by silica gel column chromatography (EA in PE from 30% to 50%) to give product 17-10 (1.9 g, 71.7%) as a solid. ESI-MS: m/z 616 [M+H] + .

Compound 17-10 (300.0 mg, 0.49 mmol) was co-evaporated with anhydrous toluene 3 times, and was dissolved in MeCN (2 mL). The mixture was treated with NMI (120.5 mg, 1.47 mmol) and the phosphorochloridate reagent (326.3 mg, 0.98 mmol) in MeCN (1 mL) at 0° C. The mixture was stirred for 18 h at R.T. and monitored by LCMS. The mixture was diluted with 10% NaHCO 3 solution, and extracted with EA (3×30 mL). The residue was purified by silica gel column chromatography (EA in PE from 30% to 50%) to give 17-11 (210 mg, 47.5%) as a solid. ESI-MS: m/z 913.0 [M+H] + .

›Example 26 · 2 of 2

Compound 17-11 (210 mg, 0.26 mmol) was treated with 80% of AcOH (15 mL), and the mixture was stirred for 18 h at R.T. Completion of the reaction was determined by LCMS. The mixture was concentrated at low pressure, and the residue was purified by silica gel column chromatography (MeOH in DCM from 1% to 3%) to give compound 17 (71.8 mg, 48.7%) as a solid. ESI-MS: m/z 641.3 [M+H] + .

›Example 27

Compounds 9, 12, 15, 26, 28, 38, 44, 46, 50, 63, 64, 69 and 76

Compounds 9, 12, 15, 26, 28, 38, 44, 46, 50, 63, 64, 69 and 76 were prepared in a manner similar to method for preparing compound 6. After the addition of POCl 3 , the mixture was kept at R.T. for 20-40 mins. The reaction was controlled by LCMS and monitored by the appearance of corresponding nucleoside 5′-monophosphate. After completion of the reaction, tetrabutylammonium salt of pyrophosphate (150 mg) was added, followed by DMF (0.5 mL) to get a homogeneous solution. After 1.5 h at ambient temperature, the reaction was diluted with water (10 mL). The triphosphate (eluted at 75-80% B) were obtained as described for compound 6.

28

556.2

−10.92 −11.03 (d)

−23.18 (t)

−11.86 −11.98 (d)

38

516.1

−7.49  −7.61 (d)

−22.42 (t)

−12.17 −12.30 (d)

9

554.0

−10.94 −11.06 (d)

−23.25 (t)

−11.85 −11.97 (d)

12

525.2

−8.53 (bs)

−22.61 (bs)

−12.17 −12.29 (d)

15

564.4

−11.05 (bs)

−23.25 (bs)

−11.96 −12.08 (d)

44

566.0

−10.92 −11.04 (d)

−23.18 (t)

−11.93  −1 (d)

46

533.3

−10.89 −11.01 (d)

−23.31 (t)

−12.49  −1 (d)

50

513.8

−8.66 (bs)

−22.80 (t)

−12.17 −12.29 (d)

26

517.7

−13.73 −13.60 (d)

−25.98 (t)

−15.18 −15.06 (d)

63

539.5

−7.42 (br · s)

−22.57 (t)

−12.23 −12.34 (d)

64

513.1

−6.36  −6.49 (d)

−22.49 (t)

−12.20 −12.33 (d)

69

526.8

−10.96 −11.08 (d)

−23.33 (t)

−12.41 −12.53 (d)

76

533.4

−10.78 (br · s)

−23.22 (t)

−12.24 −12.36 (d)

The following compounds can also be prepared using a method similar to the method described in Example 27:

›Example 28

Compound 10

Compound 10-1 (5 g, 8.79 mmol) was co-evaporated with anhydrous pyridine. To an ice-cooled solution of 10-1 in anhydrous pyridine (15 mL) was added TsCl (3.43 g, 17.58 mmol), and stirred for 1 h at 0° C. The reaction was checked by LCMS and TLC. The reaction was quenched with H 2 O, and extracted with EA. The organic phase was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. Compound 10-2 (6.35 g, 100%) was used for next step directly.

To a solution of 10-2 (31.77 g, 43.94 mmol) in acetone (300 mL) was added NaI (65.86 g, 439.4 mmol), and heated to reflux overnight. The reaction was checked by LCMS. The reaction was quenched with sat. Na 2 S 2 O 3 solution, and extracted with EA. The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (MeOH in DCM from 1% to 6%) to give 10-3 (11.5 g, 38%) as a white solid.

To a solution of 10-3 (11.5 g, 16.94 mmol) in dry THF (120 mL) was added DBU (12.87 g, 84.68 mmol), and heated to 60° C. The reaction was stirred overnight and checked by LCMS. The reaction was quenched with sat. NaHCO 3 solution, and extracted with EA. The organic phase was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (MeOH in DCM from 1% to 5%) to give 10-4 (5.5 g, 54%) as a white solid.

To an ice-cooled solution of 10-4 (500 mg, 0.90 mmol) in dry DCM (20 ml) was added AgF (618 mg, 4.9 mmol) and a solution of 12 (500 mg, 1.97 mmol) in dry DCM (20 mL). The reaction was stirred for 3 h., and checked by LCMS. The reaction was quenched with sat Na 2 S 2 O 3 solution and sat. NaHCO 3 solution, and the mixture was extracted with DCM. The organic layer was dried by anhydrous Na 2 SO 4 , and evaporated at low pressure to give crude 10-5 (420 mg, 66%).

To a solution of crude 10-5 (250 mg, 0.36 mmol) in dry DCM (8 mL) was added DMAP (0.28 g, 2.33 mmol), TEA (145 mg, 1.44 mmol) and BzCl (230 mg, 1.62 mmol) in a solution of DCM (2 mL). The reaction was stirred overnight, and checked by LCMS. The mixture was washed with sat. NaHCO 3 solution and brine. The organic layer was evaporated at low pressure. The residue was purified by prep-TLC to give crude 10-6 (150 mg, 46%).

To a solution of crude 10-6 (650 mg, 0.72 mmol) in dry HMPA (20 mL) was added NaOBz (1.03 g, 7.2 mmol) and 15-crown-5 (1.59 g, 7.2 mmol). The reaction was stirred for 2 d at 60° C. The mixture was diluted with H 2 O, and extracted with EA. The organic layer was evaporated at low pressure. The residue was purified by prep-TLC to give 10-7 (210 mg, 32.4%). ESI-MS: m/z: 900.4 [M+H] + .

A mixture of 10-7 (25 mg) and BuNH 2 (0.8 mL) was stirred overnight at R.T. The mixture was evaporated and purified on silica gel (10 g column) with CH 2 Cl 2 /MeOH (4-15% gradient) to yield 10-8 (15 mg, 91%).

A mixture of 10-8 (15 mg, 0.02 mmol) in ACN (0.25 mL) and 4 N HCL/dioxane (19 uL) was stirred at R.T. for 45 mins. The mixture was diluted with MeOH and evaporated. The crude residue was treated with MeCN, and the solid was filtered to yield compound 10 (7 mg). MS: m/z=314 [M−1] − .

›Example 29

Compounds 36 and 37

To a solution of 36-1 (150 mg, 0.24 mmol) in DCM (2.0 mL), triethylamine (141 μL, 2.0 mmol) was added at R.T. The mixture was cooled to 0 to 5° C. (ice/water bath), and freshly prepared and distilled isopropyl phosphorodichloridate (45 μL, 0.26 mmol, prepared according to a procedure, Reddy et al. J. Org. Chem. 2011, 76 (10), 3782-3790) was added. The mixture was stirred at 0 to 5° C. (ice/water bath) for 15 mins, followed by N-methylimidazole (40 μL, 0.49 mmol). The mixture was stirred for 1 h at 0 to 5° C. TLC showed the absence of starting material 36-1. EA (100 mL) was added, followed by water. The organic layer was washed with H 2 O, sat. aq. NH 4 Cl solution and brine. The organic layer was separated, dried over anhydrous MgSO 4 and filtered. The filtrate was concentrated in vacuum to give a residue, which was purified on silica gel with 0 to 10% iPrOH/DCM to give 36-2a (16.9 mg, faster eluting isomer) and 36-2b (72.7 mg, slower eluting isomer).

Compounds 36-2a and 36-2b were deprotected using a procedure described herein. Compound 36 (7.3 mg, single isomers from 36-2a (16.5 mg, 0.0235 mmol)) and compound 37 (29.0 mg. single isomers from 36-2b (72.7 mg, 0.1 mmol)) were obtained.

Compound 36: 1 H NMR (CD 3 OD-d 4 , 400 MHz) δ 7.94 (s, 1H), 6.32 (s, 1H), 6.00-5.9 (br s, 1H), 4.9-4.487 (m, 1H), 4.83-4.77 (m, 1H), 4.65-4.50 (m, 3H), 1.45-1.39 (s, 9H), 1.2 (s, 3H); 19 F NMR (CD 3 OD-d 4 ) δ −120.3 (s); 31 P NMR (CD 3 OD-d 4 ) δ −5.19 (s); ESI-LCMS: m/z=448.05 [M+H] + . Compound 37: 1 H NMR (CD 3 OD-d 4 , 400 MHz) δ 7.98 (s, 1H), 6.34 (s, 1H), 5.78-5.64 (br s, 1H), 4.95-4.48 (m, 2H), 4.62-4.52 (m, 3H), 1.48-1.42 (s, 9H), 1.1 (s, 3H); 19 F NMR (CD 3 OD-d 4 ) δ −121.3 (s); 31 P NMR (CD 3 OD-d 4 ) δ −7.38 (s); ESI-LCMS: m/z=448.05 [M+H] + .

›Example 30

Compound 48

To a solution of 48-1 (600 mg, 1.29 mmol) in anhydrous CH 3 CN (4 mL) was added DMAP (315 mg, 2.59 mmol), TEA (391 mg, 3.87 mmol) and TPSCl (782 mg, 2.58 mmol). The mixture was stirred for 3 h. under N 2 . A solution of NH 3 in THF (2 mL) was added, and stirred for 1 h. The reaction was quenched with sat. NH 4 Cl solution, and extracted with EA. The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated to dryness at low pressure. The residue was purified by column chromatography to provide 48-2 (370 mg, 62%) as a white foam solid.

Compound 48-2 (370 mg, 1.48 mmol) in methanolic ammonium was stirred at R.T. for 4 h. The solution was concentrated to dryness to give compound 48 (200 mg, 91%) as a white solid. ESI-MS: m/z 275.9 [M+H] + .

›Example 31

Compounds 18 and 19

The diastereomers of compound 2 were separated by RP-HPLC. A gradient of 10-43% ACN in H 2 O over 26 mins on a Synergi Hydro RP 30×250 m 4 u particle column (Phenomenex PN 00G-4375-U0-AX) eluted compound 19 (29.5 mins) and compound 18 (30.1 mins). Pure fractions were lyophilized to produce a white powder. Compound 19: 31 P-NMR (DMSO-d6) 3.448 ppm; MS: m/z: 544 [M−1] − ; Compound 18: 31 P-NMR (DMSO-d6) 3.538 ppm; MS: m/z: 544 [M−1] − .

›Example 32

Compounds 20 and 21

The diastereomers of compound 3 were separated by RP-HPLC. A gradient of 25-52% ACN in H 2 O over 26 mins on a Synergi Hydro RP 30×250 m 4 u particle column (Phenomenex PN 00G-4375-U0-AX) eluted compound 21 (24.8 mins) and compound 20 (25.3 mins). Pure fractions were lyophilized to produce a white powder. Compound 21: 31 P-NMR (DMSO-d6) 3.492 ppm; MS: m/z: 584 [M−1] − . Compound 20: 31 P-NMR (DMSO-d6) 3.528 ppm; MS: m/z: 584 [M−1] − .

›Example 33

Compound 13

Compound 2-1 (32 mg, 0.1 mmol) was dissolved in dry THF (3 mL) and 2M solution of isopropylmagnesium bromide in THF (0.1 mL) was added at 0° C. The reaction was left for 1 h at R.T., and phenyl(isopropyl-L-alaninyl) thiophosphorochloridate was added (0.3 mmol). The mixture was left overnight at R.T. LSMS analysis showed about 20% of unreacted starting material. The same amount of Grignard reagent and thiophosphorochloridate were added, and the mixture was heated at 37° C. for 4 h. The reaction was quenched with NH 4 Cl. The product was extracted with EA, washed with brine, dried over Na 2 SO 4 , and evaporated. The resulting oil was dissolved in 80% formic acid (4 mL) and in 1 h evaporated. Compound 13 was purified by RP HPLC in gradient of methanol in water from 30% to 95% on Synergy 4 u Hydro-RP column (Phenominex) yielding a colorless solid. Compound 13 (7 mg, yield 12.5%). MS: m/z: 560.0 [M−1] − .

›Example 34

Compound 39, Bis-Lithium Salt

Compound 39-1 was synthesized using a procedure similar for preparing compound 2 using alanine benzyl ester hydrochloride. LCMS: m/z 592 [M−1] − .

To a solution of 39-1 (1.1 g, 1.85 mmol) in dioxane (15 mL) and water (3 mL) was added aqueous triethylammonium acetate (2M, 2 mL, 4 mmol) followed by Pd—C (10%, 100 mg). The mixture was hydrogenated (balloon) for 2 h, and monitored by HPLC. The catalyst was filtered off, and the filtrate was concentrated to dryness. The residue was suspended in 3% solution of lithium perchlorate in acetone (25 mL). The solid was isolated by filtration, rinsed with acetone and dried under vacuum to give compound 39 (bis-lithium salt) (731 mg, 90%). LCMS: m/z 426 [M−1] − .

›Example 35

Compound 55

Compound 1 (40 mg, 0.14 mmol) and triethylammonium bis(pivaloyloxymethyl)phosphate (0.21 mmol, prepared from 80 mg of bis(pivaloyloxymethyl)phosphate and 30 μL of Et 3 N) were rendered anhydrous by coevaporating with pyridine, followed by toluene. The evaporated residue was dissolved in anhydrous THF (2 mL) and cooled in an ice-bath. Diisopropylethyl amine (73 μL, 3 eq.), BopCl (71 mg, 2 eq.), and 3-nitro-1,2,4-triazole (32 mg, 2 eq.) were added. The mixture was stirred at 0° C. for 90 mins. The mixture was then diluted with EtOAc, washed with sat. aq. NaHCO 3 and brine, and dried (Na 2 SO 4 ). Purification on silica gel column with CH 2 Cl 2 /i-PrOH solvent system (4-10% gradient) followed by RP-HPLC purification (A: water, B: MeCN) yielded compound 55 (13 mg, 16%). MS: m/z=1167 [2M−1].

›Example 36

Compound 45

Compound 45-1 (15.0 g, 25.55 mmol) was treated with 90% HOAc (150 mL) at R.T. The mixture was stirred at 110° C. for 12 h, and then concentrated at a low pressure. The residue was dissolved in DCM, and the solution was washed with brine. The organic phase was dried over anhydrous Na 2 SO 4 , and then concentrated at a low pressure. The residue was purified by column chromatography (5% MeOH in DCM) to give 45-2 (11.0 g, 88.9%) as a white solid.

Compound 45-2 (12.0 g, 24.79 mmol) was treated with NH 3 in MeOH (200 mL, 7 M) at R.T. The solution was stirred at R.T. for 12 h, and then concentrated at a low pressure. The residue was purified by column chromatography (10% MeOH in DCM) to give 45-3 (6.5 g, 95.0%) as a white solid.

To a stirred suspension of 45-3 (4.3 g, 15.58 mmol), PPh 3 (8.16 g, 31.15 mmol), imidazole (2.11 g, 31.15 mmol) and pyridine (15 mL) in anhydrous THF (45 mL) was added a solution of 12 (7.91 g, 31.15 mmol) in THF (100 mL) dropwise at 0° C. The mixture was slowly warmed to R.T. and stirred overnight. The mixture was quenched with MeOH (100 mL). The solvent was removed at a low pressure, and the residue was re-dissolved in a mixture of EA and THF (0.2 L, 10:1). The organic phase was washed with sat. Na 2 S 2 O 3 aq. (2×). The aqueous phase was extracted with a mixture of EA and THF (0.2 L, 10:1, 2×). The concentrated organic phase was dried over anhydrous Na 2 SO 4 . The residue was purified on a silica gel column (0-10% MeOH in DCM) to afford 45-4 (5.1 g, 85.0%) as a white solid.

Compound 45-4 (800 mg, 2.07 mmol) was dissolved in a mixture of DBU (4 mL) and THF (4 mL) at R.T. under N 2 . The solution was stirred at R.T. for 1 h. The mixture was neutralized with HOAc, and extracted with a mixture of EA and THF (10:1, 40 mL). The organic phase was washed with brine, and dried over anhydrous Na 2 SO 4 . The concentrated organic phase was purified by column chromatography (0-10% MeOH in DCM) to give 45-5 (240 mg, 44.9%) as a white solid.

To an ice-cooled solution of 45-5 (1.20 g, 4.65 mmol) in anhydrous MeCN (12 mL) was added NIS (1.57 g, 6.97 mmol) and TEA.3HF (1.12 g, 6.97 mmol) under N 2 . The mixture was stirred at R.T. for 5 h. The reaction was quenched with sat. NaHCO 3 solution, and extracted with EA (3×100 mL). The organic phase was dried over anhydrous Na 2 SO 4 , and evaporated to dryness at low pressure. The residue was purified on a silica gel column (0-5% MeOH in DCM) to give 45-6 (0.91 g, 48.6%) as a white solid.

To a stirred solution of 45-6 (1.2 g, 2.97 mmol) in anhydrous DCM (12 mL) was added BzCl (0.83 g, 5.94 mmol), TEA (0.6 g, 5.94 mmol) and DMAP (0.72 g, 5.94 mmol) successively at R.T. The mixture was stirred at R.T. for 12 h. The reaction was quenched with water, and extracted with EA (3×60 mL). The organic phase was concentrated at low pressure. The residue was purified by column chromatography (0-5% MeOH in DCM) to give 45-7 (1.2 g, 66.2%) as a white solid.

Tetra-butyl ammonium hydroxide (25.78 mL, 51.78 mmol) was neutralized with TFA (4.3 mL) to pH=4, and the solution was added to a solution of 45-7 (1.09 g, 2.14 mmol) in DCM (30 mL). m-CPBA (1.85 g, 10.74 mmol) was added portion-wise under vigorous stirring, and the mixture was stirred for 12 h. The mixture was diluted with EA (100 mL), and washed with sat. sodium bicarbonate. The organic phase was concentrated at low pressure. The residue was purified by column chromatography (50% EA in PE) to give 45-8 (350 mg, 41.1%) as a white solid.

Compound 45-8 (280 mg, 0.704 mmol) was treated with NH 3 in MeOH (10 mL, 7 M) at R.T. The mixture was stirred at R.T. for 2 h. The mixture was concentrated at a low pressure. The residue was purified by column chromatography (0-10% MeOH in DCM) to give compound 45 (110 mg, 53.1%) as a white solid. ESI-LCMS: m/z 295.1 [M+H] + .

›Example 37

Compound 54

To an ice-cooled solution of 54-1 (10 g, 42 mmol) in anhydrous MeCN (200 mL) was added TEA.3HF (10 g, 62.5 mmol) and NIS (28 g, 126 mmol). The mixture was stirred at R.T. for 1.5 h, and monitored by LCMS. After the reaction was completed, the mixture was concentrated at a low pressure. The residue was purified by silica gel column chromatography (15% MeCN in DCM) to give 54-2 (12 g, 74%) as a yellow solid.

To a solution of 54-2 (22 g, 57 mmol) in anhydrous DCM (200 mL) was added DMAP (21 g, 171 mmol) and BzCl (17.6 g, 125 mol). The mixture was stirred for 5 h at R.T., and monitored by LCMS. The solution was washed with sat. NaHCO 3 solution, brine and extracted with EA. The organic phase was dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated at low pressure. The residue was purified by silica gel column chromatography (20% EA in PE) to give 54-3 (30 g, 88%) as a white foam.

To a solution of 54-3 (6.5 g, 11 mmol) in anhydrous DMF (270 mL) was added NaOBz (15.8 g, 110 mmol) and 15-crown-5 (29 g, 132 mmol). The mixture was stirred at 95° C. for 48 h. The precipitate was removed by filtration, and the organic solvent was removed at low pressure. The residue was dissolved in EA (200 mL), and the solution was washed with sat. NaHCO 3 solution, and brine. The organic layer was dried over anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated at low pressure. The residue was purified by silica gel column chromatography (20% EA in PE) to give 54-4 (3 g crude, 46.1%) as an oil.

Compound 54-4 (3 g, crude) was treated with NH 3 in MeOH (120 mL, 7 M). The mixture was stirred for 3 h and monitored by TLC. The solution was concentrated at low pressure. The residue was purified by silica gel column chromatography (10% isopropanol in DCM) to give 54-5 (1.0 g, 67%) as a white solid. 1 H-NMR (CD 3 OD, 400 MHz) δ=1.19 (s, 3H), 3.76-3.82 (m, 2H), 4.02 (d, J=19.8 Hz, 1H), 5.70 (d, J=8.07 Hz, 1H), 6.27 (s, 1H), 7.89 (d, J=8.07 Hz, 1H).

Compound 54-5 (100 mg, 0.36 mmol) was co-evaporated with toluene 3 times. To a stirred solution of 54-5 (100 mg, 0.36 mmol) in a mixture of MeCN (1.0 mL) and NMI (295 mg, 3.6 mmol) was added a solution of 54-C (255.6 mg, 0.72 mmol, preparation described below) in MeCN (0.5 mL) at 0° C. The mixture was stirred at R.T. overnight. The reaction was quenched with water, and diluted with EA (20 mL). The organic layer was washed with water and brine. The organic layer was dried over anhydrous Na 2 SO 4 . The organic phase was concentrated at low pressure. The residue was purified on a silica gel column (5% i-PrOH in DCM) to give the crude product. The product was purified by prep-HPLC (0.1% HCOOH in water and MeCN) to give compound 54 (46.7 mg, 23.3%) as a white solid. ESI-LCMS: m/z 618 [M+Na] + .

To a stirred solution of 54-A (2.0 g, 13.16 mmol) and naphthalen-1-ol (1.89 g, 13.16 mmol) in anhydrous DCM (100 mL) was added a solution of TEA (1.33 g, 13.16 mmol) in DCM (20 mL) dropwise at −78° C. After addition, the mixture was gradually warmed to R.T., and stirred for 2 h. The solution was cooled to −78° C., and (S)-isopropyl 2-aminopropanoate hydrochloride (2.20 g, 13.16 mmol) in DCM (20 mL) was added, followed by TEA (2.66 g, 26.29 mmol) in DCM (20 mL) dropwise. The mixture was gradually warmed to R.T., and stirred for 2 h. The organic solvent was removed at low pressure. The residue was dissolved in methyl-butyl ether. The precipitate was filtered, and the filtrate was concentrated at low pressure. The residue was purified on a silica gel column (anhydrous DCM) to give 54-C (1.0 g, 24.8%) as a colorless oil.

›Example 38

Compounds 56 and 57

To a solution of 54-5 (300 mg, 1.08 mmol) and NMI (892 mg, 10 mmol) in anhydrous MeCN (4 mL) was added a solution of 57-C (736 mg, 2.17 mmol, preparation described below) in anhydrous MeCN (1 mL) dropwise at 0° C. The mixture was stirred at R.T. overnight. The reaction was quenched with water, and diluted with EA (30 mL). The organic layer was washed with water and brine. The organic phase was dried over anhydrous Na 2 SO 4 and concentrated at low pressure. The residue was purified by a silica gel column (iPrOH in DCM from 1% to 5%) to give crude compound 56 (276 mg, crude). Crude compound 56 (96 mg) was purified by prep-HPLC (0.1% HCOOH in water and MeCN) to give pure compound 56 (46 mg, 47.9%) as a white solid. ESI-LCMS: m/z 560 [M−F] + .

To a solution of compound 56 (180 mg, 0.31 mmol) in anhydrous pyridine (6 mL) was added acetic anhydride (158 mg, 1.54 mmol) dropwise at 0° C. The mixture was stirred at R.T. overnight. The solution was quenched with water and concentrated at a low pressure. The residue was dissolved in EA (10 mL), and washed with brine. The organic layer was dried over anhydrous Na 2 SO 4 . The organic phase was concentrated at low pressure. The residue was purified by silica gel column (i-PrOH in DCM from 1% to 3%) to give crude compound 57 (172 mg). Crude compound 57 was purified by prep-HPLC (0.1% HCOOH in water and MeCN) to give pure compound 57 (46 mg, 23.8%) as a white solid. ESI-LCMS: m/z 602.3 [M−F] + .

Compound 56-C (1.02 g, 23%, a colorless oil) was prepared using a procedure similar to the preparation of 54-C using 54-A (2.00 g, 13.16 mmol) and 4-chlorophenol (1.68 g, 13.16 mmol).

›Example 39

Compound 61

Compound 25 (109 mg, 0.39 mmol) and triethylammonium bis(isopropyloxycarbonyloxymethyl)phosphate (0.6 mmol, prepared from 195 mg of bis(isopropyloxycarbonyloxymethyl)phosphate and 85 μL of Et 3 N) were rendered anhydrous by coevaporating with pyridine, followed by toluene. The residue was dissolved in anhydrous THF (3 mL) and cooled in an ice-bath. Diisopropylethyl amine (0.2 mL, 3 eq.), BopCl (190 mg, 2 eq.), and 3-nitro-1,2,4-triazole (81 mg, 2 eq.) were added, and the mixture was stirred at 0° C. for 90 mins. The mixture was diluted with EtOAc, washed with sat. aq. NaHCO 3 and brine, and dried (Na 2 SO 4 ). Purification on silica gel column with CH 2 Cl 2 /i-PrOH (4-10% gradient) followed by RP-HPLC purification (A: 0.1% HCOOH in water, B: 0.1% HCOOH in MeCN) yielded compound 61 (28 mg, 12%). 1 H-NMR (CDCl 3 ): δ 7.24 (d, 1H), 6.6 (br, 1H), 5.84 (d, 1H), 5.65-5.73 (m, 4H), 4.94 (m, 2H), 4.38 (m, 2H), 4.1 (b, 1H), 2.88 (d, 1H), 1.47 (d, 3H), 1.33 (m, 12H).

›Example 40

Compound 74

Dry nucleoside (0.05 mmol) was dissolved in a mixture of PO(OMe) 3 (0.7 mL) and pyridine (0.3 mL). The mixture was evaporated in vacuum for 15 mins. at 42° C., then cooled to R.T. N-Methylimidazole (0.009 mL, 0.11 mmol) was added followed by POCl 3 (0.009 mL, 0.11 mmol). The mixture was kept at R.T. for 20-40 mins and monitored for the formation of compound 74 by LCMS. The reaction was quenched with water and isolated by RP HPLC on Synergy 4 micron Hydro-RP column (Phenominex). A linear gradient of methanol from 0 to 30% in 50 mM triethylammonium acetate buffer (pH 7.5) was used for elution. The corresponding fractions were combined, concentrated and lyophilized 3 times to remove excess of buffer. MS: m/z 396.5 [M−1] − .

›Example 41

Compound 68

The nucleoside (140 mg, 0.42 mmol) was dissolved in n-butylamine (0.5 mL). The mixture was kept for 2 h at R.T., and the amine was then evaporated. The residue was dissolved in EtOAc, and the organic layer was washed twice with 10% citric acid, dried over Na 2 SO 4 , and evaporated. The residue purified by column chromatography on silica gel in linear gradient of methanol in DCM from 0% to 12% over 10 column volumes. The fractions containing the product were concentrated and treated with 80% HCOOH for 1 h at R.T. The mixture was evaporated to dryness, and suspended in CH 3 CN. The precipitate was separated, washed with CH 3 CN (1 mL) and dried to yield compound 68 (27 mg, 50%). MS: m/z 326.5 [M−1] − .

›Example 42

Compound 62

Compound 45 (30 mg, 0.1 mmol) was dissolved in a mixture of CH 3 CN (2 mL) and N-methylimidazole (200 uL). Phosphorochloridate (100 mg, 0.3 mmol) was added, and the mixture was kept for 5 d at R.T. The mixture was distributed between water and EA. The organic layer was separated, washed with brine, dried and evaporated. The phosphoroamidate was isolated by silica gel chromatography in a gradient of methanol in DCM from 3% to 10%. The corresponding fractions were concentrated and re-purified by RP HPLC on Synergy 4 micron Hydro-RP column (Phenominex). A linear gradient of methanol in DCM from 3% to 95% containing 0.1% formic acid was used for elution. Compound 62 was obtained as a mixture Rp and Rs isomers (9 mg, 16%). MS: m/z 562.1 [M−1] − .

›Example 43

Compound 72

Compound 47 (30 mg, 0.1 mmol) was dissolved in a mixture of CH 3 CN (2 mL) and N-methylimidazole (200 uL). Phosphorochloridate (100 mg, 0.3 mmol) was added, and the mixture was kept overnight at 40° C. The temperature was increased to 65° C. and heated for 1 h. The mixture was distributed between water and EA. The organic layer was separated, washed with brine, dried and evaporated. The azido-phosphoramidate was purified by RP HPLC on Synergy 4 micron Hydro-RP column (Phenominex). A linear gradient of methanol from 30% to 100% in 50 mM triethylammonium acetate buffer (pH 7.5) was used for elution. The azido-phosphoramidate (8 mg) was dissolved in pyridine/Et 3 N (3 mL, 8:1 v/v) and cooled to 0° C. H 2 S gas was bubbled through the solution for 10 min, and the reaction was kept for 1 h at R.T. The solvents were evaporated, and the residue isolated by RP HPLC. The corresponding fractions were combined, concentrated and lyophilized 3 times to remove excess of buffer, to provide compound 72 (1.2 mg) as mixture Rp and Rs isomers. MS: m/z 544.1 [M+1] + .

›Example 44

Compound 65

To a solution of 65-1 (23.0 g, 39.5 mmol) in anhydrous toluene (200 mL) was added DAST (31.9 g, 198 mmol) dropwise at −78° C., and the solution was stirred at −78° C. for 3 h. The mixture was quenched with sat. NaHCO 3 , extracted with EA (2×200 mL) and dried over with anhydrous Na 2 SO 4 . The solution was concentrated to dryness under low pressure. The residue was purified on a silica gel column (50% EA in PE) to give 65-2 (16.5 g, 71%) as a yellow foam.

A mixture of 65-2 (16.0 g, 27.4 mmol) and NH 4 F (3.0 g, 82.2 mmol) in methanol (100 mL) was stirred at 70° C. for 12 h. The reaction was cooled, and the salt was removed by filtration. The filtrate was concentrated to dryness at low pressure. The residue was purified on a silica gel column (3% MeOH in DCM) to give 65-3 (5.1 g, 69.0%) as a white foam.

To a stirred suspension of 65-3 (4.1 g, 15.2 mmol), PPh 3 (8.0 g, 30.4 mmol), imidazole (2.1 g, 30.4 mmol) and pyridine (18.2 mL) in anhydrous THF (40 mL) was added dropwise a solution of 12 (5.8 g, 22.8 mmol) in THF (20 mL) at 0° C. The mixture was stirred at R.T. for 12 h. The reaction was quenched with MeOH (100 mL), and the solvent was removed under reduced pressure. The residue was purified on a silica gel column (4% MeOH in DCM) to give pure 65-4 (4.4 g, 77%) as a white solid. ESI-MS: m/z 381.1 [M+1] + .

To a stirred solution of 65-4 (2.5 g, 0.7 mmol) in anhydrous THF (3 mL) was added DBU (2.1 g, 14 mmol) at R.T., and the mixture was stirred at R.T. for 1 h. The reaction was quenched with HOAc, and diluted with 2-Me-tetrahydrofuran. The solution was washed with brine, dried over with anhydrous Na 2 SO 4 and concentrated to dryness at low pressure. The residue was purified on a silica gel column (MeOH 5% in DCM) to give 65-5 (1.1 g, 68.9%) as a white foam.

To a stirred solution of 65-5 (800 mg, 3.17 mmol) in anhydrous CH 3 CN (10 mL) was added TEA.3HF (510 mg, 3.17 mmol) and NIS (785 mg, 3.49 mmol) at 0° C. The mixture was stirred for 30 mins, gradually warmed to R.T., and stirred for 1 h. The mixture was quenched with sat. NaHCO 3 solution and Na 2 S 2 O 3 solution, and extracted with EA (2×20 mL). The organic layer was dried over with anhydrous Na 2 SO 4 , and concentrated to dryness at low pressure. The residue was purified on a silica gel column to give pure 65-6 (695 mg, 57.9%) as a yellow solid.

To a stirred solution of 65-6 (650 mg, 1.63 mmol) in pyridine (3 mL) was added BzCl (507 mg, 3.59 mmol) at 0° C., and stirred at R.T. for 12 h. The mixture was quenched with water, and concentrated to dryness under reducing pressure. The residue was purified on a silica gel column (EA 50% in PE) to yield 65-7 (550 mg, 67%) as a white foam.

Tetra-butylammonium hydroxide (9 mL as 54-56% aqueous solution, 72 mmol) was neutralized with TFA to pH-4 (1.5 mL), and the mixture was added to a solution of 65-7 (375 mg, 0.75 mmol) in DCM (9 mL). m-Chloroperbenzoic acid (924 mg, 60-70%, 3.75 mmol) was added in portions with vigorous stirring, and the mixture was stirred overnight. The mixture was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (EA 50% in PE) to give 65-8 (230 mg, 78.8%) as a white foam. ESI-MS: m/z 393.1 [M+1] + .

Compound 65-8 (120 mg, 0.24 mmol) was treated with 7N NH 3 .MeOH (20 mL), and stirred for 5 h. The mixture was concentrated to dryness at low pressure. The residue was purified on a silica gel column (propan-2-ol 15% in DCM) to yield compound 65 (53 mg, 60.2%) as a white solid. ESI-MS: m/z 288.8 [M+1] + .

›Example 45

Compound 70

To a solution of 70-1 (3.0 g, 18.0 mmol) and POCl 3 (1.35 g, 9.0 mmol) in DCM (80 mL) was added TEA (3.6 g, 36.0 mmol) in DCM (20 mL) dropwise at 0° C. The mixture was stirred at 0° C. for 2 h. A solution of pentafluorophenol (1.65 g, 9.0 mmol) and TEA (0.9 g, 9.0 mmol) in DCM (20 mL) was added dropwise at 0° C., and the mixture was stirred at 0° C. for 15 h. After the reaction was completed, the mixture was concentrated under reduced pressure. The residue was washed by TBME and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (20% EA in PE) to give 70-2 (2.7 g, 62.7%) as a white solid. ESI-MS: m/z 491.1 [M+1] + .

To a stirred solution of 1-((3aR,4R,6S,6aS)-6-fluoro-6-(hydroxymethyl)-2-methoxy-3a-methyltetrahydrofuro [3,4-d][1,3]dioxol-4-yl)pyrimidine-2,4(1H,3H)-dione (150 mg, 0.47 mmol) in anhydrous THF (2 mL) was added a solution of t-BuMgCl (0.46 mL, 1M in THF) dropwise at 0° C. The mixture was stirred at R.T. for 40 mins, and re-cooled to 0° C. A solution of 70-2 (462 mg, 0.94 mmol) was added, and the mixture was stirred at R.T. for 4 h. The mixture was quenched with H 2 O, and extracted with EA. The organic layer was dried over Na 2 SO 4 and concentrated under reducing pressure. The residue was purified on a silica gel column (50% EA in PE) to give 70-3 as a white foam (230 mg, 78%).

Compound 70-3 (230 mg, 0.37 mmol) was dissolved in 80% HCOOH aqueous solution (20 mL), and the mixture was stirred at R.T. for 24 h. The solvent was removed at low pressure. The residue was purified on a silica gel column to give the crude product, which was purified by RP HPLC (HCOOH system) to give compound 70 as a mixture of two P-isomers (75 mg, 33%). ESI-TOF-MS: m/z 583.0 [M+H] + .

›Example 46 · 1 of 2

Compound 75

To a solution of 75-1 (120 g, 0.26 mol) in CH 3 CN (2.0 L) was added IBX (109 g, 0.39 mol), and refluxed for 12 h. The reaction was monitored by TLC and LCMS. After cooling to R.T., the mixture was filtered, and the filtrate was concentrated at low pressure. The crude product was used directly for the next step.

Compound 75-2 (130 g, 0.26 mol) was co-evaporated with anhydrous toluene three times to remove H 2 O. To a solution of 75-2 in THF (300 mL) was added dropwise vinyl magnesium bromide (700 mL, 0.78 mol, 1N in THF) over 30 min at −78° C. The mixture was stirred for about 1 h at R.T. After the starting material was consumed, the mixture was poured into a sat. NH 4 Cl solution. The organic layer was washed with brine, dried with anhydrous Na 2 SO 4 and filtered. The solution was concentrated at low pressure to get the crude product. To a solution of this crude product (170 g, 0.346 mol) in anhydrous CH 2 Cl 2 was added TEA (105 g, 1.04 mol) and DMAP (84 g, 0.69 mol). Benzoyl chloride (146 g, 1.04 mol) was added slowly at R.T. for 12 h. The mixture was diluted with CH 2 C 12 and then washed with sat. aq. NaHCO 3 . The combined aq. phase was extracted with DCM (100 mL), and the combined organic phase was dried with Na 2 SO 4 . After filtration, the solution was evaporated to dryness under reduced pressure, and the residue was purified by column chromatography to give 75-3 (107 g, 52%).

Uracil (44.8 g, 0.4 mol) (co-evaporated with toluene twice) and NOBSA (81.4 g, 0.4 mol) were dissolved in CH 3 CN (500 mL). The mixture was refluxed for 1.5 h and then slowly cooled to R.T. The mixture was treated with 75-3 (59 g, 0.1 mol) and TMSOTf (155 g, 0.7 mol), and then warmed to 60-70° C. for 12 h. The mixture was neutralized with a sat. NaHCO 3 solution, and extracted with EA (3×1000 mL). The solution was dried over anhydrous MgSO 4 , and evaporated at low pressure. The residue was purified using a silica gel column to give pure 75-4 (40 g, 69%) as a white solid.

To a solution of 75-4 (50 g, 0.086 mol) in DMF was added PMBCl (16 g, 0.1 mol) and K 2 CO 3 (17.8 g, 0.13 mol) at 0° C., and the mixture was stirred at R.T. for 12 h. The mixture was quenched with water (100 mL), and extracted with EA (3×200 mL). The organic phase was concentrated at low pressure to give crude 75-5 (65 g) which was used in the next step without further purification.

To a solution of crude 75-5 (65 g, 0.086 mol) in MeOH/DCM (4/1) (200 mL) was added NaOMe (16.8 g, 0.3 mol), and the mixture was stirred at R.T. for 2.5 h. The reaction was quenched with dry ice, and then concentrated at low pressure. The residue was dissolved in EA (200 mL) and washed with brine. The organic layer was concentrated at low pressure, and the residue was purified using a silica gel column using 1% MeOH in CH 2 C 12 to give 75-6 as a yellow foam (25 g, 75%).

To a solution of 75-6 (25.5 g, 0.065 mol) in DMF was added NaH (10.5 g, 0.26 mol) slowly at 0° C., and the mixture was stirred for 30 mins. BnBr (36.3 g, 0.21 mol) was added, and the mixture was stirred at R.T. for 12 h. The reaction was quenched with sat. NH 4 Cl (aq.), and then extracted with EA (3×100 mL). The solution was dried over anhydrous MgSO 4 , and evaporated at low pressure. The residue was purified by a silica gel column using 10% EA in PE to give 75-7 (20 g, 46%) as a white solid.

To a solution of 75-7 (20 g, 0.03 mol) and NMMO (7 g, 0.06 mol) in THF:H 2 O (5:1) (100 mL) was added OsO 4 (2.6 g, 0.01 mol) at R.T., and the mixture was stirred at R.T. for 24 h. The mixture was quenched with a sat. Na 2 S 2 O 3 solution, and extracted with EA (3×100 mL). The organic layer was washed with brine, and dried over anhydrous MgSO 4 . The solution was evaporated at low pressure to give the crude compound, which was used in the next step without further purification.

To a solution of the crude diol (0.03 mol) in MeOH:H 2 O:THF (170 mL:30 mL:50 mL) was added NaIO 4 (9.6 g, 0.045 mol), and the mixture was stirred at R.T. for 2 h. After filtration, the filtrate was used directly in the next step. This solution was treated with NaBH 4 (1.8 g, 0.048 mol) at 0° C., and the mixture was stirred at R.T. for 30 mins. The mixture was quenched with MeOH, and evaporated at low pressure. The residue was dissolved in EA (100 mL), and washed with brine. The solution was evaporated at low pressure, and the residue was purified by a silica gel column using 20% EA in EA to give 75-8 (12 g, 61% over three steps).

To a solution of 75-8 (14 g, 21 mmol) and DMAP (5.1 g, 42 mmol) in DCM (100 mL) was added MsCl (3.1 g, 27 mmol) at 0° C., and the mixture was stirred at R.T. for 40 mins. The reaction was quenched with sat. NaHCO 3 (aq.), and washed with HCl (0.2 N) solution. The organic phase was dried over anhydrous MgSO 4 , and evaporated at low pressure. The residue was purified by a silica gel column using 5% EA in PE to give mysolate product (14 g, 90%). The MsO-product (41 g, 55 mmol) was treated with TBAF (1 N in THF, 500 mL), and the mixture was stirred at 70-80° C. for 3 d. The mixture was concentrated at low pressure, and the residue was dissolved in EA (200 mL). The solution was washed with brine, dried over anhydrous MgSO 4 and evaporated at low pressure. The residue was purified by chromatography using 10% EA in PE to give 75-9 (9.9 g, 27%).

To a solution of 75-9 (6.3 g, 9.45 mmol) in CH 3 CN:H 2 O (3:1, 36 mL:12 mL) was added CAN (15.5 g, 28.3 mmol), and the mixture was stirred at R.T. overnight. The mixture was extracted with EA (3×50 mL). The solution was dried over anhydrous MgSO 4 , and evaporated at low pressure. The residue was purified by chromatography using 20% EA in PE to give 75-10 (3.6 g, 71%) as a white solid.

To a solution of 75-10 (2.4 g, 4.4 mmol) in anhydrous DCM (10 mL) was added slowly BCl 3 (1 N, 30 mL CH 2 Cl 2 ) at −70° C., and the mixture was stirred for 2 h. at −70° C. The mixture was quenched with the slow addition of MeOH at −70° C., and the mixture was concentrated at low pressure. The residue was purified by chromatography using 50% EA in PE to give 75-11 (1.2 g, 86%) as a white solid. ESI-MS: m/z 277.1 [M+H] + .

›Example 46 · 2 of 2

To a solution of PPh 3 (3.37 g, 12.8 mmol) in pyridine (15 mL) was added 12 (3.06 g, 12 mmol) at 0° C., and the mixture was stirred at R.T. for 30-40 mins. The mixture was cooled to 0° C., and then treated with 75-11 (2.2 g, 8 mmol) in Py. (5 mL). The mixture was stirred at R.T. under N 2 for 12 h. The mixture was quenched with sat. Na 2 S 2 O 3 (aq.) and extracted with CH 2 Cl 2 (3×50 mL). The organic phase was dried over anhydrous MgSO 4 , and then concentrated at low pressure. The residue was purified by chromatography using 1-2% MeOH in CH 2 Cl 2 to yield 75-12 (1.8 g, 58%) as a white solid.

To a solution of 75-12 (1.35 g, 3.5 mmol) in THF:CH 3 CN (10 mL:5 mL) was added DBU (1.06 g, 7 mmol), and the mixture was stirred at 60-70° C. for 2 h. The mixture was concentrated at low pressure, and the residue was dissolved in EA (20 mL). The solution was washed with 10% HCl solution and brine. The organic phase was dried over anhydrous MgSO 4 and concentrated at low pressure. The residue was purified by chromatography using 30% EA in PE to give 75-13 (0.5 g, 55%).

To a solution of 75-13 (670 mg, 2.6 mmol) in CH 3 CN (6 mL) was added NIS (730 mg, 3.25 mmol) and 3HF.TEA (335 mg, 2.1 mmol) at 0° C., and the mixture was stirred at R.T. for 2 h. The mixture was quenched with sat. NaHCO 3 (aq.) and Na 2 S 2 O 3 (aq.) solution. The mixture was extracted with EA (3×20 mL), dried over anhydrous MgSO 4 and concentrated at low pressure. The residue was purified by chromatography using 1-2% MeOH in CH 2 Cl 2 to give 75-14 (1.2 g, 80%).

To a solution of 75-14 (1.0 g, 2.47 mmol), DMAP (0.75 g, 6.2 mmol) and TEA (0.75 g, 7.42 mmol) in DCM (10 mL) was added BzCl (1.15 g, 8.16 mmol) in DCM (1 mL) at 0° C., and the mixture was stirred at R.T. for 12 h. The mixture was diluted with CH 2 Cl 2 (10 mL), and then washed with HCl (0.1 N, 20 mL) solution and brine. The organic phase was dried over anhydrous MgSO 4 , and concentrated at low pressure. The residue was purified by chromatography using 20% EA in PE to afford 75-15 (850 mg, purity-80%).

To a solution of 75-15 (600 mg, 1 mmol) in DMF (25 mL) was added BzONa (1.45 g, 10 mmol), 15-crown-5 (2.2 g, 10 mmol), and the mixture was stirred at 90-100° C. for 24 h. The mixture was concentrated at low pressure, and the residue was dissolved in EA (20 mL), and washed with brine. The organic phase was dried over anhydrous MgSO 4 , and then concentrated at low pressure. The residue was purified by chromatography using 15% EA in PE to give 75-16 (275 mg, 37%) as a light yellow foam.

Compound 75-16 (250 mg, 0.41 mmol) was treated with NH 3 .MeOH (7 N, 5 mL), and the mixture stirred at R.T. for 15 h. The mixture was concentrated at low pressure, and the residue was purified by prep-HPLC to give compound 75 (33 mg, 25%) as a white solid. ESI-MS: m/z 295.1 [M+H] + .

›Example 47 · 1 of 2

Compound 73

To a solution of IBX (133.33 g, 476 mmol) in dry CH 3 CN (2 L) was added 73-1 (100.0 g, 216 mol) at R.T. The mixture was refluxed and stirred for 12 h. The mixture was filtered, and the filtrate was concentrated at low pressure to give 73-2 as a yellow oil (90.0 g, 90.4%).

Compound 73-2 (50.0 g, 108.70 mmol) was coevaporated with anhydrous toluene twice to remove H 2 O. Ethynyl magnesium bromide, (800 mL, 400.0 mmol) was added dropwise into a solution of 73-2 in THF (500 mL) over 20 mins at −78° C. The mixture was stirred for about 10 mins at −78° C. When the starting material was consumed, the ice-acetone cooling bath was removed. The mixture was quenched with a sat. NH 4 Cl solution with stirring, and then warmed to R.T. The mixture was extracted with EA, filtered through Celite and washed with brine. The combined organic phase was dried over anhydrous Na 2 SO 4 , filtered and concentrated at low pressure to give crude 73-3 as a deep yellow oil (48.0 g, yield: 90.8%).

Compound 73-3 (200.0 g, 411.52 mmol) was dissolved in anhydrous CH 2 Cl 2 (2000 mL) and then DMAP (100.41 g, 823.05 mmol) and Et 3 N (124.94 g, 1.23 mol) were added at R.T. The mixture was treated with benzoyl chloride (173.46 g, 1.23 mol) at 0° C. After stirring for 12 h at R.T., the reaction was quenched with H 2 O. The combined aq. phase was extracted with DCM. The combined organic phase was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness under reduced pressure to give a black oil. The oil was purified by column chromatography using 7%-20% EA in PE as the eluent to give a yellow oil. The residue triturated with CH 3 OH and filtered. The filter cake was concentrated in vacuo to give 73-4 as a white solid (30.0 g, 36.4%).

Uracil (34.17 g, 305.08 mmol) were coevaporated with anhydrous toluene twice to remove H 2 O. To a stirred suspension of uracil in anhydrous MeCN (150 mL) was added N,O-BSA (123.86 g, 610.17 mmol) at R.T. The mixture was refluxed for 1.5 h and then cooled to R.T. Compound 73-4 (90 g, 152.54 mmol, which were coevaporated with anhydrous toluene twice to remove H 2 O) was added. TMSOTf (237.05 g, 1.07 mol) was then added at R.T. The mixture was heated to 70° C., and then stirred overnight and then monitored by LCMS. The mixture was cooled to R.T., and quenched with a sat. NaHCO 3 solution. The solution was extracted with EA. The organic layer was dried over Na 2 SO 4 , and then concentrated at low pressure. The residue was purified using a silica gel column eluted with 10%-50% EA in PE to give 73-5 as a white solid (45 g, 50.9%).

Compound 73-5 (50 g, 86.21 mmol) was treated with NH 3 in MeOH (1 L) at R.T., and then stirred for 48 h. The mixture was concentrated at low pressure, and the residue was purified by column chromatography (10% MeOH in DCM) to give 73-6 (12.6 g, 54.55%) as a white solid.

To a solution of cyclopentanone (100 g, 1.189 mmol) and trimethyl orthoformate (150 mL) in MeOH (600 mL) was added TsOH.H 2 O (1.13 g, 5.9 mmol), and the mixture was stirred at R.T. for 30 mins. The reaction was quenched with NaOMe (0.32 g, 5.9 mmol) and H 2 O, and the solution was extracted by n-hexane. The organic layer was dried over anhydrous Na 2 SO 4 , and then concentrated at low pressure. The cyclopentyl dimethoxy acetal and 73-6 (20 g, 74.63 mmol) was dissolved in DCE (200 mL), and then treated with TsOH.H 2 O (0.71 g, 3.73 mmol). The mixture was stirred at 50° C. for 12 h, and then concentrated at low pressure. The residue was purified by silica gel column chromatography (1-10% MeOH in DCM) to give 73-7 (15.4 g, 61.8%) as a white solid.

Compound 73-7 (20.0 g, 0.06 mol) was coevaporated with anhydrous pyridine three times to remove H 2 O. To an ice-cold solution of 73-7 in anhydrous pyridine (100 ml) was added TsCl (22.8 g, 0.12 mol) at 0° C., and the mixture was stirred overnight and monitored by LCMS and TLC. The reaction was quenched with H 2 O and extracted with EA. The organic phase was dried over anhydrous NaSO 4 and evaporated at low pressure. The residue was purified by silica gel column chromatography (DCM:MeOH=100:1 to 15:1) to give 78-8 (20.0 g, 69.0%) as a white solid.

To a solution of 73-8 (20.0 g, 0.04 mol) in acetone (200 ml) was added NaI (31.0 g, 0.2 mol) and heated to reflux overnight and monitored by LCMS. The mixture was quenched with a sat. Na 2 S 2 O 3 solution, and extracted with EA. The organic phase was dried over anhydrous Na 2 SO 4 and evaporated at low pressure. The residue was purified by silica gel column chromatography (DCM:MeOH=100:1 to 15:1) to give 73-9 (15.0 g, 83.3%) as a white solid.

To 73-9 (30.0 g, 0.068 mol) in dioxane (60 mL) in sealed tube was added CuBr (4.9 g, 0.034 mol), i-Pr 2 NH (13.6 g, 0.135 mol) and (CH 2 O) n (5.1 g, 0.17 mol) under N 2 . The mixture was heated at reflux for 16 h. The mixture was diluted with EtOAc, and washed with a sat. NH 4 Cl solution and brine. The solution was dried over anhydrous MgSO 4 , and concentrated under reduced pressure. The residue was purified by column chromatography (DCM:MeOH=100:1 to 15:1) to give 73-10 (10.0 g, 32.3%) as a white solid.

Compound 73-10 (10 g, 21.83 mmol) was treated with HCOOH (80%) in H 2 O at R.T. The solution was stirred at 60° C. for 2 h, and then concentrated at a low pressure. The residue was purified by column chromatography (1%-10% MeOH in DCM) to give 73-11 (5.1 g, 58.55%) as a white solid.

Compound 73-11 (5 g, 12.79 mmol) was dissolved in anhydrous MeOH (100 mL) and treated with NaOMe (4.83 g, 89.5 mmol) at R.T. The solution was stirred at 60° C. for 36 h. The mixture was quenched with CO 2 and then concentrated at low pressure. The residue was purified by column chromatography (0-10% MeOH in DCM) to give 73-12 (2.3 g, 68.05%) as a yellow solid. 1 H-NMR (CDCl 3 , 400 MHz) δ=7.29 (d, J=8 Hz 1H), 6.10 (s, 1H), 5.71 (d, J=8.0 Hz 1H), 5.18 (t, J=6.4 Hz, 1H), 4.79-4.84 (m, 1H), 4.61 (d, J=8.0 Hz, 2H), 4.39 (s, 1H), 3.45 (s, 1H).

To an ice-cold solution of 73-12 (1.5 g, 5.68 mmol) in anhydrous MeCN (15 mL) was added NIS (1.66 g, 7.39 mmol) and TEA.3HF (0.73 g, 4.55 mmol) under N 2 . The mixture was stirred at R.T. for 1 h. The reaction was quenched with sat. NaHCO 3 and sat. Na 2 SO 3 solution, and extracted with EA (3×100 mL). The organic phase was dried over anhydrous Na 2 SO 4 , and evaporated to dryness at low pressure. The residue was purified on a silica gel column (0-5% MeOH in DCM) to give 73-13 (1.08 g, 46.2%) as a yellow solid.

›Example 47 · 2 of 2

To a stirred solution of 73-13 (1 g, 2.44 mmol) in anhydrous DCM (10 mL) was added DMAP (0.60 g, 4.88 mmol) and Et 3 N (0.74 g, 7.32 mmol) at R.T. The mixture was treated with benzoyl chloride (0.79 g, 5.61 mmol) at 0° C. and then stirred at R.T. for 3 h. The reaction was quenched with water, and extracted with EA (3×60 mL). The organic phase was concentrated at low pressure, and the residue was purified by column chromatography (0-10% MeOH in DCM) to give 73-14 (0.9 g, 59.6%) as a white solid.

Bu 4 NOH (55% in H 2 O, 13.74 mL) was treated with TFA (to adjust pH=3-4). The mixture was cooled to R.T. To a solution of 73-14 (0.9 g, 1.46 mmol) in DCM (9 mL) was added m-CPBA (80%, 1.57 g, 7.28 mmol) at R.T. The mixture was stirred at 25° C. for 48 h. The mixture was washed with sat. aq. NaHCO 3 . The organic layer was passed through an anhydrous Al 2 O 3 column, and the solution was concentrated at low pressure. The residue was purified by a silica gel column (30% EA in PE) to give 73-15 (0.26 g, 35.1%) as a yellow solid.

Compound 73-15 (0.25 g, 0.49 mmol) was dissolved in NH 3 /MeOH (5 mL, 7 M), and the mixture was stirred at R.T. for 24 h under N 2 . The mixture was concentrated at low pressure at R.T., and the residue was purified by a silica gel column (5% MeOH in DCM) to give 73-16 (100 g, 67.75%) as a white solid. 1 H-NMR (CD 3 OD, 400 MHz) δ=7.83 (d, J=8 Hz 1H), 6.29 (s, 1H), 5.67 (d, J=6.0 Hz 1H), 5.12 (t, J=6.8 Hz, 1H), 4.99-5.01 (m, 1H), 4.38 (d, J=19.6 Hz 1H), 3.74-3.81 (m, 2H), 3.35 (s, 1H).

Compound 73-16 (100 mg, 0.33 mmol) was co-evaporated with toluene three times to remove H 2 O. To a stirred solution of 73-16 (100 mg, 0.33 mmol) in a mixture of MeCN (1.0 mL) and NMI (271 mg, 3.3 mmol) was added a solution of 73-C (216.5 mg, 0.66 mmol) in MeCN (0.5 mL) at 0° C. The mixture was stirred at R.T. overnight and then reaction was quenched with water. The mixture was diluted with EA (20 mL), and the organic layer was washed with water and brine, and dried over anhydrous Na 2 SO 4 . The organic phase was concentrated at low pressure, and the residue was purified on a silica gel column (5% i-PrOH in DCM) to give the crude product. The crude product was purified by prep-HPLC (0.1% HCOOH in water and MeCN) to give compound 73 (35.6 mg, 19.0%) as a white solid. ESI-LCMS: m/z 592 [M+Na] + .

To a stirred solution of 73-A (2.0 g, 13.16 mmol) and phenol (1.22 g, 13.16 mmol) in anhydrous DCM (100 mL) was added a solution of TEA (1.33 g, 13.16 mmol) in DCM (20 mL) dropwise at −78° C. The mixture was warmed gradually to R.T., and then stirred for 2 h. The solution was re-cooled to −78° C., and (S)-isopropyl 2-aminopropanoate hydrochloride (2.20 g, 13.16 mmol) in DCM (20 mL) was added, followed by the dropwise addition of TEA (2.66 g, 26.29 mmol) in DCM (20 mL). The mixture was warmed gradually to R.T., and then stirred for 2 h. The organic solvent was removed at low pressure, and the residue was dissolved in methyl-butyl ether. The precipitate was filtered, and the filtrate was concentrated at low pressure. The residue was purified on a silica gel column (anhydrous DCM) to give 73-C (0.9 g, 22.3%) as a colorless oil.

›Example 48 · 1 of 2

Compound 66

Compound 66-2 (2648 g, 7.3 mol) was dissolved in anhydrous dichloromethane (10 L), and the solution was cooled to −40° C. with stirring under N 2 . Compound 66-1 (1 kg, 7.69 mol) was dissolved in anhydrous CH 2 Cl 2 (3 L) and added to the solution of 66-2 over 30 mins at −40 OC. The stirred mixture was allowed to warm to R.T. overnight. The mixture was concentrated under reduced pressure to dryness, and the residue was suspended in TMBE (6 L). The suspension was filtered to remove Ph 3 PO, and the filtrate was concentrated under reduced pressure to afford crude 66-3 (1230 g, 78.6%). 1 H NMR (400 Hz) (CDCl 3 ): δ 6.65 (dt, J=7.6 Hz, 1H), 4.82 (dd, J=14.8, 7.6 Hz, 1H), 4.20-4.10 (m, 3H), 3.59 (t, J=8.0 Hz, 1H), 1.86 (d, J=1.2 Hz, 3H), 1.41 (s, 3H), 1.37 (s, 3H), 1.26 (t, J=6.8 Hz, 3H).

Crude 66-3 (1230 g, 5.74 mol) was dissolved in acetone (30 L) at 0-5° C. KMnO 4 (1107 g, 5.17 mol) was added in one portion. After being stirred at 0-5° C. for 5 h, the reaction was quenched with sat. aq. sodium sulfite (20 L). After 30 mins, a colorless suspension was formed. The solid was removed by filtration and washed with EA (6 L). The filtrate was extracted with EA (3×2 L). The combined extracts were dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure to give a white solid residue. The residue was dissolved in EA, and PE was added to give a precipitate. The solid was collected by filtration and recrystallization was 3 times to give 66-4 (770 g, 53.6%) as a white solid.

To a stirred solution of 66-4 (770 g, 3.1 mol) in anhydrous DCM (5 L) and triethylamine (1.1 L, 8.05 mol) at 0° C. was added slowly sulfuryl chloride (300 mL, 3.6 mmol). The mixture was stirred at R.T. for 2 h, diluted with DCM (3 L), and washed with sat. NaHCO 3 aq. and brine. The organic phase was dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. The residue was purified by a silica gel column using PE:EA=1:0 to 10:1 as the eluent to give 66-5 (490 g, 50.6%) as an oil.

Tetraethylammonium fluoride hydrate (650 g, 3.7 mol) was added into a solution of 66-5 (490 g, 1.6 mol) in anhydrous dioxane (3 L), and the mixture was heated to 120° C. for 16 h. The mixture was then cooled to ambient temperature. 2,2-Dimethoxypropane (3 L) was added followed by conc. aq hydrochloric acid (200 mL). The mixture was stirred for 3 h at ambient temperature. The solvent was concentrated to ⅓ of the original volume, and then diluted with EA (3 L). The mixture was washed with cold sat. aq. sodium bicarbonate and brine. The combined aqueous layer was back-extracted with EA (1 L). The combined organic layer was dried over anhydrous Na 2 SO 4 , filtered, and concentrated at low pressure to give crude 66-6 (220 g, 70.8%).

Crude 66-6 (220 g, 0.89 mol) was dissolved in ethanol (2 L) and cone. aq. HCl (60 mL). The solution was stirred at ambient temperature for 48 h. and then concentrated under reduced pressure followed by co-evaporations with toluene 3 times to give 66-7 as a pale yellow solid (110 g).

Compound 66-7 (110 g) was dissolved in anhydrous pyridine (1 L). Benzoyl chloride (200 mL, 1.67 mol) was added slowly at 0-5° C. The mixture was stirred at ambient temperature for 45 mins. The reaction was quenched with ice and MeOH to form a precipitate. After filtration, the filtrate was washed with MeOH to give 66-8 (200 g, 61.2%) as a white solid.

To a solution of 66-8 (100 g, 269 mmol) in anhydrous THF (1000 ml) was added dropwise a solution of lithium tri-tert-butoxyaluminohydride (400 ml, 1M, 0.4 mol) at −78° C. under N 2 for 30 mins. The solution was stirred at −20° C. for 1 h, and TLC (PE:EA=3:1) showed that the reaction was complete. The mixture was quenched with sat.NH 4 Cl, and diluted with EA. After filtration, the filtrate was extracted with EA. The combined layers were dried over Na 2 SO 4 , and concentrated at low pressure. The residue was purified by a silica column gel (PE:EA=20:1) to give 66-9 (100 g, 100%) as a colorless oil.

To a stirred solution of PPh 3 (140 g, 382 mol) in CH 2 Cl 2 (1000 ml) was added 66-9 (100 g, 269 mmol) at −20° C. under N 2 . After stirring for 15 mins, CBr 4 (177 g, 382 mol) was added dropwise while maintaining the temperature between −25 and −20° C. under N 2 . The mixture was stirred below −17° C. for 20 mins. Silica gel was added to the mixture. The mixture was filtered through cold silica column gel and washed with PE:EA (50:1 to 4:1). The combined filtrates were concentrated under reduced pressure at R.T. to give the crude oil product. The residue was purified by a silica column gel a second time (PE:EA=50:1 to 4:1) to give 66-10 (α-isomer, 64 g, yield: 55%) as a colorless oil.

A mixture of 6-chloro-guanine (55.8 g, 316.5 mol) and t-BuOK (39.5 g, 352.7 mmol) in t-BuOH (500 mL) and MeCN (280 mL) was stirred for 30 mins. Compound 66-10 (48 g, 105.5 mmol) was added at R.T., and the mixture was heated to 50° C. and stirred overnight. The reaction was monitored by TLC (PE:EA=2:1). The mixture was quenched with solid NH 4 Cl. After stirring for 1 h, the mixture was filtered and washed with MeCN. The filtrate was evaporated at low pressure, and the residue was purified by a silica gel column to give 66-11 (33 g, 57%).

To a solution of 66-11 (49 g, 93.1 mol) in CH 2 Cl 2 (200 mL) was added AgNO 3 (31.7 g, 186 mmol), collidine (22.5 g, 186 mmol) and MMTrCl (43 g, 140 mmol) in small portions under N 2 at 0° C. The mixture was stirred at R.T., and monitored by TLC (PE:EA=4:1). After filtration, the organic phase was washed with NaHCO 3 aqueous and brine. The organic layer was dried over anhydrous Na 2 SO 4 and concentrated at low pressure. The residue was purified by a silica gel column (PE:ME=20:1 to 1:1) to give 66-12 (70 g, 94.2%).

Sodium (10.1 g, 439 mmol) was dissolved in dry EtOH (600 mL) at 70° C. and then cooled to 0° C. To a solution of 66-12 (70 g, 87.7 mmol) was added a freshly prepared NaOEt solution in portions at 0° C., and the mixture was stirred for 1 h. at R.T. After TLC and LCMS showed the reaction was completed, the reaction was quenched with carbon dioxide. The mixture was evaporated at low pressure, and the residue was purified using silica gel column chromatography (DCM:MeOH=100:1 to 20:1) to give 66-13 (50 g, yield 5%) as a yellow solid.

›Example 48 · 2 of 2

A mixture of PPh 3 (35 g, 133.5 mol) and 12 (31.75 g, 125 mmol) in anhydrous pyridine (600 mL) was stirred for 30 mins, and then a solution of 66-13 (50 g, 83.3 mmol) in pyridine (100 mL) was added at 0° C. The mixture was stirred overnight at R.T. and monitored by TLC (DCM:MeOH=50:1). The reaction was quenched with a sat. NaHCO 3 solution, and extracted with DCM (3×50 mL). The organic phase was dried over anhydrous MgSO 4 , and evaporated at low pressure. The residue was purified using silica gel column chromatography (DCM:MeOH=200:1 to 50:1) to give 66-14 (50 g, 84.7%).

To a solution of 66-14 (37 g, 52.1 mmol) in dry THF (400 mL) was added DBU (16 g, 105 mmol). The mixture was heated to reflux and stirred for 3 h. The reaction was monitored by LCMS. The reaction was quenched with a sat. NaHCO 3 solution, and extracted with EA. The combined organic layers were dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified using silica gel column chromatography (PE:EA=10:1 to 5:1) to give 66-15 (25 g, 61.1%) as a white solid.

To an ice-cold solution of 66-15 (26 g, 44.6 mmol) in dry MeCN (300 mL) was added NIS (12.68 g, 56 mmol) and NEt 3 .3HF (10.6 g, 67 mmol) at 0° C. The reaction was stirred at R.T. for 2 h. and monitored by LCMS. After the reaction was completed, the reaction was quenched with a sat Na 2 SO 3 and sat. NaHCO 3 solution, and extracted with EA. The organic layer was separated, dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified using silica gel column chromatography (PE:EA=8:1 to 1:1) to give 66-16 (21 g, 64.4%) as a white solid.

To a solution of 66-16 (21 g, 28.8 mol) in CH 2 Cl 2 (150 mL) was added AgNO 3 (9.8 g, 59.6 mmol) and collidine (7 g, 59.8 mmol) and MMTrCl (13.1 g, 42.5 mmol) in small portions under N 2 at 0° C. The mixture was stirred at R.T., and the reaction was monitored by TLC (PE:EA=2:1). After filtration, the solution was washed with sat. aq. NaHCO 3 and brine. The organic layer was separated, dried over anhydrous Na 2 SO 4 and concentrated at low pressure. The residue was purified by a silica gel column to give 66-17 (25 g, yield 86.5%).

To a solution of 66-17 (22 g, 22 mmol) in dry DMF (500 mL) was added NaOBz (31.9 g, 220 mmol) and 15-crown-5 (48.4 g, 220 mmol), and the mixture was stirred for 72 h. at 95° C. The mixture was diluted with EA, washed with water and brine, and dried over MgSO 4 . The organic layer was evaporated at low pressure, and the residue was purified using a silica gel column chromatography to give 66-18 (15 g, 68.8%) as a white solid.

Compound 66-18 (15.2 g, 15.3 mmol) was co-evaporated with anhydrous toluene 3 times to remove H 2 O. The compound was treated with NH 3 in MeOH (7 N, 200 mL) at R.T. The mixture was stirred for 18 h at R.T., and the reaction was monitored by LCMS. The residue was concentrated at low pressure, and purified using silica gel column chromatography to give 66-19 (11 g, 81%) as a white solid.

To a stirred solution of 66-20 (14 g, 15.73 mmol) in anhydrous CH 3 CN (150 mL) was added N-methylimidazole (23.5 g, 283.9 mmol) at 0 to 5° C. (ice/water bath) followed by a solution of phenyl(cyclohexanoxy-L-alaninyl)phosphorochloridate (16.33 g, 47.2 mmol, dissolved in 50 mL of CH 3 CN). The solution was stirred at 0 to 5° C. for 12 h and then diluted with EA. The solution was washed 50% aqueous citric acid solution and brine. The organic layer was separated, dried over anhydrous MgSO 4 and filtered. The filtrate was concentrated at low pressure, and the residue was purified on silica gel with PE:EA=5:1 as the eluent to give 66-20 (17.62 g, 93.4%) as a white solid.

Compound 66-20 (17.62 g, 14.7 mmol) was dissolved in 80% AcOH (200 mL), and the mixture was stirred overnight at R.T. After removal of the solvents, the reside was purified on silica gel using PE:EA=2:1 to eluent to give the crude product, which was purified on via reverse-phase HPLC using acetonitrile and water to give compound 66 (5.25 g, yield 66%) as a white solid. ESI-LCMS: m/z 655 [M+H] + .

›Example 49

Compound 67

To a solution of the nucleoside (300 mg, 1.09 mmol) and proton-sponge (467 mg, 2.18 mmol) in anhydrous CH 3 CN (5 mL) at 0° C. under N 2 was added dropwise a solution of phosphorus oxychloride (330 mg, 2.18 mmol) in anhydrous CH 3 CN (1 mL). The mixture was stirred at 0° C. for 30 mins, and the hydrogen chloride salt of (S)-ethyl 2-aminopropanoate (998 mg, 6.52 mmol) and triethylamine (1.5 mL, 10.87 mmol) at 0° C. were added. The mixture was stirred overnight at 30° C. The reaction was quenched with water, and extracted with EA (3×20 mL). The organic layer was concentrated at low pressure, and the residue was purified by reverse phase HPLC to give compound 67 (20 mg, 3%) as a white solid. ESI-LCMS: m/z 535 [M−F] + .

›Example 50

Compound 59

To a solution of sodium hydrosulfide (4.26 g, 76.0 mmol) in EtOH (100 mL) was added t-butyryl chloride (76.2 mmol; 9.35 mL) dropwise at 0° C., and the mixture was stirred at R.T. for 1 h. A solution of 2-(2-chloroethoxy)ethanol (57 mmol; 6.0 mL) and TEA (21 mL, 120 mmol) was added, and the mixture was heated at reflux for 60 h. The mixture was filtered, and then concentrated to a small volume. The residue was dissolved in EA, and then washed with water, sat. aq. NaHCO 3 and brine. The organic phase was dried over Na 2 SO 4 , filtered and concentrated in vacuo. The crude product (10.0 g) was isolated and 5 grams were purified by silica gel flash column chromatography using a gradient of 0 to 100% EA in hexane to give 59-3 (4.5 g, 22 mmol) as a clear, colorless oil. 1 H-NMR (CDCl 3 ): 3.70-3.74 (m, 2H), 3.5-3.65 (m, 4H), 3.1 (t, 2H), 1.25 (s, 9H).

A solution 59-3 (4.5 g; 21.8 mmol) and triethylamine (6.7 mL, 87.2 mmol) in tetrahydrofuran (50 mL) was added dropwise over 1 h to a stirred solution of N,N-diisopropylphosphorodichloridite (2.0 mL, 10.9 mmol) in THF (50 mL) under argon at −78° C. The mixture was stirred at R.T. for 2 h, and then diluted with EA (200 mL). The mixture was washed with sat. aq. NaCl and dried over Na 2 SO 4 . After filtration, the filtrate was evaporated under reduced pressure to give a pale yellow oil. Purification by flash column chromatography using a gradient of EA (0-5%) in hexane containing 5% triethylamine afforded 59-4 (2.5 g, 4.25 mmol) as a clear, colorless oil. 1 H-NMR (CDCl 3 ): 3.70-3.82 (m, 4H), 3.57-3.65 (m, 10H), 3.1 (t, 4H), 1.25 (s, 18H), 1.17 (t, 12H); 31 P-NMR (CDCl 3 ): 148.0 ppm.

Compound 59-5 (285 mg, 0.9 mmol) and DCI (175 mg, 1.5 mmol) were coevaporated twice with ACN and then dissolved in ACN (5 mL). Compound 59-4 (790 mg, 1.35 mmol) in ACN (4 mL) was added, and the reaction was monitored by TLC. After 15 mins, tert-butylhydroperoxide (0.5 mL of 5.5M solution in decane) was added, and the mixture was stirred for 10 mins. The mixture was diluted with EA (25 mL), washed with sat. aq. NaHCO 3 and sat. aq. NaCl solution, dried over Na 2 SO 4 , filtered and concentrated. Purification by flash column chromatography using a gradient of EA (0-100%) in hexane afforded 59-6 (0.17 g, 0.22 mmol) as a white solid. Compound 59-6 was dissolved in 80% aq. HCOOH (5 mL). After 30 mins at R.T., the solvent was removed and coevaporated twice with toluene. The residue was dissolved in methanol (10 mL) and TEA (0.2 mL) was added. After 2 mins at R.T., the solvent was removed in vacuo. Purification by flash column chromatography using a gradient of methanol (0-15%) in DCM afforded compound 59 (90 mg). 1 H-NMR (CDCl 3 ): 7.40 (d, 1H), 6.1 (s, 1H), 5.83 (d, 1H), 4.3 (t, 2H), 4.1-4.2 (m, 6H), 3.70-3.82 (m, 4H), 3.57-3.65 (m, 4H), 3.1 (t, 4H) 1.61 (s, 8H), 1.3 (s, 3H), 1.23 (s, 18H). 31 P-NMR (CDCl 3 ): −1.55 ppm.

›Example 51

Compound 60

Compound 60-1 (6.0 g, 31.6 mmol) was prepared using a similar procedure to the one used to prepared 59-3 using 4-chlorobutanol. Compound 60-1 was obtained as a clear, colorless oil. 1 H-NMR (CDCl 3 ): 3.67 (s, 2H), 2.86 (m, 2H), 1.65 (m, 4H), 1.25 (s, 9H).

Compound 60-2 (2.14 g, 4.0 mmol) was prepared using a similar procedure to the one used to prepared 59-4. Compound 60-2 was obtained as a clear, colorless oil. 1 H-NMR (CDCl 3 ): 3.67 (m, 6H), 2.86 (t, 4H), 1.65 (m, 8H), 1.25 (s, 18H), 1.17 (t, 12H). 31 P-NMR (CDCl 3 ): 143.7 ppm.

Compound 60-3 (0.23 g, 0.22 mmol) was prepared using a similar procedure to the one used to prepared 59-6 using 59-5 and 60-2. Compound 60-3 was obtained as a white solid. Using a similar procedure to the one used to prepared compound 59, 60-3 was used to prepare compound 60 (170 mg). 1 H-NMR (CDCl 3 ): 7.40 (d, 1H), 6.1 (s, 1H), 5.83 (d, 1H), 4.3 (t, 2H), 4.1-4.2 (m, 6H), 2.8 (t, 4H), 1.78 (m, 4H), 1.69 (s, 8H), 1.3 (s, 3H), 1.23 (s, 18H). 31 P-NMR (CDCl 3 ): −1.56 ppm.

›Example 52

Compound 58

Compound 58-1 was prepared according to the procedure described in Lefebre et al. J. Med. Chem. (1995) 38:3941-3950, which is hereby incorporated by reference for the limited purpose of its description of the preparation of 58-1.

Compound 58-2 (0.33 g, 0.5 mmol) was prepared using a similar procedure to the one used to prepared 59-6 using 59-5 and 58-1. Compound 58-2 was obtained as a white solid. Using a similar procedure to the one used to prepared compound 59, 58-2 was used to prepare compound 58 (130 mg). 1 H-NMR (CDCl 3 ): 7.40 (d, 1H), 6.1 (s, 1H), 5.83 (d, 1H), 4.3 (t, 2H), 4.1-4.2 (m, 6H), 3.2 (t, 4H), 1.69 (s, 4H), 1.3 (s, 3H), 1.23 (s, 18H); 31 P-NMR (CDCl 3 ): −2.4 ppm.

›Example 53

Compound 47

Compound 47-1 (1.0 g, 3.53 mmol) was coevaporated with anhydrous pyridine 3 times to remove H 2 O. To an ice-cold solution of 47-1 in anhydrous pyridine (9 mL) was added TsCl (808 mg, 4.24 mmol) in pyridine (3 mL) drop-wise at 0° C., and the mixture was stirred for 18 h. at 0° C. The reaction was monitored by LCMS, and then quenched with H 2 O. After concentration at low pressure, the residue was dissolved in EA (50 mL). The solution was washed with sat. NaHCO 3 solution and brine. The organic layer was dried over anhydrous Na 2 SO 4 and filtered. The filtrate was evaporated at low pressure, and the residue was purified by silica gel column chromatography (1% MeOH in DCM) to give 47-2 (980 mg, 63%) as a white solid.

To a solution of 47-2 (980 mg, 2.24 mmol) in acetone (10 mL) was added NaI (1.01 g, 6.73 mmol), and the mixture was heated to reflux overnight. The reaction was monitored by LCMS. After the reaction was completed, the mixture was concentrated at low pressure. The residue was dissolved in EA (50 mL). The solution was washed with brine, and dried over anhydrous Na 2 SO 4 . The solution was evaporated at low pressure, and the residue was purified by silica gel column chromatography (1% MeOH in DCM) to give 47-3 (700 mg, 79%) as a solid.

To a solution of 47-3 (700 mg, 1.78 mmol) in dry THF (9 mL) was added DBU (817 mg, 5.34 mmol), and the mixture was heated to 60° C. The mixture was stirred overnight, and monitored by LCMS. The reaction was quenched with sat. NaHCO 3 and extracted with EA (3×50 mL). The organic phase was dried over anhydrous Na 2 SO 4 , and filtered. The filtrate was evaporated at low pressure, and the residue was purified by silica gel column chromatography (1% MeOH in DCM) to give 47-4 (250 mg, 53%) as a white solid.

To an ice-clod solution of 47-4 (250 mg, 0.94 mmol) in dry MeCN (5 mL) was added NEt 3 -3HF (151 mg, 0.94 mmol) and NIS (255 mg, 1.13 mmol). The mixture was stirred at R.T., for 3 h., and checked by LCMS. The reaction was quenched with sat Na 2 S 2 O 3 and sat. NaHCO 3 solution, and extracted with EA (3×50 mL). The organic layer was separated, dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (2% acetone in DCM) to give 47-5 (170 mg, 44%).

To a solution of 47-5 (270 mg, 0.65 mmol) in dry DCM (4 mL) was added DMAP (158.6 mg, 1.3 mmol), and BzCl (137 mg, 0.98 mmol). The mixture was stirred for 4-5 h. at R.T., and checked by LCMS. The mixture was diluted with CH 2 Cl 2 , and washed with sat. NaHCO 3 solution and brine. The organic layer was evaporated at low pressure, and the residue was purified by silica gel column chromatography (20% EA in PE) to give 47-6 (290 mg, 86%) as a solid.

To a solution of 47-6 (900 mg, 1.74 mmol) in dry DMF (45 mL) was added NaOBz (2.5 g, 17.4 mmol) and 15-crown-5 (4.5 g, 20.9 mmol). The mixture was stirred for 48 h at 90-100° C. The mixture was diluted with EA (100 mL), and washed with brine. The organic layer was evaporated at low pressure, and the residue was purified by silica gel column chromatography (20% EA in PE) to give 47-7 (500 mg, 56%) as a solid.

To a solution of 47-7 (500 mg, 0.98 mmol) in anhydrous CH 3 CN (5 mL) was added TPSCl (741 mg, 2.45 mmol), DMAP (299.6 mg, 2.45 mmol) and NEt 3 (248 mg, 2.45 mmol) at R.T., and the mixture was stirred overnight. The mixture was then treated with NH 3 in THF (5 mL) and then stirred for another 30 mins. The mixture was diluted with EA (100 mL). The solution was washed with 0.5% AcOH solution. The organic solvent was dried over anhydrous MgSO 4 , and concentrated at low pressure. The crude product was purified by silica gel column chromatography (2% Acetone in DCM) to give 47-8 (257 mg, 51.6%) as a white solid. ESI-MS: m/z 509 [M+H] + .

Compound 47-8 (80 mg, 0.16 mmol) was dissolved in n-butylamine (3 mL). The mixture was kept overnight at R.T. and evaporated. The residue was crystallized from methanol to give compound 47 (30 mg). The mother liquor was purified by RP HPLC on Synergy 4 micron Hydro-RP column (Phenominex). A linear gradient of methanol from 0 to 30% in 50 mM triethylammonium acetate buffer (pH 7.5) was used for elution. The corresponding fractions were combined, concentrated and lyophilized 3 times to remove excess of buffer to yield additional compound 47 (13 mg). Compound 47 (total yield 43 mg, 73%). MS: m/z 299.7 [M−1] − .

›Example 54

Compound 83

To a stirred solution of POCl 3 (2.0 g, 13 mmol) in anhydrous DCM (10 mL) was added 1-naphthol (1.88 g, 13 mmol) at −70° C., and TEA (1.31 g, 13 mmol) in DCM (3 mL) dropwise at −70° C. The mixture was gradually warmed to R.T. and stirred for 1 h. Crude 83-1 was obtained.

To a stirred solution of (S)-isopropyl 2-aminopropanoate hydrochloride (2.17 g, 13 mmol) in DCM (10 mL) was added crude 83-1 at −70° C. TEA (2.63 g, 26 mmol) was added to the stirred solution dropwise at −70° C. The mixture was gradually warmed to R.T. and stirred for 2 h. The reaction was monitored by LCMS and quenched with n-propylamine. The mixture was concentrated at low pressure, and the residue was purified by a silica gel column (PE:MTBE=5:1˜1:1) to give pure 83-2 (1.6 g, 35%).

To a solution of 83-(A) (300 mg, 0.337 mmol) and NMI (276 mg, 3.37 mmol) in anhydrous CH 3 CN (4 mL) was added 83-2 (240 mg, 0.674 mol, in DCM (5 mL)) at 0° C. The mixture was stirred at R.T. for 10 h. The reaction was monitored by LCMS. The reaction was quenched with water, and extracted with CH 2 Cl 2 (3×20 mL). The organic phase was dried over anhydrous MgSO 4 , and concentrated at low pressure. The residue was purified by sil-gel (PE:EA=5:1˜2:1) to give 83-3 (380 mg, 93%).

Compound 83-3 (380 mg, 0.314 mmol) was dissolved in CH 3 COOH (80%, 8 mL), and stirred at 40-50° C. for 2.5 h. The reaction was monitored by LCMS. The mixture was concentrated at low pressure, and the residue was purified by chromatography (PE:EA=1:1˜EA) to give crude compound 83. The crude product was purified by prep-HPLC (neutral system, NH 4 HCO 3 ) to give pure compound 83 (70 mg, 80%) as a white solid. ESI-MS: m/z 665.1 [M+H] + .

›Example 55

Compound 79

A solution of 79-1 (16.70 g, 0.363 mol) and TEA (36.66 g, 0.363 mol) in CH 2 Cl 2 (150 mL) was added dropwise to a stirred solution of POCl 3 (55.65 g, 0.363 mol) in DCM (100 mL) over 25 mins at −78° C. After the mixture was stirred for 2 h. at R.T., the triethylamine hydrochloride salt was filtered, and washed with CH 2 Cl 2 (100 mL). The filtrate was concentrated at low pressure, and the residue was distilled under high vacuum (˜10 mm Hg) with a cow-head fraction collector. The product was collected between 45° C. (distillation head temperature) as a colorless liquid (30.5 g, 50% yield). 1 H-NMR (400 MHz, CDCl 3 ) δ=4.44 (dq, J=10.85, 7.17 Hz, 2H), 1.44-1.57 (m, 3H); 31 P-NMR (162 MHz, CDCl 3 ) δ=6.75 (br. s., 1 P).

To a stirred suspension of 83-A (93 mg, 0.15 mmol) in CH 2 Cl 2 (1 mL) was added TEA (61 mg, 0.15 mmol) at R.T. The mixture was cooled to −20° C., and then was treated with a 79-2 (35 mg, 0.21 mmol) solution dropwise over a period of 10 mins. The mixture was stirred at this temperature for 15 min., and then was treated with NMI (27 mg, 0.33 mmol). The mixture was stirred at −20° C., and then slowly warmed to R.T. The mixture was stirred overnight. The mixture was suspended in EA (15 mL), washed with brine (10 mL) and dried over anhydrous sodium sulfate. The solution was concentrated at low pressure, and the residue was purified by chromatography (DCM:MeOH=100:1) to give 79-3 (60 mg, yield: 56%) as a solid.

A solution of 79-3 (60 mg, 0.085 mmol) in 80% AcOH aqueous (2 mL) was stirred at R.T. for 2 h. The mixture was concentrated under reduced pressure, and the residue was purified by a silica gel column eluting DCM/MeOH=50/land prep-HPLC to give compound 79 (23 mg, 62%) as a white solid. ESI-MS: m/z 436.3 [M+H] + .

›Example 56

Compound 80

Compound 80-2 was prepared using a similar procedure as for the preparation of 79-2 using a solution of iso-butanol (23.9 g, 322.98 mmol) and POCl 3 (49.5 g, 322.98 mmol). Compound 80-2 (26 g, 42% yield) was obtained as a colorless liquid. 1 H-NMR (400 MHz, CDCl 3 ) δ=4.10 (dd, J=9.04, 6.39 Hz, 2H), 2.09 (dq, J=13.24, 6.67, 6.67, 6.67, 6.67 Hz, 1H), 1.01 (d, J=6.62 Hz, 6H); 31 P-NMR (162 MHz, CDCl 3 ) δ=7.06 (br. s., 1 P).

To a stirred suspension of 83-A (310 mg, 0.5 mmol) in CH 2 Cl 2 (3 mL) was added TEA (202 mg, 2 mmol) at R.T. The mixture was cooled to −20° C., and then was treated with 80-2 (134 mg, 0.7 mmol). The mixture was stirred at this temperature for 15 mins and then was treated with NMI (90 mg, 1.1 mmol). The mixture was stirred at −20° C. for 1 h., and then slowly warmed to R.T. overnight. The mixture was suspended in EA (15 mL), washed with brine (10 mL), and dried over anhydrous sodium sulfate. The organic phase was concentrated at low pressure, and the residue was purified by silica column gel (DCM:MeOH=100:1) to give 80-3 (310 mg, yield: 84%) as a solid.

A solution of 80-3 (310 mg, 0.43 mmol) in 80% AcOH aqueous (4 mL) was stirred at R.T. for 2 h. The mixture was concentrated at low pressure, and the residue was purified by a silica gel column eluting DCM/MeOH=50/1 and prep-HPLC to give compound 80 (79 mg, 50%) as a white solid. ESI-MS: m/z 464.0 [M+H] + .

›Example 57

Compound 81

Compound 81-2 was prepared using a similar procedure as for the preparation of 79-2 using a solution of isopropyl alcohol (21 g, 350 mmol) and POCl 3 (53.6 g, 350 mmol). Compound 81-2 (40.5 g, 65% yield) was obtained as a colorless liquid. 1 H-NMR (400 MHz, CDCl 3 ) δ=4.94-5.10 (m, 1H), 1.48 (d, J=6.17 Hz, 6H); 31 P-NMR (162 MHz, CDCl 3 ) δ=5.58 (br. s., 1 P).

Compound 81-3 was prepared using a similar procedure as for the preparation of 80-3 using 81-2 (124 mg, 0.7 mmol) and 83-A (310 mg, 0.5 mmol). Compound 81-3 (300 mg, 83%) was obtained as a solid.

Compound 81 was prepared using a similar procedure as for the preparation of compound 80 using 81-3 (300 mg, 0.41 mmol) in 80% AcOH aqueous (4 mL). Compound 81 (80 mg, 43%) was obtained as a white solid. ESI-MS: m/z 450.0 [M+H] + .

›Example 58 · 1 of 2

Compound 82

To an ice cooled solution of 82-1 (50 g, 204.9 mmol) in dry Py (400 mL) was added TIPDSCl (70.78 g, 225.4 mmol) dropwise. The mixture was stirred at R.T. for 16 h, and then concentrated at low pressure. The residue was purified by chromatography using 20% EA in PE to generate 82-2 (111.5 g, 100%) as a white solid.

To a solution of 82-2 (50 g, 103 mmol) in anhydrous CH 3 CN (400 mL) was added IBX (43 g, 153 mmol) at R.T. The mixture was refluxed overnight and monitored by TLC (PE:EA=1:1). The precipitate was filtered off, and the filtrate was concentrated to give the crude 82-3 (50 g, 99%) as a white solid.

To a solution of trimethylsilylacetylene (20 g, 200 mmol) in anhydrous THF (400 mL) was added dropwise n-BuLi (80 mL, 200 mL) at −78° C. The mixture was stirred at −78° C. for 30 mins, and then warmed to R.T for 10 mins. Compound 82-3 (30 g, 60 mmol) in THF (100 mL) was added to the mixture dropwise at −78° C. The mixture was stirred at −78° C. for 1 h and then slowly warmed to R.T. The mixture was stirred for 20 mins, and then the reaction was quenched with a sat. NH 4 Cl solution at −78° C. The mixture was diluted with EA. The organic phase was washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column chromatography (15% EA in PE) to give 82-4 as a white solid (14 g, 50%).

Compound 82-4 (14 g, 24 mmol) was dissolved in anhydrous toluene (100 mL) under N 2 and cooled to −78° C. DAST (19 g, 120 mmol) was added dropwise at −78° C. and stirring was continued for 1.5 h. The mixture was diluted with EA and poured into a sat. NaHCO 3 solution. The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel chromatography (20% EA in PE) to give 82-5 as a white solid (12 g, 81%).

A mixture of 82-5 (12 g, 20 mmol) and NH 4 F (11 g, 30 mmol) in MeOH (150 mL) was refluxed for 2 h. After cooling to R.T, the mixture was concentrated at low pressure, and the residue was purified by silica gel column chromatography (5% MeOH in DCM) to give 82-6 (3.1 g, 58%) as a white solid.

To a solution of 82-6 (3.1 g, 11.6 mmol) in dry Py (50 mL) was added imidazole (3.1 g, 46.4 mmol) and TBSCl (5.2 g, 34.8 mmol). The mixture was stirred at 50-60° C. for 3 h. The mixture was concentrated at low pressure, and the residue was dissolved in EA (100 mL). The solution was washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel chromatography (20% EA in PE) to give 82-7 as a white solid (5 g, 86%).

To a solution of 82-7 (4.5 g, 9 mmol) in 1,4-dioxane (45 mL) was added CuBr (643 mg, 4.5 mmol), dicyclohexylamine (3.3 g, 18 mmol) and paraformaldehyde (675 mg, 22.5 mmol). The mixture was refluxed for 24 h and then cooled to R.T. The reaction was quenched with a sat. NH 4 Cl solution. The mixture was extracted with EA (3×100 mL). The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column chromatography (15% EA in PE) to give 82-8 as a white solid (2.0 g, 43%).

A mixture of 82-8 (2 g, 4 mmol) and NH 4 F (2.2 g, 60 mmol) in MeOH (20 mL) was refluxed overnight. After cooling to R.T., the mixture was concentrated at low pressure, and the residue was purified by silica gel column chromatography (5% MeOH in DCM) to give 82-9 (946 mg, 83%) as a white solid.

To a stirred suspension of 82-9 (946 mg, 3.33 mmol), PPh 3 (1.3 g, 5 mmol), imidazole (453 mg, 6.66 mmol) and pyridine (3 mL) in anhydrous THF (12 mL) was added a solution of I 2 (1 g, 4.33 mmol) in THF (4 mL) dropwise at 0° C. The mixture was warmed to R.T. and stirred for 16 h. The reaction was quenched with a sat. Na 2 S 2 O 3 aq. solution and extracted with EA (3×60 mL). The organic layer was dried over Na 2 SO 4 and concentrated at low pressure. The residue was purified on a silica gel column (2% MeOH in DCM to 5% MeOH in DCM) to afford 82-10 (2.1 g, crude) as a white solid.

To a solution of 82-10 (2.1 g, 5.3 mmol) in THF (15 mL) was added DBU (15 g, 100 mmol) and the mixture stirred for 30 mins. The mixture was diluted with EA and neutralized with acetic acid. The solution was washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column chromatography (1.5% MeOH in DCM) to give 82-11 as a white solid (800 mg, 90%).

To an ice-cooled solution of 82-11 (800 mg, 3 mmol) in dry MeCN (1.5 mL) was added NEt 3 3HF (484 mg, 3 mmol) and NIS (1.68 g, 7.5 mmol). The mixture was stirred at R.T. for 30 mins., and the reaction was monitored by LCMS. The reaction was quenched with sat. Na 2 S 2 O 3 and sat. NaHCO 3 solution, and extracted with EA (3×50 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by a silica gel column (25% EA in PE) to afford 82-12 (850 mg, 68%) as a white solid.

To a solution of 82-12 (850 mg, 2 mmol) in dry DCM (10 mL) was added DMAP (488 mg, 4 mmol) and BzCl (422 mg, 3 mol). The mixture was stirred for 4-5 h at R.T., and the reaction was monitored by LCMS. The mixture was diluted with CH 2 Cl 2 (40 mL), and washed with a sat. NaHCO 3 solution. The organic layer was dried over anhydrous Na 2 SO 4 , and filtered. The filtrate was evaporated at low pressure, and the residue was purified by silica gel column chromatography (20% EA in PE) to give 82-13 (900 mg, 87%) as a white foam.

Tetra-butylammonium hydroxide (21 mL as 54-56% aqueous solution, 42 mmol, 24 eq.) was adjusted with TFA to pH˜4 (˜3.5 mL), and the solution was treated with a solution of 82-13 (900 mg, 1.7 mmol) in DCM (21 mL). m-Cloroperbenzoic acid (2.1 g, 60-70%, ˜8.75 mmol, ˜5 eq.) was added portionwise under vigorous stirring, and the mixture was stirred overnight. The mixture was diluted with CH 2 Cl 2 (30 mL), and washed with a saturated NaHCO 3 solution. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography in (40-70% EA in PE) to give 82-14 as an oil. The residue was purified by TLC (50% EA in PE) to give pure 82-14 (350 mg 50%).

›Example 58 · 2 of 2

Compound 82-14 (350 mg, 0.86 mg) was treated with 7N NH 3 in MeOH (15 mL). The mixture was stirred for 2-3 h and monitored by TLC. The mixture was concentrated at low pressure, and the residue was purified by silica gel column chromatography (5% isopropanol in DCM) to give 82-15 (250 mg, 96%) as a white solid. 1 H NMR (CD 3 OD, 400 M Hz) δ=7.75 (d, J=7.9 Hz, 1H), 6.60-6.35 (m, 1H), 5.72 (d, J=8.2 Hz, 1H), 5.37-5.25 (m, 1H), 5.17-5.06 (m, 1H), 5.04-4.94 (m, 1H), 4.59-4.29 (m, 1H), 3.87-3.70 (m, 2H).

To a stirred solution of 82-16 (3.79 g, 18 mmol) and 82-17 (3 g, 18 mmol) in anhydrous DCM (60 mL) was added with a solution of TEA (4 g, 39 mmol) in DCM (40 mL) dropwise at −78° C., and the mixture was stirred for 2 h. The mixture was concentrated at low pressure, and the residue was dissolved in methyl-butyl ether. The precipitate was removed by filtration, and the filtrate was concentrated to give the crude product. The residue was purified by dry column chromatography (anhydrous DCM) to give pure 82-18 as a colorless oil (3 g, 54%).

Compound 82-15 (200 mg, 0.66 mmol) was coevaporated with toluene 3 times to remove H 2 O. Compound 82-15 was treated with MeCN (1.5 mL) and NMI (541 mg, 6.6 mmol). The mixture was stirred at R.T., and then 82-18 (403 mg, 1.32 mmol) in MeCN (0.5 mL) was added. The residue was purified by a silica gel column (5% iPrOH in DCM) to give the crude product, which was purified by HPLC (0.1% HCOOH in water and MeCN) to give compound 82 (33 mg, 9%). ESI-LCMS: m/z 594 [M+Na] + .

›Example 59

Compound 84

To a stirred solution of POCl 3 (2.0 g, 13 mmol) in anhydrous DCM (10 mL) was added 1-naphthol (1.88 g, 13 mmol) at −70° C. and TEA (1.31 g, 13 mmol) in DCM (3 mL) dropwise at −70° C. The mixture was gradually warmed to R.T., and stirred for 1 h. A crude solution of 84-1 was obtained.

To a stirred solution of (S)-isobutyl 2-aminopropanoate hydrochloride (2.35 g, 13 mmol) in DCM (20 mL) was added TEA (2.63 g, 26 mmol) and a crude solution of 84-1 at −70° C. The mixture was gradually warmed to R.T., and stirred for 2 h. The reaction was monitored by LCMS and quenched with n-propylamine. The solvent was evaporated at low pressure, and the residue was purified by chromatography (PE:MTBE=5:1˜1:1) to give pure 84-2 (1.8 g, 37%).

To a solution of 83-A (300 mg, 0.337 mmol) and NMI (276 mg, 3.37 mmol) in anhydrous CH 3 CN (4 mL) was added 84-2 (249 mg, 0.674 mol, in DCM (5 mL)) at 0° C. The mixture was stirred at R.T. for 10 h. The reaction was monitored by LCMS, and then quenched with H 2 O. The mixture was extracted with CH 2 Cl 2 (3×20 mL). The organic phase was dried over anhydrous MgSO 4 , and concentrated at low pressure. The residue was purified by chromatography using PE:EA=5:1˜2:1 as the eluent to give 84-3 (360 mg, 87%).

Compound 84-3 (360 mg, 0.294 mmol) was dissolved in CH 3 COOH (80%, 8 mL), and stirred at 40-50° C. for 2.5 h. The reaction was monitored by LCMS and then quenched with MeO. The mixture was concentrated at low pressure, and the residue was purified by chromatography using PE:EA=1:1 as the eluent to generate crude compound 84. The product purified by prep-HPLC (neutral system, NH 4 HCO 3 ) to give compound 84 (70 mg, 75%) as a white solid. ESI-MS: m/z 679.2 [M+H] + .

›Example 60

Compound 85

To a stirred solution of POCl 3 (2.0 g, 13 mmol) in anhydrous DCM (10 mL) was added phenol (1.22 g, 13 mmol) at −70° C. and TEA (1.31 g, 13 mmol) in DCM (3 mL) dropwise at −70° C. The mixture was gradually warmed to R.T., and stirred for 1 h. A crude solution of 85-1 was obtained.

Compound 85 was prepared using a similar procedure as for the preparation of compound 84 using 85-2 (205 mg, 0.674 mol, in DCM (5 mL) obtained from (S)-isopropyl 2-aminopropanoate hydrochloride and 85-1) and 83-A (300 mg, 0.337 mmol). Compound 85 (50 mg, 74%) was obtained as a white solid. ESI-MS: m/z 615.2 [M+H] + .

›Example 61

Compound 86

Compound 86 was prepared using a similar procedure as for the preparation of compound 84 using 86-2 (214 mg, 0.674 mol, in DCM (5 mL) obtained from (S)-isobutyl 2-aminopropanoate hydrochloride and 86-1) and 83-A (300 mg, 0.337 mmol). Compound 86 (70 mg, 87%) was obtained as a white solid. ESI-MS: m/z 629.2 [M+H] + .

›Example 62

Compound 87

Compound 87 was prepared using a similar procedure as for the preparation of compound 84 using 87-2 (223 mg, 0.674 mol, DCM (5 mL) obtained from (S)-cyclopentyl 2-aminopropanoate hydrochloride and 87-1) and 83-A (300 mg, 0.337 mmol). Compound 87 (62 mg, 71%) was obtained as a white solid. ESI-MS: m/z 641.2 [M+H] + .

›Example 63

Compound 88

Compound 88 was prepared using a similar procedure as for the preparation of compound 84 using 88-2 (223 mg, 0.674 mol, DCM (5 mL), obtained from (S)-3-pentyl 2-aminopropanoate hydrochloride and 88-1) and 83-A (300 mg, 0.337 mmol). Compound 88 (42 mg, 60%) was obtained as a white solid. ESI-MS: m/z 643.2 [M+H] + .

›Example 64

Compound 89

A stirred solution of phosphoryl trichloride (1.00 g, 6.58 mmol) and 5-quinoline (955 mg, 6.58 mmol) in anhydrous DCM (50 mL) was treated with a solution of TEA (665 mg, 6.58 mmol) in DCM (10 mL) at −78° C. The mixture was gradually warmed to R.T., and stirred for 2 h. The solution was cooled to −78° C. and then treated with (S)-neopentyl 2-aminopropanoate hydrochloride (1.28 g, 6.58 mmol). TEA (1.33 g, 13.16 mmol) was added dropwise at −78° C. The mixture was gradually warmed to R.T., and stirred for 2 h. The mixture was concentrated at low pressure, and the residue was dissolved in methyl-butyl ether. The precipitate was filtered off, and the filtrate was concentrated at low pressure. The residue was purified by a silica gel column (pure AcOEt) to give 89-1 as colorless oil (500 mg, 20%).

To a solution of 89-2 (300 mg, 0.337 mmol) and NMI (276.6 mg, 3.37 mmol) in anhydrous CH 3 CN (0.9 mL) was added 89-1 (388 mg, 1.011 mmol) in CH 3 CN (0.3 mL) dropwise at 0° C. The mixture was stirred at R.T. overnight. The reaction was quenched with water, and extracted with AcOEt. The organic phase was washed with brine, dried over anhydrous sodium sulfate, and concentrated at low pressure. The residue was purified by silica gel column (33% EA in PE) to give 89-3 as a yellow powder (300 mg, 71.9%).

Compound 89-3 (300 mg, 0.243 mmol) was dissolved in 80% CH 3 COOH (3 mL), and the mixture was stirred at 60° C. for 2.5 h. The mixture was partitioned between AcOEt and water. The organic layer phase was washed by brine, dried over sodium sulfate and concentrated at low pressure. The residue was purified by silica gel column (50% EA in PE) to give compound 89 as a yellow powder (81 mg, crude product). The crude product (81 mg) was purified by RP HPLC to give compound 89 as a white solid. (28.7 mg, 17.1%). ESI-LCMS: m/z 694.1 [M+H] + .

›Example 65

Compound 90

Compound 90-1 was prepared using a similar procedure as for the preparation of compound 89-1 using phosphoryl trichloride (2.00 g, 13.16 mmol), 1-naphthol (1.882 g, 13.16 mmol) and (S)-neopentyl 2-aminopropanoate hydrochloride (2.549 g, 13.16 mmol). Compound 90-1 (600 mg, 12%) was obtained as a colorless oil.

A solution of 90-2 (230 mg 0.26 mmol) and NMI (212 mg 2.60 mmol) in anhydrous CH 3 CN (1 mL) was treated with a solution of 90-1 (300 mg 0.78 mmol) in anhydrous CH 3 CN (0.5 mL) at R.T. The mixture was stirred at R.T. overnight. The reaction was quenched with water, and extracted with EA (3×20 mL). The organic layer was washed with brine, dried by anhydrous sodium sulfate, and concentrated at low pressure. The residue was purified by a silica gel column (CH 3 OH in CH 2 Cl 2 from 1% to 5%) to give 90-3 (300 mg, 93%) as a white solid.

Compound 90-3 (300 mg, 0.24 mmol) was dissolved in CH 3 COOH (80%, 5 mL). The mixture was stirred at 60° C. for 2.5 h. The mixture was diluted with EA (30 mL) and washed with brine. The organic phase was dried over anhydrous sodium sulfate, and concentrated at low pressure. The residue was purified by a silica gel column (CH 3 OH in CH 2 Cl 2 from 1% to 5%) to give crude compound 90 (105 mg). The crude product was purified by HPLC (0.1% NH 4 HCO 3 in water and CH 3 CN) to give compound 90 (45 mg, 26%) as a white solid. ESI-LCMS: m/z 693.2 [M+H] + .

›Example 66

Compound 91

A stirred solution of 91-1 (2.00 g, 13.99 mmol) and 91-2 (2.00 g, 13.99 mmol) in anhydrous DCM (8 mL) was treated with a solution of TEA (3.11 g, 30.8 mmol) in DCM (20 mL) dropwise at −78° C. The mixture was stirred for 2 h. at −78° C. and then gradually warmed to R.T. The organic solvent was removed at low pressure, and the residue was dissolved in methyl-butyl ether. The precipitate was filtered off, and the filtrate was concentrated at low pressure. The residue was purified on a silica gel column (dry DCM) to give 91-3 as colorless oil (1 g, 20.96%).

Compound 91-4 (260 mg, 0.29 mmol) was coevaporated with toluene 3 times to remove H 2 O. Dried 91-4 was treated with MeCN (0.8 mL) and NMI (240 mg, 2.9 mmol) and then stirred for 10 mins. The mixture was treated with a solution of 91-3 (291 mg, 0.87 mmol) in MeCN (0.4 mL), and then concentrated at low pressure. The residue was purified on a silica gel column (75% EA in PE)) to give 91-5 (300 mg, 86%) as a white solid.

Compound 91-5 (300 mg, 0.25 mmol) was treated with CH 3 COOH (5 mL, 80%), and stirred at 50° C. for 3 h. The mixture was diluted with EA. The solution was washed with brine, dried over anhydrous Na 2 SO 4 , and concentrated at low pressure. The residue was purified by silica gel column chromatography (67% EA in PE) to give crude compound 91, which was purified by HPLC. The product was dried by lyophilization to give compound 91 (30 mg, 18.5%) as a white solid. ESI-LCMS: m/z 643 [M+H] + .

›Example 67

Compound 77

To a solution of 1,1-dimethoxycyclopentane (19.3 g, 148.52 mmol) and 77-1 (10.0 g, 37.13 mmol) in DCE (100 mL) was added TsOH.H 2 O (0.7 g, 3.71 mmol). The mixture was stirred at 50° C. for 12 h. The mixture was neutralized with Et 3 N, and concentrated at low pressure. The residue was purified by silica gel column chromatography (1-10% MeOH in DCM) to give 77-2 (8.7 g, 70.1%) as a white solid.

Compound 77-2 (20.0 g, 0.06 mol) was coevaporated with anhydrous pyridine 3 times to remove H 2 O. To an ice-cold solution of 77-2 in anhydrous pyridine (100 mL) was added TsCl (22.8 g, 0.12 mol) at 0° C., and the mixture was stirred overnight. The reaction was monitored by LCMS and TLC. The reaction was quenched with H 2 O, and the mixture extracted with EA (3×200 mL). The solution was dried over anhydrous Na 2 SO 4 and evaporated at low pressure. The residue was purified by silica gel column chromatography (DCM:MeOH=100:1 to 15:1) to give 77-3 (20.0 g, 69.0%) as a white solid.

To a solution of 77-3 (20.0 g, 0.04 mol) in acetone (200 mL) was added NaI (31.0 g, 0.2 mol), and the mixture was heated to reflux overnight. The reaction was monitored by LCMS. The reaction was quenched with a sat. Na 2 S 2 O 3 solution. The solution was extracted with EA (3×200 mL). The organic layer was dried over anhydrous Na 2 SO 4 , and evaporated at low pressure. The residue was purified by silica gel column chromatography (DCM:MeOH=100:1 to 15:1) to give 77-4 (15.0 g, 83.3%) as a white solid.

Compound 77-4 (13.4 g, 30.16 mmol) was treated with HCOOH (80%) in H 2 O at R.T. The solution was stirred at 60° C. for 2 h. The mixture was concentrated at low pressure. The residue was purified by column chromatography (1%-10% MeOH in DCM) to give 77-5 (9.1 g, 80.0%) as a white solid.

To a solution of 77-5 (5.0 g, 13.22 mmol) in anhydrous CH 3 CN/THF (50 mL, 1:1, v:v) was added DBU (6.0 g, 39.66 mmol) at R.T. The solution was stirred at 50° C. for 1.5 h. The reaction was quenched with HCOOH at 0° C., and then concentrated at low pressure. The residue was purified by column chromatography (50%-70% EA in PE) to give 77-6 (3.3 g, 48.1%) as a white solid.

To an ice-cold solution of 77-6 (2.1 g, 8.39 mmol) in anhydrous MeCN (21 mL) was added NIS (2.4 g, 10.49 mmol) and TEA.3HF (1.0 g, 6.29 mmol) under N 2 . The mixture was stirred at R.T. for 1 h. The reaction was quenched with sat. NaHCO 3 and sat. Na 2 SO 3 solution, and extracted with EA (3×100 mL). The organic phase was dried over anhydrous Na 2 SO 4 , and evaporated to dryness at low pressure. The residue was purified on a silica gel column (30%-50% EA in PE) to give 77-7 (1.3 g, 39.3%) as a light yellow solid.

To a stirred solution of 77-7 (3.2 g, 8.08 mmol) in anhydrous DCM (32 mL) was added DMAP (2.5 g, 20.20 mmol) and Et 3 N (2.5 g, 24.24 mmol) at R.T. The mixture was treated with BzCl (3.7 g, 26.66 mmol) at 0° C. and then stirred at R.T. overnight. The reaction was quenched with water, and extracted with EA (3×60 mL). The organic phase was concentrated at low pressure, and the residue was purified by column chromatography (20%-30% EA in PE) to give 77-8 (1.8 g, 31.6%) as a white solid.

Bu 4 NOH (8.0 g, 13.74 mL, 55% in H 2 O) was adjusted to pH=3-4 with TFA, and then cooled to R.T. To a solution of 77-8 (600 mg, 0.85 mmol) in DCM (10 mL) was added the Bu 4 NOH solution and m-CPBA (917 mg, 4.25 mmol, 80%) at R.T. The mixture was stirred at 25° C. for 48 h and then washed with a sat. NaHCO 3 solution. The organic layer was directly passed through basic Al 2 O 3 column, and the solvent was concentrated at low pressure. The residue was purified by a silica gel column (20%-30% EA in PE) to give 77-9 (123 mg, 24.3%) as a white solid.

To a solution of 77-9 (300 mg, 0.50 mmol) in EA/hexane (20 mL, 1:1, v:v) was added Lindlar catalyst (200 mg) under N 2 . The mixture was stirred under H 2 (40 Psi) at 2° C. for 1.5 h. The suspension was filtered, and the filtrate was treated with Lindlar catalyst (200 mg) under N 2 , and stirred under H 2 (40 Psi) at 25° C. for 1.5 h. The mixture was filtered, and the filtrate was concentrated at low pressure to give crude 77-10 (287 mg) as a white solid.

Compound 77-10 (287 mg, 0.48 mmol) was dissolved in NH 3 /MeOH (30 mL, 7 M). The mixture was stirred at R.T. for 24 h under N 2 and then concentrated at low pressure. The residue was purified by prep-HPLC (0.1% HCOOH in water and MeCN) to give 77-11 (50 mg, 34.7% over two steps) as a white solid. 1 H-NMR (CD 3 OD, 400 MHz) δ=7.86 (d, J=8.0 Hz 1H), 6.26 (s, 1H), 5.62-5.86 (m, 1H), 5.49 (d, J=17.1 Hz, 1H), 5.30 (d, J=10.5 Hz, 1H), 4.41 (d, J=19.3 Hz, 1H), 3.71-3.86 (m, 1H).

Compound 77-11 (113 mg, 0.39 mmol) was co-evaporated with toluene 3 times to remove H 2 O. To a stirred solution of 77-11 (113 mg, 0.39 mmol) in a mixture of MeCN (0.5 mL) and NMI (320 mg, 3.90 mmol) was added a solution of 73-C (256 mg, 0.66 mmol) in MeCN (0.5 mL) at 0° C. The mixture was stirred at R.T. overnight and then concentrated at low pressure. The residue was purified on a silica gel column (5% MeOH in DCM) to give crude compound 77, which purified by prep-HPLC (0.1% HCOOH in water and MeCN) to give compound 77 (45 mg, 20.1%) as a white solid. ESI-MS: m/z 538.2 [M−F] + ESI-MS: m/z 580.2 [M+Na] + .

›Example 68

Compound 78

To a solution of 77-9 (300 mg, 0.50 mmol) in MeOH (30 mL) was added wet Pd/C (300 mg, 10%) under N 2 . The mixture was stirred under H 2 (1 atm) at 25° C. for 1.5 h. The suspension was filtered, and then concentrated at low pressure to give crude 78-1 (307 mg) as a white solid.

Compound 78-1 (307 mg, 0.48 mmol) was dissolved in NH 3 /MeOH (30 mL, 7 M). The mixture was stirred at R.T. for 24 h under N 2 then concentrated at low pressure. The residue was purified by prep-HPLC (0.1% HCOOH in water and MeCN) to give 78-2 (30 mg, 21% over two steps) as a white solid.

Compound 78-2 (91 mg, 0.31 mmol) was co-evaporated with toluene 3 times to remove H 2 O. To a stirred solution of 78-2 (91 mg, 0.31 mmol) in a mixture of MeCN (0.5 mL) and NMI (254 mg, 3.90 mmol) was added a solution 73-C (203 mg, 0.66 mmol) in MeCN (0.5 mL) at 0° C. The mixture was stirred at R.T. overnight and then concentrated at low pressure. The residue was purified on a silica gel column (5% MeOH in DCM) to the crude compound 78, which purified by prep-HPLC (0.1% HCOOH in water and MeCN) to give compound 78 (30 mg, 17%) as a white solid. ESI-MS: m/z 540.1 [M−F] + .

›Example 69

Additional Compounds of Formula (I)

The foregoing syntheses are exemplary and can be used as a starting point to prepare a large number of additional compounds. Examples of compounds of Formula (I) that can be prepared in various ways, including those synthetic schemes shown and described herein, are provided below. Those skilled in the art will be able to recognize modifications of the disclosed syntheses and to devise routes based on the disclosures herein; all such modifications and alternate routes are within the scope of the claims.

›Example 70

HCV Replicon Assay

Cells

Huh-7 cells containing the self-replicating, subgenomic HCV replicon with a stable luciferase (LUC) reporter were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 2 mM L-glutamine and supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% penicillin-streptomyocin, 1% nonessential amino acids, and 0.5 mg/mL G418.

Determination of Anti-HCV Activity

Determination of 50% inhibitory concentration (EC 50 ) of compounds in HCV replicon cells were performed by the following procedure. On the first day, 5,000 HCV replicon cells were plated per well in a 96-well plate. On the following day, test compounds were solubilized in 100% DMSO to 100× the desired final testing concentration. Each compound was then serially diluted (1:3) up to 9 different concentrations. Compounds in 100% DMSO are reduced to 10% DMSO by diluting 1:10 in cell culture media. The compounds were diluted to 10% DMSO with cell culture media, which were used to dose the HCV replicon cells in 96-well format. The final DMSO concentration was 1%. The HCV replicon cells were incubated at 37° C. for 72 h. At 72 h, cells were processed when the cells are still subconfluent. Compounds that reduce the LUC signal are determined by Bright-Glo Luciferase Assay (Promega, Madison, Wis.). % Inhibition was determined for each compound concentration in relation to the control cells (untreated HCV replicon) to calculate the EC 50 .

Compounds of Formula (I) are active in the replicon assay. The antiviral activity of exemplary compounds is shown in Table 2, where ‘A’ indicates an EC 50 <1 μM, ‘B’ indicates an EC 50 ≥1 μM and <10 μM, and ‘C’ indicates an EC 50 ≥10 μM and <100 μM.

›Example 71

NS5B Inhibition Assay

The enzyme activity of NS5B570-Con1 (Delta-21) was measured as an incorporation of tritiated NMP into acid-insoluble RNA products. The complementary IRES (cIRES) RNA sequence was used as a template, corresponding to 377 nucleotides from the 3′-end of HCV (−) strand RNA of the Con-1 strain, with a base content of 21% Ade, 23% Ura, 28% Cyt, and 28% Gua. The cIRES RNA was transcribed in vitro using a T7 transcription kit (Ambion, Inc.) and purified using the Qiagen RNeasy maxi kit. HCV polymerase reactions contained 50 nM NS5B570-Con1, 50 nM cIRES RNA, about 0.5 μCi tritiated NTP, 1 μM of competing cold NTP, 20 mM NaCl, 40 mM Tris-HCl (pH 8.0), 4 mM dithiothreitol, and 4 mM MgCl 2 . Standard reactions were incubated for 2 h at 37° C., in the presence of increasing concentration of inhibitor. At the end of the reaction, RNA was precipitated with 10% TCA, and acid-insoluble RNA products were filtered on a size exclusion 96-well plate. After washing of the plate, scintillation liquid was added and radio labeled RNA products were detected according to standard procedures with a Trilux Topcount scintillation counter. The compound concentration at which the enzyme-catalyzed rate was reduced by 50% (IC 50 ) was calculated by fitting the data to a non-linear regression (sigmoidal). The IC 50 values were derived from the mean of several independent experiments and are shown in Table 3. Compounds of Formula (I) showed activity in this assay. A value of ‘A’ in the table below indicates an IC 50 of <1 μM, a value of ‘B’ indicates an IC 50 ≥1 μM and <10 μM, and a value of ‘C’ indicates an IC 50 value of ≥10 μM and <100 μM.

›Example 72 · 1 of 2

Assessment of Inhibition of Mitochondrial Function

Drug-associated dysfunction of mitochondria is believed to play a role in the etiology of the various adverse symptoms that occur in patients treated with antiviral nucleoside/nucleotides. For this reason, evaluation of compounds for their potential to inhibit mitochondrial function is useful. To assess the potential for nucleotide/nucleoside analogs to interfere with normal mitochondrial functions and exhibit mitochondrial toxicity, the following were measured: (1) the ability of nucleotides to be incorporated by human mitochondrial RNA polymerase in vitro and (2) the cellular inhibition of the synthesis of the mitochondrial DNA (mtDNA)-encoded protein, cytochrome c oxidase (COX-I), relative to the nuclear DNA (nDNA)-encoded mitochondrial protein succinate dehydrogenase subunit A (SDH-A) in HepG2 cells. Control compounds and compounds of Formula (I) were studied in these assays.

Biochemical Assay

Arnold et al. “Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides” PLoS Pathog (2012) 8(11): e1003030. doi:10.1371/journal.ppat.1003030, which is hereby incorporated by reference in its entirety.

Assessment of Incorporation of Nucleotides by Human Mitochondrial RNA Polymerase (HMRP)

DdRp Assay with Human Mitochondrial RNA Polymerase

The DdRp assay with human mitochondrial RNA polymerase was performed under single turnover conditions where enzyme concentration is in excess of the primer/template. The 33 P-RNA/DNA primer/template was used at a concentration of 100 nM, together with 320 nM enzyme. The standard 10-μL reactions were carried out at 30° C. for 1 minute with 100 μM of each nucleotide 5′-triphosphate (NTP), 10 mM MgCl 2 , 50 mM NaCl, 40 mM Tris, pH 7.5, and 1 mM DTT. The reaction was stopped by adding 20 μL of formamide loading dye containing 50 mM EDTA. RNA products were resolved by electrophoresis on 22.5% TBE Urea polyacrylamide sequencing gels that were scanned using a TYPHOON PhosphorImager.

Results

As shown in both FIGS. 10 and 11 , the appropriate natural nucleotides were shown to be good substrates for incorporation by HMRP in each template. The template in FIG. 10 was designed to measure incorporation of UTP analogs. Primer/Template: (SEQ ID NO: 1) UUUUGCCGCGCC and (SEQ ID NO: 2) GGGAATGCTAGGCGCGGC. In the control water lanes, wherein no nucleotides were added, no incorporation was observed as indicated by the lack of product band. As shown in FIG. 10 , UTP and 3′-deoxy-UTP were efficient substrates for incorporation as indicated by the prominent product band. The potential for misincorporation was assessed using the control nucleotide CTP. As provided in FIG. 10 , CTP was incorporated to a lesser extent relative to UTP. In contrast to UTP and 3′-deoxy-UTP, compounds of Formula (I) and 2′-Me-2′-F-UTP were not efficient substrates for incorporation by HMRP as demonstrated by the lack of product band.

The template strand shown in FIG. 11 was designed to measure the incorporation of GTP analogs. Primer/Template: (SEQ ID NO: 3) UUUUGCCGCGCC and (SEQ ID NO: 4) GGGAATGCACGGCGCGGC. In the control water lanes, no incorporation was observed as indicated by the lack of product band. GTP and 3′-deoxy-GTP were found to be efficient substrates for incorporation as demonstrated by the significant product bands. The potential for misincorporation was assessed using the control nucleotide ATP. As shown by the lack of product band in FIG. 11 , control ATP was a poor substrate for incorporation. Nucleotide analog 2′-Me-GTP (the nucleotide metabolite of monophosphate prodrug INX-0189/BMS-986094) was tested and found to be a good substrate for incorporation by HMRP as indicated by the product band. Nucleotide analog 2′-Me-2′-F-GTP (nucleotide metabolite of monophosphate prodrug GS-938) was tested and also found to be incorporated by HMRP. In contrast, compounds of Formula (I) were not efficient substrates for incorporation into the template strand by HMRP as indicated by the lack of product bands in FIG. 11 .

Assessment of Inhibition of Mitochondrial Protein Synthesis—Cell Based Assay

Assay Principle

MitoBiogenesis™ In Cell ELISA kits (Cat. # MS643) were obtained from Mitosciences, OR, USA. The MitoBiogenesis™ In Cell ELISA kit is a duplexing 96 well assay that ratios both an mtDNA and an nDNA encoded mitochondrial protein. Cells were seeded in 96 microplates and after exposure to compounds for several cell doublings, the levels of the two mitochondrial proteins were measured simultaneously in each well. The two proteins assayed were each subunits of different oxidative phosphorylation enzyme complexes, one protein being subunit I of Complex IV (cytochrome c oxidase; COX I) that is mtDNA encoded and the other being the 70 kDa subunit of Complex II (succinate dehydrogenase subunit A; SDH A) that is nDNA encoded. Complex IV includes several proteins that are encoded by the mtDNA while the proteins of Complex II are entirely encoded by nDNA. To control for the density of cells present at the end of the culture period, the number of cells were assessed by staining with Janus Green and the levels of COX I/SDH A normalized to the final cell density.

96 Well Plate Assay Format for HepG2 Cells

On the first day, 1000 HepG2 cells per well were plated in a 96 well plate. On the following day, compounds to be tested were solubilized in 100% DMSO to 100× the desired final testing concentration. Each compound was serially diluted (1:3) up to 9 distinct concentrations. Compounds in 100% DMSO were reduced to 10% (v/v) DMSO by diluting 1:10 in cell culture media. A 10 μL aliquot of the compounds diluted to 10% (v/v) DMSO with cell culture media was used to dose the cells in duplicate. The final DMSO concentration was 1% (v/v). Untreated cells and wells containing no cells were included on the plate to serve as controls. Cells were then incubated with compounds and observed for 8 days at 37° C. and 5% CO 2 . Plates were processed as described below in the assay procedure.

›Example 72 · 2 of 2

Batch Assay Format for HepG2 Cells

An alternate cell culture procedure was employed to test the potential to mediate mitochondrial toxicity at higher concentrations than achievable in the 96 well plate format. HepG2 cells were grown either in media/DMSO alone or in a series of compound concentrations in 15 cm 2 dishes or 6 well plates at an initial cell seeding density of 5×10 6 and 5×10 4 cells/mL, respectively. Cells were then incubated and observed for 8 days at 37° C. and 5% CO 2 . After 8 days, the cells were harvested by trypsinization, counted, and seeded in 96 well plates at a density of 25,000 cells/well in 16 replicate wells. Cells were allowed to adhere overnight and then the plates were processed as described below in the assay procedure.

Assay Procedure

The assay was performed according to the manufacturer's instructions. Briefly, after the end of the culture period the cell culture media was gently aspirated from the wells of the plate and replaced with 100 μL of 4% (v/v) paraformaldehyde solution in phosphate buffered saline (PBS, Electron Microscopy Sciences Cat. #15713). After a 20 mins incubation at R.T., the solution was removed and the wells washed 3× with 300 μL of PBS. After the final wash, the PBS was removed and the wells overlayed with 100 μL PBS. The plates were then sealed and stored at 4° C. until used. To perform the assay, the PBS overlay was removed by blotting on a paper towel and 100 μL of 0.5% (v/v) acetic acid added to each well to block endogenous alkaline phosphatase activity. After a 5 mins incubation at R.T., the acetic acid solution was removed and the cells washed once with 200 μL PBS. Then, 100 μL of permeabilization buffer (0.1% (v/v) Triton X 100) was added to each well. After 30 mins incubation at R.T., the permeabilization buffer was removed and each well was blocked with 200 μL of 2× blocking solution for 2 h at R.T. The 2× blocking solution was then removed and 100 μL of primary antibody solution containing anti COX I and anti SDH A antibodies in 1× blocking solution was added to each well. Plates were then sealed and incubated overnight at 4° C. The primary antibody/blocking solution was removed and the plate washed 3× with 250 μL 0.05% (v/v) Tween 20 in PBS. Then, 100 μL of secondary antibody solution containing alkaline phosphatase (AP) labeled anti SDH A antibody and horseradish peroxidase (HRP) labeled anti COX I antibody was added and incubated for 1 h at R.T. The plate was then washed 4× with 250 μL 0.05% (v/v) Tween 20 in PBS. After blotting the plate dry 100 μL of AP detection reagent was added to each well, and the plate incubated in the dark for 30 mins at R.T. The optical density of each well was then measured at 405 nm. The AP detection reagent was then removed and replaced with 100 μL of HRP detection reagent, and the plate incubated in the dark for a further 30 mins at R.T. The optical density of each well was then measured at 600 nm. The HRP detection reagent was then removed and each well was then stained with 50 μL of 1× Janus Green Stain for 5 mins at R.T. After removal of the dye, the plates were washed 5× in ultrapure water to remove any remaining dye. The Janus Green stain was then solubilized by the addition of 100 μL of 0.5 M HCl and incubated for 10 mins. The optical density of each well was then measured at 595 nm.

Data Analysis

The average of all replicate background measurements from each experimental condition was calculated and subtracted from the experimental values of the same condition. The SDH A and COX I signals were then plotted as a ratio (COX I/SDH A) and normalized to the Janus Green staining intensity to correct for differences in cell density.

Results

Control compound d4T was tested and found not to inhibit mitochondrial protein synthesis at concentrations up to 100 μM as shown in FIGS. 12A-D . Control compound ddC was tested and found to strongly inhibit mitochondrial protein synthesis. See FIGS. 12A-D . As demonstrated in FIG. 12A , nucleoside monophosphate prodrug INX-08189/BMS-986094 (which delivers 2′-Me-GTP) was tested in the assay and found to strongly inhibit mitochondrial protein synthesis. In contrast, compounds of Formula (I) were tested and found to not inhibit mitochondrial protein synthesis at concentrations up to 100 μM as shown in FIGS. 12B-D .

›Example 73

Combination of Compounds

Combination Testing

Two or more test compounds were tested in combination with each other using an HCV genotype 1b HCV replicon harbored in Huh7 cells with a stable luciferase (LUC) reporter. Cells were cultured under standard conditions in Dulbecco's modified Eagle's medium (DMEM; Mediatech Inc, Herndon, Va.) containing 10% heat-inactivated fetal bovine serum (FBS; Mediatech Inc, Herndon, Va.) 2 mM L-glutamine, and nonessential amino acids (JRH Biosciences). HCV replicon cells were plated in a 96-well plate at a density of 10 4 cells per well in DMEM with 10% FBS. On the following day, the culture medium was replaced with DMEM containing either no compound as a control, the test compounds serially diluted in the presence of 2% FBS and 0.5% DMSO, or a combination of compound 18 with one or more test compounds serially diluted in the presence of 2% FBS and 0.5% DMSO. The cells were incubated with no compound as a control, with the test compounds, or the combination of compounds for 72 h. The direct effects of the combination of the test compounds were examined using a luciferase (LUC) based reporter as determined by the Bright-Glo Luciferase Assay (Promega, Madison, Wis.). Dose-response curves were determined for individual compounds and fixed ratio combinations of two or more test compounds.

The method utilized for evaluating combination effects used a program called MacSynergy II. MacSynergy II software was kindly provided by Dr. M. Prichard (University of Michigan). The Prichard Model allows for a three-dimensional examination of drug interactions and a calculation of the synergy volume (units: μM 2 %) generated from running the replicon assay using a checkerboard combination of two or more inhibitors. The volumes of synergy (positive volumes) or antagonism (negative volumes) represent the relative quantity of synergism or antagonism per change in the concentrations of the two drugs. Synergy and antagonism volumes are defined based on the Bliss independence model. In this model, synergy volumes of less than −25 indicate antagonistic interactions, volumes in the −25-25 range indicate additive behavior, volumes in the 25-100 range indicate synergistic behavior and volumes >100 indicate strong synergistic behavior. Determination of in vitro additive, synergistic and strongly synergistic behavior for combinations of compounds can be of utility in predicting therapeutic benefits for administering the combinations of compounds in vivo to infected patients.

The synergy volume results for the combinations are provided in Table 4.

Although the foregoing has been described in some detail by way of illustrations and examples for purposes of clarity and understanding, it will be understood by those of skill in the art that numerous and various modifications can be made without departing from the spirit of the present disclosure. Therefore, it should be clearly understood that the forms disclosed herein are illustrative only and are not intended to limit the scope of the present disclosure, but rather to also cover all modification and alternatives coming with the true scope and spirit of the invention.

›Tables in the description — 7
TABLE 1
PercentagePercentagePercentagePercentageNumberSeverity
of non-ofofof viralof sideof side
respondersrelapsersresistanceload reboundeffectseffects
10% less10% less10% less10% less10% less10% less
25% less25% less25% less25% less25% less25% less
40% less40% less40% less40% less40% less40% less
50% less50% less50% less50% less50% less50% less
60% less60% less60% less60% less60% less60% less
70% less70% less70% less70% less70% less70% less
80% less80% less80% less80% less80% less80% less
90% less90% less90% less90% less90% less90% less
about 10%about 10%about 10%about 10%about 10%about 10%
to aboutto aboutto aboutto aboutto aboutto about
30% less30% less30% less30% less30% less30% less
about 20%about 20%about 20%about 20%about 20%about 20%
to aboutto aboutto aboutto aboutto aboutto about
50% less50% less50% less50% less50% less50% less
about 30%about 30%about 30%about 30%about 30%about 30%
to aboutto aboutto aboutto aboutto aboutto about
70% less70% less70% less70% less70% less70% less
about 20%about 20%about 20%about 20%about 20%about 20%
to aboutto aboutto aboutto aboutto aboutto about
80% less80% less80% less80% less80% less80% less
TABLE A Example combinations of a compound X with a compound Y.
X:YX:YX:YX:YX:YX:Y
1001:90001001:90011001:90021001:90031001:90041001:9005
1002:90001002:90011002:90021002:90031002:90041002:9005
1003:90001003:90011003:90021003:90031003:90041003:9005
1004:90001004:90011004:90021004:90031004:90041004:9005
1005:90001005:90011005:90021005:90031005:90041005:9005
1006:90001006:90011006:90021006:90031006:90041006:9005
1007:90001007:90011007:90021007:90031007:90041007:9005
1008:90001008:90011008:90021008:90031008:90041008:9005
1009:90001009:90011009:90021009:90031009:90041009:9005
1010:90001010:90011010:90021010:90031010:90041010:9005
1011:90001011:90011011:90021011:90031011:90041011:9005
1012:90001012:90011012:90021012:90031012:90041012:9005
1013:90001013:90011013:90021013:90031013:90041013:9005
1014:90001014:90011014:90021014:90031014:90041014:9005
1015:90001015:90011015:90021015:90031015:90041015:9005
1016:90001016:90011016:90021016:90031016:90041016:9005
2001:90002001:90012001:90022001:90032001:90042001:9005
2002:90002002:90012002:90022002:90032002:90042002:9005
2003:90002003:90012003:90022003:90032003:90042003:9005
2004:90002004:90012004:90022004:90032004:90042004:9005
2005:90002005:90012005:90022005:90032005:90042005:9005
2006:90002006:90012006:90022006:90032006:90042006:9005
2007:90002007:90012007:90022007:90032007:90042007:9005
2008:90002008:90012008:90022008:90032008:90042008:9005
2009:90002009:90012009:90022009:90032009:90042009:9005
2010:90002010:90012010:90022010:90032010:90042010:9005
2011:90002011:90012011:90022011:90032011:90042011:9005
2012:90002012:90012012:90022012:90032012:90042012:9005
1001:90061001:90071001:90081001:90091001:90101001:9011
1002:90061002:90071002:90081002:90091002:90101002:9011
1003:90061003:90071003:90081003:90091003:90101003:9011
1004:90061004:90071004:90081004:90091004:90101004:9011
1005:90061005:90071005:90081005:90091005:90101005:9011
1006:90061006:90071006:90081006:90091006:90101006:9011
1007:90061007:90071007:90081007:90091007:90101007:9011
1008:90061008:90071008:90081008:90091008:90101008:9011
1009:90061009:90071009:90081009:90091009:90101009:9011
1010:90061010:90071010:90081010:90091010:90101010:9011
1011:90061011:90071011:90081011:90091011:90101011:9011
1012:90061012:90071012:90081012:90091012:90101012:9011
1013:90061013:90071013:90081013:90091013:90101013:9011
1014:90061014:90071014:90081014:90091014:90101014:9011
1015:90061015:90071015:90081015:90091015:90101015:9011
1016:90061016:90071016:90081016:90091016:90101016:9011
2001:90062001:90072001:90082001:90092001:90102001:9011
2002:90062002:90072002:90082002:90092002:90102002:9011
2003:90062003:90072003:90082003:90092003:90102003:9011
2004:90062004:90072004:90082004:90092004:90102004:9011
2005:90062005:90072005:90082005:90092005:90102005:9011
2006:90062006:90072006:90082006:90092006:90102006:9011
2007:90062007:90072007:90082007:90092007:90102007:9011
2008:90062008:90072008:90082008:90092008:90102008:9011
2009:90062009:90072009:90082009:90092009:90102009:9011
2010:90062010:90072010:90082010:90092010:90102010:9011
2011:90062011:90072011:90082011:90092011:90102011:9011
2012:90062012:90072012:90082012:90092012:90102012:9011
1001:90121001:90131001:90141001:90151001:90161001:9017
1002:90121002:90131002:90141002:90151002:90161002:9017
1003:90121003:90131003:90141003:90151003:90161003:9017
1004:90121004:90131004:90141004:90151004:90161004:9017
1005:90121005:90131005:90141005:90151005:90161005:9017
1006:90121006:90131006:90141006:90151006:90161006:9017
1007:90121007:90131007:90141007:90151007:90161007:9017
1008:90121008:90131008:90141008:90151008:90161008:9017
1009:90121009:90131009:90141009:90151009:90161009:9017
1010:90121010:90131010:90141010:90151010:90161010:9017
1011:90121011:90131011:90141011:90151011:90161011:9017
1012:90121012:90131012:90141012:90151012:90161012:9017
1013:90121013:90131013:90141013:90151013:90161013:9017
1014:90121014:90131014:90141014:90151014:90161014:9017
1015:90121015:90131015:90141015:90151015:90161015:9017
1016:90121016:90131016:90141016:90151016:90161016:9017
2001:90122001:90132001:90142001:90152001:90162001:9017
2002:90122002:90132002:90142002:90152002:90162002:9017
2003:90122003:90132003:90142003:90152003:90162003:9017
2004:90122004:90132004:90142004:90152004:90162004:9017
2005:90122005:90132005:90142005:90152005:90162005:9017
2006:90122006:90132006:90142006:90152006:90162006:9017
2007:90122007:90132007:90142007:90152007:90162007:9017
2008:90122008:90132008:90142008:90152008:90162008:9017
2009:90122009:90132009:90142009:90152009:90162009:9017
2010:90122010:90132010:90142010:90152010:90162010:9017
2011:90122011:90132011:90142011:90152011:90162011:9017
2012:90122012:90132012:90142012:90152012:90162012:9017
1001:90181001:90191001:90201001:90211001:90221001:9023
1002:90181002:90191002:90201002:90211002:90221002:9023
1003:90181003:90191003:90201003:90211003:90221003:9023
1004:90181004:90191004:90201004:90211004:90221004:9023
1005:90181005:90191005:90201005:90211005:90221005:9023
1006:90181006:90191006:90201006:90211006:90221006:9023
1007:90181007:90191007:90201007:90211007:90221007:9023
1008:90181008:90191008:90201008:90211008:90221008:9023
1009:90181009:90191009:90201009:90211009:90221009:9023
1010:90181010:90191010:90201010:90211010:90221010:9023
1011:90181011:90191011:90201011:90211011:90221011:9023
1012:90181012:90191012:90201012:90211012:90221012:9023
1013:90181013:90191013:90201013:90211013:90221013:9023
1014:90181014:90191014:90201014:90211014:90221014:9023
1015:90181015:90191015:90201015:90211015:90221015:9023
1016:90181016:90191016:90201016:90211016:90221016:9023
2001:90182001:90192001:90202001:90212001:90222001:9023
2002:90182002:90192002:90202002:90212002:90222002:9023
2003:90182003:90192003:90202003:90212003:90222003:9023
2004:90182004:90192004:90202004:90212004:90222004:9023
2005:90182005:90192005:90202005:90212005:90222005:9023
2006:90182006:90192006:90202006:90212006:90222006:9023
2007:90182007:90192007:90202007:90212007:90222007:9023
2008:90182008:90192008:90202008:90212008:90222008:9023
2009:90182009:90192009:90202009:90212009:90222009:9023
2010:90182010:90192010:90202010:90212010:90222010:9023
2011:90182011:90192011:90202011:90212011:90222011:9023
2012:90182012:90192012:90202012:90212012:90222012:9023
1001:90241001:90251001:90261001:90271001:90281001:9029
1002:90241002:90251002:90261002:90271002:90281002:9029
1003:90241003:90251003:90261003:90271003:90281003:9029
1004:90241004:90251004:90261004:90271004:90281004:9029
1005:90241005:90251005:90261005:90271005:90281005:9029
1006:90241006:90251006:90261006:90271006:90281006:9029
1007:90241007:90251007:90261007:90271007:90281007:9029
1008:90241008:90251008:90261008:90271008:90281008:9029
1009:90241009:90251009:90261009:90271009:90281009:9029
1010:90241010:90251010:90261010:90271010:90281010:9029
1011:90241011:90251011:90261011:90271011:90281011:9029
1012:90241012:90251012:90261012:90271012:90281012:9029
1013:90241013:90251013:90261013:90271013:90281013:9029
1014:90241014:90251014:90261014:90271014:90281014:9029
1015:90241015:90251015:90261015:90271015:90281015:9029
1016:90241016:90251016:90261016:90271016:90281016:9029
2001:90242001:90252001:90262001:90272001:90282001:9029
2002:90242002:90252002:90262002:90272002:90282002:9029
2003:90242003:90252003:90262003:90272003:90282003:9029
2004:90242004:90252004:90262004:90272004:90282004:9029
2005:90242005:90252005:90262005:90272005:90282005:9029
2006:90242006:90252006:90262006:90272006:90282006:9029
2007:90242007:90252007:90262007:90272007:90282007:9029
2008:90242008:90252008:90262008:90272008:90282008:9029
2009:90242009:90252009:90262009:90272009:90282009:9029
2010:90242010:90252010:90262010:90272010:90282010:9029
2011:90242011:90252011:90262011:90272011:90282011:9029
2012:90242012:90252012:90262012:90272012:90282012:9029
1001:90301001:90311001:90321001:90331001:90341001:9035
1002:90301002:90311002:90321002:90331002:90341002:9035
1003:90301003:90311003:90321003:90331003:90341003:9035
1004:90301004:90311004:90321004:90331004:90341004:9035
1005:90301005:90311005:90321005:90331005:90341005:9035
1006:90301006:90311006:90321006:90331006:90341006:9035
1007:90301007:90311007:90321007:90331007:90341007:9035
1008:90301008:90311008:90321008:90331008:90341008:9035
1009:90301009:90311009:90321009:90331009:90341009:9035
1010:90301010:90311010:90321010:90331010:90341010:9035
1011:90301011:90311011:90321011:90331011:90341011:9035
1012:90301012:90311012:90321012:90331012:90341012:9035
1013:90301013:90311013:90321013:90331013:90341013:9035
1014:90301014:90311014:90321014:90331014:90341014:9035
1015:90301015:90311015:90321015:90331015:90341015:9035
1016:90301016:90311016:90321016:90331016:90341016:9035
2001:90302001:90312001:90322001:90332001:90342001:9035
2002:90302002:90312002:90322002:90332002:90342002:9035
2003:90302003:90312003:90322003:90332003:90342003:9035
2004:90302004:90312004:90322004:90332004:90342004:9035
2005:90302005:90312005:90322005:90332005:90342005:9035
2006:90302006:90312006:90322006:90332006:90342006:9035
2007:90302007:90312007:90322007:90332007:90342007:9035
2008:90302008:90312008:90322008:90332008:90342008:9035
2009:90302009:90312009:90322009:90332009:90342009:9035
2010:90302010:90312010:90322010:90332010:90342010:9035
2011:90302011:90312011:90322011:90332011:90342011:9035
2012:90302012:90312012:90322012:90332012:90342012:9035
1001:90361001:90371001:90381001:90391001:90401001:9041
1002:90361002:90371002:90381002:90391002:90401002:9041
1003:90361003:90371003:90381003:90391003:90401003:9041
1004:90361004:90371004:90381004:90391004:90401004:9041
1005:90361005:90371005:90381005:90391005:90401005:9041
1006:90361006:90371006:90381006:90391006:90401006:9041
1007:90361007:90371007:90381007:90391007:90401007:9041
1008:90361008:90371008:90381008:90391008:90401008:9041
1009:90361009:90371009:90381009:90391009:90401009:9041
1010:90361010:90371010:90381010:90391010:90401010:9041
1011:90361011:90371011:90381011:90391011:90401011:9041
1012:90361012:90371012:90381012:90391012:90401012:9041
1013:90361013:90371013:90381013:90391013:90401013:9041
1014:90361014:90371014:90381014:90391014:90401014:9041
1015:90361015:90371015:90381015:90391015:90401015:9041
1016:90361016:90371016:90381016:90391016:90401016:9041
2001:90362001:90372001:90382001:90392001:90402001:9041
2002:90362002:90372002:90382002:90392002:90402002:9041
2003:90362003:90372003:90382003:90392003:90402003:9041
2004:90362004:90372004:90382004:90392004:90402004:9041
2005:90362005:90372005:90382005:90392005:90402005:9041
2006:90362006:90372006:90382006:90392006:90402006:9041
2007:90362007:90372007:90382007:90392007:90402007:9041
2008:90362008:90372008:90382008:90392008:90402008:9041
2009:90362009:90372009:90382009:90392009:90402009:9041
2010:90362010:90372010:90382010:90392010:90402010:9041
2011:90362011:90372011:90382011:90392011:90402011:9041
2012:90362012:90372012:90382012:90392012:90402012:9041
1001:90421001:90431001:90441001:90451001:90461001:9047
1002:90421002:90431002:90441002:90451002:90461002:9047
1003:90421003:90431003:90441003:90451003:90461003:9047
1004:90421004:90431004:90441004:90451004:90461004:9047
1005:90421005:90431005:90441005:90451005:90461005:9047
1006:90421006:90431006:90441006:90451006:90461006:9047
1007:90421007:90431007:90441007:90451007:90461007:9047
1008:90421008:90431008:90441008:90451008:90461008:9047
1009:90421009:90431009:90441009:90451009:90461009:9047
1010:90421010:90431010:90441010:90451010:90461010:9047
1011:90421011:90431011:90441011:90451011:90461011:9047
1012:90421012:90431012:90441012:90451012:90461012:9047
1013:90421013:90431013:90441013:90451013:90461013:9047
1014:90421014:90431014:90441014:90451014:90461014:9047
1015:90421015:90431015:90441015:90451015:90461015:9047
1016:90421016:90431016:90441016:90451016:90461016:9047
2001:90422001:90432001:90442001:90452001:90462001:9047
2002:90422002:90432002:90442002:90452002:90462002:9047
2003:90422003:90432003:90442003:90452003:90462003:9047
2004:90422004:90432004:90442004:90452004:90462004:9047
2005:90422005:90432005:90442005:90452005:90462005:9047
2006:90422006:90432006:90442006:90452006:90462006:9047
2007:90422007:90432007:90442007:90452007:90462007:9047
2008:90422008:90432008:90442008:90452008:90462008:9047
2009:90422009:90432009:90442009:90452009:90462009:9047
2010:90422010:90432010:90442010:90452010:90462010:9047
2011:90422011:90432011:90442011:90452011:90462011:9047
2012:90422012:90432012:90442012:90452012:90462012:9047
1001:90481001:90491001:90501001:90511001:90521001:9053
1002:90481002:90491002:90501002:90511002:90521002:9053
1003:90481003:90491003:90501003:90511003:90521003:9053
1004:90481004:90491004:90501004:90511004:90521004:9053
1005:90481005:90491005:90501005:90511005:90521005:9053
1006:90481006:90491006:90501006:90511006:90521006:9053
1007:90481007:90491007:90501007:90511007:90521007:9053
1008:90481008:90491008:90501008:90511008:90521008:9053
1009:90481009:90491009:90501009:90511009:90521009:9053
1010:90481010:90491010:90501010:90511010:90521010:9053
1011:90481011:90491011:90501011:90511011:90521011:9053
1012:90481012:90491012:90501012:90511012:90521012:9053
1013:90481013:90491013:90501013:90511013:90521013:9053
1014:90481014:90491014:90501014:90511014:90521014:9053
1015:90481015:90491015:90501015:90511015:90521015:9053
1016:90481016:90491016:90501016:90511016:90521016:9053
2001:90482001:90492001:90502001:90512001:90522001:9053
2002:90482002:90492002:90502002:90512002:90522002:9053
2003:90482003:90492003:90502003:90512003:90522003:9053
2004:90482004:90492004:90502004:90512004:90522004:9053
2005:90482005:90492005:90502005:90512005:90522005:9053
2006:90482006:90492006:90502006:90512006:90522006:9053
2007:90482007:90492007:90502007:90512007:90522007:9053
2008:90482008:90492008:90502008:90512008:90522008:9053
2009:90482009:90492009:90502009:90512009:90522009:9053
2010:90482010:90492010:90502010:90512010:90522010:9053
2011:90482011:90492011:90502011:90512011:90522011:9053
2012:90482012:90492012:90502012:90512012:90522012:9053
1001:90541001:90551001:90561001:90571001:90581001:9059
1002:90541002:90551002:90561002:90571002:90581002:9059
1003:90541003:90551003:90561003:90571003:90581003:9059
1004:90541004:90551004:90561004:90571004:90581004:9059
1005:90541005:90551005:90561005:90571005:90581005:9059
1006:90541006:90551006:90561006:90571006:90581006:9059
1007:90541007:90551007:90561007:90571007:90581007:9059
1008:90541008:90551008:90561008:90571008:90581008:9059
1009:90541009:90551009:90561009:90571009:90581009:9059
1010:90541010:90551010:90561010:90571010:90581010:9059
1011:90541011:90551011:90561011:90571011:90581011:9059
1012:90541012:90551012:90561012:90571012:90581012:9059
1013:90541013:90551013:90561013:90571013:90581013:9059
1014:90541014:90551014:90561014:90571014:90581014:9059
1015:90541015:90551015:90561015:90571015:90581015:9059
1016:90541016:90551016:90561016:90571016:90581016:9059
2001:90542001:90552001:90562001:90572001:90582001:9059
2002:90542002:90552002:90562002:90572002:90582002:9059
2003:90542003:90552003:90562003:90572003:90582003:9059
2004:90542004:90552004:90562004:90572004:90582004:9059
2005:90542005:90552005:90562005:90572005:90582005:9059
2006:90542006:90552006:90562006:90572006:90582006:9059
2007:90542007:90552007:90562007:90572007:90582007:9059
2008:90542008:90552008:90562008:90572008:90582008:9059
2009:90542009:90552009:90562009:90572009:90582009:9059
2010:90542010:90552010:90562010:90572010:90582010:9059
2011:90542011:90552011:90562011:90572011:90582011:9059
2012:90542012:90552012:90562012:90572012:90582012:9059
1001:90601001:90611001:90621001:90631001:90641001:9065
1002:90601002:90611002:90621002:90631002:90641002:9065
1003:90601003:90611003:90621003:90631003:90641003:9065
1004:90601004:90611004:90621004:90631004:90641004:9065
1005:90601005:90611005:90621005:90631005:90641005:9065
1006:90601006:90611006:90621006:90631006:90641006:9065
1007:90601007:90611007:90621007:90631007:90641007:9065
1008:90601008:90611008:90621008:90631008:90641008:9065
1009:90601009:90611009:90621009:90631009:90641009:9065
1010:90601010:90611010:90621010:90631010:90641010:9065
1011:90601011:90611011:90621011:90631011:90641011:9065
1012:90601012:90611012:90621012:90631012:90641012:9065
1013:90601013:90611013:90621013:90631013:90641013:9065
1014:90601014:90611014:90621014:90631014:90641014:9065
1015:90601015:90611015:90621015:90631015:90641015:9065
1016:90601016:90611016:90621016:90631016:90641016:9065
2001:90602001:90612001:90622001:90632001:90642001:9065
2002:90602002:90612002:90622002:90632002:90642002:9065
2003:90602003:90612003:90622003:90632003:90642003:9065
2004:90602004:90612004:90622004:90632004:90642004:9065
2005:90602005:90612005:90622005:90632005:90642005:9065
2006:90602006:90612006:90622006:90632006:90642006:9065
2007:90602007:90612007:90622007:90632007:90642007:9065
2008:90602008:90612008:90622008:90632008:90642008:9065
2009:90602009:90612009:90622009:90632009:90642009:9065
2010:90602010:90612010:90622010:90632010:90642010:9065
2011:90602011:90612011:90622011:90632011:90642011:9065
2012:90602012:90612012:90622012:90632012:90642012:9065
1001:90661001:90671001:90681001:90691001:90701001:9071
1002:90661002:90671002:90681002:90691002:90701002:9071
1003:90661003:90671003:90681003:90691003:90701003:9071
1004:90661004:90671004:90681004:90691004:90701004:9071
1005:90661005:90671005:90681005:90691005:90701005:9071
1006:90661006:90671006:90681006:90691006:90701006:9071
1007:90661007:90671007:90681007:90691007:90701007:9071
1008:90661008:90671008:90681008:90691008:90701008:9071
1009:90661009:90671009:90681009:90691009:90701009:9071
1010:90661010:90671010:90681010:90691010:90701010:9071
1011:90661011:90671011:90681011:90691011:90701011:9071
1012:90661012:90671012:90681012:90691012:90701012:9071
1013:90661013:90671013:90681013:90691013:90701013:9071
1014:90661014:90671014:90681014:90691014:90701014:9071
1015:90661015:90671015:90681015:90691015:90701015:9071
1016:90661016:90671016:90681016:90691016:90701016:9071
2001:90662001:90672001:90682001:90692001:90702001:9071
2002:90662002:90672002:90682002:90692002:90702002:9071
2003:90662003:90672003:90682003:90692003:90702003:9071
2004:90662004:90672004:90682004:90692004:90702004:9071
2005:90662005:90672005:90682005:90692005:90702005:9071
2006:90662006:90672006:90682006:90692006:90702006:9071
2007:90662007:90672007:90682007:90692007:90702007:9071
2008:90662008:90672008:90682008:90692008:90702008:9071
2009:90662009:90672009:90682009:90692009:90702009:9071
2010:90662010:90672010:90682010:90692010:90702010:9071
2011:90662011:90672011:90682011:90692011:90702011:9071
2012:90662012:90672012:90682012:90692012:90702012:9071
1001:90721001:90731001:90741001:90751001:90761001:9077
1002:90721002:90731002:90741002:90751002:90761002:9077
1003:90721003:90731003:90741003:90751003:90761003:9077
1004:90721004:90731004:90741004:90751004:90761004:9077
1005:90721005:90731005:90741005:90751005:90761005:9077
1006:90721006:90731006:90741006:90751006:90761006:9077
1007:90721007:90731007:90741007:90751007:90761007:9077
1008:90721008:90731008:90741008:90751008:90761008:9077
1009:90721009:90731009:90741009:90751009:90761009:9077
1010:90721010:90731010:90741010:90751010:90761010:9077
1011:90721011:90731011:90741011:90751011:90761011:9077
1012:90721012:90731012:90741012:90751012:90761012:9077
1013:90721013:90731013:90741013:90751013:90761013:9077
1014:90721014:90731014:90741014:90751014:90761014:9077
1015:90721015:90731015:90741015:90751015:90761015:9077
1016:90721016:90731016:90741016:90751016:90761016:9077
2001:90722001:90732001:90742001:90752001:90762001:9077
2002:90722002:90732002:90742002:90752002:90762002:9077
2003:90722003:90732003:90742003:90752003:90762003:9077
2004:90722004:90732004:90742004:90752004:90762004:9077
2005:90722005:90732005:90742005:90752005:90762005:9077
2006:90722006:90732006:90742006:90752006:90762006:9077
2007:90722007:90732007:90742007:90752007:90762007:9077
2008:90722008:90732008:90742008:90752008:90762008:9077
2009:90722009:90732009:90742009:90752009:90762009:9077
2010:90722010:90732010:90742010:90752010:90762010:9077
2011:90722011:90732011:90742011:90752011:90762011:9077
2012:90722012:90732012:90742012:90752012:90762012:9077
1001:90781001:90791001:90801001:90811001:90821001:9083
1002:90781002:90791002:90801002:90811002:90821002:9083
1003:90781003:90791003:90801003:90811003:90821003:9083
1004:90781004:90791004:90801004:90811004:90821004:9083
1005:90781005:90791005:90801005:90811005:90821005:9083
1006:90781006:90791006:90801006:90811006:90821006:9083
1007:90781007:90791007:90801007:90811007:90821007:9083
1008:90781008:90791008:90801008:90811008:90821008:9083
1009:90781009:90791009:90801009:90811009:90821009:9083
1010:90781010:90791010:90801010:90811010:90821010:9083
1011:90781011:90791011:90801011:90811011:90821011:9083
1012:90781012:90791012:90801012:90811012:90821012:9083
1013:90781013:90791013:90801013:90811013:90821013:9083
1014:90781014:90791014:90801014:90811014:90821014:9083
1015:90781015:90791015:90801015:90811015:90821015:9083
1016:90781016:90791016:90801016:90811016:90821016:9083
2001:90782001:90792001:90802001:90812001:90822001:9083
2002:90782002:90792002:90802002:90812002:90822002:9083
2003:90782003:90792003:90802003:90812003:90822003:9083
2004:90782004:90792004:90802004:90812004:90822004:9083
2005:90782005:90792005:90802005:90812005:90822005:9083
2006:90782006:90792006:90802006:90812006:90822006:9083
2007:90782007:90792007:90802007:90812007:90822007:9083
2008:90782008:90792008:90802008:90812008:90822008:9083
2009:90782009:90792009:90802009:90812009:90822009:9083
2010:90782010:90792010:90802010:90812010:90822010:9083
2011:90782011:90792011:90802011:90812011:90822011:9083
2012:90782012:90792012:90802012:90812012:90822012:9083
1001:90841001:90851001:90861001:90871001:90881001:9089
1002:90841002:90851002:90861002:90871002:90881002:9089
1003:90841003:90851003:90861003:90871003:90881003:9089
1004:90841004:90851004:90861004:90871004:90881004:9089
1005:90841005:90851005:90861005:90871005:90881005:9089
1006:90841006:90851006:90861006:90871006:90881006:9089
1007:90841007:90851007:90861007:90871007:90881007:9089
1008:90841008:90851008:90861008:90871008:90881008:9089
1009:90841009:90851009:90861009:90871009:90881009:9089
1010:90841010:90851010:90861010:90871010:90881010:9089
1011:90841011:90851011:90861011:90871011:90881011:9089
1012:90841012:90851012:90861012:90871012:90881012:9089
1013:90841013:90851013:90861013:90871013:90881013:9089
1014:90841014:90851014:90861014:90871014:90881014:9089
1015:90841015:90851015:90861015:90871015:90881015:9089
1016:90841016:90851016:90861016:90871016:90881016:9089
2001:90842001:90852001:90862001:90872001:90882001:9089
2002:90842002:90852002:90862002:90872002:90882002:9089
2003:90842003:90852003:90862003:90872003:90882003:9089
2004:90842004:90852004:90862004:90872004:90882004:9089
2005:90842005:90852005:90862005:90872005:90882005:9089
2006:90842006:90852006:90862006:90872006:90882006:9089
2007:90842007:90852007:90862007:90872007:90882007:9089
2008:90842008:90852008:90862008:90872008:90882008:9089
2009:90842009:90852009:90862009:90872009:90882009:9089
2010:90842010:90852010:90862010:90872010:90882010:9089
2011:90842011:90852011:90862011:90872011:90882011:9089
2012:90842012:90852012:90862012:90872012:90882012:9089
1001:90901001:90911001:90921001:90931001:90941001:9095
1002:90901002:90911002:90921002:90931002:90941002:9095
1003:90901003:90911003:90921003:90931003:90941003:9095
1004:90901004:90911004:90921004:90931004:90941004:9095
1005:90901005:90911005:90921005:90931005:90941005:9095
1006:90901006:90911006:90921006:90931006:90941006:9095
1007:90901007:90911007:90921007:90931007:90941007:9095
1008:90901008:90911008:90921008:90931008:90941008:9095
1009:90901009:90911009:90921009:90931009:90941009:9095
1010:90901010:90911010:90921010:90931010:90941010:9095
1011:90901011:90911011:90921011:90931011:90941011:9095
1012:90901012:90911012:90921012:90931012:90941012:9095
1013:90901013:90911013:90921013:90931013:90941013:9095
1014:90901014:90911014:90921014:90931014:90941014:9095
1015:90901015:90911015:90921015:90931015:90941015:9095
1016:90901016:90911016:90921016:90931016:90941016:9095
2001:90902001:90912001:90922001:90932001:90942001:9095
2002:90902002:90912002:90922002:90932002:90942002:9095
2003:90902003:90912003:90922003:90932003:90942003:9095
2004:90902004:90912004:90922004:90932004:90942004:9095
2005:90902005:90912005:90922005:90932005:90942005:9095
2006:90902006:90912006:90922006:90932006:90942006:9095
2007:90902007:90912007:90922007:90932007:90942007:9095
2008:90902008:90912008:90922008:90932008:90942008:9095
2009:90902009:90912009:90922009:90932009:90942009:9095
2010:90902010:90912010:90922010:90932010:90942010:9095
2011:90902011:90912011:90922011:90932011:90942011:9095
2012:90902012:90912012:90922012:90932012:90942012:9095
1001:90961001:90971001:90981001:90991001:91001001:9101
1002:90961002:90971002:90981002:90991002:91001002:9101
1003:90961003:90971003:90981003:90991003:91001003:9101
1004:90961004:90971004:90981004:90991004:91001004:9101
1005:90961005:90971005:90981005:90991005:91001005:9101
1006:90961006:90971006:90981006:90991006:91001006:9101
1007:90961007:90971007:90981007:90991007:91001007:9101
1008:90961008:90971008:90981008:90991008:91001008:9101
1009:90961009:90971009:90981009:90991009:91001009:9101
1010:90961010:90971010:90981010:90991010:91001010:9101
1011:90961011:90971011:90981011:90991011:91001011:9101
1012:90961012:90971012:90981012:90991012:91001012:9101
1013:90961013:90971013:90981013:90991013:91001013:9101
1014:90961014:90971014:90981014:90991014:91001014:9101
1015:90961015:90971015:90981015:90991015:91001015:9101
1016:90961016:90971016:90981016:90991016:91001016:9101
2001:90962001:90972001:90982001:90992001:91002001:9101
2002:90962002:90972002:90982002:90992002:91002002:9101
2003:90962003:90972003:90982003:90992003:91002003:9101
2004:90962004:90972004:90982004:90992004:91002004:9101
2005:90962005:90972005:90982005:90992005:91002005:9101
2006:90962006:90972006:90982006:90992006:91002006:9101
2007:90962007:90972007:90982007:90992007:91002007:9101
2008:90962008:90972008:90982008:90992008:91002008:9101
2009:90962009:90972009:90982009:90992009:91002009:9101
2010:90962010:90972010:90982010:90992010:91002010:9101
2011:90962011:90972011:90982011:90992011:91002011:9101
2012:90962012:90972012:90982012:90992012:91002012:9101
1001:91021001:91031001:91041001:9105——
1002:91021002:91031002:91041002:9105
1003:91021003:91031003:91041003:9105
1004:91021004:91031004:91041004:9105
1005:91021005:91031005:91041005:9105
1006:91021006:91031006:91041006:9105
1007:91021007:91031007:91041007:9105
1008:91021008:91031008:91041008:9105
1009:91021009:91031009:91041009:9105
1010:91021010:91031010:91041010:9105
1011:91021011:91031011:91041011:9105
1012:91021012:91031012:91041012:9105
1013:91021013:91031013:91041013:9105
1014:91021014:91031014:91041014:9105
1015:91021015:91031015:91041015:9105
1016:91021016:91031016:91041016:9105
2001:91022001:91032001:91042001:9105
2002:91022002:91032002:91042002:9105
2003:91022003:91032003:91042003:9105
2004:91022004:91032004:91042004:9105
2005:91022005:91032005:91042005:9105
2006:91022006:91032006:91042006:9105
2007:91022007:91032007:91042007:9105
2008:91022008:91032008:91042008:9105
2009:91022009:91032009:91042009:9105
2010:91022010:91032010:91042010:9105
2011:91022011:91032011:91042011:9105
2012:91022012:91032012:91042012:9105
TABLE B
Example combinations of a compound X with a compound Y.
X:YX:YX:YX:YX:YX:Y
3001:90003001:90013001:90023001:90033001:90043001:9005
3002:90003002:90013002:90023002:90033002:90043002:9005
3003:90003003:90013003:90023003:90033003:90043003:9005
3004:90003004:90013004:90023004:90033004:90043004:9005
3005:90003005:90013005:90023005:90033005:90043005:9005
3006:90003006:90013006:90023006:90033006:90043006:9005
3007:90003007:90013007:90023007:90033007:90043007:9005
3008:90003008:90013008:90023008:90033008:90043008:9005
3009:90003009:90013009:90023009:90033009:90043009:9005
3010:90003010:90013010:90023010:90033010:90043010:9005
3011:90003011:90013011:90023011:90033011:90043011:9005
3012:90003012:90013012:90023012:90033012:90043012:9005
3013:90003013:90013013:90023013:90033013:90043013:9005
3014:90003014:90013014:90023014:90033014:90043014:9005
4001:90004001:90014001:90024001:90034001:90044001:9005
4002:90004002:90014002:90024002:90034002:90044002:9005
4003:90004003:90014003:90024003:90034003:90044003:9005
4004:90004004:90014004:90024004:90034004:90044004:9005
4005:90004005:90014005:90024005:90034005:90044005:9005
4006:90004006:90014006:90024006:90034006:90044006:9005
4007:90004007:90014007:90024007:90034007:90044007:9005
4008:90004008:90014008:90024008:90034008:90044008:9005
4009:90004009:90014009:90024009:90034009:90044009:9005
4010:90004010:90014010:90024010:90034010:90044010:9005
4011:90004011:90014011:90024011:90034011:90044011:9005
4012:90004012:90014012:90024012:90034012:90044012:9005
5001:90005001:90015001:90025001:90035001:90045001:9005
5002:90005002:90015002:90025002:90035002:90045002:9005
5003:90005003:90015003:90025003:90035003:90045003:9005
5004:90005004:90015004:90025004:90035004:90045004:9005
5005:90005005:90015005:90025005:90035005:90045005:9005
5006:90005006:90015006:90025006:90035006:90045006:9005
5007:90005007:90015007:90025007:90035007:90045007:9005
5008:90005008:90015008:90025008:90035008:90045008:9005
5009:90005009:90015009:90025009:90035009:90045009:9005
5010:90005010:90015010:90025010:90035010:90045010:9005
5011:90005011:90015011:90025011:90035011:90045011:9005
5012:90005012:90015012:90025012:90035012:90045012:9005
3001:90063001:90073001:90083001:90093001:90103001:9011
3002:90063002:90073002:90083002:90093002:90103002:9011
3003:90063003:90073003:90083003:90093003:90103003:9011
3004:90063004:90073004:90083004:90093004:90103004:9011
3005:90063005:90073005:90083005:90093005:90103005:9011
3006:90063006:90073006:90083006:90093006:90103006:9011
3007:90063007:90073007:90083007:90093007:90103007:9011
3008:90063008:90073008:90083008:90093008:90103008:9011
3009:90063009:90073009:90083009:90093009:90103009:9011
3010:90063010:90073010:90083010:90093010:90103010:9011
3011:90063011:90073011:90083011:90093011:90103011:9011
3012:90063012:90073012:90083012:90093012:90103012:9011
3013:90063013:90073013:90083013:90093013:90103013:9011
3014:90063014:90073014:90083014:90093014:90103014:9011
4001:90064001:90074001:90084001:90094001:90104001:9011
4002:90064002:90074002:90084002:90094002:90104002:9011
4003:90064003:90074003:90084003:90094003:90104003:9011
4004:90064004:90074004:90084004:90094004:90104004:9011
4005:90064005:90074005:90084005:90094005:90104005:9011
4006:90064006:90074006:90084006:90094006:90104006:9011
4007:90064007:90074007:90084007:90094007:90104007:9011
4008:90064008:90074008:90084008:90094008:90104008:9011
4009:90064009:90074009:90084009:90094009:90104009:9011
4010:90064010:90074010:90084010:90094010:90104010:9011
4011:90064011:90074011:90084011:90094011:90104011:9011
4012:90064012:90074012:90084012:90094012:90104012:9011
5001:90065001:90075001:90085001:90095001:90105001:9011
5002:90065002:90075002:90085002:90095002:90105002:9011
5003:90065003:90075003:90085003:90095003:90105003:9011
5004:90065004:90075004:90085004:90095004:90105004:9011
5005:90065005:90075005:90085005:90095005:90105005:9011
5006:90065006:90075006:90085006:90095006:90105006:9011
5007:90065007:90075007:90085007:90095007:90105007:9011
5008:90065008:90075008:90085008:90095008:90105008:9011
5009:90065009:90075009:90085009:90095009:90105009:9011
5010:90065010:90075010:90085010:90095010:90105010:9011
5011:90065011:90075011:90085011:90095011:90105011:9011
5012:90065012:90075012:90085012:90095012:90105012:9011
3001:90123001:90133001:90143001:90153001:90163001:9017
3002:90123002:90133002:90143002:90153002:90163002:9017
3003:90123003:90133003:90143003:90153003:90163003:9017
3004:90123004:90133004:90143004:90153004:90163004:9017
3005:90123005:90133005:90143005:90153005:90163005:9017
3006:90123006:90133006:90143006:90153006:90163006:9017
3007:90123007:90133007:90143007:90153007:90163007:9017
3008:90123008:90133008:90143008:90153008:90163008:9017
3009:90123009:90133009:90143009:90153009:90163009:9017
3010:90123010:90133010:90143010:90153010:90163010:9017
3011:90123011:90133011:90143011:90153011:90163011:9017
3012:90123012:90133012:90143012:90153012:90163012:9017
3013:90123013:90133013:90143013:90153013:90163013:9017
3014:90123014:90133014:90143014:90153014:90163014:9017
4001:90124001:90134001:90144001:90154001:90164001:9017
4002:90124002:90134002:90144002:90154002:90164002:9017
4003:90124003:90134003:90144003:90154003:90164003:9017
4004:90124004:90134004:90144004:90154004:90164004:9017
4005:90124005:90134005:90144005:90154005:90164005:9017
4006:90124006:90134006:90144006:90154006:90164006:9017
4007:90124007:90134007:90144007:90154007:90164007:9017
4008:90124008:90134008:90144008:90154008:90164008:9017
4009:90124009:90134009:90144009:90154009:90164009:9017
4010:90124010:90134010:90144010:90154010:90164010:9017
4011:90124011:90134011:90144011:90154011:90164011:9017
4012:90124012:90134012:90144012:90154012:90164012:9017
5001:90125001:90135001:90145001:90155001:90165001:9017
5002:90125002:90135002:90145002:90155002:90165002:9017
5003:90125003:90135003:90145003:90155003:90165003:9017
5004:90125004:90135004:90145004:90155004:90165004:9017
5005:90125005:90135005:90145005:90155005:90165005:9017
5006:90125006:90135006:90145006:90155006:90165006:9017
5007:90125007:90135007:90145007:90155007:90165007:9017
5008:90125008:90135008:90145008:90155008:90165008:9017
5009:90125009:90135009:90145009:90155009:90165009:9017
5010:90125010:90135010:90145010:90155010:90165010:9017
5011:90125011:90135011:90145011:90155011:90165011:9017
5012:90125012:90135012:90145012:90155012:90165012:9017
3001:90183001:90193001:90203001:90213001:90223001:9023
3002:90183002:90193002:90203002:90213002:90223002:9023
3003:90183003:90193003:90203003:90213003:90223003:9023
3004:90183004:90193004:90203004:90213004:90223004:9023
3005:90183005:90193005:90203005:90213005:90223005:9023
3006:90183006:90193006:90203006:90213006:90223006:9023
3007:90183007:90193007:90203007:90213007:90223007:9023
3008:90183008:90193008:90203008:90213008:90223008:9023
3009:90183009:90193009:90203009:90213009:90223009:9023
3010:90183010:90193010:90203010:90213010:90223010:9023
3011:90183011:90193011:90203011:90213011:90223011:9023
3012:90183012:90193012:90203012:90213012:90223012:9023
3013:90183013:90193013:90203013:90213013:90223013:9023
3014:90183014:90193014:90203014:90213014:90223014:9023
4001:90184001:90194001:90204001:90214001:90224001:9023
4002:90184002:90194002:90204002:90214002:90224002:9023
4003:90184003:90194003:90204003:90214003:90224003:9023
4004:90184004:90194004:90204004:90214004:90224004:9023
4005:90184005:90194005:90204005:90214005:90224005:9023
4006:90184006:90194006:90204006:90214006:90224006:9023
4007:90184007:90194007:90204007:90214007:90224007:9023
4008:90184008:90194008:90204008:90214008:90224008:9023
4009:90184009:90194009:90204009:90214009:90224009:9023
4010:90184010:90194010:90204010:90214010:90224010:9023
4011:90184011:90194011:90204011:90214011:90224011:9023
4012:90184012:90194012:90204012:90214012:90224012:9023
5001:90185001:90195001:90205001:90215001:90225001:9023
5002:90185002:90195002:90205002:90215002:90225002:9023
5003:90185003:90195003:90205003:90215003:90225003:9023
5004:90185004:90195004:90205004:90215004:90225004:9023
5005:90185005:90195005:90205005:90215005:90225005:9023
5006:90185006:90195006:90205006:90215006:90225006:9023
5007:90185007:90195007:90205007:90215007:90225007:9023
5008:90185008:90195008:90205008:90215008:90225008:9023
5009:90185009:90195009:90205009:90215009:90225009:9023
5010:90185010:90195010:90205010:90215010:90225010:9023
5011:90185011:90195011:90205011:90215011:90225011:9023
5012:90185012:90195012:90205012:90215012:90225012:9023
3001:90243001:90253001:90263001:90273001:90283001:9029
3002:90243002:90253002:90263002:90273002:90283002:9029
3003:90243003:90253003:90263003:90273003:90283003:9029
3004:90243004:90253004:90263004:90273004:90283004:9029
3005:90243005:90253005:90263005:90273005:90283005:9029
3006:90243006:90253006:90263006:90273006:90283006:9029
3007:90243007:90253007:90263007:90273007:90283007:9029
3008:90243008:90253008:90263008:90273008:90283008:9029
3009:90243009:90253009:90263009:90273009:90283009:9029
3010:90243010:90253010:90263010:90273010:90283010:9029
3011:90243011:90253011:90263011:90273011:90283011:9029
3012:90243012:90253012:90263012:90273012:90283012:9029
3013:90243013:90253013:90263013:90273013:90283013:9029
3014:90243014:90253014:90263014:90273014:90283014:9029
4001:90244001:90254001:90264001:90274001:90284001:9029
4002:90244002:90254002:90264002:90274002:90284002:9029
4003:90244003:90254003:90264003:90274003:90284003:9029
4004:90244004:90254004:90264004:90274004:90284004:9029
4005:90244005:90254005:90264005:90274005:90284005:9029
4006:90244006:90254006:90264006:90274006:90284006:9029
4007:90244007:90254007:90264007:90274007:90284007:9029
4008:90244008:90254008:90264008:90274008:90284008:9029
4009:90244009:90254009:90264009:90274009:90284009:9029
4010:90244010:90254010:90264010:90274010:90284010:9029
4011:90244011:90254011:90264011:90274011:90284011:9029
4012:90244012:90254012:90264012:90274012:90284012:9029
5001:90245001:90255001:90265001:90275001:90285001:9029
5002:90245002:90255002:90265002:90275002:90285002:9029
5003:90245003:90255003:90265003:90275003:90285003:9029
5004:90245004:90255004:90265004:90275004:90285004:9029
5005:90245005:90255005:90265005:90275005:90285005:9029
5006:90245006:90255006:90265006:90275006:90285006:9029
5007:90245007:90255007:90265007:90275007:90285007:9029
5008:90245008:90255008:90265008:90275008:90285008:9029
5009:90245009:90255009:90265009:90275009:90285009:9029
5010:90245010:90255010:90265010:90275010:90285010:9029
5011:90245011:90255011:90265011:90275011:90285011:9029
5012:90245012:90255012:90265012:90275012:90285012:9029
3001:90303001:90313001:90323001:90333001:90343001:9035
3002:90303002:90313002:90323002:90333002:90343002:9035
3003:90303003:90313003:90323003:90333003:90343003:9035
3004:90303004:90313004:90323004:90333004:90343004:9035
3005:90303005:90313005:90323005:90333005:90343005:9035
3006:90303006:90313006:90323006:90333006:90343006:9035
3007:90303007:90313007:90323007:90333007:90343007:9035
3008:90303008:90313008:90323008:90333008:90343008:9035
3009:90303009:90313009:90323009:90333009:90343009:9035
3010:90303010:90313010:90323010:90333010:90343010:9035
3011:90303011:90313011:90323011:90333011:90343011:9035
3012:90303012:90313012:90323012:90333012:90343012:9035
3013:90303013:90313013:90323013:90333013:90343013:9035
3014:90303014:90313014:90323014:90333014:90343014:9035
4001:90304001:90314001:90324001:90334001:90344001:9035
4002:90304002:90314002:90324002:90334002:90344002:9035
4003:90304003:90314003:90324003:90334003:90344003:9035
4004:90304004:90314004:90324004:90334004:90344004:9035
4005:90304005:90314005:90324005:90334005:90344005:9035
4006:90304006:90314006:90324006:90334006:90344006:9035
4007:90304007:90314007:90324007:90334007:90344007:9035
4008:90304008:90314008:90324008:90334008:90344008:9035
4009:90304009:90314009:90324009:90334009:90344009:9035
4010:90304010:90314010:90324010:90334010:90344010:9035
4011:90304011:90314011:90324011:90334011:90344011:9035
4012:90304012:90314012:90324012:90334012:90344012:9035
5001:90305001:90315001:90325001:90335001:90345001:9035
5002:90305002:90315002:90325002:90335002:90345002:9035
5003:90305003:90315003:90325003:90335003:90345003:9035
5004:90305004:90315004:90325004:90335004:90345004:9035
5005:90305005:90315005:90325005:90335005:90345005:9035
5006:90305006:90315006:90325006:90335006:90345006:9035
5007:90305007:90315007:90325007:90335007:90345007:9035
5008:90305008:90315008:90325008:90335008:90345008:9035
5009:90305009:90315009:90325009:90335009:90345009:9035
5010:90305010:90315010:90325010:90335010:90345010:9035
5011:90305011:90315011:90325011:90335011:90345011:9035
5012:90305012:90315012:90325012:90335012:90345012:9035
3001:90363001:90373001:90383001:90393001:90403001:9041
3002:90363002:90373002:90383002:90393002:90403002:9041
3003:90363003:90373003:90383003:90393003:90403003:9041
3004:90363004:90373004:90383004:90393004:90403004:9041
3005:90363005:90373005:90383005:90393005:90403005:9041
3006:90363006:90373006:90383006:90393006:90403006:9041
3007:90363007:90373007:90383007:90393007:90403007:9041
3008:90363008:90373008:90383008:90393008:90403008:9041
3009:90363009:90373009:90383009:90393009:90403009:9041
3010:90363010:90373010:90383010:90393010:90403010:9041
3011:90363011:90373011:90383011:90393011:90403011:9041
3012:90363012:90373012:90383012:90393012:90403012:9041
3013:90363013:90373013:90383013:90393013:90403013:9041
3014:90363014:90373014:90383014:90393014:90403014:9041
4001:90364001:90374001:90384001:90394001:90404001:9041
4002:90364002:90374002:90384002:90394002:90404002:9041
4003:90364003:90374003:90384003:90394003:90404003:9041
4004:90364004:90374004:90384004:90394004:90404004:9041
4005:90364005:90374005:90384005:90394005:90404005:9041
4006:90364006:90374006:90384006:90394006:90404006:9041
4007:90364007:90374007:90384007:90394007:90404007:9041
4008:90364008:90374008:90384008:90394008:90404008:9041
4009:90364009:90374009:90384009:90394009:90404009:9041
4010:90364010:90374010:90384010:90394010:90404010:9041
4011:90364011:90374011:90384011:90394011:90404011:9041
4012:90364012:90374012:90384012:90394012:90404012:9041
5001:90365001:90375001:90385001:90395001:90405001:9041
5002:90365002:90375002:90385002:90395002:90405002:9041
5003:90365003:90375003:90385003:90395003:90405003:9041
5004:90365004:90375004:90385004:90395004:90405004:9041
5005:90365005:90375005:90385005:90395005:90405005:9041
5006:90365006:90375006:90385006:90395006:90405006:9041
5007:90365007:90375007:90385007:90395007:90405007:9041
5008:90365008:90375008:90385008:90395008:90405008:9041
5009:90365009:90375009:90385009:90395009:90405009:9041
5010:90365010:90375010:90385010:90395010:90405010:9041
5011:90365011:90375011:90385011:90395011:90405011:9041
5012:90365012:90375012:90385012:90395012:90405012:9041
3001:90423001:90433001:90443001:90453001:90463001:9047
3002:90423002:90433002:90443002:90453002:90463002:9047
3003:90423003:90433003:90443003:90453003:90463003:9047
3004:90423004:90433004:90443004:90453004:90463004:9047
3005:90423005:90433005:90443005:90453005:90463005:9047
3006:90423006:90433006:90443006:90453006:90463006:9047
3007:90423007:90433007:90443007:90453007:90463007:9047
3008:90423008:90433008:90443008:90453008:90463008:9047
3009:90423009:90433009:90443009:90453009:90463009:9047
3010:90423010:90433010:90443010:90453010:90463010:9047
3011:90423011:90433011:90443011:90453011:90463011:9047
3012:90423012:90433012:90443012:90453012:90463012:9047
3013:90423013:90433013:90443013:90453013:90463013:9047
3014:90423014:90433014:90443014:90453014:90463014:9047
4001:90424001:90434001:90444001:90454001:90464001:9047
4002:90424002:90434002:90444002:90454002:90464002:9047
4003:90424003:90434003:90444003:90454003:90464003:9047
4004:90424004:90434004:90444004:90454004:90464004:9047
4005:90424005:90434005:90444005:90454005:90464005:9047
4006:90424006:90434006:90444006:90454006:90464006:9047
4007:90424007:90434007:90444007:90454007:90464007:9047
4008:90424008:90434008:90444008:90454008:90464008:9047
4009:90424009:90434009:90444009:90454009:90464009:9047
4010:90424010:90434010:90444010:90454010:90464010:9047
4011:90424011:90434011:90444011:90454011:90464011:9047
4012:90424012:90434012:90444012:90454012:90464012:9047
5001:90425001:90435001:90445001:90455001:90465001:9047
5002:90425002:90435002:90445002:90455002:90465002:9047
5003:90425003:90435003:90445003:90455003:90465003:9047
5004:90425004:90435004:90445004:90455004:90465004:9047
5005:90425005:90435005:90445005:90455005:90465005:9047
5006:90425006:90435006:90445006:90455006:90465006:9047
5007:90425007:90435007:90445007:90455007:90465007:9047
5008:90425008:90435008:90445008:90455008:90465008:9047
5009:90425009:90435009:90445009:90455009:90465009:9047
5010:90425010:90435010:90445010:90455010:90465010:9047
5011:90425011:90435011:90445011:90455011:90465011:9047
5012:90425012:90435012:90445012:90455012:90465012:9047
3001:90483001:90493001:90503001:90513001:90523001:9053
3002:90483002:90493002:90503002:90513002:90523002:9053
3003:90483003:90493003:90503003:90513003:90523003:9053
3004:90483004:90493004:90503004:90513004:90523004:9053
3005:90483005:90493005:90503005:90513005:90523005:9053
3006:90483006:90493006:90503006:90513006:90523006:9053
3007:90483007:90493007:90503007:90513007:90523007:9053
3008:90483008:90493008:90503008:90513008:90523008:9053
3009:90483009:90493009:90503009:90513009:90523009:9053
3010:90483010:90493010:90503010:90513010:90523010:9053
3011:90483011:90493011:90503011:90513011:90523011:9053
3012:90483012:90493012:90503012:90513012:90523012:9053
3013:90483013:90493013:90503013:90513013:90523013:9053
3014:90483014:90493014:90503014:90513014:90523014:9053
4001:90484001:90494001:90504001:90514001:90524001:9053
4002:90484002:90494002:90504002:90514002:90524002:9053
4003:90484003:90494003:90504003:90514003:90524003:9053
4004:90484004:90494004:90504004:90514004:90524004:9053
4005:90484005:90494005:90504005:90514005:90524005:9053
4006:90484006:90494006:90504006:90514006:90524006:9053
4007:90484007:90494007:90504007:90514007:90524007:9053
4008:90484008:90494008:90504008:90514008:90524008:9053
4009:90484009:90494009:90504009:90514009:90524009:9053
4010:90484010:90494010:90504010:90514010:90524010:9053
4011:90484011:90494011:90504011:90514011:90524011:9053
4012:90484012:90494012:90504012:90514012:90524012:9053
5001:90485001:90495001:90505001:90515001:90525001:9053
5002:90485002:90495002:90505002:90515002:90525002:9053
5003:90485003:90495003:90505003:90515003:90525003:9053
5004:90485004:90495004:90505004:90515004:90525004:9053
5005:90485005:90495005:90505005:90515005:90525005:9053
5006:90485006:90495006:90505006:90515006:90525006:9053
5007:90485007:90495007:90505007:90515007:90525007:9053
5008:90485008:90495008:90505008:90515008:90525008:9053
5009:90485009:90495009:90505009:90515009:90525009:9053
5010:90485010:90495010:90505010:90515010:90525010:9053
5011:90485011:90495011:90505011:90515011:90525011:9053
5012:90485012:90495012:90505012:90515012:90515012:9053
3001:90543001:90553001:90563001:90573001:90583001:9059
3002:90543002:90553002:90563002:90573002:90583002:9059
3003:90543003:90553003:90563003:90573003:90583003:9059
3004:90543004:90553004:90563004:90573004:90583004:9059
3005:90543005:90553005:90563005:90573005:90583005:9059
3006:90543006:90553006:90563006:90573006:90583006:9059
3007:90543007:90553007:90563007:90573007:90583007:9059
3008:90543008:90553008:90563008:90573008:90583008:9059
3009:90543009:90553009:90563009:90573009:90583009:9059
3010:90543010:90553010:90563010:90573010:90583010:9059
3011:90543011:90553011:90563011:90573011:90583011:9059
3012:90543012:90553012:90563012:90573012:90583012:9059
3013:90543013:90553013:90563013:90573013:90583013:9059
3014:90543014:90553014:90563014:90573014:90583014:9059
4001:90544001:90554001:90564001:90574001:90584001:9059
4002:90544002:90554002:90564002:90574002:90584002:9059
4003:90544003:90554003:90564003:90574003:90584003:9059
4004:90544004:90554004:90564004:90574004:90584004:9059
4005:90544005:90554005:90564005:90574005:90584005:9059
4006:90544006:90554006:90564006:90574006:90584006:9059
4007:90544007:90554007:90564007:90574007:90584007:9059
4008:90544008:90554008:90564008:90574008:90584008:9059
4009:90544009:90554009:90564009:90574009:90584009:9059
4010:90544010:90554010:90564010:90574010:90584010:9059
4011:90544011:90554011:90564011:90574011:90584011:9059
4012:90544012:90554012:90564012:90574012:90584012:9059
5001:90545001:90555001:90565001:90575001:90585001:9059
5002:90545002:90555002:90565002:90575002:90585002:9059
5003:90545003:90555003:90565003:90575003:90585003:9059
5004:90545004:90555004:90565004:90575004:90585004:9059
5005:90545005:90555005:90565005:90575005:90585005:9059
5006:90545006:90555006:90565006:90575006:90585006:9059
5007:90545007:90555007:90565007:90575007:90585007:9059
5008:90545008:90555008:90565008:90575008:90585008:9059
5009:90545009:90555009:90565009:90575009:90585009:9059
5010:90545010:90555010:90565010:90575010:90585010:9059
5011:90545011:90555011:90565011:90575011:90585011:9059
5012:90545012:90555012:90565012:90575012:90585012:9059
3001:90603001:90613001:90623001:90633001:90643001:9065
3002:90603002:90613002:90623002:90633002:90643002:9065
3003:90603003:90613003:90623003:90633003:90643003:9065
3004:90603004:90613004:90623004:90633004:90643004:9065
3005:90603005:90613005:90623005:90633005:90643005:9065
3006:90603006:90613006:90623006:90633006:90643006:9065
3007:90603007:90613007:90623007:90633007:90643007:9065
3008:90603008:90613008:90623008:90633008:90643008:9065
3009:90603009:90613009:90623009:90633009:90643009:9065
3010:90603010:90613010:90623010:90633010:90643010:9065
3011:90603011:90613011:90623011:90633011:90643011:9065
3012:90603012:90613012:90623012:90633012:90643012:9065
3013:90603013:90613013:90623013:90633013:90643013:9065
3014:90603014:90613014:90623014:90633014:90643014:9065
4001:90604001:90614001:90624001:90634001:90644001:9065
4002:90604002:90614002:90624002:90634002:90644002:9065
4003:90604003:90614003:90624003:90634003:90644003:9065
4004:90604004:90614004:90624004:90634004:90644004:9065
4005:90604005:90614005:90624005:90634005:90644005:9065
4006:90604006:90614006:90624006:90634006:90644006:9065
4007:90604007:90614007:90624007:90634007:90644007:9065
4008:90604008:90614008:90624008:90634008:90644008:9065
4009:90604009:90614009:90624009:90634009:90644009:9065
4010:90604010:90614010:90624010:90634010:90644010:9065
4011:90604011:90614011:90624011:90634011:90644011:9065
4012:90604012:90614012:90624012:90634012:90644012:9065
5001:90605001:90615001:90625001:90635001:90645001:9065
5002:90605002:90615002:90625002:90635002:90645002:9065
5003:90605003:90615003:90625003:90635003:90645003:9065
5004:90605004:90615004:90625004:90635004:90645004:9065
5005:90605005:90615005:90625005:90635005:90645005:9065
5006:90605006:90615006:90625006:90635006:90645006:9065
5007:90605007:90615007:90625007:90635007:90645007:9065
5008:90605008:90615008:90625008:90635008:90645008:9065
5009:90605009:90615009:90625009:90635009:90645009:9065
5010:90605010:90615010:90625010:90635010:90645010:9065
5011:90605011:90615011:90625011:90635011:90645011:9065
5012:90605012:90615012:90625012:90635012:90645012:9065
3001:90663001:90673001:90683001:90693001:90703001:9071
3002:90663002:90673002:90683002:90693002:90703002:9071
3003:90663003:90673003:90683003:90693003:90703003:9071
3004:90663004:90673004:90683004:90693004:90703004:9071
3005:90663005:90673005:90683005:90693005:90703005:9071
3006:90663006:90673006:90683006:90693006:90703006:9071
3007:90663007:90673007:90683007:90693007:90703007:9071
3008:90663008:90673008:90683008:90693008:90703008:9071
3009:90663009:90673009:90683009:90693009:90703009:9071
3010:90663010:90673010:90683010:90693010:90703010:9071
3011:90663011:90673011:90683011:90693011:90703011:9071
3012:90663012:90673012:90683012:90693012:90703012:9071
3013:90663013:90673013:90683013:90693013:90703013:9071
3014:90663014:90673014:90683014:90693014:90703014:9071
4001:90664001:90674001:90684001:90694001:90704001:9071
4002:90664002:90674002:90684002:90694002:90704002:9071
4003:90664003:90674003:90684003:90694003:90704003:9071
4004:90664004:90674004:90684004:90694004:90704004:9071
4005:90664005:90674005:90684005:90694005:90704005:9071
4006:90664006:90674006:90684006:90694006:90704006:9071
4007:90664007:90674007:90684007:90694007:90704007:9071
4008:90664008:90674008:90684008:90694008:90704008:9071
4009:90664009:90674009:90684009:90694009:90704009:9071
4010:90664010:90674010:90684010:90694010:90704010:9071
4011:90664011:90674011:90684011:90694011:90704011:9071
4012:90664012:90674012:90684012:90694012:90704012:9071
5001:90665001:90675001:90685001:90695001:90705001:9071
5002:90665002:90675002:90685002:90695002:90705002:9071
5003:90665003:90675003:90685003:90695003:90705003:9071
5004:90665004:90675004:90685004:90695004:90705004:9071
5005:90665005:90675005:90685005:90695005:90705005:9071
5006:90665006:90675006:90685006:90695006:90705006:9071
5007:90665007:90675007:90685007:90695007:90705007:9071
5008:90665008:90675008:90685008:90695008:90705008:9071
5009:90665009:90675009:90685009:90695009:90705009:9071
5010:90665010:90675010:90685010:90695010:90705010:9071
5011:90665011:90675011:90685011:90695011:90705011:9071
5012:90665012:90675012:90685012:90695012:90705012:9071
3001:90723001:90733001:90743001:90753001:90763001:9077
3002:90723002:90733002:90743002:90753002:90763002:9077
3003:90723003:90733003:90743003:90753003:90763003:9077
3004:90723004:90733004:90743004:90753004:90763004:9077
3005:90723005:90733005:90743005:90753005:90763005:9077
3006:90723006:90733006:90743006:90753006:90763006:9077
3007:90723007:90733007:90743007:90753007:90763007:9077
3008:90723008:90733008:90743008:90753008:90763008:9077
3009:90723009:90733009:90743009:90753009:90763009:9077
3010:90723010:90733010:90743010:90753010:90763010:9077
3011:90723011:90733011:90743011:90753011:90763011:9077
3012:90723012:90733012:90743012:90753012:90763012:9077
3013:90723013:90733013:90743013:90753013:90763013:9077
3014:90723014:90733014:90743014:90753014:90763014:9077
4001:90724001:90734001:90744001:90754001:90764001:9077
4002:90724002:90734002:90744002:90754002:90764002:9077
4003:90724003:90734003:90744003:90754003:90764003:9077
4004:90724004:90734004:90744004:90754004:90764004:9077
4005:90724005:90734005:90744005:90754005:90764005:9077
4006:90724006:90734006:90744006:90754006:90764006:9077
4007:90724007:90734007:90744007:90754007:90764007:9077
4008:90724008:90734008:90744008:90754008:90764008:9077
4009:90724009:90734009:90744009:90754009:90764009:9077
4010:90724010:90734010:90744010:90754010:90764010:9077
4011:90724011:90734011:90744011:90754011:90764011:9077
4012:90724012:90734012:90744012:90754012:90764012:9077
5001:90725001:90735001:90745001:90755001:90765001:9077
5002:90725002:90735002:90745002:90755002:90765002:9077
5003:90725003:90735003:90745003:90755003:90765003:9077
5004:90725004:90735004:90745004:90755004:90765004:9077
5005:90725005:90735005:90745005:90755005:90765005:9077
5006:90725006:90735006:90745006:90755006:90765006:9077
5007:90725007:90735007:90745007:90755007:90765007:9077
5008:90725008:90735008:90745008:90755008:90765008:9077
5009:90725009:90735009:90745009:90755009:90765009:9077
5010:90725010:90735010:90745010:90755010:90765010:9077
5011:90725011:90735011:90745011:90755011:90765011:9077
5012:90725012:90735012:90745012:90755012:90765012:9077
3001:90783001:90793001:90803001:90813001:90823001:9083
3002:90783002:90793002:90803002:90813002:90823002:9083
3003:90783003:90793003:90803003:90813003:90823003:9083
3004:90783004:90793004:90803004:90813004:90823004:9083
3005:90783005:90793005:90803005:90813005:90823005:9083
3006:90783006:90793006:90803006:90813006:90823006:9083
3007:90783007:90793007:90803007:90813007:90823007:9083
3008:90783008:90793008:90803008:90813008:90823008:9083
3009:90783009:90793009:90803009:90813009:90823009:9083
3010:90783010:90793010:90803010:90813010:90823010:9083
3011:90783011:90793011:90803011:90813011:90823011:9083
3012:90783012:90793012:90803012:90813012:90823012:9083
3013:90783013:90793013:90803013:90813013:90823013:9083
3014:90783014:90793014:90803014:90813014:90823014:9083
4001:90784001:90794001:90804001:90814001:90824001:9083
4002:90784002:90794002:90804002:90814002:90824002:9083
4003:90784003:90794003:90804003:90814003:90824003:9083
4004:90784004:90794004:90804004:90814004:90824004:9083
4005:90784005:90794005:90804005:90814005:90824005:9083
4006:90784006:90794006:90804006:90814006:90824006:9083
4007:90784007:90794007:90804007:90814007:90824007:9083
4008:90784008:90794008:90804008:90814008:90824008:9083
4009:90784009:90794009:90804009:90814009:90824009:9083
4010:90784010:90794010:90804010:90814010:90824010:9083
4011:90784011:90794011:90804011:90814011:90824011:9083
4012:90784012:90794012:90804012:90814012:90824012:9083
5001:90785001:90795001:90805001:90815001:90825001:9083
5002:90785002:90795002:90805002:90815002:90825002:9083
5003:90785003:90795003:90805003:90815003:90825003:9083
5004:90785004:90795004:90805004:90815004:90825004:9083
5005:90785005:90795005:90805005:90815005:90825005:9083
5006:90785006:90795006:90805006:90815006:90825006:9083
5007:90785007:90795007:90805007:90815007:90825007:9083
5008:90785008:90795008:90805008:90815008:90825008:9083
5009:90785009:90795009:90805009:90815009:90825009:9083
5010:90785010:90795010:90805010:90815010:90825010:9083
5011:90785011:90795011:90805011:90815011:90825011:9083
5012:90785012:90795012:90805012:90815012:90825012:9083
3001:90843001:90853001:90863001:90873001:90883001:9089
3002:90843002:90853002:90863002:90873002:90883002:9089
3003:90843003:90853003:90863003:90873003:90883003:9089
3004:90843004:90853004:90863004:90873004:90883004:9089
3005:90843005:90853005:90863005:90873005:90883005:9089
3006:90843006:90853006:90863006:90873006:90883006:9089
3007:90843007:90853007:90863007:90873007:90883007:9089
3008:90843008:90853008:90863008:90873008:90883008:9089
3009:90843009:90853009:90863009:90873009:90883009:9089
3010:90843010:90853010:90863010:90873010:90883010:9089
3011:90843011:90853011:90863011:90873011:90883011:9089
3012:90843012:90853012:90863012:90873012:90883012:9089
3013:90843013:90853013:90863013:90873013:90883013:9089
3014:90843014:90853014:90863014:90873014:90883014:9089
4001:90844001:90854001:90864001:90874001:90884001:9089
4002:90844002:90854002:90864002:90874002:90884002:9089
4003:90844003:90854003:90864003:90874003:90884003:9089
4004:90844004:90854004:90864004:90874004:90884004:9089
4005:90844005:90854005:90864005:90874005:90884005:9089
4006:90844006:90854006:90864006:90874006:90884006:9089
4007:90844007:90854007:90864007:90874007:90884007:9089
4008:90844008:90854008:90864008:90874008:90884008:9089
4009:90844009:90854009:90864009:90874009:90884009:9089
4010:90844010:90854010:90864010:90874010:90884010:9089
4011:90844011:90854011:90864011:90874011:90884011:9089
4012:90844012:90854012:90864012:90874012:90884012:9089
5001:90845001:90855001:90865001:90875001:90885001:9089
5002:90845002:90855002:90865002:90875002:90885002:9089
5003:90845003:90855003:90865003:90875003:90885003:9089
5004:90845004:90855004:90865004:90875004:90885004:9089
5005:90845005:90855005:90865005:90875005:90885005:9089
5006:90845006:90855006:90865006:90875006:90885006:9089
5007:90845007:90855007:90865007:90875007:90885007:9089
5008:90845008:90855008:90865008:90875008:90885008:9089
5009:90845009:90855009:90865009:90875009:90885009:9089
5010:90845010:90855010:90865010:90875010:90885010:9089
5011:90845011:90855011:90865011:90875011:90885011:9089
5012:90845012:90855012:90865012:90875012:90885012:9089
3001:90903001:90913001:90923001:90933001:90943001:9095
3002:90903002:90913002:90923002:90933002:90943002:9095
3003:90903003:90913003:90923003:90933003:90943003:9095
3004:90903004:90913004:90923004:90933004:90943004:9095
3005:90903005:90913005:90923005:90933005:90943005:9095
3006:90903006:90913006:90923006:90933006:90943006:9095
3007:90903007:90913007:90923007:90933007:90943007:9095
3008:90903008:90913008:90923008:90933008:90943008:9095
3009:90903009:90913009:90923009:90933009:90943009:9095
3010:90903010:90913010:90923010:90933010:90943010:9095
3011:90903011:90913011:90923011:90933011:90943011:9095
3012:90903012:90913012:90923012:90933012:90943012:9095
3013:90903013:90913013:90923013:90933013:90943013:9095
3014:90903014:90913014:90923014:90933014:90943014:9095
4001:90904001:90914001:90924001:90934001:90944001:9095
4002:90904002:90914002:90924002:90934002:90944002:9095
4003:90904003:90914003:90924003:90934003:90944003:9095
4004:90904004:90914004:90924004:90934004:90944004:9095
4005:90904005:90914005:90924005:90934005:90944005:9095
4006:90904006:90914006:90924006:90934006:90944006:9095
4007:90904007:90914007:90924007:90934007:90944007:9095
4008:90904008:90914008:90924008:90934008:90944008:9095
4009:90904009:90914009:90924009:90934009:90944009:9095
4010:90904010:90914010:90924010:90934010:90944010:9095
4011:90904011:90914011:90924011:90934011:90944011:9095
4012:90904012:90914012:90924012:90934012:90944012:9095
5001:90905001:90915001:90925001:90935001:90945001:9095
5002:90905002:90915002:90925002:90935002:90945002:9095
5003:90905003:90915003:90925003:90935003:90945003:9095
5004:90905004:90915004:90925004:90935004:90945004:9095
5005:90905005:90915005:90925005:90935005:90945005:9095
5006:90905006:90915006:90925006:90935006:90945006:9095
5007:90905007:90915007:90925007:90935007:90945007:9095
5008:90905008:90915008:90925008:90935008:90945008:9095
5009:90905009:90915009:90925009:90935009:90945009:9095
5010:90905010:90915010:90925010:90935010:90945010:9095
5011:90905011:90915011:90925011:90935011:90945011:9095
5012:90905012:90915012:90925012:90935012:90945012:9095
3001:90963001:90973001:90983001:90993001:91003001:9101
3002:90963002:90973002:90983002:90993002:91003002:9101
3003:90963003:90973003:90983003:90993003:91003003:9101
3004:90963004:90973004:90983004:90993004:91003004:9101
3005:90963005:90973005:90983005:90993005:91003005:9101
3006:90963006:90973006:90983006:90993006:91003006:9101
3007:90963007:90973007:90983007:90993007:91003007:9101
3008:90963008:90973008:90983008:90993008:91003008:9101
3009:90963009:90973009:90983009:90993009:91003009:9101
3010:90963010:90973010:90983010:90993010:91003010:9101
3011:90963011:90973011:90983011:90993011:91003011:9101
3012:90963012:90973012:90983012:90993012:91003012:9101
3013:90963013:90973013:90983013:90993013:91003013:9101
3014:90963014:90973014:90983014:90993014:91003014:9101
4001:90964001:90974001:90984001:90994001:91004001:9101
4002:90964002:90974002:90984002:90994002:91004002:9101
4003:90964003:90974003:90984003:90994003:91004003:9101
4004:90964004:90974004:90984004:90994004:91004004:9101
4005:90964005:90974005:90984005:90994005:91004005:9101
4006:90964006:90974006:90984006:90994006:91004006:9101
4007:90964007:90974007:90984007:90994007:91004007:9101
4008:90964008:90974008:90984008:90994008:91004008:9101
4009:90964009:90974009:90984009:90994009:91004009:9101
4010:90964010:90974010:90984010:90994010:91004010:9101
4011:90964011:90974011:90984011:90994011:91004011:9101
4012:90964012:90974012:90984012:90994012:91004012:9101
5001:90965001:90975001:90985001:90995001:91005001:9101
5002:90965002:90975002:90985002:90995002:91005002:9101
5003:90965003:90975003:90985003:90995003:91005003:9101
5004:90965004:90975004:90985004:90995004:91005004:9101
5005:90965005:90975005:90985005:90995005:91005005:9101
5006:90965006:90975006:90985006:90995006:91005006:9101
5007:90965007:90975007:90985007:90995007:91005007:9101
5008:90965008:90975008:90985008:90995008:91005008:9101
5009:90965009:90975009:90985009:90995009:91005009:9101
5010:90965010:90975010:90985010:90995010:91005010:9101
5011:90965011:90975011:90985011:90995011:91005011:9101
5012:90965012:90975012:90985012:90995012:91005012:9101
3001:91023001:91033001:91043001:9105——
3002:91023002:91033002:91043002:9105
3003:91023003:91033003:91043003:9105
3004:91023004:91033004:91043004:9105
3005:91023005:91033005:91043005:9105
3006:91023006:91033006:91043006:9105
3007:91023007:91033007:91043007:9105
3008:91023008:91033008:91043008:9105
3009:91023009:91033009:91043009:9105
3010:91023010:91033010:91043010:9105
3011:91023011:91033011:91043011:9105
3012:91023012:91033012:91043012:9105
3013:91023013:91033013:91043013:9105
3014:91023014:91033014:91043014:9105
4001:91024001:91034001:91044001:9105
4002:91024002:91034002:91044002:9105
4003:91024003:91034003:91044003:9105
4004:91024004:91034004:91044004:9105
4005:91024005:91034005:91044005:9105
4006:91024006:91034006:91044006:9105
4007:91024007:91034007:91044007:9105
4008:91024008:91034008:91044008:9105
4009:91024009:91034009:91044009:9105
4010:91024010:91034010:91044010:9105
4011:91024011:91034011:91044011:9105
4012:91024012:91034012:91044012:9105
5001:91025001:91035001:91045001:9105
5002:91025002:91035002:91045002:9105
5003:91025003:91035003:91045003:9105
5004:91025004:91035004:91045004:9105
5005:91025005:91035005:91045005:9105
5006:91025006:91035006:91045006:9105
5007:91025007:91035007:91045007:9105
5008:91025008:91035008:91045008:9105
5009:91025009:91035009:91045009:9105
5010:91025010:91035010:91045010:9105
5011:91025011:91035011:91045011:9105
5012:91025012:91035012:91045012:9105
TABLE C — Example combinations of a compound X with a compound Y.
X:YX:YX:YX:YX:YX:Y
9000:70009001:70009002:70009003:70009004:70009005:7000
9000:70019001:70019002:70019003:70019004:70019005:7001
9000:70029001:70029002:70029003:70029004:70029005:7002
9000:70039001:70039002:70039003:70039004:70039005:7003
9000:70049001:70049002:70049003:70049004:70049005:7004
9000:70059001:70059002:70059003:70059004:70059005:7005
9000:70069001:70069002:70069003:70069004:70069005:7006
9000:70079001:70079002:70079003:70079004:70079005:7007
9000:70089001:70089002:70089003:70089004:70089005:7008
9000:70099001:70099002:70099003:70099004:70099005:7009
9000:70109001:70109002:70109003:70109004:70109005:7010
9000:70119001:70119002:70119003:70119004:70119005:7011
9000:70129001:70129002:70129003:70129004:70129005:7012
9000:70139001:70139002:70139003:70139004:70139005:7013
9000:70149001:70149002:70149003:70149004:70149005:7014
9000:70159001:70159002:70159003:70159004:70159005:7015
9000:70169001:70169002:70169003:70169004:70169005:7016
9000:70179001:70179002:70179003:70179004:70179005:7017
9000:70189001:70189002:70189003:70189004:70189005:7018
9000:70199001:70199002:70199003:70199004:70199005:7019
9000:70209001:70209002:70209003:70209004:70209005:7020
9000:70219001:70219002:70219003:70219004:70219005:7021
9000:70229001:70229002:70229003:70229004:70229005:7022
9000:70239001:70239002:70239003:70239004:70239005:7023
9000:70249001:70249002:70249003:70249004:70249005:7024
9000:70259001:70259002:70259003:70259004:70259005:7025
9000:70269001:70269002:70269003:70269004:70269005:7026
9000:70279001:70279002:70279003:70279004:70279005:7027
9006:70009007:70009008:70009009:70009010:70009011:7000
9006:70019007:70019008:70019009:70019010:70019011:7001
9006:70029007:70029008:70029009:70029010:70029011:7002
9006:70039007:70039008:70039009:70039010:70039011:7003
9006:70049007:70049008:70049009:70049010:70049011:7004
9006:70059007:70059008:70059009:70059010:70059011:7005
9006:70069007:70069008:70069009:70069010:70069011:7006
9006:70079007:70079008:70079009:70079010:70079011:7007
9006:70089007:70089008:70089009:70089010:70089011:7008
9006:70099007:70099008:70099009:70099010:70099011:7009
9006:70109007:70109008:70109009:70109010:70109011:7010
9006:70119007:70119008:70119009:70119010:70119011:7011
9006:70129007:70129008:70129009:70129010:70129011:7012
9006:70139007:70139008:70139009:70139010:70139011:7013
9006:70149007:70149008:70149009:70149010:70149011:7014
9006:70159007:70159008:70159009:70159010:70159011:7015
9006:70169007:70169008:70169009:70169010:70169011:7016
9006:70179007:70179008:70179009:70179010:70179011:7017
9006:70189007:70189008:70189009:70189010:70189011:7018
9006:70199007:70199008:70199009:70199010:70199011:7019
9006:70209007:70209008:70209009:70209010:70209011:7020
9006:70219007:70219008:70219009:70219010:70219011:7021
9006:70229007:70229008:70229009:70229010:70229011:7022
9006:70239007:70239008:70239009:70239010:70239011:7023
9006:70249007:70249008:70249009:70249010:70249011:7024
9006:70259007:70259008:70259009:70259010:70259011:7025
9006:70269007:70269008:70269009:70269010:70269011:7026
9006:70279007:70279008:70279009:70279010:70279011:7027
9012:70009013:70009014:70009015:70009016:70009017:7000
9012:70019013:70019014:70019015:70019016:70019017:7001
9012:70029013:70029014:70029015:70029016:70029017:7002
9012:70039013:70039014:70039015:70039016:70039017:7003
9012:70049013:70049014:70049015:70049016:70049017:7004
9012:70059013:70059014:70059015:70059016:70059017:7005
9012:70069013:70069014:70069015:70069016:70069017:7006
9012:70079013:70079014:70079015:70079016:70079017:7007
9012:70089013:70089014:70089015:70089016:70089017:7008
9012:70099013:70099014:70099015:70099016:70099017:7009
9012:70109013:70109014:70109015:70109016:70109017:7010
9012:70119013:70119014:70119015:70119016:70119017:7011
9012:70129013:70129014:70129015:70129016:70129017:7012
9012:70139013:70139014:70139015:70139016:70139017:7013
9012:70149013:70149014:70149015:70149016:70149017:7014
9012:70159013:70159014:70159015:70159016:70159017:7015
9012:70169013:70169014:70169015:70169016:70169017:7016
9012:70179013:70179014:70179015:70179016:70179017:7017
9012:70189013:70189014:70189015:70189016:70189017:7018
9012:70199013:70199014:70199015:70199016:70199017:7019
9012:70209013:70209014:70209015:70209016:70209017:7020
9012:70219013:70219014:70219015:70219016:70219017:7021
9012:70229013:70229014:70229015:70229016:70229017:7022
9012:70239013:70239014:70239015:70239016:70239017:7023
9012:70249013:70249014:70249015:70249016:70249017:7024
9012:70259013:70259014:70259015:70259016:70259017:7025
9012:70269013:70269014:70269015:70269016:70269017:7026
9012:70279013:70279014:70279015:70279016:70279017:7027
9018:70009019:70009020:70009021:70009022:70009023:7000
9018:70019019:70019020:70019021:70019022:70019023:7001
9018:70029019:70029020:70029021:70029022:70029023:7002
9018:70039019:70039020:70039021:70039022:70039023:7003
9018:70049019:70049020:70049021:70049022:70049023:7004
9018:70059019:70059020:70059021:70059022:70059023:7005
9018:70069019:70069020:70069021:70069022:70069023:7006
9018:70079019:70079020:70079021:70079022:70079023:7007
9018:70089019:70089020:70089021:70089022:70089023:7008
9018:70099019:70099020:70099021:70099022:70099023:7009
9018:70109019:70109020:70109021:70109022:70109023:7010
9018:70119019:70119020:70119021:70119022:70119023:7011
9018:70129019:70129020:70129021:70129022:70129023:7012
9018:70139019:70139020:70139021:70139022:70139023:7013
9018:70149019:70149020:70149021:70149022:70149023:7014
9018:70159019:70159020:70159021:70159022:70159023:7015
9018:70169019:70169020:70169021:70169022:70169023:7016
9018:70179019:70179020:70179021:70179022:70179023:7017
9018:70189019:70189020:70189021:70189022:70189023:7018
9018:70199019:70199020:70199021:70199022:70199023:7019
9018:70209019:70209020:70209021:70209022:70209023:7020
9018:70219019:70219020:70219021:70219022:70219023:7021
9018:70229019:70229020:70229021:70229022:70229023:7022
9018:70239019:70239020:70239021:70239022:70239023:7023
9018:70249019:70249020:70249021:70249022:70249023:7024
9018:70259019:70259020:70259021:70259022:70259023:7025
9018:70269019:70269020:70269021:70269022:70269023:7026
9018:70279019:70279020:70279021:70279022:70279023:7027
9024:70009025:70009026:70009027:70009028:70009029:7000
9024:70019025:70019026:70019027:70019028:70019029:7001
9024:70029025:70029026:70029027:70029028:70029029:7002
9024:70039025:70039026:70039027:70039028:70039029:7003
9024:70049025:70049026:70049027:70049028:70049029:7004
9024:70059025:70059026:70059027:70059028:70059029:7005
9024:70069025:70069026:70069027:70069028:70069029:7006
9024:70079025:70079026:70079027:70079028:70079029:7007
9024:70089025:70089026:70089027:70089028:70089029:7008
9024:70099025:70099026:70099027:70099028:70099029:7009
9024:70109025:70109026:70109027:70109028:70109029:7010
9024:70119025:70119026:70119027:70119028:70119029:7011
9024:70129025:70129026:70129027:70129028:70129029:7012
9024:70139025:70139026:70139027:70139028:70139029:7013
9024:70149025:70149026:70149027:70149028:70149029:7014
9024:70159025:70159026:70159027:70159028:70159029:7015
9024:70169025:70169026:70169027:70169028:70169029:7016
9024:70179025:70179026:70179027:70179028:70179029:7017
9024:70189025:70189026:70189027:70189028:70189029:7018
9024:70199025:70199026:70199027:70199028:70199029:7019
9024:70209025:70209026:70209027:70209028:70209029:7020
9024:70219025:70219026:70219027:70219028:70219029:7021
9024:70229025:70229026:70229027:70229028:70229029:7022
9024:70239025:70239026:70239027:70239028:70239029:7023
9024:70249025:70249026:70249027:70249028:70249029:7024
9024:70259025:70259026:70259027:70259028:70259029:7025
9024:70269025:70269026:70269027:70269028:70269029:7026
9024:70279025:70279026:70279027:70279028:70279029:7027
9030:70009031:70009032:70009033:70009034:70009035:7000
9030:70019031:70019032:70019033:70019034:70019035:7001
9030:70029031:70029032:70029033:70029034:70029035:7002
9030:70039031:70039032:70039033:70039034:70039035:7003
9030:70049031:70049032:70049033:70049034:70049035:7004
9030:70059031:70059032:70059033:70059034:70059035:7005
9030:70069031:70069032:70069033:70069034:70069035:7006
9030:70079031:70079032:70079033:70079034:70079035:7007
9030:70089031:70089032:70089033:70089034:70089035:7008
9030:70099031:70099032:70099033:70099034:70099035:7009
9030:70109031:70109032:70109033:70109034:70109035:7010
9030:70119031:70119032:70119033:70119034:70119035:7011
9030:70129031:70129032:70129033:70129034:70129035:7012
9030:70139031:70139032:70139033:70139034:70139035:7013
9030:70149031:70149032:70149033:70149034:70149035:7014
9030:70159031:70159032:70159033:70159034:70159035:7015
9030:70169031:70169032:70169033:70169034:70169035:7016
9030:70179031:70179032:70179033:70179034:70179035:7017
9030:70189031:70189032:70189033:70189034:70189035:7018
9030:70199031:70199032:70199033:70199034:70199035:7019
9030:70209031:70209032:70209033:70209034:70209035:7020
9030:70219031:70219032:70219033:70219034:70219035:7021
9030:70229031:70229032:70229033:70229034:70229035:7022
9030:70239031:70239032:70239033:70239034:70239035:7023
9030:70249031:70249032:70249033:70249034:70249035:7024
9030:70259031:70259032:70259033:70259034:70259035:7025
9030:70269031:70269032:70269033:70269034:70269035:7026
9030:70279031:70279032:70279033:70279034:70279035:7027
9036:70009037:70009038:70009039:70009040:70009041:7000
9036:70019037:70019038:70019039:70019040:70019041:7001
9036:70029037:70029038:70029039:70029040:70029041:7002
9036:70039037:70039038:70039039:70039040:70039041:7003
9036:70049037:70049038:70049039:70049040:70049041:7004
9036:70059037:70059038:70059039:70059040:70059041:7005
9036:70069037:70069038:70069039:70069040:70069041:7006
9036:70079037:70079038:70079039:70079040:70079041:7007
9036:70089037:70089038:70089039:70089040:70089041:7008
9036:70099037:70099038:70099039:70099040:70099041:7009
9036:70109037:70109038:70109039:70109040:70109041:7010
9036:70119037:70119038:70119039:70119040:70119041:7011
9036:70129037:70129038:70129039:70129040:70129041:7012
9036:70139037:70139038:70139039:70139040:70139041:7013
9036:70149037:70149038:70149039:70149040:70149041:7014
9036:70159037:70159038:70159039:70159040:70159041:7015
9036:70169037:70169038:70169039:70169040:70169041:7016
9036:70179037:70179038:70179039:70179040:70179041:7017
9036:70189037:70189038:70189039:70189040:70189041:7018
9036:70199037:70199038:70199039:70199040:70199041:7019
9036:70209037:70209038:70209039:70209040:70209041:7020
9036:70219037:70219038:70219039:70219040:70219041:7021
9036:70229037:70229038:70229039:70229040:70229041:7022
9036:70239037:70239038:70239039:70239040:70239041:7023
9036:70249037:70249038:70249039:70249040:70249041:7024
9036:70259037:70259038:70259039:70259040:70259041:7025
9036:70269037:70269038:70269039:70269040:70269041:7026
9036:70279037:70279038:70279039:70279040:70279041:7027
9042:70009043:70009044:70009045:70009046:70009047:7000
9042:70019043:70019044:70019045:70019046:70019047:7001
9042:70029043:70029044:70029045:70029046:70029047:7002
9042:70039043:70039044:70039045:70039046:70039047:7003
9042:70049043:70049044:70049045:70049046:70049047:7004
9042:70059043:70059044:70059045:70059046:70059047:7005
9042:70069043:70069044:70069045:70069046:70069047:7006
9042:70079043:70079044:70079045:70079046:70079047:7007
9042:70089043:70089044:70089045:70089046:70089047:7008
9042:70099043:70099044:70099045:70099046:70099047:7009
9042:70109043:70109044:70109045:70109046:70109047:7010
9042:70119043:70119044:70119045:70119046:70119047:7011
9042:70129043:70129044:70129045:70129046:70129047:7012
9042:70139043:70139044:70139045:70139046:70139047:7013
9042:70149043:70149044:70149045:70149046:70149047:7014
9042:70159043:70159044:70159045:70159046:70159047:7015
9042:70169043:70169044:70169045:70169046:70169047:7016
9042:70179043:70179044:70179045:70179046:70179047:7017
9042:70189043:70189044:70189045:70189046:70189047:7018
9042:70199043:70199044:70199045:70199046:70199047:7019
9042:70209043:70209044:70209045:70209046:70209047:7020
9042:70219043:70219044:70219045:70219046:70219047:7021
9042:70229043:70229044:70229045:70229046:70229047:7022
9042:70239043:70239044:70239045:70239046:70239047:7023
9042:70249043:70249044:70249045:70249046:70249047:7024
9042:70259043:70259044:70259045:70259046:70259047:7025
9042:70269043:70269044:70269045:70269046:70269047:7026
9042:70279043:70279044:70279045:70279046:70279047:7027
9048:70009049:70009050:70009051:70009052:70009053:7000
9048:70019049:70019050:70019051:70019052:70019053:7001
9048:70029049:70029050:70029051:70029052:70029053:7002
9048:70039049:70039050:70039051:70039052:70039053:7003
9048:70049049:70049050:70049051:70049052:70049053:7004
9048:70059049:70059050:70059051:70059052:70059053:7005
9048:70069049:70069050:70069051:70069052:70069053:7006
9048:70079049:70079050:70079051:70079052:70079053:7007
9048:70089049:70089050:70089051:70089052:70089053:7008
9048:70099049:70099050:70099051:70099052:70099053:7009
9048:70109049:70109050:70109051:70109052:70109053:7010
9048:70119049:70119050:70119051:70119052:70119053:7011
9048:70129049:70129050:70129051:70129052:70129053:7012
9048:70139049:70139050:70139051:70139052:70139053:7013
9048:70149049:70149050:70149051:70149052:70149053:7014
9048:70159049:70159050:70159051:70159052:70159053:7015
9048:70169049:70169050:70169051:70169052:70169053:7016
9048:70179049:70179050:70179051:70179052:70179053:7017
9048:70189049:70189050:70189051:70189052:70189053:7018
9048:70199049:70199050:70199051:70199052:70199053:7019
9048:70209049:70209050:70209051:70209052:70209053:7020
9048:70219049:70219050:70219051:70219052:70219053:7021
9048:70229049:70229050:70229051:70229052:70229053:7022
9048:70239049:70239050:70239051:70239052:70239053:7023
9048:70249049:70249050:70249051:70249052:70249053:7024
9048:70259049:70259050:70259051:70259052:70259053:7025
9048:70269049:70269050:70269051:70269052:70269053:7026
9048:70279049:70279050:70279051:70279052:70279053:7027
9054:70009055:70009056:70009057:70009058:70009059:7000
9054:70019055:70019056:70019057:70019058:70019059:7001
9054:70029055:70029056:70029057:70029058:70029059:7002
9054:70039055:70039056:70039057:70039058:70039059:7003
9054:70049055:70049056:70049057:70049058:70049059:7004
9054:70059055:70059056:70059057:70059058:70059059:7005
9054:70069055:70069056:70069057:70069058:70069059:7006
9054:70079055:70079056:70079057:70079058:70079059:7007
9054:70089055:70089056:70089057:70089058:70089059:7008
9054:70099055:70099056:70099057:70099058:70099059:7009
9054:70109055:70109056:70109057:70109058:70109059:7010
9054:70119055:70119056:70119057:70119058:70119059:7011
9054:70129055:70129056:70129057:70129058:70129059:7012
9054:70139055:70139056:70139057:70139058:70139059:7013
9054:70149055:70149056:70149057:70149058:70149059:7014
9054:70159055:70159056:70159057:70159058:70159059:7015
9054:70169055:70169056:70169057:70169058:70169059:7016
9054:70179055:70179056:70179057:70179058:70179059:7017
9054:70189055:70189056:70189057:70189058:70189059:7018
9054:70199055:70199056:70199057:70199058:70199059:7019
9054:70209055:70209056:70209057:70209058:70209059:7020
9054:70219055:70219056:70219057:70219058:70219059:7021
9054:70229055:70229056:70229057:70229058:70229059:7022
9054:70239055:70239056:70239057:70239058:70239059:7023
9054:70249055:70249056:70249057:70249058:70249059:7024
9054:70259055:70259056:70259057:70259058:70259059:7025
9054:70269055:70269056:70269057:70269058:70269059:7026
9054:70279055:70279056:70279057:70279058:70279059:7027
9060:70009061:70009062:70009063:70009064:70009065:7000
9060:70019061:70019062:70019063:70019064:70019065:7001
9060:70029061:70029062:70029063:70029064:70029065:7002
9060:70039061:70039062:70039063:70039064:70039065:7003
9060:70049061:70049062:70049063:70049064:70049065:7004
9060:70059061:70059062:70059063:70059064:70059065:7005
9060:70069061:70069062:70069063:70069064:70069065:7006
9060:70079061:70079062:70079063:70079064:70079065:7007
9060:70089061:70089062:70089063:70089064:70089065:7008
9060:70099061:70099062:70099063:70099064:70099065:7009
9060:70109061:70109062:70109063:70109064:70109065:7010
9060:70119061:70119062:70119063:70119064:70119065:7011
9060:70129061:70129062:70129063:70129064:70129065:7012
9060:70139061:70139062:70139063:70139064:70139065:7013
9060:70149061:70149062:70149063:70149064:70149065:7014
9060:70159061:70159062:70159063:70159064:70159065:7015
9060:70169061:70169062:70169063:70169064:70169065:7016
9060:70179061:70179062:70179063:70179064:70179065:7017
9060:70189061:70189062:70189063:70189064:70189065:7018
9060:70199061:70199062:70199063:70199064:70199065:7019
9060:70209061:70209062:70209063:70209064:70209065:7020
9060:70219061:70219062:70219063:70219064:70219065:7021
9060:70229061:70229062:70229063:70229064:70229065:7022
9060:70239061:70239062:70239063:70239064:70239065:7023
9060:70249061:70249062:70249063:70249064:70249065:7024
9060:70259061:70259062:70259063:70259064:70259065:7025
9060:70269061:70269062:70269063:70269064:70269065:7026
9060:70279061:70279062:70279063:70279064:70279065:7027
9066:70009067:70009068:70009069:70009070:70009071:7000
9066:70019067:70019068:70019069:70019070:70019071:7001
9066:70029067:70029068:70029069:70029070:70029071:7002
9066:70039067:70039068:70039069:70039070:70039071:7003
9066:70049067:70049068:70049069:70049070:70049071:7004
9066:70059067:70059068:70059069:70059070:70059071:7005
9066:70069067:70069068:70069069:70069070:70069071:7006
9066:70079067:70079068:70079069:70079070:70079071:7007
9066:70089067:70089068:70089069:70089070:70089071:7008
9066:70099067:70099068:70099069:70099070:70099071:7009
9066:70109067:70109068:70109069:70109070:70109071:7010
9066:70119067:70119068:70119069:70119070:70119071:7011
9066:70129067:70129068:70129069:70129070:70129071:7012
9066:70139067:70139068:70139069:70139070:70139071:7013
9066:70149067:70149068:70149069:70149070:70149071:7014
9066:70159067:70159068:70159069:70159070:70159071:7015
9066:70169067:70169068:70169069:70169070:70169071:7016
9066:70179067:70179068:70179069:70179070:70179071:7017
9066:70189067:70189068:70189069:70189070:70189071:7018
9066:70199067:70199068:70199069:70199070:70199071:7019
9066:70209067:70209068:70209069:70209070:70209071:7020
9066:70219067:70219068:70219069:70219070:70219071:7021
9066:70229067:70229068:70229069:70229070:70229071:7022
9066:70239067:70239068:70239069:70239070:70239071:7023
9066:70249067:70249068:70249069:70249070:70249071:7024
9066:70259067:70259068:70259069:70259070:70259071:7025
9066:70269067:70269068:70269069:70269070:70269071:7026
9066:70279067:70279068:70279069:70279070:70279071:7027
9072:70009073:70009074:70009075:70009076:70009077:7000
9072:70019073:70019074:70019075:70019076:70019077:7001
9072:70029073:70029074:70029075:70029076:70029077:7002
9072:70039073:70039074:70039075:70039076:70039077:7003
9072:70049073:70049074:70049075:70049076:70049077:7004
9072:70059073:70059074:70059075:70059076:70059077:7005
9072:70069073:70069074:70069075:70069076:70069077:7006
9072:70079073:70079074:70079075:70079076:70079077:7007
9072:70089073:70089074:70089075:70089076:70089077:7008
9072:70099073:70099074:70099075:70099076:70099077:7009
9072:70109073:70109074:70109075:70109076:70109077:7010
9072:70119073:70119074:70119075:70119076:70119077:7011
9072:70129073:70129074:70129075:70129076:70129077:7012
9072:70139073:70139074:70139075:70139076:70139077:7013
9072:70149073:70149074:70149075:70149076:70149077:7014
9072:70159073:70159074:70159075:70159076:70159077:7015
9072:70169073:70169074:70169075:70169076:70169077:7016
9072:70179073:70179074:70179075:70179076:70179077:7017
9072:70189073:70189074:70189075:70189076:70189077:7018
9072:70199073:70199074:70199075:70199076:70199077:7019
9072:70209073:70209074:70209075:70209076:70209077:7020
9072:70219073:70219074:70219075:70219076:70219077:7021
9072:70229073:70229074:70229075:70229076:70229077:7022
9072:70239073:70239074:70239075:70239076:70239077:7023
9072:70249073:70249074:70249075:70249076:70249077:7024
9072:70259073:70259074:70259075:70259076:70259077:7025
9072:70269073:70269074:70269075:70269076:70269077:7026
9072:70279073:70279074:70279075:70279076:70279077:7027
9078:70009079:70009080:70009081:70009082:70009083:7000
9078:70019079:70019080:70019081:70019082:70019083:7001
9078:70029079:70029080:70029081:70029082:70029083:7002
9078:70039079:70039080:70039081:70039082:70039083:7003
9078:70049079:70049080:70049081:70049082:70049083:7004
9078:70059079:70059080:70059081:70059082:70059083:7005
9078:70069079:70069080:70069081:70069082:70069083:7006
9078:70079079:70079080:70079081:70079082:70079083:7007
9078:70089079:70089080:70089081:70089082:70089083:7008
9078:70099079:70099080:70099081:70099082:70099083:7009
9078:70109079:70109080:70109081:70109082:70109083:7010
9078:70119079:70119080:70119081:70119082:70119083:7011
9078:70129079:70129080:70129081:70129082:70129083:7012
9078:70139079:70139080:70139081:70139082:70139083:7013
9078:70149079:70149080:70149081:70149082:70149083:7014
9078:70159079:70159080:70159081:70159082:70159083:7015
9078:70169079:70169080:70169081:70169082:70169083:7016
9078:70179079:70179080:70179081:70179082:70179083:7017
9078:70189079:70189080:70189081:70189082:70189083:7018
9078:70199079:70199080:70199081:70199082:70199083:7019
9078:70209079:70209080:70209081:70209082:70209083:7020
9078:70219079:70219080:70219081:70219082:70219083:7021
9078:70229079:70229080:70229081:70229082:70229083:7022
9078:70239079:70239080:70239081:70239082:70239083:7023
9078:70249079:70249080:70249081:70249082:70249083:7024
9078:70259079:70259080:70259081:70259082:70259083:7025
9078:70269079:70269080:70269081:70269082:70269083:7026
9078:70279079:70279080:70279081:70279082:70279083:7027
9084:70009085:70009086:70009087:70009088:70009089:7000
9084:70019085:70019086:70019087:70019088:70019089:7001
9084:70029085:70029086:70029087:70029088:70029089:7002
9084:70039085:70039086:70039087:70039088:70039089:7003
9084:70049085:70049086:70049087:70049088:70049089:7004
9084:70059085:70059086:70059087:70059088:70059089:7005
9084:70069085:70069086:70069087:70069088:70069089:7006
9084:70079085:70079086:70079087:70079088:70079089:7007
9084:70089085:70089086:70089087:70089088:70089089:7008
9084:70099085:70099086:70099087:70099088:70099089:7009
9084:70109085:70109086:70109087:70109088:70109089:7010
9084:70119085:70119086:70119087:70119088:70119089:7011
9084:70129085:70129086:70129087:70129088:70129089:7012
9084:70139085:70139086:70139087:70139088:70139089:7013
9084:70149085:70149086:70149087:70149088:70149089:7014
9084:70159085:70159086:70159087:70159088:70159089:7015
9084:70169085:70169086:70169087:70169088:70169089:7016
9084:70179085:70179086:70179087:70179088:70179089:7017
9084:70189085:70189086:70189087:70189088:70189089:7018
9084:70199085:70199086:70199087:70199088:70199089:7019
9084:70209085:70209086:70209087:70209088:70209089:7020
9084:70219085:70219086:70219087:70219088:70219089:7021
9084:70229085:70229086:70229087:70229088:70229089:7022
9084:70239085:70239086:70239087:70239088:70239089:7023
9084:70249085:70249086:70249087:70249088:70249089:7024
9084:70259085:70259086:70259087:70259088:70259089:7025
9084:70269085:70269086:70269087:70269088:70269089:7026
9084:70279085:70279086:70279087:70279088:70279089:7027
9090:70009091:70009092:70009093:70009094:70009095:7000
9090:70019091:70019092:70019093:70019094:70019095:7001
9090:70029091:70029092:70029093:70029094:70029095:7002
9090:70039091:70039092:70039093:70039094:70039095:7003
9090:70049091:70049092:70049093:70049094:70049095:7004
9090:70059091:70059092:70059093:70059094:70059095:7005
9090:70069091:70069092:70069093:70069094:70069095:7006
9090:70079091:70079092:70079093:70079094:70079095:7007
9090:70089091:70089092:70089093:70089094:70089095:7008
9090:70099091:70099092:70099093:70099094:70099095:7009
9090:70109091:70109092:70109093:70109094:70109095:7010
9090:70119091:70119092:70119093:70119094:70119095:7011
9090:70129091:70129092:70129093:70129094:70129095:7012
9090:70139091:70139092:70139093:70139094:70139095:7013
9090:70149091:70149092:70149093:70149094:70149095:7014
9090:70159091:70159092:70159093:70159094:70159095:7015
9090:70169091:70169092:70169093:70169094:70169095:7016
9090:70179091:70179092:70179093:70179094:70179095:7017
9090:70189091:70189092:70189093:70189094:70189095:7018
9090:70199091:70199092:70199093:70199094:70199095:7019
9090:70209091:70209092:70209093:70209094:70209095:7020
9090:70219091:70219092:70219093:70219094:70219095:7021
9090:70229091:70229092:70229093:70229094:70229095:7022
9090:70239091:70239092:70239093:70239094:70239095:7023
9090:70249091:70249092:70249093:70249094:70249095:7024
9090:70259091:70259092:70259093:70259094:70259095:7025
9090:70269091:70269092:70269093:70269094:70269095:7026
9090:70279091:70279092:70279093:70279094:70279095:7027
9096:70009097:70009098:70009099:70009100:70009101:7000
9096:70019097:70019098:70019099:70019100:70019101:7001
9096:70029097:70029098:70029099:70029100:70029101:7002
9096:70039097:70039098:70039099:70039100:70039101:7003
9096:70049097:70049098:70049099:70049100:70049101:7004
9096:70059097:70059098:70059099:70059100:70059101:7005
9096:70069097:70069098:70069099:70069100:70069101:7006
9096:70079097:70079098:70079099:70079100:70079101:7007
9096:70089097:70089098:70089099:70089100:70089101:7008
9096:70099097:70099098:70099099:70099100:70099101:7009
9096:70109097:70109098:70109099:70109100:70109101:7010
9096:70119097:70119098:70119099:70119100:70119101:7011
9096:70129097:70129098:70129099:70129100:70129101:7012
9096:70139097:70139098:70139099:70139100:70139101:7013
9096:70149097:70149098:70149099:70149100:70149101:7014
9096:70159097:70159098:70159099:70159100:70159101:7015
9096:70169097:70169098:70169099:70169100:70169101:7016
9096:70179097:70179098:70179099:70179100:70179101:7017
9096:70189097:70189098:70189099:70189100:70189101:7018
9096:70199097:70199098:70199099:70199100:70199101:7019
9096:70209097:70209098:70209099:70209100:70209101:7020
9096:70219097:70219098:70219099:70219100:70219101:7021
9096:70229097:70229098:70229099:70229100:70229101:7022
9096:70239097:70239098:70239099:70239100:70239101:7023
9096:70249097:70249098:70249099:70249100:70249101:7024
9096:70259097:70259098:70259099:70259100:70259101:7025
9096:70269097:70269098:70269099:70269100:70269101:7026
9096:70279097:70279098:70279099:70279100:70279101:7027
9102:70009103:70009104:70009105:7000——
9102:70019103:70019104:70019105:7001
9102:70029103:70029104:70029105:7002
9102:70039103:70039104:70039105:7003
9102:70049103:70049104:70049105:7004
9102:70059103:70059104:70059105:7005
9102:70069103:70069104:70069105:7006
9102:70079103:70079104:70079105:7007
9102:70089103:70089104:70089105:7008
9102:70099103:70099104:70099105:7009
9102:70109103:70109104:70109105:7010
9102:70119103:70119104:70119105:7011
9102:70129103:70129104:70129105:7012
9102:70139103:70139104:70139105:7013
9102:70149103:70149104:70149105:7014
9102:70159103:70159104:70159105:7015
9102:70169103:70169104:70169105:7016
9102:70179103:70179104:70179105:7017
9102:70189103:70189104:70189105:7018
9102:70199103:70199104:70199105:7019
9102:70209103:70209104:70209105:7020
9102:70219103:70219104:70219105:7021
9102:70229103:70229104:70229105:7022
9102:70239103:70239104:70239105:7023
9102:70249103:70249104:70249105:7024
9102:70259103:70259104:70259105:7025
9102:70269103:70269104:70269105:7026
9102:70279103:70279104:70279105:7027
TABLE D
Example combinations of a compound X with a compound Y.
X:YX:YX:YX:YX:YX:Y
6000:90006040:90006000:90016040:90016000:90026040:9002
6001:90006041:90006001:90016041:90016001:90026041:9002
6002:90006042:90006002:90016042:90016002:90026042:9002
6003:90006043:90006003:90016043:90016003:90026043:9002
6004:90006044:90006004:90016044:90016004:90026044:9002
6005:90006045:90006005:90016045:90016005:90026045:9002
6006:90006046:90006006:90016046:90016006:90026046:9002
6007:90006047:90006007:90016047:90016007:90026047:9002
6008:90006048:90006008:90016048:90016008:90026048:9002
6009:90006049:90006009:90016049:90016009:90026049:9002
6010:90006050:90006010:90016050:90016010:90026050:9002
6011:90006051:90006011:90016051:90016011:90026051:9002
6012:90006052:90006012:90016052:90016012:90026052:9002
6013:90006053:90006013:90016053:90016013:90026053:9002
6014:90006054:90006014:90016054:90016014:90026054:9002
6015:90006055:90006015:90016055:90016015:90026055:9002
6016:90006056:90006016:90016056:90016016:90026056:9002
6017:90006057:90006017:90016057:90016017:90026057:9002
6018:90006058:90006018:90016058:90016018:90026058:9002
6019:90006059:90006019:90016059:90016019:90026059:9002
6020:90006060:90006020:90016060:90016020:90026060:9002
6021:90006061:90006021:90016061:90016021:90026061:9002
6022:90006062:90006022:90016062:90016022:90026062:9002
6023:90006063:90006023:90016063:90016023:90026063:9002
6024:90006064:90006024:90016064:90016024:90026064:9002
6025:90006065:90006025:90016065:90016025:90026065:9002
6026:90006066:90006026:90016066:90016026:90026066:9002
6027:90006067:90006027:90016067:90016027:90026067:9002
6028:90006068:90006028:90016068:90016028:90026068:9002
6029:90006069:90006029:90016069:90016029:90026069:9002
6030:90006070:90006030:90016070:90016030:90026070:9002
6031:90006071:90006031:90016071:90016031:90026071:9002
6032:90006072:90006032:90016072:90016032:90026072:9002
6033:90006073:90006033:90016073:90016033:90026073:9002
6034:90006074:90006034:90016074:90016034:90026074:9002
6035:90006075:90006035:90016075:90016035:90026075:9002
6036:90006076:90006036:90016076:90016036:90026076:9002
6037:90006077:90006037:90016077:90016037:90026077:9002
6038:90006078:90006038:90016078:90016038:90026078:9002
6039:90006039:90016039:9002
6000:90036040:90036000:90046040:90046000:90056040:9005
6001:90036041:90036001:90046041:90046001:90056041:9005
6002:90036042:90036002:90046042:90046002:90056042:9005
6003:90036043:90036003:90046043:90046003:90056043:9005
6004:90036044:90036004:90046044:90046004:90056044:9005
6005:90036045:90036005:90046045:90046005:90056045:9005
6006:90036046:90036006:90046046:90046006:90056046:9005
6007:90036047:90036007:90046047:90046007:90056047:9005
6008:90036048:90036008:90046048:90046008:90056048:9005
6009:90036049:90036009:90046049:90046009:90056049:9005
6010:90036050:90036010:90046050:90046010:90056050:9005
6011:90036051:90036011:90046051:90046011:90056051:9005
6012:90036052:90036012:90046052:90046012:90056052:9005
6013:90036053:90036013:90046053:90046013:90056053:9005
6014:90036054:90036014:90046054:90046014:90056054:9005
6015:90036055:90036015:90046055:90046015:90056055:9005
6016:90036056:90036016:90046056:90046016:90056056:9005
6017:90036057:90036017:90046057:90046017:90056057:9005
6018:90036058:90036018:90046058:90046018:90056058:9005
6019:90036059:90036019:90046059:90046019:90056059:9005
6020:90036060:90036020:90046060:90046020:90056060:9005
6021:90036061:90036021:90046061:90046021:90056061:9005
6022:90036062:90036022:90046062:90046022:90056062:9005
6023:90036063:90036023:90046063:90046023:90056063:9005
6024:90036064:90036024:90046064:90046024:90056064:9005
6025:90036065:90036025:90046065:90046025:90056065:9005
6026:90036066:90036026:90046066:90046026:90056066:9005
6027:90036067:90036027:90046067:90046027:90056067:9005
6028:90036068:90036028:90046068:90046028:90056068:9005
6029:90036069:90036029:90046069:90046029:90056069:9005
6030:90036070:90036030:90046070:90046030:90056070:9005
6031:90036071:90036031:90046071:90046031:90056071:9005
6032:90036072:90036032:90046072:90046032:90056072:9005
6033:90036073:90036033:90046073:90046033:90056073:9005
6034:90036074:90036034:90046074:90046034:90056074:9005
6035:90036075:90036035:90046075:90046035:90056075:9005
6036:90036076:90036036:90046076:90046036:90056076:9005
6037:90036077:90036037:90046077:90046037:90056077:9005
6038:90036078:90036038:90046078:90046038:90056078:9005
6039:90036039:90046039:9005
6000:90066040:90066000:90076040:90076000:90086040:9008
6001:90066041:90066001:90076041:90076001:90086041:9008
6002:90066042:90066002:90076042:90076002:90086042:9008
6003:90066043:90066003:90076043:90076003:90086043:9008
6004:90066044:90066004:90076044:90076004:90086044:9008
6005:90066045:90066005:90076045:90076005:90086045:9008
6006:90066046:90066006:90076046:90076006:90086046:9008
6007:90066047:90066007:90076047:90076007:90086047:9008
6008:90066048:90066008:90076048:90076008:90086048:9008
6009:90066049:90066009:90076049:90076009:90086049:9008
6010:90066050:90066010:90076050:90076010:90086050:9008
6011:90066051:90066011:90076051:90076011:90086051:9008
6012:90066052:90066012:90076052:90076012:90086052:9008
6013:90066053:90066013:90076053:90076013:90086053:9008
6014:90066054:90066014:90076054:90076014:90086054:9008
6015:90066055:90066015:90076055:90076015:90086055:9008
6016:90066056:90066016:90076056:90076016:90086056:9008
6017:90066057:90066017:90076057:90076017:90086057:9008
6018:90066058:90066018:90076058:90076018:90086058:9008
6019:90066059:90066019:90076059:90076019:90086059:9008
6020:90066060:90066020:90076060:90076020:90086060:9008
6021:90066061:90066021:90076061:90076021:90086061:9008
6022:90066062:90066022:90076062:90076022:90086062:9008
6023:90066063:90066023:90076063:90076023:90086063:9008
6024:90066064:90066024:90076064:90076024:90086064:9008
6025:90066065:90066025:90076065:90076025:90086065:9008
6026:90066066:90066026:90076066:90076026:90086066:9008
6027:90066067:90066027:90076067:90076027:90086067:9008
6028:90066068:90066028:90076068:90076028:90086068:9008
6029:90066069:90066029:90076069:90076029:90086069:9008
6030:90066070:90066030:90076070:90076030:90086070:9008
6031:90066071:90066031:90076071:90076031:90086071:9008
6032:90066072:90066032:90076072:90076032:90086072:9008
6033:90066073:90066033:90076073:90076033:90086073:9008
6034:90066074:90066034:90076074:90076034:90086074:9008
6035:90066075:90066035:90076075:90076035:90086075:9008
6036:90066076:90066036:90076076:90076036:90086076:9008
6037:90066077:90066037:90076077:90076037:90086077:9008
6038:90066078:90066038:90076078:90076038:90086078:9008
6039:90066039:90076039:9008
6000:90096040:90096000:90106040:90106000:90116040:9011
6001:90096041:90096001:90106041:90106001:90116041:9011
6002:90096042:90096002:90106042:90106002:90116042:9011
6003:90096043:90096003:90106043:90106003:90116043:9011
6004:90096044:90096004:90106044:90106004:90116044:9011
6005:90096045:90096005:90106045:90106005:90116045:9011
6006:90096046:90096006:90106046:90106006:90116046:9011
6007:90096047:90096007:90106047:90106007:90116047:9011
6008:90096048:90096008:90106048:90106008:90116048:9011
6009:90096049:90096009:90106049:90106009:90116049:9011
6010:90096050:90096010:90106050:90106010:90116050:9011
6011:90096051:90096011:90106051:90106011:90116051:9011
6012:90096052:90096012:90106052:90106012:90116052:9011
6013:90096053:90096013:90106053:90106013:90116053:9011
6014:90096054:90096014:90106054:90106014:90116054:9011
6015:90096055:90096015:90106055:90106015:90116055:9011
6016:90096056:90096016:90106056:90106016:90116056:9011
6017:90096057:90096017:90106057:90106017:90116057:9011
6018:90096058:90096018:90106058:90106018:90116058:9011
6019:90096059:90096019:90106059:90106019:90116059:9011
6020:90096060:90096020:90106060:90106020:90116060:9011
6021:90096061:90096021:90106061:90106021:90116061:9011
6022:90096062:90096022:90106062:90106022:90116062:9011
6023:90096063:90096023:90106063:90106023:90116063:9011
6024:90096064:90096024:90106064:90106024:90116064:9011
6025:90096065:90096025:90106065:90106025:90116065:9011
6026:90096066:90096026:90106066:90106026:90116066:9011
6027:90096067:90096027:90106067:90106027:90116067:9011
6028:90096068:90096028:90106068:90106028:90116068:9011
6029:90096069:90096029:90106069:90106029:90116069:9011
6030:90096070:90096030:90106070:90106030:90116070:9011
6031:90096071:90096031:90106071:90106031:90116071:9011
6032:90096072:90096032:90106072:90106032:90116072:9011
6033:90096073:90096033:90106073:90106033:90116073:9011
6034:90096074:90096034:90106074:90106034:90116074:9011
6035:90096075:90096035:90106075:90106035:90116075:9011
6036:90096076:90096036:90106076:90106036:90116076:9011
6037:90096077:90096037:90106077:90106037:90116077:9011
6038:90096078:90096038:90106078:90106038:90116078:9011
6039:90096039:90106039:9011
6000:90126040:90126000:90136040:90136000:90146040:9014
6001:90126041:90126001:90136041:90136001:90146041:9014
6002:90126042:90126002:90136042:90136002:90146042:9014
6003:90126043:90126003:90136043:90136003:90146043:9014
6004:90126044:90126004:90136044:90136004:90146044:9014
6005:90126045:90126005:90136045:90136005:90146045:9014
6006:90126046:90126006:90136046:90136006:90146046:9014
6007:90126047:90126007:90136047:90136007:90146047:9014
6008:90126048:90126008:90136048:90136008:90146048:9014
6009:90126049:90126009:90136049:90136009:90146049:9014
6010:90126050:90126010:90136050:90136010:90146050:9014
6011:90126051:90126011:90136051:90136011:90146051:9014
6012:90126052:90126012:90136052:90136012:90146052:9014
6013:90126053:90126013:90136053:90136013:90146053:9014
6014:90126054:90126014:90136054:90136014:90146054:9014
6015:90126055:90126015:90136055:90136015:90146055:9014
6016:90126056:90126016:90136056:90136016:90146056:9014
6017:90126057:90126017:90136057:90136017:90146057:9014
6018:90126058:90126018:90136058:90136018:90146058:9014
6019:90126059:90126019:90136059:90136019:90146059:9014
6020:90126060:90126020:90136060:90136020:90146060:9014
6021:90126061:90126021:90136061:90136021:90146061:9014
6022:90126062:90126022:90136062:90136022:90146062:9014
6023:90126063:90126023:90136063:90136023:90146063:9014
6024:90126064:90126024:90136064:90136024:90146064:9014
6025:90126065:90126025:90136065:90136025:90146065:9014
6026:90126066:90126026:90136066:90136026:90146066:9014
6027:90126067:90126027:90136067:90136027:90146067:9014
6028:90126068:90126028:90136068:90136028:90146068:9014
6029:90126069:90126029:90136069:90136029:90146069:9014
6030:90126070:90126030:90136070:90136030:90146070:9014
6031:90126071:90126031:90136071:90136031:90146071:9014
6032:90126072:90126032:90136072:90136032:90146072:9014
6033:90126073:90126033:90136073:90136033:90146073:9014
6034:90126074:90126034:90136074:90136034:90146074:9014
6035:90126075:90126035:90136075:90136035:90146075:9014
6036:90126076:90126036:90136076:90136036:90146076:9014
6037:90126077:90126037:90136077:90136037:90146077:9014
6038:90126078:90126038:90136078:90136038:90146078:9014
6039:90126039:90136039:9014
6000:90156040:90156000:90166040:90166000:90176040:9017
6001:90156041:90156001:90166041:90166001:90176041:9017
6002:90156042:90156002:90166042:90166002:90176042:9017
6003:90156043:90156003:90166043:90166003:90176043:9017
6004:90156044:90156004:90166044:90166004:90176044:9017
6005:90156045:90156005:90166045:90166005:90176045:9017
6006:90156046:90156006:90166046:90166006:90176046:9017
6007:90156047:90156007:90166047:90166007:90176047:9017
6008:90156048:90156008:90166048:90166008:90176048:9017
6009:90156049:90156009:90166049:90166009:90176049:9017
6010:90156050:90156010:90166050:90166010:90176050:9017
6011:90156051:90156011:90166051:90166011:90176051:9017
6012:90156052:90156012:90166052:90166012:90176052:9017
6013:90156053:90156013:90166053:90166013:90176053:9017
6014:90156054:90156014:90166054:90166014:90176054:9017
6015:90156055:90156015:90166055:90166015:90176055:9017
6016:90156056:90156016:90166056:90166016:90176056:9017
6017:90156057:90156017:90166057:90166017:90176057:9017
6018:90156058:90156018:90166058:90166018:90176058:9017
6019:90156059:90156019:90166059:90166019:90176059:9017
6020:90156060:90156020:90166060:90166020:90176060:9017
6021:90156061:90156021:90166061:90166021:90176061:9017
6022:90156062:90156022:90166062:90166022:90176062:9017
6023:90156063:90156023:90166063:90166023:90176063:9017
6024:90156064:90156024:90166064:90166024:90176064:9017
6025:90156065:90156025:90166065:90166025:90176065:9017
6026:90156066:90156026:90166066:90166026:90176066:9017
6027:90156067:90156027:90166067:90166027:90176067:9017
6028:90156068:90156028:90166068:90166028:90176068:9017
6029:90156069:90156029:90166069:90166029:90176069:9017
6030:90156070:90156030:90166070:90166030:90176070:9017
6031:90156071:90156031:90166071:90166031:90176071:9017
6032:90156072:90156032:90166072:90166032:90176072:9017
6033:90156073:90156033:90166073:90166033:90176073:9017
6034:90156074:90156034:90166074:90166034:90176074:9017
6035:90156075:90156035:90166075:90166035:90176075:9017
6036:90156076:90156036:90166076:90166036:90176076:9017
6037:90156077:90156037:90166077:90166037:90176077:9017
6038:90156078:90156038:90166078:90166038:90176078:9017
6039:90156039:90166039:9017
6000:90186040:90186000:90196040:90196000:90206040:9020
6001:90186041:90186001:90196041:90196001:90206041:9020
6002:90186042:90186002:90196042:90196002:90206042:9020
6003:90186043:90186003:90196043:90196003:90206043:9020
6004:90186044:90186004:90196044:90196004:90206044:9020
6005:90186045:90186005:90196045:90196005:90206045:9020
6006:90186046:90186006:90196046:90196006:90206046:9020
6007:90186047:90186007:90196047:90196007:90206047:9020
6008:90186048:90186008:90196048:90196008:90206048:9020
6009:90186049:90186009:90196049:90196009:90206049:9020
6010:90186050:90186010:90196050:90196010:90206050:9020
6011:90186051:90186011:90196051:90196011:90206051:9020
6012:90186052:90186012:90196052:90196012:90206052:9020
6013:90186053:90186013:90196053:90196013:90206053:9020
6014:90186054:90186014:90196054:90196014:90206054:9020
6015:90186055:90186015:90196055:90196015:90206055:9020
6016:90186056:90186016:90196056:90196016:90206056:9020
6017:90186057:90186017:90196057:90196017:90206057:9020
6018:90186058:90186018:90196058:90196018:90206058:9020
6019:90186059:90186019:90196059:90196019:90206059:9020
6020:90186060:90186020:90196060:90196020:90206060:9020
6021:90186061:90186021:90196061:90196021:90206061:9020
6022:90186062:90186022:90196062:90196022:90206062:9020
6023:90186063:90186023:90196063:90196023:90206063:9020
6024:90186064:90186024:90196064:90196024:90206064:9020
6025:90186065:90186025:90196065:90196025:90206065:9020
6026:90186066:90186026:90196066:90196026:90206066:9020
6027:90186067:90186027:90196067:90196027:90206067:9020
6028:90186068:90186028:90196068:90196028:90206068:9020
6029:90186069:90186029:90196069:90196029:90206069:9020
6030:90186070:90186030:90196070:90196030:90206070:9020
6031:90186071:90186031:90196071:90196031:90206071:9020
6032:90186072:90186032:90196072:90196032:90206072:9020
6033:90186073:90186033:90196073:90196033:90206073:9020
6034:90186074:90186034:90196074:90196034:90206074:9020
6035:90186075:90186035:90196075:90196035:90206075:9020
6036:90186076:90186036:90196076:90196036:90206076:9020
6037:90186077:90186037:90196077:90196037:90206077:9020
6038:90186078:90186038:90196078:90196038:90206078:9020
6039:90186039:90196039:9020
6000:90216040:90216000:90226040:90226000:90236040:9023
6001:90216041:90216001:90226041:90226001:90236041:9023
6002:90216042:90216002:90226042:90226002:90236042:9023
6003:90216043:90216003:90226043:90226003:90236043:9023
6004:90216044:90216004:90226044:90226004:90236044:9023
6005:90216045:90216005:90226045:90226005:90236045:9023
6006:90216046:90216006:90226046:90226006:90236046:9023
6007:90216047:90216007:90226047:90226007:90236047:9023
6008:90216048:90216008:90226048:90226008:90236048:9023
6009:90216049:90216009:90226049:90226009:90236049:9023
6010:90216050:90216010:90226050:90226010:90236050:9023
6011:90216051:90216011:90226051:90226011:90236051:9023
6012:90216052:90216012:90226052:90226012:90236052:9023
6013:90216053:90216013:90226053:90226013:90236053:9023
6014:90216054:90216014:90226054:90226014:90236054:9023
6015:90216055:90216015:90226055:90226015:90236055:9023
6016:90216056:90216016:90226056:90226016:90236056:9023
6017:90216057:90216017:90226057:90226017:90236057:9023
6018:90216058:90216018:90226058:90226018:90236058:9023
6019:90216059:90216019:90226059:90226019:90236059:9023
6020:90216060:90216020:90226060:90226020:90236060:9023
6021:90216061:90216021:90226061:90226021:90236061:9023
6022:90216062:90216022:90226062:90226022:90236062:9023
6023:90216063:90216023:90226063:90226023:90236063:9023
6024:90216064:90216024:90226064:90226024:90236064:9023
6025:90216065:90216025:90226065:90226025:90236065:9023
6026:90216066:90216026:90226066:90226026:90236066:9023
6027:90216067:90216027:90226067:90226027:90236067:9023
6028:90216068:90216028:90226068:90226028:90236068:9023
6029:90216069:90216029:90226069:90226029:90236069:9023
6030:90216070:90216030:90226070:90226030:90236070:9023
6031:90216071:90216031:90226071:90226031:90236071:9023
6032:90216072:90216032:90226072:90226032:90236072:9023
6033:90216073:90216033:90226073:90226033:90236073:9023
6034:90216074:90216034:90226074:90226034:90236074:9023
6035:90216075:90216035:90226075:90226035:90236075:9023
6036:90216076:90216036:90226076:90226036:90236076:9023
6037:90216077:90216037:90226077:90226037:90236077:9023
6038:90216078:90216038:90226078:90226038:90236078:9023
6039:90216039:90226039:9023
6000:90246040:90246000:90256040:90256000:90266040:9026
6001:90246041:90246001:90256041:90256001:90266041:9026
6002:90246042:90246002:90256042:90256002:90266042:9026
6003:90246043:90246003:90256043:90256003:90266043:9026
6004:90246044:90246004:90256044:90256004:90266044:9026
6005:90246045:90246005:90256045:90256005:90266045:9026
6006:90246046:90246006:90256046:90256006:90266046:9026
6007:90246047:90246007:90256047:90256007:90266047:9026
6008:90246048:90246008:90256048:90256008:90266048:9026
6009:90246049:90246009:90256049:90256009:90266049:9026
6010:90246050:90246010:90256050:90256010:90266050:9026
6011:90246051:90246011:90256051:90256011:90266051:9026
6012:90246052:90246012:90256052:90256012:90266052:9026
6013:90246053:90246013:90256053:90256013:90266053:9026
6014:90246054:90246014:90256054:90256014:90266054:9026
6015:90246055:90246015:90256055:90256015:90266055:9026
6016:90246056:90246016:90256056:90256016:90266056:9026
6017:90246057:90246017:90256057:90256017:90266057:9026
6018:90246058:90246018:90256058:90256018:90266058:9026
6019:90246059:90246019:90256059:90256019:90266059:9026
6020:90246060:90246020:90256060:90256020:90266060:9026
6021:90246061:90246021:90256061:90256021:90266061:9026
6022:90246062:90246022:90256062:90256022:90266062:9026
6023:90246063:90246023:90256063:90256023:90266063:9026
6024:90246064:90246024:90256064:90256024:90266064:9026
6025:90246065:90246025:90256065:90256025:90266065:9026
6026:90246066:90246026:90256066:90256026:90266066:9026
6027:90246067:90246027:90256067:90256027:90266067:9026
6028:90246068:90246028:90256068:90256028:90266068:9026
6029:90246069:90246029:90256069:90256029:90266069:9026
6030:90246070:90246030:90256070:90256030:90266070:9026
6031:90246071:90246031:90256071:90256031:90266071:9026
6032:90246072:90246032:90256072:90256032:90266072:9026
6033:90246073:90246033:90256073:90256033:90266073:9026
6034:90246074:90246034:90256074:90256034:90266074:9026
6035:90246075:90246035:90256075:90256035:90266075:9026
6036:90246076:90246036:90256076:90256036:90266076:9026
6037:90246077:90246037:90256077:90256037:90266077:9026
6038:90246078:90246038:90256078:90256038:90266078:9026
6039:90246039:90256039:9026
6000:90276040:90276000:90286040:90286000:90296040:9029
6001:90276041:90276001:90286041:90286001:90296041:9029
6002:90276042:90276002:90286042:90286002:90296042:9029
6003:90276043:90276003:90286043:90286003:90296043:9029
6004:90276044:90276004:90286044:90286004:90296044:9029
6005:90276045:90276005:90286045:90286005:90296045:9029
6006:90276046:90276006:90286046:90286006:90296046:9029
6007:90276047:90276007:90286047:90286007:90296047:9029
6008:90276048:90276008:90286048:90286008:90296048:9029
6009:90276049:90276009:90286049:90286009:90296049:9029
6010:90276050:90276010:90286050:90286010:90296050:9029
6011:90276051:90276011:90286051:90286011:90296051:9029
6012:90276052:90276012:90286052:90286012:90296052:9029
6013:90276053:90276013:90286053:90286013:90296053:9029
6014:90276054:90276014:90286054:90286014:90296054:9029
6015:90276055:90276015:90286055:90286015:90296055:9029
6016:90276056:90276016:90286056:90286016:90296056:9029
6017:90276057:90276017:90286057:90286017:90296057:9029
6018:90276058:90276018:90286058:90286018:90296058:9029
6019:90276059:90276019:90286059:90286019:90296059:9029
6020:90276060:90276020:90286060:90286020:90296060:9029
6021:90276061:90276021:90286061:90286021:90296061:9029
6022:90276062:90276022:90286062:90286022:90296062:9029
6023:90276063:90276023:90286063:90286023:90296063:9029
6024:90276064:90276024:90286064:90286024:90296064:9029
6025:90276065:90276025:90286065:90286025:90296065:9029
6026:90276066:90276026:90286066:90286026:90296066:9029
6027:90276067:90276027:90286067:90286027:90296067:9029
6028:90276068:90276028:90286068:90286028:90296068:9029
6029:90276069:90276029:90286069:90286029:90296069:9029
6030:90276070:90276030:90286070:90286030:90296070:9029
6031:90276071:90276031:90286071:90286031:90296071:9029
6032:90276072:90276032:90286072:90286032:90296072:9029
6033:90276073:90276033:90286073:90286033:90296073:9029
6034:90276074:90276034:90286074:90286034:90296074:9029
6035:90276075:90276035:90286075:90286035:90296075:9029
6036:90276076:90276036:90286076:90286036:90296076:9029
6037:90276077:90276037:90286077:90286037:90296077:9029
6038:90276078:90276038:90286078:90286038:90296078:9029
6039:90276039:90286039:9029
6000:90306040:90306000:90316040:90316000:90326040:9032
6001:90306041:90306001:90316041:90316001:90326041:9032
6002:90306042:90306002:90316042:90316002:90326042:9032
6003:90306043:90306003:90316043:90316003:90326043:9032
6004:90306044:90306004:90316044:90316004:90326044:9032
6005:90306045:90306005:90316045:90316005:90326045:9032
6006:90306046:90306006:90316046:90316006:90326046:9032
6007:90306047:90306007:90316047:90316007:90326047:9032
6008:90306048:90306008:90316048:90316008:90326048:9032
6009:90306049:90306009:90316049:90316009:90326049:9032
6010:90306050:90306010:90316050:90316010:90326050:9032
6011:90306051:90306011:90316051:90316011:90326051:9032
6012:90306052:90306012:90316052:90316012:90326052:9032
6013:90306053:90306013:90316053:90316013:90326053:9032
6014:90306054:90306014:90316054:90316014:90326054:9032
6015:90306055:90306015:90316055:90316015:90326055:9032
6016:90306056:90306016:90316056:90316016:90326056:9032
6017:90306057:90306017:90316057:90316017:90326057:9032
6018:90306058:90306018:90316058:90316018:90326058:9032
6019:90306059:90306019:90316059:90316019:90326059:9032
6020:90306060:90306020:90316060:90316020:90326060:9032
6021:90306061:90306021:90316061:90316021:90326061:9032
6022:90306062:90306022:90316062:90316022:90326062:9032
6023:90306063:90306023:90316063:90316023:90326063:9032
6024:90306064:90306024:90316064:90316024:90326064:9032
6025:90306065:90306025:90316065:90316025:90326065:9032
6026:90306066:90306026:90316066:90316026:90326066:9032
6027:90306067:90306027:90316067:90316027:90326067:9032
6028:90306068:90306028:90316068:90316028:90326068:9032
6029:90306069:90306029:90316069:90316029:90326069:9032
6030:90306070:90306030:90316070:90316030:90326070:9032
6031:90306071:90306031:90316071:90316031:90326071:9032
6032:90306072:90306032:90316072:90316032:90326072:9032
6033:90306073:90306033:90316073:90316033:90326073:9032
6034:90306074:90306034:90316074:90316034:90326074:9032
6035:90306075:90306035:90316075:90316035:90326075:9032
6036:90306076:90306036:90316076:90316036:90326076:9032
6037:90306077:90306037:90316077:90316037:90326077:9032
6038:90306078:90306038:90316078:90316038:90326078:9032
6039:90306039:90316039:9032
6000:90336040:90336000:90346040:90346000:90356040:9035
6001:90336041:90336001:90346041:90346001:90356041:9035
6002:90336042:90336002:90346042:90346002:90356042:9035
6003:90336043:90336003:90346043:90346003:90356043:9035
6004:90336044:90336004:90346044:90346004:90356044:9035
6005:90336045:90336005:90346045:90346005:90356045:9035
6006:90336046:90336006:90346046:90346006:90356046:9035
6007:90336047:90336007:90346047:90346007:90356047:9035
6008:90336048:90336008:90346048:90346008:90356048:9035
6009:90336049:90336009:90346049:90346009:90356049:9035
6010:90336050:90336010:90346050:90346010:90356050:9035
6011:90336051:90336011:90346051:90346011:90356051:9035
6012:90336052:90336012:90346052:90346012:90356052:9035
6013:90336053:90336013:90346053:90346013:90356053:9035
6014:90336054:90336014:90346054:90346014:90356054:9035
6015:90336055:90336015:90346055:90346015:90356055:9035
6016:90336056:90336016:90346056:90346016:90356056:9035
6017:90336057:90336017:90346057:90346017:90356057:9035
6018:90336058:90336018:90346058:90346018:90356058:9035
6019:90336059:90336019:90346059:90346019:90356059:9035
6020:90336060:90336020:90346060:90346020:90356060:9035
6021:90336061:90336021:90346061:90346021:90356061:9035
6022:90336062:90336022:90346062:90346022:90356062:9035
6023:90336063:90336023:90346063:90346023:90356063:9035
6024:90336064:90336024:90346064:90346024:90356064:9035
6025:90336065:90336025:90346065:90346025:90356065:9035
6026:90336066:90336026:90346066:90346026:90356066:9035
6027:90336067:90336027:90346067:90346027:90356067:9035
6028:90336068:90336028:90346068:90346028:90356068:9035
6029:90336069:90336029:90346069:90346029:90356069:9035
6030:90336070:90336030:90346070:90346030:90356070:9035
6031:90336071:90336031:90346071:90346031:90356071:9035
6032:90336072:90336032:90346072:90346032:90356072:9035
6033:90336073:90336033:90346073:90346033:90356073:9035
6034:90336074:90336034:90346074:90346034:90356074:9035
6035:90336075:90336035:90346075:90346035:90356075:9035
6036:90336076:90336036:90346076:90346036:90356076:9035
6037:90336077:90336037:90346077:90346037:90356077:9035
6038:90336078:90336038:90346078:90346038:90356078:9035
6039:90336039:90346039:9035
6000:90366040:90366000:90376040:90376000:90386040:9038
6001:90366041:90366001:90376041:90376001:90386041:9038
6002:90366042:90366002:90376042:90376002:90386042:9038
6003:90366043:90366003:90376043:90376003:90386043:9038
6004:90366044:90366004:90376044:90376004:90386044:9038
6005:90366045:90366005:90376045:90376005:90386045:9038
6006:90366046:90366006:90376046:90376006:90386046:9038
6007:90366047:90366007:90376047:90376007:90386047:9038
6008:90366048:90366008:90376048:90376008:90386048:9038
6009:90366049:90366009:90376049:90376009:90386049:9038
6010:90366050:90366010:90376050:90376010:90386050:9038
6011:90366051:90366011:90376051:90376011:90386051:9038
6012:90366052:90366012:90376052:90376012:90386052:9038
6013:90366053:90366013:90376053:90376013:90386053:9038
6014:90366054:90366014:90376054:90376014:90386054:9038
6015:90366055:90366015:90376055:90376015:90386055:9038
6016:90366056:90366016:90376056:90376016:90386056:9038
6017:90366057:90366017:90376057:90376017:90386057:9038
6018:90366058:90366018:90376058:90376018:90386058:9038
6019:90366059:90366019:90376059:90376019:90386059:9038
6020:90366060:90366020:90376060:90376020:90386060:9038
6021:90366061:90366021:90376061:90376021:90386061:9038
6022:90366062:90366022:90376062:90376022:90386062:9038
6023:90366063:90366023:90376063:90376023:90386063:9038
6024:90366064:90366024:90376064:90376024:90386064:9038
6025:90366065:90366025:90376065:90376025:90386065:9038
6026:90366066:90366026:90376066:90376026:90386066:9038
6027:90366067:90366027:90376067:90376027:90386067:9038
6028:90366068:90366028:90376068:90376028:90386068:9038
6029:90366069:90366029:90376069:90376029:90386069:9038
6030:90366070:90366030:90376070:90376030:90386070:9038
6031:90366071:90366031:90376071:90376031:90386071:9038
6032:90366072:90366032:90376072:90376032:90386072:9038
6033:90366073:90366033:90376073:90376033:90386073:9038
6034:90366074:90366034:90376074:90376034:90386074:9038
6035:90366075:90366035:90376075:90376035:90386075:9038
6036:90366076:90366036:90376076:90376036:90386076:9038
6037:90366077:90366037:90376077:90376037:90386077:9038
6038:90366078:90366038:90376078:90376038:90386078:9038
6039:90366039:90376039:9038
6000:90396040:90396000:90406040:90406000:90416040:9041
6001:90396041:90396001:90406041:90406001:90416041:9041
6002:90396042:90396002:90406042:90406002:90416042:9041
6003:90396043:90396003:90406043:90406003:90416043:9041
6004:90396044:90396004:90406044:90406004:90416044:9041
6005:90396045:90396005:90406045:90406005:90416045:9041
6006:90396046:90396006:90406046:90406006:90416046:9041
6007:90396047:90396007:90406047:90406007:90416047:9041
6008:90396048:90396008:90406048:90406008:90416048:9041
6009:90396049:90396009:90406049:90406009:90416049:9041
6010:90396050:90396010:90406050:90406010:90416050:9041
6011:90396051:90396011:90406051:90406011:90416051:9041
6012:90396052:90396012:90406052:90406012:90416052:9041
6013:90396053:90396013:90406053:90406013:90416053:9041
6014:90396054:90396014:90406054:90406014:90416054:9041
6015:90396055:90396015:90406055:90406015:90416055:9041
6016:90396056:90396016:90406056:90406016:90416056:9041
6017:90396057:90396017:90406057:90406017:90416057:9041
6018:90396058:90396018:90406058:90406018:90416058:9041
6019:90396059:90396019:90406059:90406019:90416059:9041
6020:90396060:90396020:90406060:90406020:90416060:9041
6021:90396061:90396021:90406061:90406021:90416061:9041
6022:90396062:90396022:90406062:90406022:90416062:9041
6023:90396063:90396023:90406063:90406023:90416063:9041
6024:90396064:90396024:90406064:90406024:90416064:9041
6025:90396065:90396025:90406065:90406025:90416065:9041
6026:90396066:90396026:90406066:90406026:90416066:9041
6027:90396067:90396027:90406067:90406027:90416067:9041
6028:90396068:90396028:90406068:90406028:90416068:9041
6029:90396069:90396029:90406069:90406029:90416069:9041
6030:90396070:90396030:90406070:90406030:90416070:9041
6031:90396071:90396031:90406071:90406031:90416071:9041
6032:90396072:90396032:90406072:90406032:90416072:9041
6033:90396073:90396033:90406073:90406033:90416073:9041
6034:90396074:90396034:90406074:90406034:90416074:9041
6035:90396075:90396035:90406075:90406035:90416075:9041
6036:90396076:90396036:90406076:90406036:90416076:9041
6037:90396077:90396037:90406077:90406037:90416077:9041
6038:90396078:90396038:90406078:90406038:90416078:9041
6039:90396039:90406039:9041
6000:90426040:90426000:90436040:90436000:90446040:9044
6001:90426041:90426001:90436041:90436001:90446041:9044
6002:90426042:90426002:90436042:90436002:90446042:9044
6003:90426043:90426003:90436043:90436003:90446043:9044
6004:90426044:90426004:90436044:90436004:90446044:9044
6005:90426045:90426005:90436045:90436005:90446045:9044
6006:90426046:90426006:90436046:90436006:90446046:9044
6007:90426047:90426007:90436047:90436007:90446047:9044
6008:90426048:90426008:90436048:90436008:90446048:9044
6009:90426049:90426009:90436049:90436009:90446049:9044
6010:90426050:90426010:90436050:90436010:90446050:9044
6011:90426051:90426011:90436051:90436011:90446051:9044
6012:90426052:90426012:90436052:90436012:90446052:9044
6013:90426053:90426013:90436053:90436013:90446053:9044
6014:90426054:90426014:90436054:90436014:90446054:9044
6015:90426055:90426015:90436055:90436015:90446055:9044
6016:90426056:90426016:90436056:90436016:90446056:9044
6017:90426057:90426017:90436057:90436017:90446057:9044
6018:90426058:90426018:90436058:90436018:90446058:9044
6019:90426059:90426019:90436059:90436019:90446059:9044
6020:90426060:90426020:90436060:90436020:90446060:9044
6021:90426061:90426021:90436061:90436021:90446061:9044
6022:90426062:90426022:90436062:90436022:90446062:9044
6023:90426063:90426023:90436063:90436023:90446063:9044
6024:90426064:90426024:90436064:90436024:90446064:9044
6025:90426065:90426025:90436065:90436025:90446065:9044
6026:90426066:90426026:90436066:90436026:90446066:9044
6027:90426067:90426027:90436067:90436027:90446067:9044
6028:90426068:90426028:90436068:90436028:90446068:9044
6029:90426069:90426029:90436069:90436029:90446069:9044
6030:90426070:90426030:90436070:90436030:90446070:9044
6031:90426071:90426031:90436071:90436031:90446071:9044
6032:90426072:90426032:90436072:90436032:90446072:9044
6033:90426073:90426033:90436073:90436033:90446073:9044
6034:90426074:90426034:90436074:90436034:90446074:9044
6035:90426075:90426035:90436075:90436035:90446075:9044
6036:90426076:90426036:90436076:90436036:90446076:9044
6037:90426077:90426037:90436077:90436037:90446077:9044
6038:90426078:90426038:90436078:90436038:90446078:9044
6039:90426039:90436039:9044
6000:90456040:90456000:90466040:90466000:90476040:9047
6001:90456041:90456001:90466041:90466001:90476041:9047
6002:90456042:90456002:90466042:90466002:90476042:9047
6003:90456043:90456003:90466043:90466003:90476043:9047
6004:90456044:90456004:90466044:90466004:90476044:9047
6005:90456045:90456005:90466045:90466005:90476045:9047
6006:90456046:90456006:90466046:90466006:90476046:9047
6007:90456047:90456007:90466047:90466007:90476047:9047
6008:90456048:90456008:90466048:90466008:90476048:9047
6009:90456049:90456009:90466049:90466009:90476049:9047
6010:90456050:90456010:90466050:90466010:90476050:9047
6011:90456051:90456011:90466051:90466011:90476051:9047
6012:90456052:90456012:90466052:90466012:90476052:9047
6013:90456053:90456013:90466053:90466013:90476053:9047
6014:90456054:90456014:90466054:90466014:90476054:9047
6015:90456055:90456015:90466055:90466015:90476055:9047
6016:90456056:90456016:90466056:90466016:90476056:9047
6017:90456057:90456017:90466057:90466017:90476057:9047
6018:90456058:90456018:90466058:90466018:90476058:9047
6019:90456059:90456019:90466059:90466019:90476059:9047
6020:90456060:90456020:90466060:90466020:90476060:9047
6021:90456061:90456021:90466061:90466021:90476061:9047
6022:90456062:90456022:90466062:90466022:90476062:9047
6023:90456063:90456023:90466063:90466023:90476063:9047
6024:90456064:90456024:90466064:90466024:90476064:9047
6025:90456065:90456025:90466065:90466025:90476065:9047
6026:90456066:90456026:90466066:90466026:90476066:9047
6027:90456067:90456027:90466067:90466027:90476067:9047
6028:90456068:90456028:90466068:90466028:90476068:9047
6029:90456069:90456029:90466069:90466029:90476069:9047
6030:90456070:90456030:90466070:90466030:90476070:9047
6031:90456071:90456031:90466071:90466031:90476071:9047
6032:90456072:90456032:90466072:90466032:90476072:9047
6033:90456073:90456033:90466073:90466033:90476073:9047
6034:90456074:90456034:90466074:90466034:90476074:9047
6035:90456075:90456035:90466075:90466035:90476075:9047
6036:90456076:90456036:90466076:90466036:90476076:9047
6037:90456077:90456037:90466077:90466037:90476077:9047
6038:90456078:90456038:90466078:90466038:90476078:9047
6039:90456039:90466039:9047
6000:90486040:90486000:90496040:90496000:90506040:9050
6001:90486041:90486001:90496041:90496001:90506041:9050
6002:90486042:90486002:90496042:90496002:90506042:9050
6003:90486043:90486003:90496043:90496003:90506043:9050
6004:90486044:90486004:90496044:90496004:90506044:9050
6005:90486045:90486005:90496045:90496005:90506045:9050
6006:90486046:90486006:90496046:90496006:90506046:9050
6007:90486047:90486007:90496047:90496007:90506047:9050
6008:90486048:90486008:90496048:90496008:90506048:9050
6009:90486049:90486009:90496049:90496009:90506049:9050
6010:90486050:90486010:90496050:90496010:90506050:9050
6011:90486051:90486011:90496051:90496011:90506051:9050
6012:90486052:90486012:90496052:90496012:90506052:9050
6013:90486053:90486013:90496053:90496013:90506053:9050
6014:90486054:90486014:90496054:90496014:90506054:9050
6015:90486055:90486015:90496055:90496015:90506055:9050
6016:90486056:90486016:90496056:90496016:90506056:9050
6017:90486057:90486017:90496057:90496017:90506057:9050
6018:90486058:90486018:90496058:90496018:90506058:9050
6019:90486059:90486019:90496059:90496019:90506059:9050
6020:90486060:90486020:90496060:90496020:90506060:9050
6021:90486061:90486021:90496061:90496021:90506061:9050
6022:90486062:90486022:90496062:90496022:90506062:9050
6023:90486063:90486023:90496063:90496023:90506063:9050
6024:90486064:90486024:90496064:90496024:90506064:9050
6025:90486065:90486025:90496065:90496025:90506065:9050
6026:90486066:90486026:90496066:90496026:90506066:9050
6027:90486067:90486027:90496067:90496027:90506067:9050
6028:90486068:90486028:90496068:90496028:90506068:9050
6029:90486069:90486029:90496069:90496029:90506069:9050
6030:90486070:90486030:90496070:90496030:90506070:9050
6031:90486071:90486031:90496071:90496031:90506071:9050
6032:90486072:90486032:90496072:90496032:90506072:9050
6033:90486073:90486033:90496073:90496033:90506073:9050
6034:90486074:90486034:90496074:90496034:90506074:9050
6035:90486075:90486035:90496075:90496035:90506075:9050
6036:90486076:90486036:90496076:90496036:90506076:9050
6037:90486077:90486037:90496077:90496037:90506077:9050
6038:90486078:90486038:90496078:90496038:90506078:9050
6039:90486039:90496039:9050
6000:90516040:90516000:90526040:90526000:90536040:9053
6001:90516041:90516001:90526041:90526001:90536041:9053
6002:90516042:90516002:90526042:90526002:90536042:9053
6003:90516043:90516003:90526043:90526003:90536043:9053
6004:90516044:90516004:90526044:90526004:90536044:9053
6005:90516045:90516005:90526045:90526005:90536045:9053
6006:90516046:90516006:90526046:90526006:90536046:9053
6007:90516047:90516007:90526047:90526007:90536047:9053
6008:90516048:90516008:90526048:90526008:90536048:9053
6009:90516049:90516009:90526049:90526009:90536049:9053
6010:90516050:90516010:90526050:90526010:90536050:9053
6011:90516051:90516011:90526051:90526011:90536051:9053
6012:90516052:90516012:90526052:90526012:90536052:9053
6013:90516053:90516013:90526053:90526013:90536053:9053
6014:90516054:90516014:90526054:90526014:90536054:9053
6015:90516055:90516015:90526055:90526015:90536055:9053
6016:90516056:90516016:90526056:90526016:90536056:9053
6017:90516057:90516017:90526057:90526017:90536057:9053
6018:90516058:90516018:90526058:90526018:90536058:9053
6019:90516059:90516019:90526059:90526019:90536059:9053
6020:90516060:90516020:90526060:90526020:90536060:9053
6021:90516061:90516021:90526061:90526021:90536061:9053
6022:90516062:90516022:90526062:90526022:90536062:9053
6023:90516063:90516023:90526063:90526023:90536063:9053
6024:90516064:90516024:90526064:90526024:90536064:9053
6025:90516065:90516025:90526065:90526025:90536065:9053
6026:90516066:90516026:90526066:90526026:90536066:9053
6027:90516067:90516027:90526067:90526027:90536067:9053
6028:90516068:90516028:90526068:90526028:90536068:9053
6029:90516069:90516029:90526069:90526029:90536069:9053
6030:90516070:90516030:90526070:90526030:90536070:9053
6031:90516071:90516031:90526071:90526031:90536071:9053
6032:90516072:90516032:90526072:90526032:90536072:9053
6033:90516073:90516033:90526073:90526033:90536073:9053
6034:90516074:90516034:90526074:90526034:90536074:9053
6035:90516075:90516035:90526075:90526035:90536075:9053
6036:90516076:90516036:90526076:90526036:90536076:9053
6037:90516077:90516037:90526077:90526037:90536077:9053
6038:90516078:90516038:90526078:90526038:90536078:9053
6039:90516039:90526039:9053
6000:90546040:90546000:90556040:90556000:90566040:9056
6001:90546041:90546001:90556041:90556001:90566041:9056
6002:90546042:90546002:90556042:90556002:90566042:9056
6003:90546043:90546003:90556043:90556003:90566043:9056
6004:90546044:90546004:90556044:90556004:90566044:9056
6005:90546045:90546005:90556045:90556005:90566045:9056
6006:90546046:90546006:90556046:90556006:90566046:9056
6007:90546047:90546007:90556047:90556007:90566047:9056
6008:90546048:90546008:90556048:90556008:90566048:9056
6009:90546049:90546009:90556049:90556009:90566049:9056
6010:90546050:90546010:90556050:90556010:90566050:9056
6011:90546051:90546011:90556051:90556011:90566051:9056
6012:90546052:90546012:90556052:90556012:90566052:9056
6013:90546053:90546013:90556053:90556013:90566053:9056
6014:90546054:90546014:90556054:90556014:90566054:9056
6015:90546055:90546015:90556055:90556015:90566055:9056
6016:90546056:90546016:90556056:90556016:90566056:9056
6017:90546057:90546017:90556057:90556017:90566057:9056
6018:90546058:90546018:90556058:90556018:90566058:9056
6019:90546059:90546019:90556059:90556019:90566059:9056
6020:90546060:90546020:90556060:90556020:90566060:9056
6021:90546061:90546021:90556061:90556021:90566061:9056
6022:90546062:90546022:90556062:90556022:90566062:9056
6023:90546063:90546023:90556063:90556023:90566063:9056
6024:90546064:90546024:90556064:90556024:90566064:9056
6025:90546065:90546025:90556065:90556025:90566065:9056
6026:90546066:90546026:90556066:90556026:90566066:9056
6027:90546067:90546027:90556067:90556027:90566067:9056
6028:90546068:90546028:90556068:90556028:90566068:9056
6029:90546069:90546029:90556069:90556029:90566069:9056
6030:90546070:90546030:90556070:90556030:90566070:9056
6031:90546071:90546031:90556071:90556031:90566071:9056
6032:90546072:90546032:90556072:90556032:90566072:9056
6033:90546073:90546033:90556073:90556033:90566073:9056
6034:90546074:90546034:90556074:90556034:90566074:9056
6035:90546075:90546035:90556075:90556035:90566075:9056
6036:90546076:90546036:90556076:90556036:90566076:9056
6037:90546077:90546037:90556077:90556037:90566077:9056
6038:90546078:90546038:90556078:90556038:90566078:9056
6039:90546039:90556039:9056
6000:90576040:90576000:90586040:90586000:90596040:9059
6001:90576041:90576001:90586041:90586001:90596041:9059
6002:90576042:90576002:90586042:90586002:90596042:9059
6003:90576043:90576003:90586043:90586003:90596043:9059
6004:90576044:90576004:90586044:90586004:90596044:9059
6005:90576045:90576005:90586045:90586005:90596045:9059
6006:90576046:90576006:90586046:90586006:90596046:9059
6007:90576047:90576007:90586047:90586007:90596047:9059
6008:90576048:90576008:90586048:90586008:90596048:9059
6009:90576049:90576009:90586049:90586009:90596049:9059
6010:90576050:90576010:90586050:90586010:90596050:9059
6011:90576051:90576011:90586051:90586011:90596051:9059
6012:90576052:90576012:90586052:90586012:90596052:9059
6013:90576053:90576013:90586053:90586013:90596053:9059
6014:90576054:90576014:90586054:90586014:90596054:9059
6015:90576055:90576015:90586055:90586015:90596055:9059
6016:90576056:90576016:90586056:90586016:90596056:9059
6017:90576057:90576017:90586057:90586017:90596057:9059
6018:90576058:90576018:90586058:90586018:90596058:9059
6019:90576059:90576019:90586059:90586019:90596059:9059
6020:90576060:90576020:90586060:90586020:90596060:9059
6021:90576061:90576021:90586061:90586021:90596061:9059
6022:90576062:90576022:90586062:90586022:90596062:9059
6023:90576063:90576023:90586063:90586023:90596063:9059
6024:90576064:90576024:90586064:90586024:90596064:9059
6025:90576065:90576025:90586065:90586025:90596065:9059
6026:90576066:90576026:90586066:90586026:90596066:9059
6027:90576067:90576027:90586067:90586027:90596067:9059
6028:90576068:90576028:90586068:90586028:90596068:9059
6029:90576069:90576029:90586069:90586029:90596069:9059
6030:90576070:90576030:90586070:90586030:90596070:9059
6031:90576071:90576031:90586071:90586031:90596071:9059
6032:90576072:90576032:90586072:90586032:90596072:9059
6033:90576073:90576033:90586073:90586033:90596073:9059
6034:90576074:90576034:90586074:90586034:90596074:9059
6035:90576075:90576035:90586075:90586035:90596075:9059
6036:90576076:90576036:90586076:90586036:90596076:9059
6037:90576077:90576037:90586077:90586037:90596077:9059
6038:90576078:90576038:90586078:90586038:90596078:9059
6039:90576039:90586039:9059
6000:90606040:90606000:90616040:90616000:90626040:9062
6001:90606041:90606001:90616041:90616001:90626041:9062
6002:90606042:90606002:90616042:90616002:90626042:9062
6003:90606043:90606003:90616043:90616003:90626043:9062
6004:90606044:90606004:90616044:90616004:90626044:9062
6005:90606045:90606005:90616045:90616005:90626045:9062
6006:90606046:90606006:90616046:90616006:90626046:9062
6007:90606047:90606007:90616047:90616007:90626047:9062
6008:90606048:90606008:90616048:90616008:90626048:9062
6009:90606049:90606009:90616049:90616009:90626049:9062
6010:90606050:90606010:90616050:90616010:90626050:9062
6011:90606051:90606011:90616051:90616011:90626051:9062
6012:90606052:90606012:90616052:90616012:90626052:9062
6013:90606053:90606013:90616053:90616013:90626053:9062
6014:90606054:90606014:90616054:90616014:90626054:9062
6015:90606055:90606015:90616055:90616015:90626055:9062
6016:90606056:90606016:90616056:90616016:90626056:9062
6017:90606057:90606017:90616057:90616017:90626057:9062
6018:90606058:90606018:90616058:90616018:90626058:9062
6019:90606059:90606019:90616059:90616019:90626059:9062
6020:90606060:90606020:90616060:90616020:90626060:9062
6021:90606061:90606021:90616061:90616021:90626061:9062
6022:90606062:90606022:90616062:90616022:90626062:9062
6023:90606063:90606023:90616063:90616023:90626063:9062
6024:90606064:90606024:90616064:90616024:90626064:9062
6025:90606065:90606025:90616065:90616025:90626065:9062
6026:90606066:90606026:90616066:90616026:90626066:9062
6027:90606067:90606027:90616067:90616027:90626067:9062
6028:90606068:90606028:90616068:90616028:90626068:9062
6029:90606069:90606029:90616069:90616029:90626069:9062
6030:90606070:90606030:90616070:90616030:90626070:9062
6031:90606071:90606031:90616071:90616031:90626071:9062
6032:90606072:90606032:90616072:90616032:90626072:9062
6033:90606073:90606033:90616073:90616033:90626073:9062
6034:90606074:90606034:90616074:90616034:90626074:9062
6035:90606075:90606035:90616075:90616035:90626075:9062
6036:90606076:90606036:90616076:90616036:90626076:9062
6037:90606077:90606037:90616077:90616037:90626077:9062
6038:90606078:90606038:90616078:90616038:90626078:9062
6039:90606039:90616039:9062
6000:90636040:90636000:90646040:90646000:90656040:9065
6001:90636041:90636001:90646041:90646001:90656041:9065
6002:90636042:90636002:90646042:90646002:90656042:9065
6003:90636043:90636003:90646043:90646003:90656043:9065
6004:90636044:90636004:90646044:90646004:90656044:9065
6005:90636045:90636005:90646045:90646005:90656045:9065
6006:90636046:90636006:90646046:90646006:90656046:9065
6007:90636047:90636007:90646047:90646007:90656047:9065
6008:90636048:90636008:90646048:90646008:90656048:9065
6009:90636049:90636009:90646049:90646009:90656049:9065
6010:90636050:90636010:90646050:90646010:90656050:9065
6011:90636051:90636011:90646051:90646011:90656051:9065
6012:90636052:90636012:90646052:90646012:90656052:9065
6013:90636053:90636013:90646053:90646013:90656053:9065
6014:90636054:90636014:90646054:90646014:90656054:9065
6015:90636055:90636015:90646055:90646015:90656055:9065
6016:90636056:90636016:90646056:90646016:90656056:9065
6017:90636057:90636017:90646057:90646017:90656057:9065
6018:90636058:90636018:90646058:90646018:90656058:9065
6019:90636059:90636019:90646059:90646019:90656059:9065
6020:90636060:90636020:90646060:90646020:90656060:9065
6021:90636061:90636021:90646061:90646021:90656061:9065
6022:90636062:90636022:90646062:90646022:90656062:9065
6023:90636063:90636023:90646063:90646023:90656063:9065
6024:90636064:90636024:90646064:90646024:90656064:9065
6025:90636065:90636025:90646065:90646025:90656065:9065
6026:90636066:90636026:90646066:90646026:90656066:9065
6027:90636067:90636027:90646067:90646027:90656067:9065
6028:90636068:90636028:90646068:90646028:90656068:9065
6029:90636069:90636029:90646069:90646029:90656069:9065
6030:90636070:90636030:90646070:90646030:90656070:9065
6031:90636071:90636031:90646071:90646031:90656071:9065
6032:90636072:90636032:90646072:90646032:90656072:9065
6033:90636073:90636033:90646073:90646033:90656073:9065
6034:90636074:90636034:90646074:90646034:90656074:9065
6035:90636075:90636035:90646075:90646035:90656075:9065
6036:90636076:90636036:90646076:90646036:90656076:9065
6037:90636077:90636037:90646077:90646037:90656077:9065
6038:90636078:90636038:90646078:90646038:90656078:9065
6039:90636039:90646039:9065
6000:90666040:90666000:90676040:90676000:90686040:9068
6001:90666041:90666001:90676041:90676001:90686041:9068
6002:90666042:90666002:90676042:90676002:90686042:9068
6003:90666043:90666003:90676043:90676003:90686043:9068
6004:90666044:90666004:90676044:90676004:90686044:9068
6005:90666045:90666005:90676045:90676005:90686045:9068
6006:90666046:90666006:90676046:90676006:90686046:9068
6007:90666047:90666007:90676047:90676007:90686047:9068
6008:90666048:90666008:90676048:90676008:90686048:9068
6009:90666049:90666009:90676049:90676009:90686049:9068
6010:90666050:90666010:90676050:90676010:90686050:9068
6011:90666051:90666011:90676051:90676011:90686051:9068
6012:90666052:90666012:90676052:90676012:90686052:9068
6013:90666053:90666013:90676053:90676013:90686053:9068
6014:90666054:90666014:90676054:90676014:90686054:9068
6015:90666055:90666015:90676055:90676015:90686055:9068
6016:90666056:90666016:90676056:90676016:90686056:9068
6017:90666057:90666017:90676057:90676017:90686057:9068
6018:90666058:90666018:90676058:90676018:90686058:9068
6019:90666059:90666019:90676059:90676019:90686059:9068
6020:90666060:90666020:90676060:90676020:90686060:9068
6021:90666061:90666021:90676061:90676021:90686061:9068
6022:90666062:90666022:90676062:90676022:90686062:9068
6023:90666063:90666023:90676063:90676023:90686063:9068
6024:90666064:90666024:90676064:90676024:90686064:9068
6025:90666065:90666025:90676065:90676025:90686065:9068
6026:90666066:90666026:90676066:90676026:90686066:9068
6027:90666067:90666027:90676067:90676027:90686067:9068
6028:90666068:90666028:90676068:90676028:90686068:9068
6029:90666069:90666029:90676069:90676029:90686069:9068
6030:90666070:90666030:90676070:90676030:90686070:9068
6031:90666071:90666031:90676071:90676031:90686071:9068
6032:90666072:90666032:90676072:90676032:90686072:9068
6033:90666073:90666033:90676073:90676033:90686073:9068
6034:90666074:90666034:90676074:90676034:90686074:9068
6035:90666075:90666035:90676075:90676035:90686075:9068
6036:90666076:90666036:90676076:90676036:90686076:9068
6037:90666077:90666037:90676077:90676037:90686077:9068
6038:90666078:90666038:90676078:90676038:90686078:9068
6039:90666039:90676039:9068
6000:90696040:90696000:90706040:90706000:90716040:9071
6001:90696041:90696001:90706041:90706001:90716041:9071
6002:90696042:90696002:90706042:90706002:90716042:9071
6003:90696043:90696003:90706043:90706003:90716043:9071
6004:90696044:90696004:90706044:90706004:90716044:9071
6005:90696045:90696005:90706045:90706005:90716045:9071
6006:90696046:90696006:90706046:90706006:90716046:9071
6007:90696047:90696007:90706047:90706007:90716047:9071
6008:90696048:90696008:90706048:90706008:90716048:9071
6009:90696049:90696009:90706049:90706009:90716049:9071
6010:90696050:90696010:90706050:90706010:90716050:9071
6011:90696051:90696011:90706051:90706011:90716051:9071
6012:90696052:90696012:90706052:90706012:90716052:9071
6013:90696053:90696013:90706053:90706013:90716053:9071
6014:90696054:90696014:90706054:90706014:90716054:9071
6015:90696055:90696015:90706055:90706015:90716055:9071
6016:90696056:90696016:90706056:90706016:90716056:9071
6017:90696057:90696017:90706057:90706017:90716057:9071
6018:90696058:90696018:90706058:90706018:90716058:9071
6019:90696059:90696019:90706059:90706019:90716059:9071
6020:90696060:90696020:90706060:90706020:90716060:9071
6021:90696061:90696021:90706061:90706021:90716061:9071
6022:90696062:90696022:90706062:90706022:90716062:9071
6023:90696063:90696023:90706063:90706023:90716063:9071
6024:90696064:90696024:90706064:90706024:90716064:9071
6025:90696065:90696025:90706065:90706025:90716065:9071
6026:90696066:90696026:90706066:90706026:90716066:9071
6027:90696067:90696027:90706067:90706027:90716067:9071
6028:90696068:90696028:90706068:90706028:90716068:9071
6029:90696069:90696029:90706069:90706029:90716069:9071
6030:90696070:90696030:90706070:90706030:90716070:9071
6031:90696071:90696031:90706071:90706031:90716071:9071
6032:90696072:90696032:90706072:90706032:90716072:9071
6033:90696073:90696033:90706073:90706033:90716073:9071
6034:90696074:90696034:90706074:90706034:90716074:9071
6035:90696075:90696035:90706075:90706035:90716075:9071
6036:90696076:90696036:90706076:90706036:90716076:9071
6037:90696077:90696037:90706077:90706037:90716077:9071
6038:90696078:90696038:90706078:90706038:90716078:9071
6039:90696039:90706039:9071
6000:90726040:90726000:90736040:90736000:90746040:9074
6001:90726041:90726001:90736041:90736001:90746041:9074
6002:90726042:90726002:90736042:90736002:90746042:9074
6003:90726043:90726003:90736043:90736003:90746043:9074
6004:90726044:90726004:90736044:90736004:90746044:9074
6005:90726045:90726005:90736045:90736005:90746045:9074
6006:90726046:90726006:90736046:90736006:90746046:9074
6007:90726047:90726007:90736047:90736007:90746047:9074
6008:90726048:90726008:90736048:90736008:90746048:9074
6009:90726049:90726009:90736049:90736009:90746049:9074
6010:90726050:90726010:90736050:90736010:90746050:9074
6011:90726051:90726011:90736051:90736011:90746051:9074
6012:90726052:90726012:90736052:90736012:90746052:9074
6013:90726053:90726013:90736053:90736013:90746053:9074
6014:90726054:90726014:90736054:90736014:90746054:9074
6015:90726055:90726015:90736055:90736015:90746055:9074
6016:90726056:90726016:90736056:90736016:90746056:9074
6017:90726057:90726017:90736057:90736017:90746057:9074
6018:90726058:90726018:90736058:90736018:90746058:9074
6019:90726059:90726019:90736059:90736019:90746059:9074
6020:90726060:90726020:90736060:90736020:90746060:9074
6021:90726061:90726021:90736061:90736021:90746061:9074
6022:90726062:90726022:90736062:90736022:90746062:9074
6023:90726063:90726023:90736063:90736023:90746063:9074
6024:90726064:90726024:90736064:90736024:90746064:9074
6025:90726065:90726025:90736065:90736025:90746065:9074
6026:90726066:90726026:90736066:90736026:90746066:9074
6027:90726067:90726027:90736067:90736027:90746067:9074
6028:90726068:90726028:90736068:90736028:90746068:9074
6029:90726069:90726029:90736069:90736029:90746069:9074
6030:90726070:90726030:90736070:90736030:90746070:9074
6031:90726071:90726031:90736071:90736031:90746071:9074
6032:90726072:90726032:90736072:90736032:90746072:9074
6033:90726073:90726033:90736073:90736033:90746073:9074
6034:90726074:90726034:90736074:90736034:90746074:9074
6035:90726075:90726035:90736075:90736035:90746075:9074
6036:90726076:90726036:90736076:90736036:90746076:9074
6037:90726077:90726037:90736077:90736037:90746077:9074
6038:90726078:90726038:90736078:90736038:90746078:9074
6039:90726039:90736039:9074
6000:90756040:90756000:90766040:90766000:90776040:9077
6001:90756041:90756001:90766041:90766001:90776041:9077
6002:90756042:90756002:90766042:90766002:90776042:9077
6003:90756043:90756003:90766043:90766003:90776043:9077
6004:90756044:90756004:90766044:90766004:90776044:9077
6005:90756045:90756005:90766045:90766005:90776045:9077
6006:90756046:90756006:90766046:90766006:90776046:9077
6007:90756047:90756007:90766047:90766007:90776047:9077
6008:90756048:90756008:90766048:90766008:90776048:9077
6009:90756049:90756009:90766049:90766009:90776049:9077
6010:90756050:90756010:90766050:90766010:90776050:9077
6011:90756051:90756011:90766051:90766011:90776051:9077
6012:90756052:90756012:90766052:90766012:90776052:9077
6013:90756053:90756013:90766053:90766013:90776053:9077
6014:90756054:90756014:90766054:90766014:90776054:9077
6015:90756055:90756015:90766055:90766015:90776055:9077
6016:90756056:90756016:90766056:90766016:90776056:9077
6017:90756057:90756017:90766057:90766017:90776057:9077
6018:90756058:90756018:90766058:90766018:90776058:9077
6019:90756059:90756019:90766059:90766019:90776059:9077
6020:90756060:90756020:90766060:90766020:90776060:9077
6021:90756061:90756021:90766061:90766021:90776061:9077
6022:90756062:90756022:90766062:90766022:90776062:9077
6023:90756063:90756023:90766063:90766023:90776063:9077
6024:90756064:90756024:90766064:90766024:90776064:9077
6025:90756065:90756025:90766065:90766025:90776065:9077
6026:90756066:90756026:90766066:90766026:90776066:9077
6027:90756067:90756027:90766067:90766027:90776067:9077
6028:90756068:90756028:90766068:90766028:90776068:9077
6029:90756069:90756029:90766069:90766029:90776069:9077
6030:90756070:90756030:90766070:90766030:90776070:9077
6031:90756071:90756031:90766071:90766031:90776071:9077
6032:90756072:90756032:90766072:90766032:90776072:9077
6033:90756073:90756033:90766073:90766033:90776073:9077
6034:90756074:90756034:90766074:90766034:90776074:9077
6035:90756075:90756035:90766075:90766035:90776075:9077
6036:90756076:90756036:90766076:90766036:90776076:9077
6037:90756077:90756037:90766077:90766037:90776077:9077
6038:90756078:90756038:90766078:90766038:90776078:9077
6039:90756039:90766039:9077
6000:90786040:90786000:90796040:90796000:90806040:9080
6001:90786041:90786001:90796041:90796001:90806041:9080
6002:90786042:90786002:90796042:90796002:90806042:9080
6003:90786043:90786003:90796043:90796003:90806043:9080
6004:90786044:90786004:90796044:90796004:90806044:9080
6005:90786045:90786005:90796045:90796005:90806045:9080
6006:90786046:90786006:90796046:90796006:90806046:9080
6007:90786047:90786007:90796047:90796007:90806047:9080
6008:90786048:90786008:90796048:90796008:90806048:9080
6009:90786049:90786009:90796049:90796009:90806049:9080
6010:90786050:90786010:90796050:90796010:90806050:9080
6011:90786051:90786011:90796051:90796011:90806051:9080
6012:90786052:90786012:90796052:90796012:90806052:9080
6013:90786053:90786013:90796053:90796013:90806053:9080
6014:90786054:90786014:90796054:90796014:90806054:9080
6015:90786055:90786015:90796055:90796015:90806055:9080
6016:90786056:90786016:90796056:90796016:90806056:9080
6017:90786057:90786017:90796057:90796017:90806057:9080
6018:90786058:90786018:90796058:90796018:90806058:9080
6019:90786059:90786019:90796059:90796019:90806059:9080
6020:90786060:90786020:90796060:90796020:90806060:9080
6021:90786061:90786021:90796061:90796021:90806061:9080
6022:90786062:90786022:90796062:90796022:90806062:9080
6023:90786063:90786023:90796063:90796023:90806063:9080
6024:90786064:90786024:90796064:90796024:90806064:9080
6025:90786065:90786025:90796065:90796025:90806065:9080
6026:90786066:90786026:90796066:90796026:90806066:9080
6027:90786067:90786027:90796067:90796027:90806067:9080
6028:90786068:90786028:90796068:90796028:90806068:9080
6029:90786069:90786029:90796069:90796029:90806069:9080
6030:90786070:90786030:90796070:90796030:90806070:9080
6031:90786071:90786031:90796071:90796031:90806071:9080
6032:90786072:90786032:90796072:90796032:90806072:9080
6033:90786073:90786033:90796073:90796033:90806073:9080
6034:90786074:90786034:90796074:90796034:90806074:9080
6035:90786075:90786035:90796075:90796035:90806075:9080
6036:90786076:90786036:90796076:90796036:90806076:9080
6037:90786077:90786037:90796077:90796037:90806077:9080
6038:90786078:90786038:90796078:90796038:90806078:9080
6039:90786039:90796039:9080
6000:90816040:90816000:90826040:90826000:90836040:9083
6001:90816041:90816001:90826041:90826001:90836041:9083
6002:90816042:90816002:90826042:90826002:90836042:9083
6003:90816043:90816003:90826043:90826003:90836043:9083
6004:90816044:90816004:90826044:90826004:90836044:9083
6005:90816045:90816005:90826045:90826005:90836045:9083
6006:90816046:90816006:90826046:90826006:90836046:9083
6007:90816047:90816007:90826047:90826007:90836047:9083
6008:90816048:90816008:90826048:90826008:90836048:9083
6009:90816049:90816009:90826049:90826009:90836049:9083
6010:90816050:90816010:90826050:90826010:90836050:9083
6011:90816051:90816011:90826051:90826011:90836051:9083
6012:90816052:90816012:90826052:90826012:90836052:9083
6013:90816053:90816013:90826053:90826013:90836053:9083
6014:90816054:90816014:90826054:90826014:90836054:9083
6015:90816055:90816015:90826055:90826015:90836055:9083
6016:90816056:90816016:90826056:90826016:90836056:9083
6017:90816057:90816017:90826057:90826017:90836057:9083
6018:90816058:90816018:90826058:90826018:90836058:9083
6019:90816059:90816019:90826059:90826019:90836059:9083
6020:90816060:90816020:90826060:90826020:90836060:9083
6021:90816061:90816021:90826061:90826021:90836061:9083
6022:90816062:90816022:90826062:90826022:90836062:9083
6023:90816063:90816023:90826063:90826023:90836063:9083
6024:90816064:90816024:90826064:90826024:90836064:9083
6025:90816065:90816025:90826065:90826025:90836065:9083
6026:90816066:90816026:90826066:90826026:90836066:9083
6027:90816067:90816027:90826067:90826027:90836067:9083
6028:90816068:90816028:90826068:90826028:90836068:9083
6029:90816069:90816029:90826069:90826029:90836069:9083
6030:90816070:90816030:90826070:90826030:90836070:9083
6031:90816071:90816031:90826071:90826031:90836071:9083
6032:90816072:90816032:90826072:90826032:90836072:9083
6033:90816073:90816033:90826073:90826033:90836073:9083
6034:90816074:90816034:90826074:90826034:90836074:9083
6035:90816075:90816035:90826075:90826035:90836075:9083
6036:90816076:90816036:90826076:90826036:90836076:9083
6037:90816077:90816037:90826077:90826037:90836077:9083
6038:90816078:90816038:90826078:90826038:90836078:9083
6039:90816039:90826039:9083
6000:90846040:90846000:90856040:90856000:90866040:9086
6001:90846041:90846001:90856041:90856001:90866041:9086
6002:90846042:90846002:90856042:90856002:90866042:9086
6003:90846043:90846003:90856043:90856003:90866043:9086
6004:90846044:90846004:90856044:90856004:90866044:9086
6005:90846045:90846005:90856045:90856005:90866045:9086
6006:90846046:90846006:90856046:90856006:90866046:9086
6007:90846047:90846007:90856047:90856007:90866047:9086
6008:90846048:90846008:90856048:90856008:90866048:9086
6009:90846049:90846009:90856049:90856009:90866049:9086
6010:90846050:90846010:90856050:90856010:90866050:9086
6011:90846051:90846011:90856051:90856011:90866051:9086
6012:90846052:90846012:90856052:90856012:90866052:9086
6013:90846053:90846013:90856053:90856013:90866053:9086
6014:90846054:90846014:90856054:90856014:90866054:9086
6015:90846055:90846015:90856055:90856015:90866055:9086
6016:90846056:90846016:90856056:90856016:90866056:9086
6017:90846057:90846017:90856057:90856017:90866057:9086
6018:90846058:90846018:90856058:90856018:90866058:9086
6019:90846059:90846019:90856059:90856019:90866059:9086
6020:90846060:90846020:90856060:90856020:90866060:9086
6021:90846061:90846021:90856061:90856021:90866061:9086
6022:90846062:90846022:90856062:90856022:90866062:9086
6023:90846063:90846023:90856063:90856023:90866063:9086
6024:90846064:90846024:90856064:90856024:90866064:9086
6025:90846065:90846025:90856065:90856025:90866065:9086
6026:90846066:90846026:90856066:90856026:90866066:9086
6027:90846067:90846027:90856067:90856027:90866067:9086
6028:90846068:90846028:90856068:90856028:90866068:9086
6029:90846069:90846029:90856069:90856029:90866069:9086
6030:90846070:90846030:90856070:90856030:90866070:9086
6031:90846071:90846031:90856071:90856031:90866071:9086
6032:90846072:90846032:90856072:90856032:90866072:9086
6033:90846073:90846033:90856073:90856033:90866073:9086
6034:90846074:90846034:90856074:90856034:90866074:9086
6035:90846075:90846035:90856075:90856035:90866075:9086
6036:90846076:90846036:90856076:90856036:90866076:9086
6037:90846077:90846037:90856077:90856037:90866077:9086
6038:90846078:90846038:90856078:90856038:90866078:9086
6039:90846039:90856039:9086
6000:90876040:90876000:90886040:90886000:90896040:9089
6001:90876041:90876001:90886041:90886001:90896041:9089
6002:90876042:90876002:90886042:90886002:90896042:9089
6003:90876043:90876003:90886043:90886003:90896043:9089
6004:90876044:90876004:90886044:90886004:90896044:9089
6005:90876045:90876005:90886045:90886005:90896045:9089
6006:90876046:90876006:90886046:90886006:90896046:9089
6007:90876047:90876007:90886047:90886007:90896047:9089
6008:90876048:90876008:90886048:90886008:90896048:9089
6009:90876049:90876009:90886049:90886009:90896049:9089
6010:90876050:90876010:90886050:90886010:90896050:9089
6011:90876051:90876011:90886051:90886011:90896051:9089
6012:90876052:90876012:90886052:90886012:90896052:9089
6013:90876053:90876013:90886053:90886013:90896053:9089
6014:90876054:90876014:90886054:90886014:90896054:9089
6015:90876055:90876015:90886055:90886015:90896055:9089
6016:90876056:90876016:90886056:90886016:90896056:9089
6017:90876057:90876017:90886057:90886017:90896057:9089
6018:90876058:90876018:90886058:90886018:90896058:9089
6019:90876059:90876019:90886059:90886019:90896059:9089
6020:90876060:90876020:90886060:90886020:90896060:9089
6021:90876061:90876021:90886061:90886021:90896061:9089
6022:90876062:90876022:90886062:90886022:90896062:9089
6023:90876063:90876023:90886063:90886023:90896063:9089
6024:90876064:90876024:90886064:90886024:90896064:9089
6025:90876065:90876025:90886065:90886025:90896065:9089
6026:90876066:90876026:90886066:90886026:90896066:9089
6027:90876067:90876027:90886067:90886027:90896067:9089
6028:90876068:90876028:90886068:90886028:90896068:9089
6029:90876069:90876029:90886069:90886029:90896069:9089
6030:90876070:90876030:90886070:90886030:90896070:9089
6031:90876071:90876031:90886071:90886031:90896071:9089
6032:90876072:90876032:90886072:90886032:90896072:9089
6033:90876073:90876033:90886073:90886033:90896073:9089
6034:90876074:90876034:90886074:90886034:90896074:9089
6035:90876075:90876035:90886075:90886035:90896075:9089
6036:90876076:90876036:90886076:90886036:90896076:9089
6037:90876077:90876037:90886077:90886037:90896077:9089
6038:90876078:90876038:90886078:90886038:90896078:9089
6039:90876039:90886039:9089
6000:90906040:90906000:90916040:90916000:90926040:9092
6001:90906041:90906001:90916041:90916001:90926041:9092
6002:90906042:90906002:90916042:90916002:90926042:9092
6003:90906043:90906003:90916043:90916003:90926043:9092
6004:90906044:90906004:90916044:90916004:90926044:9092
6005:90906045:90906005:90916045:90916005:90926045:9092
6006:90906046:90906006:90916046:90916006:90926046:9092
6007:90906047:90906007:90916047:90916007:90926047:9092
6008:90906048:90906008:90916048:90916008:90926048:9092
6009:90906049:90906009:90916049:90916009:90926049:9092
6010:90906050:90906010:90916050:90916010:90926050:9092
6011:90906051:90906011:90916051:90916011:90926051:9092
6012:90906052:90906012:90916052:90916012:90926052:9092
6013:90906053:90906013:90916053:90916013:90926053:9092
6014:90906054:90906014:90916054:90916014:90926054:9092
6015:90906055:90906015:90916055:90916015:90926055:9092
6016:90906056:90906016:90916056:90916016:90926056:9092
6017:90906057:90906017:90916057:90916017:90926057:9092
6018:90906058:90906018:90916058:90916018:90926058:9092
6019:90906059:90906019:90916059:90916019:90926059:9092
6020:90906060:90906020:90916060:90916020:90926060:9092
6021:90906061:90906021:90916061:90916021:90926061:9092
6022:90906062:90906022:90916062:90916022:90926062:9092
6023:90906063:90906023:90916063:90916023:90926063:9092
6024:90906064:90906024:90916064:90916024:90926064:9092
6025:90906065:90906025:90916065:90916025:90926065:9092
6026:90906066:90906026:90916066:90916026:90926066:9092
6027:90906067:90906027:90916067:90916027:90926067:9092
6028:90906068:90906028:90916068:90916028:90926068:9092
6029:90906069:90906029:90916069:90916029:90926069:9092
6030:90906070:90906030:90916070:90916030:90926070:9092
6031:90906071:90906031:90916071:90916031:90926071:9092
6032:90906072:90906032:90916072:90916032:90926072:9092
6033:90906073:90906033:90916073:90916033:90926073:9092
6034:90906074:90906034:90916074:90916034:90926074:9092
6035:90906075:90906035:90916075:90916035:90926075:9092
6036:90906076:90906036:90916076:90916036:90926076:9092
6037:90906077:90906037:90916077:90916037:90926077:9092
6038:90906078:90906038:90916078:90916038:90926078:9092
6039:90906039:90916039:9092
6000:90936040:90936000:90946040:90946000:90956040:9095
6001:90936041:90936001:90946041:90946001:90956041:9095
6002:90936042:90936002:90946042:90946002:90956042:9095
6003:90936043:90936003:90946043:90946003:90956043:9095
6004:90936044:90936004:90946044:90946004:90956044:9095
6005:90936045:90936005:90946045:90946005:90956045:9095
6006:90936046:90936006:90946046:90946006:90956046:9095
6007:90936047:90936007:90946047:90946007:90956047:9095
6008:90936048:90936008:90946048:90946008:90956048:9095
6009:90936049:90936009:90946049:90946009:90956049:9095
6010:90936050:90936010:90946050:90946010:90956050:9095
6011:90936051:90936011:90946051:90946011:90956051:9095
6012:90936052:90936012:90946052:90946012:90956052:9095
6013:90936053:90936013:90946053:90946013:90956053:9095
6014:90936054:90936014:90946054:90946014:90956054:9095
6015:90936055:90936015:90946055:90946015:90956055:9095
6016:90936056:90936016:90946056:90946016:90956056:9095
6017:90936057:90936017:90946057:90946017:90956057:9095
6018:90936058:90936018:90946058:90946018:90956058:9095
6019:90936059:90936019:90946059:90946019:90956059:9095
6020:90936060:90936020:90946060:90946020:90956060:9095
6021:90936061:90936021:90946061:90946021:90956061:9095
6022:90936062:90936022:90946062:90946022:90956062:9095
6023:90936063:90936023:90946063:90946023:90956063:9095
6024:90936064:90936024:90946064:90946024:90956064:9095
6025:90936065:90936025:90946065:90946025:90956065:9095
6026:90936066:90936026:90946066:90946026:90956066:9095
6027:90936067:90936027:90946067:90946027:90956067:9095
6028:90936068:90936028:90946068:90946028:90956068:9095
6029:90936069:90936029:90946069:90946029:90956069:9095
6030:90936070:90936030:90946070:90946030:90956070:9095
6031:90936071:90936031:90946071:90946031:90956071:9095
6032:90936072:90936032:90946072:90946032:90956072:9095
6033:90936073:90936033:90946073:90946033:90956073:9095
6034:90936074:90936034:90946074:90946034:90956074:9095
6035:90936075:90936035:90946075:90946035:90956075:9095
6036:90936076:90936036:90946076:90946036:90956076:9095
6037:90936077:90936037:90946077:90946037:90956077:9095
6038:90936078:90936038:90946078:90946038:90956078:9095
6039:90936039:90946039:9095
6000:90966040:90966000:90976040:90976000:90986040:9098
6001:90966041:90966001:90976041:90976001:90986041:9098
6002:90966042:90966002:90976042:90976002:90986042:9098
6003:90966043:90966003:90976043:90976003:90986043:9098
6004:90966044:90966004:90976044:90976004:90986044:9098
6005:90966045:90966005:90976045:90976005:90986045:9098
6006:90966046:90966006:90976046:90976006:90986046:9098
6007:90966047:90966007:90976047:90976007:90986047:9098
6008:90966048:90966008:90976048:90976008:90986048:9098
6009:90966049:90966009:90976049:90976009:90986049:9098
6010:90966050:90966010:90976050:90976010:90986050:9098
6011:90966051:90966011:90976051:90976011:90986051:9098
6012:90966052:90966012:90976052:90976012:90986052:9098
6013:90966053:90966013:90976053:90976013:90986053:9098
6014:90966054:90966014:90976054:90976014:90986054:9098
6015:90966055:90966015:90976055:90976015:90986055:9098
6016:90966056:90966016:90976056:90976016:90986056:9098
6017:90966057:90966017:90976057:90976017:90986057:9098
6018:90966058:90966018:90976058:90976018:90986058:9098
6019:90966059:90966019:90976059:90976019:90986059:9098
6020:90966060:90966020:90976060:90976020:90986060:9098
6021:90966061:90966021:90976061:90976021:90986061:9098
6022:90966062:90966022:90976062:90976022:90986062:9098
6023:90966063:90966023:90976063:90976023:90986063:9098
6024:90966064:90966024:90976064:90976024:90986064:9098
6025:90966065:90966025:90976065:90976025:90986065:9098
6026:90966066:90966026:90976066:90976026:90986066:9098
6027:90966067:90966027:90976067:90976027:90986067:9098
6028:90966068:90966028:90976068:90976028:90986068:9098
6029:90966069:90966029:90976069:90976029:90986069:9098
6030:90966070:90966030:90976070:90976030:90986070:9098
6031:90966071:90966031:90976071:90976031:90986071:9098
6032:90966072:90966032:90976072:90976032:90986072:9098
6033:90966073:90966033:90976073:90976033:90986073:9098
6034:90966074:90966034:90976074:90976034:90986074:9098
6035:90966075:90966035:90976075:90976035:90986075:9098
6036:90966076:90966036:90976076:90976036:90986076:9098
6037:90966077:90966037:90976077:90976037:90986077:9098
6038:90966078:90966038:90976078:90976038:90986078:9098
6039:90966039:90976039:9098
6000:90996040:90996000:91006040:91006000:91016040:9101
6001:90996041:90996001:91006041:91006001:91016041:9101
6002:90996042:90996002:91006042:91006002:91016042:9101
6003:90996043:90996003:91006043:91006003:91016043:9101
6004:90996044:90996004:91006044:91006004:91016044:9101
6005:90996045:90996005:91006045:91006005:91016045:9101
6006:90996046:90996006:91006046:91006006:91016046:9101
6007:90996047:90996007:91006047:91006007:91016047:9101
6008:90996048:90996008:91006048:91006008:91016048:9101
6009:90996049:90996009:91006049:91006009:91016049:9101
6010:90996050:90996010:91006050:91006010:91016050:9101
6011:90996051:90996011:91006051:91006011:91016051:9101
6012:90996052:90996012:91006052:91006012:91016052:9101
6013:90996053:90996013:91006053:91006013:91016053:9101
6014:90996054:90996014:91006054:91006014:91016054:9101
6015:90996055:90996015:91006055:91006015:91016055:9101
6016:90996056:90996016:91006056:91006016:91016056:9101
6017:90996057:90996017:91006057:91006017:91016057:9101
6018:90996058:90996018:91006058:91006018:91016058:9101
6019:90996059:90996019:91006059:91006019:91016059:9101
6020:90996060:90996020:91006060:91006020:91016060:9101
6021:90996061:90996021:91006061:91006021:91016061:9101
6022:90996062:90996022:91006062:91006022:91016062:9101
6023:90996063:90996023:91006063:91006023:91016063:9101
6024:90996064:90996024:91006064:91006024:91016064:9101
6025:90996065:90996025:91006065:91006025:91016065:9101
6026:90996066:90996026:91006066:91006026:91016066:9101
6027:90996067:90996027:91006067:91006027:91016067:9101
6028:90996068:90996028:91006068:91006028:91016068:9101
6029:90996069:90996029:91006069:91006029:91016069:9101
6030:90996070:90996030:91006070:91006030:91016070:9101
6031:90996071:90996031:91006071:91006031:91016071:9101
6032:90996072:90996032:91006072:91006032:91016072:9101
6033:90996073:90996033:91006073:91006033:91016073:9101
6034:90996074:90996034:91006074:91006034:91016074:9101
6035:90996075:90996035:91006075:91006035:91016075:9101
6036:90996076:90996036:91006076:91006036:91016076:9101
6037:90996077:90996037:91006077:91006037:91016077:9101
6038:90996078:90996038:91006078:91006038:91016078:9101
6039:90996039:91006039:9101
6000:91026040:91026000:91036040:91036000:91046040:9104
6001:91026041:91026001:91036041:91036001:91046041:9104
6002:91026042:91026002:91036042:91036002:91046042:9104
6003:91026043:91026003:91036043:91036003:91046043:9104
6004:91026044:91026004:91036044:91036004:91046044:9104
6005:91026045:91026005:91036045:91036005:91046045:9104
6006:91026046:91026006:91036046:91036006:91046046:9104
6007:91026047:91026007:91036047:91036007:91046047:9104
6008:91026048:91026008:91036048:91036008:91046048:9104
6009:91026049:91026009:91036049:91036009:91046049:9104
6010:91026050:91026010:91036050:91036010:91046050:9104
6011:91026051:91026011:91036051:91036011:91046051:9104
6012:91026052:91026012:91036052:91036012:91046052:9104
6013:91026053:91026013:91036053:91036013:91046053:9104
6014:91026054:91026014:91036054:91036014:91046054:9104
6015:91026055:91026015:91036055:91036015:91046055:9104
6016:91026056:91026016:91036056:91036016:91046056:9104
6017:91026057:91026017:91036057:91036017:91046057:9104
6018:91026058:91026018:91036058:91036018:91046058:9104
6019:91026059:91026019:91036059:91036019:91046059:9104
6020:91026060:91026020:91036060:91036020:91046060:9104
6021:91026061:91026021:91036061:91036021:91046061:9104
6022:91026062:91026022:91036062:91036022:91046062:9104
6023:91026063:91026023:91036063:91036023:91046063:9104
6024:91026064:91026024:91036064:91036024:91046064:9104
6025:91026065:91026025:91036065:91036025:91046065:9104
6026:91026066:91026026:91036066:91036026:91046066:9104
6027:91026067:91026027:91036067:91036027:91046067:9104
6028:91026068:91026028:91036068:91036028:91046068:9104
6029:91026069:91026029:91036069:91036029:91046069:9104
6030:91026070:91026030:91036070:91036030:91046070:9104
6031:91026071:91026031:91036071:91036031:91046071:9104
6032:91026072:91026032:91036072:91036032:91046072:9104
6033:91026073:91026033:91036073:91036033:91046073:9104
6034:91026074:91026034:91036074:91036034:91046074:9104
6035:91026075:91026035:91036075:91036035:91046075:9104
6036:91026076:91026036:91036076:91036036:91046076:9104
6037:91026077:91026037:91036077:91036037:91046077:9104
6038:91026078:91026038:91036078:91036038:91046078:9104
6039:91026039:91036039:9104
6000:91056040:9105————
6001:91056041:9105
6002:91056042:9105
6003:91056043:9105
6004:91056044:9105
6005:91056045:9105
6006:91056046:9105
6007:91056047:9105
6008:91056048:9105
6009:91056049:9105
6010:91056050:9105
6011:91056051:9105
6012:91056052:9105
6013:91056053:9105
6014:91056054:9105
6015:91056055:9105
6016:91056056:9105
6017:91056057:9105
6018:91056058:9105
6019:91056059:9105
6020:91056060:9105
6021:91056061:9105
6022:91056062:9105
6023:91056063:9105
6024:91056064:9105
6025:91056065:9105
6026:91056066:9105
6027:91056067:9105
6028:91056068:9105
6029:91056069:9105
6030:91056070:9105
6031:91056071:9105
6032:91056072:9105
6033:91056073:9105
6034:91056074:9105
6035:91056075:9105
6036:91056076:9105
6037:91056077:9105
6038:91056078:9105
6039:9105
TABLE E
Example combinations of a compound X with a compound Y.
X:YX:YX:YX:YX:YX:Y
8000:90008000:90018000:90028000:90038000:90048000:9005
8001:90008001:90018001:90028001:90038001:90048001:9005
8002:90008002:90018002:90028002:90038002:90048002:9005
8003:90008003:90018003:90028003:90038003:90048003:9005
8004:90008004:90018004:90028004:90038004:90048004:9005
8005:90008005:90018005:90028005:90038005:90048005:9005
8006:90008006:90018006:90028006:90038006:90048006:9005
8007:90008007:90018007:90028007:90038007:90048007:9005
8008:90008008:90018008:90028008:90038008:90048008:9005
8009:90008009:90018009:90028009:90038009:90048009:9005
8010:90008010:90018010:90028010:90038010:90048010:9005
8011:90008011:90018011:90028011:90038011:90048011:9005
8012:90008012:90018012:90028012:90038012:90048012:9005
8013:90008013:90018013:90028013:90038013:90048013:9005
8014:90008014:90018014:90028014:90038014:90048014:9005
8015:90008015:90018015:90028015:90038015:90048015:9005
8016:90008016:90018016:90028016:90038016:90048016:9005
8000:90068000:90078000:90088000:90098000:90108000:9011
8001:90068001:90078001:90088001:90098001:90108001:9011
8002:90068002:90078002:90088002:90098002:90108002:9011
8003:90068003:90078003:90088003:90098003:90108003:9011
8004:90068004:90078004:90088004:90098004:90108004:9011
8005:90068005:90078005:90088005:90098005:90108005:9011
8006:90068006:90078006:90088006:90098006:90108006:9011
8007:90068007:90078007:90088007:90098007:90108007:9011
8008:90068008:90078008:90088008:90098008:90108008:9011
8009:90068009:90078009:90088009:90098009:90108009:9011
8010:90068010:90078010:90088010:90098010:90108010:9011
8011:90068011:90078011:90088011:90098011:90108011:9011
8012:90068012:90078012:90088012:90098012:90108012:9011
8013:90068013:90078013:90088013:90098013:90108013:9011
8014:90068014:90078014:90088014:90098014:90108014:9011
8015:90068015:90078015:90088015:90098015:90108015:9011
8016:90068016:90078016:90088016:90098016:90108016:9011
8000:90128000:90138000:90148000:90158000:90168000:9017
8001:90128001:90138001:90148001:90158001:90168001:9017
8002:90128002:90138002:90148002:90158002:90168002:9017
8003:90128003:90138003:90148003:90158003:90168003:9017
8004:90128004:90138004:90148004:90158004:90168004:9017
8005:90128005:90138005:90148005:90158005:90168005:9017
8006:90128006:90138006:90148006:90158006:90168006:9017
8007:90128007:90138007:90148007:90158007:90168007:9017
8008:90128008:90138008:90148008:90158008:90168008:9017
8009:90128009:90138009:90148009:90158009:90168009:9017
8010:90128010:90138010:90148010:90158010:90168010:9017
8011:90128011:90138011:90148011:90158011:90168011:9017
8012:90128012:90138012:90148012:90158012:90168012:9017
8013:90128013:90138013:90148013:90158013:90168013:9017
8014:90128014:90138014:90148014:90158014:90168014:9017
8015:90128015:90138015:90148015:90158015:90168015:9017
8016:90128016:90138016:90148016:90158016:90168016:9017
8000:90188000:90198000:90208000:90218000:90228000:9023
8001:90188001:90198001:90208001:90218001:90228001:9023
8002:90188002:90198002:90208002:90218002:90228002:9023
8003:90188003:90198003:90208003:90218003:90228003:9023
8004:90188004:90198004:90208004:90218004:90228004:9023
8005:90188005:90198005:90208005:90218005:90228005:9023
8006:90188006:90198006:90208006:90218006:90228006:9023
8007:90188007:90198007:90208007:90218007:90228007:9023
8008:90188008:90198008:90208008:90218008:90228008:9023
8009:90188009:90198009:90208009:90218009:90228009:9023
8010:90188010:90198010:90208010:90218010:90228010:9023
8011:90188011:90198011:90208011:90218011:90228011:9023
8012:90188012:90198012:90208012:90218012:90228012:9023
8013:90188013:90198013:90208013:90218013:90228013:9023
8014:90188014:90198014:90208014:90218014:90228014:9023
8015:90188015:90198015:90208015:90218015:90228015:9023
8016:90188016:90198016:90208016:90218016:90228016:9023
8000:90248000:90258000:90268000:90278000:90288000:9029
8001:90248001:90258001:90268001:90278001:90288001:9029
8002:90248002:90258002:90268002:90278002:90288002:9029
8003:90248003:90258003:90268003:90278003:90288003:9029
8004:90248004:90258004:90268004:90278004:90288004:9029
8005:90248005:90258005:90268005:90278005:90288005:9029
8006:90248006:90258006:90268006:90278006:90288006:9029
8007:90248007:90258007:90268007:90278007:90288007:9029
8008:90248008:90258008:90268008:90278008:90288008:9029
8009:90248009:90258009:90268009:90278009:90288009:9029
8010:90248010:90258010:90268010:90278010:90288010:9029
8011:90248011:90258011:90268011:90278011:90288011:9029
8012:90248012:90258012:90268012:90278012:90288012:9029
8013:90248013:90258013:90268013:90278013:90288013:9029
8014:90248014:90258014:90268014:90278014:90288014:9029
8015:90248015:90258015:90268015:90278015:90288015:9029
8016:90248016:90258016:90268016:90278016:90288016:9029
8000:90308000:90318000:90328000:90338000:90348000:9035
8001:90308001:90318001:90328001:90338001:90348001:9035
8002:90308002:90318002:90328002:90338002:90348002:9035
8003:90308003:90318003:90328003:90338003:90348003:9035
8004:90308004:90318004:90328004:90338004:90348004:9035
8005:90308005:90318005:90328005:90338005:90348005:9035
8006:90308006:90318006:90328006:90338006:90348006:9035
8007:90308007:90318007:90328007:90338007:90348007:9035
8008:90308008:90318008:90328008:90338008:90348008:9035
8009:90308009:90318009:90328009:90338009:90348009:9035
8010:90308010:90318010:90328010:90338010:90348010:9035
8011:90308011:90318011:90328011:90338011:90348011:9035
8012:90308012:90318012:90328012:90338012:90348012:9035
8013:90308013:90318013:90328013:90338013:90348013:9035
8014:90308014:90318014:90328014:90338014:90348014:9035
8015:90308015:90318015:90328015:90338015:90348015:9035
8016:90308016:90318016:90328016:90338016:90348016:9035
8000:90368000:90378000:90388000:90398000:90408000:9041
8001:90368001:90378001:90388001:90398001:90408001:9041
8002:90368002:90378002:90388002:90398002:90408002:9041
8003:90368003:90378003:90388003:90398003:90408003:9041
8004:90368004:90378004:90388004:90398004:90408004:9041
8005:90368005:90378005:90388005:90398005:90408005:9041
8006:90368006:90378006:90388006:90398006:90408006:9041
8007:90368007:90378007:90388007:90398007:90408007:9041
8008:90368008:90378008:90388008:90398008:90408008:9041
8009:90368009:90378009:90388009:90398009:90408009:9041
8010:90368010:90378010:90388010:90398010:90408010:9041
8011:90368011:90378011:90388011:90398011:90408011:9041
8012:90368012:90378012:90388012:90398012:90408012:9041
8013:90368013:90378013:90388013:90398013:90408013:9041
8014:90368014:90378014:90388014:90398014:90408014:9041
8015:90368015:90378015:90388015:90398015:90408015:9041
8016:90368016:90378016:90388016:90398016:90408016:9041
8000:90428000:90438000:90448000:90458000:90468000:9047
8001:90428001:90438001:90448001:90458001:90468001:9047
8002:90428002:90438002:90448002:90458002:90468002:9047
8003:90428003:90438003:90448003:90458003:90468003:9047
8004:90428004:90438004:90448004:90458004:90468004:9047
8005:90428005:90438005:90448005:90458005:90468005:9047
8006:90428006:90438006:90448006:90458006:90468006:9047
8007:90428007:90438007:90448007:90458007:90468007:9047
8008:90428008:90438008:90448008:90458008:90468008:9047
8009:90428009:90438009:90448009:90458009:90468009:9047
8010:90428010:90438010:90448010:90458010:90468010:9047
8011:90428011:90438011:90448011:90458011:90468011:9047
8012:90428012:90438012:90448012:90458012:90468012:9047
8013:90428013:90438013:90448013:90458013:90468013:9047
8014:90428014:90438014:90448014:90458014:90468014:9047
8015:90428015:90438015:90448015:90458015:90468015:9047
8016:90428016:90438016:90448016:90458016:90468016:9047
8000:90488000:90498000:90508000:90518000:90528000:9053
8001:90488001:90498001:90508001:90518001:90528001:9053
8002:90488002:90498002:90508002:90518002:90528002:9053
8003:90488003:90498003:90508003:90518003:90528003:9053
8004:90488004:90498004:90508004:90518004:90528004:9053
8005:90488005:90498005:90508005:90518005:90528005:9053
8006:90488006:90498006:90508006:90518006:90528006:9053
8007:90488007:90498007:90508007:90518007:90528007:9053
8008:90488008:90498008:90508008:90518008:90528008:9053
8009:90488009:90498009:90508009:90518009:90528009:9053
8010:90488010:90498010:90508010:90518010:90528010:9053
8011:90488011:90498011:90508011:90518011:90528011:9053
8012:90488012:90498012:90508012:90518012:90528012:9053
8013:90488013:90498013:90508013:90518013:90528013:9053
8014:90488014:90498014:90508014:90518014:90528014:9053
8015:90488015:90498015:90508015:90518015:90528015:9053
8016:90488016:90498016:90508016:90518016:90528016:9053
8000:90548000:90558000:90568000:90578000:90588000:9059
8001:90548001:90558001:90568001:90578001:90588001:9059
8002:90548002:90558002:90568002:90578002:90588002:9059
8003:90548003:90558003:90568003:90578003:90588003:9059
8004:90548004:90558004:90568004:90578004:90588004:9059
8005:90548005:90558005:90568005:90578005:90588005:9059
8006:90548006:90558006:90568006:90578006:90588006:9059
8007:90548007:90558007:90568007:90578007:90588007:9059
8008:90548008:90558008:90568008:90578008:90588008:9059
8009:90548009:90558009:90568009:90578009:90588009:9059
8010:90548010:90558010:90568010:90578010:90588010:9059
8011:90548011:90558011:90568011:90578011:90588011:9059
8012:90548012:90558012:90568012:90578012:90588012:9059
8013:90548013:90558013:90568013:90578013:90588013:9059
8014:90548014:90558014:90568014:90578014:90588014:9059
8015:90548015:90558015:90568015:90578015:90588015:9059
8016:90548016:90558016:90568016:90578016:90588016:9059
8000:90608000:90618000:90628000:90638000:90648000:9065
8001:90608001:90618001:90628001:90638001:90648001:9065
8002:90608002:90618002:90628002:90638002:90648002:9065
8003:90608003:90618003:90628003:90638003:90648003:9065
8004:90608004:90618004:90628004:90638004:90648004:9065
8005:90608005:90618005:90628005:90638005:90648005:9065
8006:90608006:90618006:90628006:90638006:90648006:9065
8007:90608007:90618007:90628007:90638007:90648007:9065
8008:90608008:90618008:90628008:90638008:90648008:9065
8009:90608009:90618009:90628009:90638009:90648009:9065
8010:90608010:90618010:90628010:90638010:90648010:9065
8011:90608011:90618011:90628011:90638011:90648011:9065
8012:90608012:90618012:90628012:90638012:90648012:9065
8013:90608013:90618013:90628013:90638013:90648013:9065
8014:90608014:90618014:90628014:90638014:90648014:9065
8015:90608015:90618015:90628015:90638015:90648015:9065
8016:90608016:90618016:90628016:90638016:90648016:9065
8000:90668000:90678000:90688000:90698000:90708000:9071
8001:90668001:90678001:90688001:90698001:90708001:9071
8002:90668002:90678002:90688002:90698002:90708002:9071
8003:90668003:90678003:90688003:90698003:90708003:9071
8004:90668004:90678004:90688004:90698004:90708004:9071
8005:90668005:90678005:90688005:90698005:90708005:9071
8006:90668006:90678006:90688006:90698006:90708006:9071
8007:90668007:90678007:90688007:90698007:90708007:9071
8008:90668008:90678008:90688008:90698008:90708008:9071
8009:90668009:90678009:90688009:90698009:90708009:9071
8010:90668010:90678010:90688010:90698010:90708010:9071
8011:90668011:90678011:90688011:90698011:90708011:9071
8012:90668012:90678012:90688012:90698012:90708012:9071
8013:90668013:90678013:90688013:90698013:90708013:9071
8014:90668014:90678014:90688014:90698014:90708014:9071
8015:90668015:90678015:90688015:90698015:90708015:9071
8016:90668016:90678016:90688016:90698016:90708016:9071
8000:90728000:90738000:90748000:90758000:90768000:9077
8001:90728001:90738001:90748001:90758001:90768001:9077
8002:90728002:90738002:90748002:90758002:90768002:9077
8003:90728003:90738003:90748003:90758003:90768003:9077
8004:90728004:90738004:90748004:90758004:90768004:9077
8005:90728005:90738005:90748005:90758005:90768005:9077
8006:90728006:90738006:90748006:90758006:90768006:9077
8007:90728007:90738007:90748007:90758007:90768007:9077
8008:90728008:90738008:90748008:90758008:90768008:9077
8009:90728009:90738009:90748009:90758009:90768009:9077
8010:90728010:90738010:90748010:90758010:90768010:9077
8011:90728011:90738011:90748011:90758011:90768011:9077
8012:90728012:90738012:90748012:90758012:90768012:9077
8013:90728013:90738013:90748013:90758013:90768013:9077
8014:90728014:90738014:90748014:90758014:90768014:9077
8015:90728015:90738015:90748015:90758015:90768015:9077
8016:90728016:90738016:90748016:90758016:90768016:9077
8000:90788000:90798000:90808000:90818000:90828000:9083
8001:90788001:90798001:90808001:90818001:90828001:9083
8002:90788002:90798002:90808002:90818002:90828002:9083
8003:90788003:90798003:90808003:90818003:90828003:9083
8004:90788004:90798004:90808004:90818004:90828004:9083
8005:90788005:90798005:90808005:90818005:90828005:9083
8006:90788006:90798006:90808006:90818006:90828006:9083
8007:90788007:90798007:90808007:90818007:90828007:9083
8008:90788008:90798008:90808008:90818008:90828008:9083
8009:90788009:90798009:90808009:90818009:90828009:9083
8010:90788010:90798010:90808010:90818010:90828010:9083
8011:90788011:90798011:90808011:90818011:90828011:9083
8012:90788012:90798012:90808012:90818012:90828012:9083
8013:90788013:90798013:90808013:90818013:90828013:9083
8014:90788014:90798014:90808014:90818014:90828014:9083
8015:90788015:90798015:90808015:90818015:90828015:9083
8016:90788016:90798016:90808016:90818016:90828016:9083
8000:90848000:90858000:90868000:90878000:90888000:9089
8001:90848001:90858001:90868001:90878001:90888001:9089
8002:90848002:90858002:90868002:90878002:90888002:9089
8003:90848003:90858003:90868003:90878003:90888003:9089
8004:90848004:90858004:90868004:90878004:90888004:9089
8005:90848005:90858005:90868005:90878005:90888005:9089
8006:90848006:90858006:90868006:90878006:90888006:9089
8007:90848007:90858007:90868007:90878007:90888007:9089
8008:90848008:90858008:90868008:90878008:90888008:9089
8009:90848009:90858009:90868009:90878009:90888009:9089
8010:90848010:90858010:90868010:90878010:90888010:9089
8011:90848011:90858011:90868011:90878011:90888011:9089
8012:90848012:90858012:90868012:90878012:90888012:9089
8013:90848013:90858013:90868013:90878013:90888013:9089
8014:90848014:90858014:90868014:90878014:90888014:9089
8015:90848015:90858015:90868015:90878015:90888015:9089
8016:90848016:90858016:90868016:90878016:90888016:9089
8000:90908000:90918000:90928000:90938000:90948000:9095
8001:90908001:90918001:90928001:90938001:90948001:9095
8002:90908002:90918002:90928002:90938002:90948002:9095
8003:90908003:90918003:90928003:90938003:90948003:9095
8004:90908004:90918004:90928004:90938004:90948004:9095
8005:90908005:90918005:90928005:90938005:90948005:9095
8006:90908006:90918006:90928006:90938006:90948006:9095
8007:90908007:90918007:90928007:90938007:90948007:9095
8008:90908008:90918008:90928008:90938008:90948008:9095
8009:90908009:90918009:90928009:90938009:90948009:9095
8010:90908010:90918010:90928010:90938010:90948010:9095
8011:90908011:90918011:90928011:90938011:90948011:9095
8012:90908012:90918012:90928012:90938012:90948012:9095
8013:90908013:90918013:90928013:90938013:90948013:9095
8014:90908014:90918014:90928014:90938014:90948014:9095
8015:90908015:90918015:90928015:90938015:90948015:9095
8016:90908016:90918016:90928016:90938016:90948016:9095
8000:90968000:90978000:90988000:90998000:91008000:9101
8001:90968001:90978001:90988001:90998001:91008001:9101
8002:90968002:90978002:90988002:90998002:91008002:9101
8003:90968003:90978003:90988003:90998003:91008003:9101
8004:90968004:90978004:90988004:90998004:91008004:9101
8005:90968005:90978005:90988005:90998005:91008005:9101
8006:90968006:90978006:90988006:90998006:91008006:9101
8007:90968007:90978007:90988007:90998007:91008007:9101
8008:90968008:90978008:90988008:90998008:91008008:9101
8009:90968009:90978009:90988009:90998009:91008009:9101
8010:90968010:90978010:90988010:90998010:91008010:9101
8011:90968011:90978011:90988011:90998011:91008011:9101
8012:90968012:90978012:90988012:90998012:91008012:9101
8013:90968013:90978013:90988013:90998013:91008013:9101
8014:90968014:90978014:90988014:90998014:91008014:9101
8015:90968015:90978015:90988015:90998015:91008015:9101
8016:90968016:90978016:90988016:90998016:91008016:9101
8000:91028000:91038000:91048000:9105——
8001:91028001:91038001:91048001:9105
8002:91028002:91038002:91048002:9105
8003:91028003:91038003:91048003:9105
8004:91028004:91038004:91048004:9105
8005:91028005:91038005:91048005:9105
8006:91028006:91038006:91048006:9105
8007:91028007:91038007:91048007:9105
8008:91028008:91038008:91048008:9105
8009:91028009:91038009:91048009:9105
8010:91028010:91038010:91048010:9105
8011:91028011:91038011:91048011:9105
8012:91028012:91038012:91048012:9105
8013:91028013:91038013:91048013:9105
8014:91028014:91038014:91048014:9105
8015:91028015:91038015:91048015:9105
8016:91028016:91038016:91048016:9105
MS31 P NMR
Structure[M − 1] −P (α)P (β)P (γ)
TABLE 2
Compound #EC 50
2A
3A
5A
11A
13B
14A
16A
17A
18A
19A
20A
21A
22A
27C
28A
29C
30A
31A
32A
33A
34A
35A
36A
37A
40B
41B
42A
43A
49A
51B
52A
53A
54A
55A
56A
57A
58A
59C
60C
61A
62A
66A
67B
70B
73B
77B
79A
80B
81A
83A
84A
85A
86A
87A
88A
89A
90A
91A
TABLE 3
Compound #IC 50
6A
7aA
7bB
9A
12A
15A
26A
28A
38A
44A
46A
50A
63A
64A
69A
76A
TABLE 4
CombinationSynergy Volume
Compound(μM 2 %)Determination
ANA-598 (3002)29.46Synergistic
HCV-796 (3004)81.72Synergistic
Ribavirin (5012)6.77Additive
Filibuvir (3007)23.51Additive
VX-222 (3003)32.35Synergistic
BMS-790052 (4001)38.01Synergistic
VX-950 (1001)32.28Synergistic
TMC-435 (1013)97.17Synergistic

Claims as granted

5 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

8 codes
IPC · International Patent Classification
Section A — Human necessities
  • A61P31/14
Section C — Chemistry; metallurgy
  • C07H19/213
  • C07H19/16
  • C07H19/20
  • C07H19/10
  • C07H19/173
  • C07H19/06
  • C07H19/207

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomOct 2018Jan 2019Apr 2019Jul 2019Oct 2019Jan 2020Apr 2020Jul 2020USPTOApplicantNotice of allowance
USPTOApplicanthover for detail · click to open
Pendency
1.5 y
566 days filing → grant
Office actions
0
none on record
Responses
1
no RCE
Examiner
Traviss C McIntosh, III
art unit 1623 · TC 1600
Citations: 297 back · 2 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom2020202220242026202820302032203420362038Owner 2
Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock